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This thesis outlines the synthetic chemistry involved in the preparation of 
a range of novel indazole compounds and details the subsequent investigation into 
their potential as biologically active agents. The synthetic route utilised in this 
research to form the indazole structure was the [3+2] dipolar cycloaddition of 
diazo carbonyl compounds with reactive aryne intermediates generated in situ. 
 The preparation of further novel indazole derivatives containing different 
functional groups and substituents was performed by synthesising alternative 1,3-
dipole and dipolarophile analogues and provided additionally diverse compounds. 
Further derivatisation of the indazole product was made possible by deacylation 
and alkylation methods. Transformation reactions were performed on alkene-
containing ester side chains to provide novel epoxide, aldehyde and tertiary amine 
derivatives.  
The first chapter is a review of the literature beginning with a short 
overview on the structure, reactivity and common synthetic routes to diazo 
carbonyl derivatives. More attention is given to the use of diazo compounds as 
1,3-dipoles in cycloaddition reactions or where the diazo group is incorporated 
into the final product. A review of the interesting background, structure and 
reactivity of aryne intermediates is also presented. In addition, some common 
syntheses of indazole compounds are presented as well as a brief discussion on the 
importance of indazole compounds as therapeutic agents. 
The second chapter discusses the synthetic routes employed towards the 
synthesis of the range of indazoles. Initially, the syntheses of the diazo carbonyl 
and aryne precursors are described. Next, the synthetic methods to prepare the 
indazole compounds are provided followed by discussion on derivatisation of the 
indazole compounds including N-deacylation, N-benzylation and ester side-chain 
transformation of some alkene-containing indazoles. A series of novel indazole 
derivatives were submitted for anti-cancer screening at the U.S National Cancer 
Institute (NCI). A number of these derivatives were identified as hit compounds, 
with excellent growth inhibition. The results obtained from biological evaluation 
from the NCI are provided with further results pending from the Community for 
Open Antimicrobial Drug Discovery. 
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The third chapter details the full experimental procedures, including 
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“Son, if you really want something in this life, you have to work for it. Now 
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1.1 α-Diazocarbonyl compounds 
1.1.1 Structure and reactivity  
α-Diazocarbonyl compounds and their derivatives play an important role 
in organic synthesis. They are easily prepared in high yield and can undergo a 
range of chemical transformations due to their high reactivity, depending on the 
conditions employed.1  Most of these transformations are initiated by loss of 
nitrogen from α-diazo carbonyl compounds, achieved under thermal, 
photochemical or catalytic conditions, generating reactive carbene intermediates 
which  are known to undergo a significant number of reactions such as those 
outlined in Scheme 1.1.2-6 
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The resonance structures of the α-diazocarbonyl group are shown in 
Figure 1.1. The carbon attached to the diazo group has a partial negative charge 





Figure 1.1 Ambiphilic nature of diazo carbonyl derivatives 
Compounds containing diazo groups are some of the more synthetically 
useful 1,3-dipoles, however their participation in cycloaddition reactions has not 
been extensively examined in comparison to other 1,3-dipoles such as nitrile 
oxides, azomethine ylides, carbonyl ylides and nitrones.7 This is possibly due to 
diazo compounds originally described in the literature not being readily available, 
being thermally unstable and not being suitable for prolonged storage.8 The diazo 
group is analogous to propargyl/allenyl anion-type 1,3-dipoles which are linear in 
structure and contain a positive charge on the central nitrogen and the 
delocalisation of the anion over the carbon and the terminal nitrogen providing 






Figure 1.2 Propargyl and allenyl anion-type diazo 1,3-dipoles 
1.1.2 Synthesis of α-diazocarbonyl compounds 
The most common route to α-diazocarbonyl compounds involves the 
introduction of the diazo group using methodology developed by Regitz.4 The 
complete diazo group is transferred from a donor, usually a sulfonyl azide, to an 
acceptor such as a ketone, ester or carboxylic acid by a reaction known as diazo 
transfer. The Regitz methodology requires a base of sufficient strength to 
deprotonate the α-protons and works well when the methylene group is activated 
   Chapter 1: Introduction 
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by two carbonyl groups. Compounds such β-diketones, β-ketoesters and β-
ketoamides 1 are very reactive towards diazo transfer and form α-diazo-β-
dicarbonyl products 3 (and para-toluenesulfonylamide by-product 4) in a facile 
manner by reaction with a diazo transfer reagent such as para-toluenesulfonyl 
azide 2 in organic solvents like acetonitrile and dichlormethane using a base such 






There are a wide range of diazo transfer reagents available10-15 with 
reviews in the literature on their utility4,5,16 and on their individual properties such 
as stability, safety and associated hazards.11,17 The least hazardous reagent 
described in the literature is p-dodecylbenzenesulfonyl azide 5 (Figure 1.3), which 
has a low impact sensitivity (exhibits no shock sensitivity at the highest test level 
of 150 kg.cm) and has been used in large scale reactions in industry for over a 
decade without incident.8 Tosyl azide 2 (Figure 1.3), in comparison, is reported 
to be one of the most dangerous diazo transfer reagents due to its high impact 
sensitivity (50 kg.cm) and large heat of decomposition.8,17 Tosyl azide 2 is still 
viewed as one of the more stable azides however, as the initiation temperature of 
the decomposition is >120 ºC. It is nevertheless regarded as a potential explosive 





Figure 1.3 p-Dodecylbenzenesulfonyl azide 5 and tosyl azide 2 
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Cycloaddition reactions involving diazo compounds were first reported in 
the 1880s.18,19 In the following 100 years, synthetic applications of these dipoles 
was limited to the preparation of pyrazole-type structures, after aromatisation of 
the initial [3+2] adduct and preparation of cyclopropane derivatives, following 




Since the 1980s, major developments in their use as substrates in 
cycloaddition reactions have occurred, including their reaction with a range of 
novel dipolarophiles leading to new and established heterocycles,7 some of which 
will be discussed herein.  
 
1.1.3 Cycloadditions with carbon-carbon double and triple bonds 
The most common diazoalkane 1,3-dipolar cycloaddition reactions are 
addition to alkenes and alkynes. Diazo dipoles can participate in a range of 
cycloaddition reactions with both carbon-carbon double and triple bonds and the 
process can be promoted by electron-withdrawing substituents on the 
dipolarophiles. These general 1,3-dipolar cycloadditions are depicted in Scheme 
1.4. The initial 1-pyrazoline adduct 8 of the diazo compound 7 and alkene 
dipolarophile 6 can isomerise to a 2-pyrazoline 9 [Scheme 1.4 (a)],20,21 and the 
product of the reaction with an alkyne dipolarophile 10 produces a pyrazole 12 
[Scheme 1.4 (b)]. 






1.1.4 Cycloadditions with carbon-nitrogen double and triple bonds 
The first reactions of strained cyclic imines, such as 2H-azirines 13 with 
diazomethane 14 to give allyl azides 16 and 17 via 1,2,3-triazabicyclo[3.1.0]hex-
2-ene 15 was reported more than 50 years ago.22 The 1,3-dipolar cycloaddition 
was found to proceed relatively slowly in comparison to the fragmentation of the 
postulated intermediate to yield the final products. Due to this, the structure of the 
short-lived 1,2,3-triazabicyclo[3.1.0]hex-2-ene 15 could not be proven by 1H and 





































6 7 8 9
10 11
R = H, aryl, alkyl, vinyl, RCOOR1














13 15 16 17
14
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Further investigations into the reactions of strained cyclic imines were 
carried out by the Regitz group in 1988.24 In their studies, the kinetically stabilised 
azete (azacyclobutadiene) 18 reacts with diazomethane 14 across the C=C bond to 
form the bicyclic 2,3,7-triazoline derivative 19. More sterically hindered diazo 
compounds like 1-diazo-1-phenylethane 20 added across the C=N of the azete, to 
furnish two products in a quantitative overall yield. The bicyclic 1,3,4-triazoline 
derivative 21 is initially produced and attributed for 57% of the final product yield. 
Rearrangement occurs under thermal or photolytic conditions for ca. half of this 


















Diazo compounds have been known to react with activated nitriles, such 
as those with an electron-withdrawing group attached, leading to 1,2,3-triazole 
derivatives.25 In a recent publication by Tyrkov and co-workers, the cycloaddition 
of 23 with excess diazomethane 14 occurs under mild conditions to form two 
separable isomeric products 24 and 25. The nitrile dipolarophile 23 is activated by 
the dinitrotetrazolylmethyl group. The initial NH-triazole cycloadduct is not 
   Chapter 1: Introduction 
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isolated due to rapid deprotonation and N-methylation with the excess 
diazomethane (Scheme 1.7).26  
 
Scheme 1.7 
1.1.5 Cycloaddition with thioketone C=S and subsequent nitrogen exclusion 
Diazo compounds were shown to react with thioketones in a Schönberg 
cycloaddition reaction to yield 1,3-dithiolanes and/or thiiranes as far back as 
1920,27 with the mechanism being confirmed by Huisgen and co-workers in 
1981.28,29 The thioketone C=S bonds have high reactivity towards diazo dipoles in 
comparison to other common dipolarophiles. This can be explained by molecular 
orbital theory where the HOMO-LUMO energy separation of thiocarbonyl 
compounds are much smaller than their related C=O ketone compounds.30 
Thiobenzophenone 26 and diazomethane 14 react to form the thiadiazole 
cycloadduct intermediate 27, which rapidly eliminates nitrogen to form the 
thiocarbonyl ylide 28. This can then dimerise to form the dithiane 29 at -30 ºC; 
cyclise to form the thiirane 30 which can form product 31 by sulfur extrusion, or 
be trapped by a range of other dipolarophiles in another cycloaddition reaction 













1.1.6 Cycloadditions with aryne intermediates 
The first 1,3-dipolar cycloaddition reaction between diazo compounds and 
aryne intermediates was briefly mentioned by Huisgen in 196131 and again in 
publications by Shechter and co-workers in subsequent years32,33 where the 
authors published their research on the synthesis of 1-acylindazole. The authors 
demonstrated that benzyne 33, generated from the zwitterion of diazotised 
anthranilic acid 32 and 1-diazo-1-phenylpropan-2-one 34 undergo a cycloaddition 
reaction to give the 1,3-dipolar adduct intermediate 35, which rapidly rearranges 
to the 2-acyl indazole 36 exclusively, before thermal isomerisation to the 1-acyl 















However, due to limited methods to generate the aryne intermediate, 
research in this area did not advance greatly until 2007 when Yamamoto and co-
workers34 and Larock and co-workers35 almost simultaneously reported 1,3-
dipolar cycloaddition between diazo compounds and arynes to form 1H-indazole 
heterocycles. The development of commercially available aryne precursors and 
mild generation methods have paved the way for the aryne dipolarophile 
intermediate to be used in these cycloaddition reactions. 
Yamamoto and co-workers were able to take advantage of the newly 
commercially available aryne precursors 38 in their reported synthesis of indazole 
derivatives 40, using an efficient and general procedure employing the [3+2] 
cycloaddition of arynes and various diazo derivatives 39.34 Larock and co-workers 
reported similar findings in their publication a few months later, with slightly 
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1.1.7 Diaza-Wittig reactions 
Although not a 1,3-dipole cycloaddition, the Diaza-Wittig reaction36 is of 
interest as incorporation of the diazo group into heterocycles allows the 
preparation of “privileged” structures such as pyridazine (Scheme 1.11)37,38 and 
phthalazine (Scheme 1.12). Privileged structures are defined as molecular 
frameworks which are capable of providing useful ligands for more than one type 
of receptor or enzyme target by judicious structural modifications.39 Herdewijn 
and co-workers have reported novel syntheses of these derivatives that allow the 
introduction of various substitution patterns and do not require purification. Mild 
oxidation of the diazo 41 with IBX (2-iodobenzoic acid) followed by treatment 
with tributylphosphine in diisopropyl ether for 30 min in a Diazo-Wittig reaction 
led to the desired pyridazine derivatives 42 in good yields (Scheme 1.11).37  
Scheme 1.11 
[1,6]-Ring closure of diazo 43 was achieved by an intramolecular Diaza-
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Diazo compounds are important 1,3-dipoles in modern organic synthesis. 
They readily undergo a range of cycloaddition reactions, leading to a variety of 
interesting cycloadducts, dependant on the dipolarophile. These cycloadducts can 
contain the original diazo group or expel nitrogen from the product after the initial 
























1.2.1 History and background  
  In 1902, Stoermer and co-workers were the first to postulate the existence 
of an aryne when they proposed the formation of 2,3-didehydrobenzofuran 46 as 
an intermediate on treatment of 3-bromobenzofuran 45 with sodium ethoxide in 
ethanol to form 2-ethoxybenzofuran 47 among other products (Scheme 1.13).40 
Although doubt has been cast over the conclusions drawn from these experiments 






Bachmann and co-workers then proposed ‘free phenylene’ 49 as a reactive 
intermediate in 1927 when the Wurtz-Fittig reactions with chlorobenzene 48 and 
sodium to produce biphenyl 50, also produced compounds 51-53 that could not be 
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Several decades later, Wittig reported unusual rearrangements of benzene 
derivatives and initially suggested a zwitterionic intermediate structure 55 formed 
from loss of LiF from 55 in his work with fluorobenzene 54 and phenyllithium 
bases. It was thought that 56 underwent rapid reaction with phenyllithium to yield 
2-lithiobiphenyl 57 (Scheme 1.15).43 
 
Scheme 1.15 
Roberts obtained definitive evidence for the existence of these reactive 
intermediates with his experiments on the reaction of 14C-labelled chlorobenzene 
58 with potassium amide to give equimolar mixture of products 59 and 60 
(Scheme 1.16). This was rationalised by proposing the presence of benzyne 
intermediate 33.44 
 
Scheme 1.16          * = 14C label 
Shortly after, Huisgen provided further evidence for the benzyne structure 
by demonstrating that identical major 64 and minor 65 carboxylic acid products 
were obtained on treatment of both 2- and 3-fluoroanisole 61 and 62 with 
phenyllithium followed by carboxylation (Scheme 1.17), and concluding that a 
common intermediate 63 must be involved.45,46 
 





Finally, the Diels-Alder trapping with furan by Wittig added more support 
to the existence of benzyne. Treatment of dihalobenzene 66 with lithium amalgam 
in furan led to the isolation of cycloadduct 67, displaying the dienophilic character 
of the intermediate (Scheme 1.18).47 These studies were the first concrete 
evidence of aryne intermediates and inspired the development of much of the 





1.2.2 Structure and reactivity  
Arynes are neutral intermediates that can be derived from aromatic rings 
following di-elimination of substituents, leaving two atomic orbitals 
(perpendicular to the aromatic π system) occupied by two electrons. These 
intermediates possess a degree of triple bond character and their reactivity can be 
compared to that of alkynes 68. Due to the nature of the triple bond, the 
intermediate is very reactive as the p orbitals are distorted to accommodate the 
triple bond within the ring system, impeding effective overlap and reducing 
stability.49,50  
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Radziszewski and co-workers investigated and analysed the IR spectra 
obtained of the benzyne triple bond from direct matrix isolation at low 
temperatures and assigned the frequency of the stretching vibration of the benzyne 
C-C triple bond to be max 1846 cm-1 in 1992.51 Radziszewski was also involved 
in a publication in 1996 that reported the bond length of the C-C triple bond, found 





Figure 1.4 Comparison of ethyne 68 and benzyne 33 triple bond 
Aryne systems are extensively studied and are no longer a chemical 
curiosity, even if some of their reactivity is still not fully understood. They have 
proven to be useful synthetic intermediates as milder methods for their generation 
have been reported, undergoing a range of chemical transformations, allowing for 
many synthetic applications.37,50,53-61 Even at low temperatures arynes are very 
labile and are known to form dimers.62 Their reactivity can be attributed to their 
kinetic instability and their highly strained structure.48,50,58 
Despite this broad range of practical applications, their structural 
characterisation has been the subject of debate and remains a challenge. ortho-
Benzyne 33, which has the molecular formula C6H4, is the most well-known aryne. 
The original structure proposed for this reactive intermediate was a zwitterion of 
benzene 56. After more research, this idea was then replaced by the strained alkyne 
structure 33. This is now the widely accepted representation of ortho-benzyne 33 
as its alkyne-like character is demonstrated by its reactivity patterns and will be 
employed herein. The biradical 49 and cumulene/cyclohexatetraene 69 
representations are also significant resonance contributors. The two p orbitals in 
representation 70 are distorted to accommodate the triple bond, reducing their 
effective overlap, resulting in a highly reactive intermediate (Figure 1.5).   





Figure 1.5 Representations of o-benzyne structure 
Microwave and IR spectroscopic studies on benzyne 33 in the gas phase 
or isolated in cryogenic matrices have supported the electronic structure best 
portrayed by a resonant form with a triple bond between two adjacent carbon 
atoms.63 Theoretical calculations also suggest a structure containing more triple 
bond character than cumulene character.63,64 Solution 1H and 13C NMR spectra of 
benzyne 33, generated inside a hemicarcerand molecular container, indicate a 
cumulene structure.64 
Pavlicek and co-workers have recently been able to obtain direct imaging 
of the chemical structure of ortho-arynes for the first time using atomic force 
microscopy. Their experiments provided insight into the transient species that had 
been vague up until this point. Analysis of bond-order-related contrast indicated 
that the cumulene representation 71 was the dominant form for the aryne generated 
under these conditions, along with the triple bond 72 and biradical 73 resonance 
forms (Figure 1.6).63  
 
Figure 1.6 Representations of dominant aryne structural forms 
Pyrolysis of cis-3-hexen-1,5-diyne 74 generated the first known para-
benzyne 75 via the spontaneous Bergmann cycloaromatisation reaction which was 
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confirmed using product trapping experiments and isotope-labelling studies to 






para-Benzyne has generated a lot of interest lately due to the discovery of 
the naturally occurring enediyne cytostatics (e.g. calicheamicin 77), a class of 
antitumour-antibiotics.66,67 The para-benzyne intermediate formed from these 
structures can undergo radical reactions, unlike its ortho-benzyne 33 counterpart; 
they can abstract a hydrogen atom from the deoxyribose sugar in both strands of 
double-stranded DNA, causing irreversible DNA cleavage in vivo, destroying the 
cancer cells.66,68 
Calicheamicin 77, isolated from a soil sample in 1987,69,70 was found to be 
an incredibly potent cytotoxic agent by inciting DNA cleavage (Scheme 1.20).46  
It undergoes a Bergmann cyclisation, generating a biradical species 78 and causes 
double strand scission. The first total synthesis of calicheamicin 77 in its naturally 
occurring enantiomeric form was reported in 1992 by Nicolaou and co-
workers.71 Unfortunately, the delayed high cytotoxicity of the natural antibiotics 
hinders their clinical use but it is hoped that newer synthetic derivatives may 
provide effective treatment in the future.66 
Scheme 1.20 
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Of the three benzynes possible (ortho-, meta- and para-benzyne), meta-
benzyne has received the least attention. meta-Benzyne 81 was first generated by 
Washburn in 1975 by dehydrohalogenation of exo,exo-2,6-dibromobicyclo[3.1.0]-
hex-2-ene 79.72 These early trapping experiments suggested that both bicyclic 80 
and biradical 81 structures were possible for this intermediate. Since then, 
however, several methods have been developed for its generation and rather than 
the highly strained, anti-Bredt (bridged bicyclic systems containing ring strain due 
to the presence of a bridgehead alkene), tri-alkenyl bicyclic structure 80, it was 
determined explicitly to have a biradical structure with major distortion of the 
benzene hexagon shape 82. This distortion is due to the occurrence of coupling of 
the formally unpaired electrons by through-space and through-bond interactions 
of the radical lobes (Scheme 1.21).73-78 
 
Scheme 1.21 
The radical reactivity of the meta-benzyne structures is reduced due to 
strong coupling between the proximate radical sites which may pave the way for 
a more beneficial target for antitumor agents than the para-benzyne 
analogues.73,74,77 An improved understanding of the reactivity of meta-benzyne 
could, therefore, be useful for the design of new synthetic DNA cleaving agents; 
however, this is still a challenge due to their high reactivities and the difficulty in 
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1.2.3 Heterocyclic arynes 
Although the majority of aryne research has focused on carbocyclic aryne 
intermediates, there are many examples of well-known heterocyclic arynes and 







Figure 1.7 Well-known and postulated hetaryne intermediates 
A major challenge in the early study of hetarynes had been that they could 
not be readily observed in reactions, with the evidence of their existence coming 
from the products formed in the reactions.41 This could have led to incorrect 
conclusions due to multiple possible pathways that potentially led to proposed 
hetaryne products without forming the hetaryne intermediate. It is feasible also 
that aryne and non-aryne pathways are proceeding competitively in a given 
reaction.41 Therefore, according to Reinecke, many of the heterocyclic arynes 
proposed in reported reactions may not actually be involved as an intermediate.41 
Reported hetaryne reactions frequently give low yields of desired products, 
in part due to their high reactivity, with major side reactions causing the formation 
of unmanageable tars.79 As a consequence of this, they have not been seen as 
synthetically useful and have not been studied to the same extent as carbocyclic 
arynes. The most well studied hetaryne intermediates are pyridynes 84 and 85, and 
indolynes 88-91 (where X = O) derivatives, which have been employed as useful 
intermediates in organic synthesis and have been reviewed recently by Goetz and 





X = N, O, S
83 84 85 86 87
88 89 90 91
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The 3,4-pyridyne isomer 85 is the most stable of the isomers (due to the 
formal C-C triple bond length being close in the length to the benzyne 33 C-C 
triple bond) followed by the 2,3-isomer 84 which contains a more elongated C-C 
triple bond (Figure 1.8). The 1,2-pyridyne 83 can also be represented as the 2-
pyridyl cation but attempts to study this intermediate in solution were unsuccessful 
with only gas phase studies showing some evidence for its formation.81 Much 
synthetic effort has gone into the study of these intermediates in the preparation of 






Figure 1.8 Comparison of aryne triple bond lengths 
In the synthesis of ellipticine-type compounds 93, procedures by both 
Gribble83 and Moody84 involve the use of 3,4-pyridyne 85 (generated from 92) 
with  furoindole 94 and indolopyrone 95 respectively. Both of these routes, 
although short and convergent, are of limited synthetic use due to low yielding 
reactions and lack of regioselectivity in the cycloadditions (Scheme 1.22).57  
Scheme 1.22 
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Díaz and co-workers used a variation of these methodologies and were able 
to control the regiochemistry by introducing a chlorine substituent near the triple 
bond in 97 that could influence the inductive and/or steric effects of the reactions.57 
These halide directing group substituents, which were relatively easy to introduce 
by using pyridine precursor 96, would cause the desired effect, and are easy to 
remove after the cycloaddition, forming the same compounds ellipticine 93 and 
isoellipticine 100 as described by Gribble and Moody (Scheme 1.23). Though the 
factors affecting the regioselectivity of the cycloadditions are not well understood, 
using Moody’s indolopyrone 95, protecting the nitrogen and having the 2-chloro 
substituent in the 3,4-pyridyne 97 improved the regioselectively and the overall 
yield of the reaction. 
Scheme 1.23 
Carroll and co-workers used the trapping of 2,3-pyridyne 84 generated 
from 101 with N-protected pyrrole 102 as a key step in the synthesis of a range of 
epibatidine analogues. The initial cycloadduct 103 is reduced and deprotected to 
form 104 and 105 (Scheme 1.24).85 Epibatidine 106 is a toxic alkaloid secreted by 
poisonous frogs found in Ecuador. Initially, it was thought that it could be useful 
as an analgesic drug but as of yet there have been no successful attempts in the 








































1.2.4 Generation of ortho-arynes 
Even at low temperatures, arynes such as benzyne 33 are highly unstable 
reactive intermediates and must be generated in situ. Traditionally arynes were 
generated using harsh reaction conditions such as: fragmentation of aminotriazoles 
107 using lead tetraacetate 108, loss of carbon dioxide and nitrogen from the 
zwitterion of diazotised anthranilic acid 32 and 1,2-elimination from 66 using 
strong bases.49 However, mild methods of generation, such as fluoride induced 
desilylation of 38 have been reported in recent years and is currently one of the 
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Mild generation methodologies have renewed the attractiveness of arynes 
as reagents in organic synthesis and a number of aryne precursors are also now 
commercially available. It is important to note that some routes have been shown 
to sometimes affect the reactivity of the intermediate, where a reaction does not 
proceed using one approach over another.33,35  
The attractiveness of arynes as reagents in organic synthesis was 
revolutionised in 1983, when a route for fluoride-ion induced aryne formation was 
designed.91 Treatment of 2-trialkylsilylaryl triflates with a fluoride ion source is 
the most frequently reported method used for aryne generation in the literature 
today. In Scheme 1.26, a fluoride ion displaces a trimethylsilyl group from 38, 
forming the benzyne 33 as the triflate leaving group is lost.  Common fluoride ion 
sources are tetra-n-butyl-ammonium fluoride (TBAF) in THF or caesium fluoride 
in acetonitrile. Advantages of this method of aryne formation include the ease of 
handling of the reagents, commercial availability of precursors, it is very mild in 
comparison to some of the methods previously outlined above in which harsh 
conditions are employed and the rate of aryne production using a fluoride source 







Scheme 1.26  
Recent research into altering the triflate group was undertaken to create a 
range of aryne precursors with excellent results. In 2011, Akai and co-workers 
described a novel preparation of benzyne 33 from 2-trimethylsilylphenol 109 by a 
process that uses the nonafluorobutanesulfonyl fluoride (the nonaflyl group is a 
C4 triflyl homologue) to prepare a 2-trimethylsilylphenylnonaflate derivative 
110.92 This method is more beneficial than using the triflating reagents (which are 
more unstable and expensive); and it is also attractive from the viewpoint of atom 
economy because of its dual reactivity used to nonaflate the hydroxyl group and 
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subsequently as a fluoride ion carrier for the desilylation and aryne formation. This 
method does not require the isolation of the unstable 2-trimethylsilylarylnonaflate 
intermediate 110 (Scheme 1.27).92,93  
 
Scheme 1.27 
Chen and co-workers developed a similar class of aryne precursors where 
a sulfonyl fluoride group is used as a triflate alternative.93 Sulfuryl fluoride is a 
cheap starting material and in the presence of triethylamine, can convert 2-
trimethylsilylphenols 109 into aryne precursors 111 that have been successfully 
applied to a range of aryne-trapping reactions. The authors demonstrated that the 




Yoshida and co-workers concurrently reported the preparation of arynes 
from 2-trimethylsilylaryltriflates by caesium carbonate activation in the presence 
of a crown ether, negating the requirement for a fluoride source.88  
More recently, benzynes have been generated by cycloisomerization of 
triyne precursors, opening up even more opportunities in aryne chemistry.94 
Benzyne 33 was first suggested as an intermediate in a cycloaddition reaction 
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when benzene was isolated after the pyrolysis of ethyne 68 in 1967.95 This was 
suggested to proceed via a cycloaddition reaction of ethyne 68 and butadiyne 113 







This route was reported as a viable route to arynes independently by both 
Miyawaki96 and Bradley97 in 1997 but it was not seen as a useful method of aryne 
generation and remained unexploited until Yun98 and Hoye99 demonstrated the 
broad scope of the reaction in recent years. This transformation was termed a 
hexadehydro-Diels-Alder (HDDA) by Hoye and involves inter- or intramolecular 
cycloaddition of triynes (which are easily accessed), mild and versatile reaction 
conditions and it is an efficient and novel approach to ortho-arynes. The most 
likely mechanism of the simple cycloaddition of 1,3,8-nonatriyne is a [4+2] 
cycloaddition to form the cumulene aryne, followed by a reduction under pyrolytic 
conditions, supported by deuterium labelling studies that ruled out a possible 
Bergman cyclisation pathway.94,95 The HDDA reaction is a unique approach to 
ortho-arynes and diverse functional groups present in the starting material are 
preserved in the product, allowing strategic design and synthesis of complex 
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1.2.5 Reactions of arynes 
Arynes participate in a wide range of reactions with the three main 
categories being: 1) Pericyclic reactions of arynes; 2) nucleophilic additions to 
arynes and 3) transition metal-catalysed reactions of arynes. Examples from each 
category are discussed below. 
1.2.5.1 Pericyclic reactions of arynes 
Arynes readily partake in pericyclic reactions due to their electrophilic 
character, as long as they are generated in the absence of competing nucleophilic 
reactants. Some reactions of this type are described herein. 
Diels-Alder cycloaddition reaction 
Since Wittig reported trapping benzyne 33 with furan in 1955,45 the Diels 
Alder reaction has become one of the most important reactions of arynes and is 
used both as an aryne detection method and in synthetic applications.50 Because 
of the highly electrophilic character of arynes, they readily undergo reactions with 
a wide range of diene partners such as cyclic dienes and heterodienes (Scheme 
1.31). Reactions with functionalised acyclic dienes are less common due to 
competing [2+2] cycloaddition and ene reaction pathways. Aromatic five-
membered heterocycles 114 react efficiently with arynes 33 to furnish the [4+2] 
cycloadducts 115. The cycloadducts of furan and its derivatives are useful 
intermediates in the synthesis of naphthalenes as the endoxide bridge readily 





The Diels-Alder reaction of arynes and cyclopentadiene 117, remains the 
only direct approach to 5-haloderivatives of 1,4-dihydro-1,4-methano-
naphthalenes. The original approach used to access these important 
pharmaceutical intermediates  involved the zwitterion of diazotised anthranilic 
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acid derived benzyne generation route over three steps in poor yield.101 In search 
of a more controlled, scalable and direct synthesis towards these compounds, Coe 
and co-workers used trihalobenzenes 116 under halogen-magnesium conditions as 
aryne precursors with cyclopentadiene 117 derivatives and observed mixed 
fluoride 118 and iodide 119 products (Scheme 1.32).102 The formation of the 







Coe also revealed that when n-BuLi is used instead of magnesium and by 
altering the reaction solvent, they were able to control product formation (Table 
1.1). The authors concluded that solvent association with intermediates and the 
departing lithium halide affected the reaction course. This cycloaddition reaction 
methodology allowed for a straightforward preparation of 1,4-methano-1,4-
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[2+2] Cycloaddition reactions 
The [2+2] cycloadditions of arynes with alkenes are seen as an efficient 
route to benzocyclobutenes, a unique class of reactive molecules.103 The 
thermodynamic stability of the aromatic system and the kinetic reactivity of the 
strained cyclobutene ring give rise to these polycyclic compounds having unique 
reactivity, such as isomerisation to ortho-xylylenes, which can be used as building 
blocks in the synthesis of natural products, new polymers and advanced 
materials.104 
In a synthesis described by Tsujiyama and co-workers, treatment of ortho-
iodoaryl triflate 123 with n-BuLi at -78 ºC rapidly generates an aryne which 
undergoes a [2+2]-cycloaddition with ketene silyl acetal 124 yielding the 
corresponding cycloadduct 125.86 Desilylation with hydrofluoric acid affords 
benzocyclobutenone 126 in high yields (Scheme 1.33). The methodology has 





[3+2] Cycloaddition reactions  
A range of 1,3-dipole compounds undergo cycloadditions with arynes. 
Diazo, azide, nitrone, sydnone and azomethine imine are among the most intensely 
investigated substrates.34,35,59,87 The azide dipole in particular is used in trapping 
reactions of arynes, as well as a route towards benzotriazole 
synthesis.34,35,59,87,105-108 
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Li and co-workers developed a one-pot procedure for the synthesis of 
functionalized dihydrobenzisoxazoles 131 from arynes and nitrones without the 
need to isolate the nitrone dipole.106 Using substituted hydroxylamines 128 and 
alkynyldicarboxylates 127, a nitrone 130 is generated and undergoes a [3+2]-
cycloaddition with the benzyne 33 via generation of both reactive intermediates in 
situ from 129 and 38 respectively (Scheme 1.34). 
 
Scheme 1.34 
Larock and co-workers have reported frequently on dipolar cycloaddition 
reactions involving arynes. In 2012, the group published a review on the use of 
arynes in heterocycle synthesis that included considerable work carried out in their 
laboratories over the last decade.58 Some examples are outlined in Scheme 1.35. 
The reaction of benzyne 33 and azides 132 give rise to benzotriazoles 133 
in good to excellent yields.109 Benzisoxalzoles 135 are prepared from reaction with 
nitrile oxides, generated from dehydrohalogenation of chlorooximes 134 by 
caesium fluoride.110 The reaction with tosylate-stabilised pyridinium imides 136 
proceeds to form pyrido[1,2-b]indazoles 137 in good yields and tolerates a variety 
of functional groups.111 Indoles 139 are prepared in a two-step process whereby 
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N-tosylhydrazones 138 are arylated by an aryne, followed by acid-catalysed 
























R= Ar, HetAr, alkyl,










R1,R2 = alkyl, aryl
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1.2.5.2 Nucleophilic additions to arynes 
Arynes are strong electrophiles due to their low-lying unoccupied 
molecular orbitals (LUMO) and even neutral nucleophiles readily react with 
arynes whereas no reaction would occur with alkynes. Nucleophilic addition leads 
to formation of an aryl carbocation or zwitterion which can then be trapped with 
an electrophile or proton. Herein, an example of each, neutral and anionic 
nucleophilic additions to arynes, will be discussed. 
Neutral nucleophiles 
The reaction of arynes with amines provides a convenient route to 
alkylated anilines and intramolecular nucleophilic addition of amines to arynes 
can be used to access alkaloid derivatives. Rather than the formation of an aniline 
derivative, Yoshida and co-workers reported the preparation of anthranilic acid 
derivatives 141 of great synthetic value via incorporation of a dialkylamine and 
carbon dioxide into an aryne to form intermediate 140 in a three-component 
coupling reaction.89 These reactions occurred with nucleophilic attack of 
dipropylamine on benzyne 33 generated from 38 with a fluoride source in THF 
under a carbon dioxide atmosphere at 0 ºC (Scheme 1.36). 
Scheme 1.36 
Anionic nucleophiles 
The nucleophilic addition of fluoride ions to substituted benzynes under 
mild conditions is an important approach to the synthesis of biologically active 
fluorinated aromatic scaffolds. In a recent publication by Ikawa and co-workers, 
the authors report that the nucleophilic fluorination of benzynes occurs in one-pot 
by the successive nonaflation of 2-trialkylsilylphenol 142, benzyne generation and 
subsequent nucleophilic fluorination to form 143 (Scheme 1.37).112  







1.2.5.3 Transition metal-catalysed reactions of arynes 
In 1998, Guitián and co-workers reported that palladium(0) complexes can 
catalyse the cyclotrimerization of benzyne, generated from 38, to provide 






Since then, the scope of the reaction has expanded to polycyclic aryne 
compounds in the formation of large polycyclic aromatic hydrocarbons in an effort 
to prepare and study applications of graphene-like materials like starphenes 144 








Figure 1.9 Benzyne-derived polycyclic aromatic hydrocarbons  
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Chen and co-workers reported a mild and general approach to triphenylene  
derivatives 50 recently under mild conditions that were not air or moisture 
sensitive.115 The desired products can be prepared in good yields using PPh3AuCl 
as an efficient catalyst for the cyclotrimerization of arynes. The authors proposed 
a plausible mechanism which is similar to Pd(0)-catalysed cyclotrimerisation. 
Benzyne 33 formed from 38 interacts with PPh3Au+ 146, which is postulated to be 
formed in the presence of caesium fluoride, to form complex 147. 
Cyclometallation with another molecule of 147 provides intermediate 148 
followed by another benzyne insertion to produce 149 which eliminates PPh3Au+ 










1.3.1 Characterisation and background 
Indazole is a bicyclic ten π-electron heteroaromatic compound containing 
two adjacent nitrogen atoms. As a member of the azole family, it can be thought 
of as a pyrazole and benzene ring fused together. Alternative names such as 
benzo[c]pyrazole, 1,2-benzodiazole and isoindazone are rarely used. The “1H” 
indicates the nitrogen with the hydrogen and the structure is numbered around the 






Figure 1.10 1H-Indazole numbering convention 
 The 1H-indazole 150 has two other potential tautomers, however, these 
only exist in substituted derivatives; the prototropic annular quinonoid 2H-
indazole 151 and the benzenoid 3H-indazole 152 (Figure 1.11). The 1H-indazole 
150 is 2.3 kcal.mol-1 more stable than the 2H-indazole 151 and is the predominant 
form in both solid and gaseous states. 3H-Indazoles 152 lack heteroaromatic 





Figure 1.11 Indazole tautomer forms 
The first reported indazole preparations were in the 1880s by Fischer and 
Kuzel.121 On replicating the conditions to obtain indazolone 154 from 2-hydrazine 
benzoic acid 153, heating 2-hydrazinocinnamic acid 155 provided low yields of 
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indazole 156 among other products (Scheme 1.40). Von Auwers carried out 
investigations on the indazole nucleus in the 1920s which provided the initial 









Considerable interest has been directed towards indazole derivatives in the 
last few decades, due to the broad variety of biological activities associated with 
them, which has led to the development of a number of new syntheses.124,125 In 
comparison to indole and benzimidazole derivatives, however, indazole 
heterocycles remain poorly studied.  
1.3.2 Naturally occuring indazole compounds 
Natural products containing the indazole moiety are rare with only eight 
examples currently known, four of which were isolated in the past two years 
(Figure 1.12): nigellicine 157,126 nigellidine 158127,128 and derivatives 159 and 160 
from Nigella sativa (found in black cumin); nigeglanine 161,126,128 nigeglaquine 
162, nigeglipine 163 and methyl-derivative 164 from Nigella glandulifera.126,128 
The zwitterionic heterocyclic system represents an interesting class of pseudo-
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Figure 1.12 Indazole natural products   
Nigellidine derivatives 158 and 159, and nigeglanine 161 can also be 
represented by neutral canonical structures, setting them apart from classical 
mesomeric betaines (Figure 1.13).120 Glycosylated and sulfated alkaloids are very 
uncommon in natural products. The plants from which the indazoles are isolated 
have been used in Middle-Eastern traditional medicine for centuries and some of 
the isolated derivatives are now undergoing biological testing.129  
 
Figure 1.13 Resonance forms with neutral structure             
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1.3.3 Synthesis of 1H-indazoles 
Synthetic routes towards the synthesis of the indazole nucleus are desirable 
as they have been shown to be an effective pharmacophore in medicinal chemistry. 
There are two principal synthetically useful routes whereby indazoles are 
accessed. The first route involves ring-closure reactions of a range of possible 
indazole fragments.125 Some of the more common routes are discussed below. The 
second route is by ring transformation, forming indazoles by rearrangement, 
insertion or extrusion reactions.125 Indazoles with substituents that are difficult to 
obtain or could not be obtained by ring-closure routes can be accessed via this 
route. Usually, harsh reaction conditions are involved in these syntheses with the 
use of strong acids or high temperatures.125 
 
1.3.3.1 Ring closure reactions 
One of the the most common approaches used today for the synthesis of 
indazoles involves the diazotisation of 2-aminotoluenes followed by spontaneous 
cyclisation of an N-nitroso intermediate.125 These reactions are often limited to 
indazoles bearing an electron-withdrawing substitutent. The Jacobson 
modification introduces an acetylation step that provides 1-acetyl indazoles which 
can be deacetylated to form 1H-indazoles 168 avoiding the necessity of an 
electron-withdrawing group.130 
Schumann and co-workers reported using the Jacobson ring closure 
reaction with a range of substituted 2-aminotoluenes 165.131 The authors found 
that using a phase transfer catalyst to form a 2-methylbenzendiazonium 
tetrafluoroborate salt 166 (Method 1) operated best for most substituents but 
cyclisation of N-nitroso derivatives 167 (Method 2) was found to be more 











Another attractive route to indazoles is from the reaction of hydrazines 
with 1,2-disubstituted arenes.125 One substituent is often a carbonyl group and the 
other is usually a good leaving group. The intermediate benzoyl hydrazine or 
arylhydrazine cyclises to form the indazole.   
A modification involving cyclohexanones and hydrazines to form 
tetrahydroindazoles is also available.124 Nakhai and Bergman have recently 
reported a route towards tetrahydroindazoles 170 from α-β-unsaturated ketone 169 
and methylhydrazine which could be aromatised using DDQ in excellent yields to 
form 1H-indazoles 171 (Scheme 1.42).132 
 
Scheme 1.42 
An interesting approach to 1H-indazoles is the [3+2]-cycloaddition 
reaction of arynes and diazo 1,3-dipole derivatives. Notably, the Larock research 
group have developed efficient methods for the synthesis of both 1H- and 2H-
indazole compounds using diazo and sydnone 1,3-dipoles, respectively (Scheme 
1.43). The initial 3,3-disubstituted cycloadduct from the reaction with arynes 33 
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generated from 2-trimethylsilylaryltriflates 38 and the diazo compound 172 
undergoes acyl migration to form 1H-indazole product 174.35 The initial 
cycloadduct from reaction with N-phenyl-sydnone 173 readily undergoes 
spontaneous extrusion of a molecule of carbon dioxide in a retro-[4 + 2] fashion 




 The van Alphen-Hüttel rearrangement is the expansion of 
diazocyclopentadienes on addition of alkynes with electron-withdrawing 
groups.133 Mataka et al. investigated the reaction of diazoindenothiophenes 176 
and dimethyl acetylenedicaboxylate 127. The initial unstable spiro compound 177 
formed readily rearranges to the isomer 178 at room temperature and acid 





































1H-Indazoles can be prepared from isatins (1H-indole-2,3-diones) 180 by 
the Schad 3-carboxyindazole synthesis, a commonly used synthetic route to 
indazoles in industrial preparations.135 Johnson and Rodgers reported an approach 
to principal intermediates in HIV protease inhibitor synthesis using this 
methodology with a slight modification (Scheme 1.45).136 Alkaline ring-opening 
of 180 followed by diazotisation forms 181. Reduction by addition of the solution 
to tin(II) chloride provides 185 which is cyclised to 186 and subsequent 
dehydration provides the desired product 187 in reproducible and high yields. It 
was necessary to invert the key reduction step by adding the diazonium solution 
slowly to the tin chloride mixture to suppress the formation of the by-product 184 

















   Chapter 1: Introduction 
45 
 
1.3.4 Biological importance of indazole compounds 
Interest in indazole compounds has greatly increased in recent years due to 
a number of derivatives linked to a broad variety of activities. As well as 
pharmaceutical applications, the heterocyclic moiety is present in herbicides,137 
dyes138 and sweeteners.139 In a 2012 review, Thangadurai et al.140 documented the 
range of pharmacological activities of indazoles which include anti-inflammatory, 
anti-microbial, anti-HIV and anti-cancer effects.  
Examples of anti-inflammatory drug compounds containing the indazole-
scaffold currently on the market include bendazac 188 and benzydamine 189 
(Figure 1.14).   
 
Figure 1.14 Indazoles with anti-inflammatory properties 
Bendazac 188 is an oxyacetic acid and is marketed as its lysine salt for 
improved oral absorption.141 It is an NSAID used topically in the treatment of joint 
and muscular pain and has also shown a beneficial effect in managing cataracts. 
In Ireland, benzydamine 189 is marketed as Difflam™ in its hydrochloride salt 
form. It is also an NSAID, acting via inhibition of the COX enzymes.142 It 
possesses local anaesthetic and analgesic properties and is mostly used in 
treatment of mouth and throat inflammation.143  Bindarit 190 has been investigated 
in multiple animal models of human disease and in human clinical trials to 
examine its potential as a therapeutic agent for a variety of inflammatory 
conditions such as arthritis, pancreatitis and diabetic nephropathy.144-146 
Encouraging results in all cases strongly support the development of Bindarit 190 
as a potential therapeutically available agent.  
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Some indazole derivatives currently used therapeutically in cancer 
chemotherapy are shown in Figure 1.15. Indazolium trans-[tetrachlorobis-(1H-
indazole)] ruthenate (III) 191 has a selective effect on solid metastasising tumours 
of the lung and is only the second ruthenium-based anti-cancer drug to reach 
clinical trial stages. The ruthenium species is thought to bind with transferrin and 
enter the cell using the transferrin receptor, targeting tumour cells which 
overexpress the transferrin receptor.  It is reduced in the cell to the activated 
ruthenium (II) species, where it binds to DNA and induces apoptosis at a non-toxic 
level. Phase 1 clinical trials resulted in no serious side-effects experienced with 
disease stabilisation in five out of six cases and phase 2 clinical trials are in 
progress.147 
Lonidamine 192 is an anti-cancer drug in its own right that impressively 
also increases the effectiveness of several experimental multiple chemotherapy 
protocols without increasing toxicity. It has an interesting mechanism of action 
whereby it interferes with energy metabolism of tumour cells.148-150 
Pazopanib 193 is a tyrosine kinase inhibitor that blocks tumour growth and 
inhibits angiogenesis. It is approved for renal cancer treatment and has also 
demonstrated efficacy in patients with ovarian and non-small cell lung cancer. 




Figure 1.15 Indazole-containing drugs used in cancer chemotherapy 
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Gamendazole 195 and Adjudin 197 (Figure 1.16) are analogues of 
Lonidamine 192 that have shown potential to be developed as a non-hormonal 
male oral contraceptives due to potent anti-spermatogenic activity, with little 
associated toxicity and fertility recovery following withdrawal of the drug.154-157 
H2-Gamendazole 196 (Figure 1.16) is a derivative identified as being closest to 
human clinical trials, displaying 100% oral bioavailability, 100% infertility 
followed by 100% recovery of fertility in rats and similar results in non-human 
primate studies.158-160  
 
Figure 1.16 Gamendazole, H2-Gamendazole and Adjudin 
A number of synthetic cannabinoid (SC) receptor agonists (a rapidly 
growing class of recreational psychoactive designer drugs) contain the indazole 
scaffold. These illicit drugs are being detected and identified increasingly by both 
forensic researchers and law enforcement.161,162 Most of these novel indazoles had 
no precedent in scientific literature before their identification as designer drugs, 
although AB- and ADB-FUBINACA 198 and 199, and 5F-AB- and AB-PINACA 
200 and 201 were originally developed by Pfizer as analgesic agents, acting as 
potent agonists for the CB1 and CB2 receptors.163 5F-CUMYL-PINACA 202 is a 
derivative of 5F-AB-PINACA where the 1-amino-3-methyl-1-oxobutanyl group 
is replaced with a cumyl group. No official studies have been conducted on the 
physiological or toxicological effects of SCs in humans but reports have been 
published describing the effects seen in patients seeking medical care after taking 
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 Some of the interesting reactivity of diazo and aryne derivatives has been 
described herein. Well-established synthetic routes to diazo compounds allows the 
facile preparation of a versatile range of diazo compounds which can be employed 
as 1,3-dipoles in cycloaddition reactions. Methods for the mild generation of aryne 
intermediates, as well as the commercial availability of inexpensive precursors, 
has placed arynes into an important role in organic synthesis.  
An appealing synthetic application that utilises both reactive intermediates 
is in the formation of novel indazole compounds. Methods that construct the 
indazole nucleus in a mild manner compared to current common procedures are 
extremely desirable. Although indazole natural products are rare they have a 
disproportionate number of biologically active compounds exhibiting ability 
across many pharmaceutical applications without the expected associated toxicity. 
Of particular note is the large number of biologically active indazole compounds 
observed that contain benzyl groups and/or fluorine substituents. 
The utilisation and modification of established procedures for [3+2]-
cycloaddition reactions of aryne intermediates, generated from easily accessible 
precursors, and a range of diazocarbonyl 1,3-dipole analogues proved very 
appealing in the synthesis of novel indazole derivatives. Evaluation of novel 
indazole compounds for biological activity with well-known research agencies is 
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2.1 Introduction  
2.1.1 Aims and Objectives 
A number of projects within the research group are based around chemical 
transformations of diazo dicarbonyl derivatives, usually initiated by loss of 
nitrogen through transition metal catalysis, photolysis or heat, to generate a highly 
reactive carbene-type intermediate that allows them to participate in a variety of 
reaction pathways. This project is designed and aimed towards incorporating the 
diazo functionality into indazole products by using the diazo group as a 1,3-dipole 
and aryne dipolarophiles as reactive intermediates, via their subsequent  
cycloaddition reactions (Scheme 2.1).  
 
Scheme 2.1 
A search of the literature revealed that reactions between diazo compounds 
and arynes had been reported in 1961, but that process employed an explosive 
benzyne precursor, benzenediazonium 2-carboxylate,1 and the only example 
reported did not quote a yield.2 Research into this area has developed due to the 
commercial availability of aryne precursors, and in recent years more examples of 
1,3-dipolar cycloaddition reactions of diazo compounds and arynes have been 
reported.2-5 The initial aim of this work was to utilise the established method 
published by Jin and Yamamoto4 and Larock,5 using 2-trimethylsilylphenyltriflate 
derivatives and caesium fluoride to generate arynes in situ, which would undergo 
cycloaddition reactions as dipolarophiles with diazo dicarbonyl derivatives (as the 
1,3-dipole) to form indazole intermediates. Using this methodology, it was 
envisioned that a range of novel indazoles could be synthesised and easily 
diversified by altering the diazo or aryne starting materials. 




 Another aim of the project was to establish a general, mild method for N-
deacylation of N-acyl indazoles. This could allow the synthesis of a number of 
novel indazoles with the potential for derivatisation at the N-1 position. One of the 
main derivatisation reactions of interest was benzylation of the 1H-indazoles 
which would give rise to the formation of both N-1- and N-2-benzylated isomers.   
 Initial investigations into side chain transformations such as epoxidation, 
oxidative cleavage and reductive amination were to be conducted on the 
functionalisable, alkene-containing ester group of some indazole derivatives.  
 Due to the presence of the indazole core structure in many pharmaceutical 
compounds, novel indazole compounds would be sent to the National Cancer 
Institute (NCI) and the Community for Open Antimicrobial Drug Discovery (CO-


















2.2 Synthesis of α-diazocarbonyl compounds 
 As a prerequisite for the indazole-forming cycloaddition reactions, a 
number of diazo compounds were required. Initially, commercially available β-
ketoesters would be used to provide the α-diazo-β-ketoester derivatives. A method 
to prepare a wider range of β-ketoester derivatives, that were either not available 
commercially or prohibitively expensive, was required. Subsequent diazo transfer 
would give a broader variety of novel α-diazo-β-ketoesters starting materials for 
use in this project. The synthesis of α-diazo-β-diketone and α-diazo-β-ketoamide 
derivatives from commercially available starting materials would also provide a 
broad range of substrates to be used as 1,3-dipole compounds in the cycloaddition 
reactions. 
 
2.2.1 Preparation of ester derivatives by transesterification  
The method chosen for the formation of the β-ketoester derivatives was a 
transesterification reaction optimised within the group following a publication by 
Tale and co-workers that reported successful transesterification of a wide range of 
esters with various alcohols.6 The reaction is catalysed by 3-nitrophenylboronic 
acid 1, which is both an efficient and environmentally friendly catalyst. It is easy 
to handle, exhibits low toxicity and is highly stable, ultimately oxidising slowly to 
boric acid. 
 The standard procedure for the reaction involves heating the ester and 
desired alcohol in the presence of 2.5 mol% 3-nitrophenylboronic acid 1 in toluene 
under reflux. The toluene-alcohol azeotrope is continuously removed from the 
reaction mixture using a Dean-Stark condenser ensuring reaction completion. The 










A mechanism for the reaction was proposed by Kondaiah as illustrated in 
Scheme 2.3. 7 It is believed that the boronic acid catalyses the enolisation of the 
β-ketoester to form intermediate A, which through the loss of R1OH is converted 
to cyclic intermediate B. Subsequent nucleophilic ring-opening by the alcohol 
would give the desired ester product along with regeneration of the catalyst.  
 
 
Scheme 2.3  
This methodology was utilised as an efficient route for the synthesis of a 
variety of β-ketoester precursors required for this research. The reaction progress 
was monitored by TLC analysis and it was found that in general a reaction time of 
5 h gave complete conversion to the desired β-ketoester products. A range of 
structurally diverse β-ketoesters were synthesised as shown in Figure 2.1, which 
allowed access to a series of non-commercially available esters to use as 
diazocarbonyl precursors.  These esters were chosen for their side chain 




































Figure 2.1 Summary of β-ketoesters synthesised by transesterification 
 The 1H NMR spectra of the crude β-ketoesters 2, 3, 5, 6, 10 and 11 obtained 
after transesterification showed the compounds in high purity, with no further 
purification required. However, β-ketoesters 4 and 7-9 required purification by 
column chromatography on silica gel. All β-ketoesters were obtained as oils, 
which were stable in storage over a period of many months at room temperature 
without noticeable deterioration.  




All ester derivatives were obtained in moderate to good yields, especially 
where the crude product was pure by 1H NMR analysis, with slight reductions in 
yield for those requiring further purification by column chromatography on silica 
gel.    
The most characteristic signal in the 1H NMR spectra of the β-ketoesters 
is the 2H singlet in the region of δH 3.34-3.49 ppm, assigned to the methylene 
protons between the ester and the ketone. Characteristic absorption bands in the 
IR spectra for these β-ketoesters were seen at max 1734-1750 cm-1 (carbonyl 
stretch of esters) and max 1716-1720 cm-1 (carbonyl stretch of ketones).  
 Interestingly, most of the β-ketoester derivatives exhibited keto-enol 
tautomerisation which was visible in the 13C NMR spectra but not the 1H NMR 
spectra. Longer ester side chain derivatives had very visible enol tautomer peaks, 
while they were a lot less visible for the shorter chain ester derivatives. The more 
substituted enol is present in all cases as it is stabilised by the ester carbonyl 




The enol-form 12 was characterised by the enolic CH and COH signals in 
the regions of δC 89.3-90.1 and 175.2-175.4 ppm respectively and also the ester 
carbonyl signal from 172.4-172.8 ppm in the 13C NMR spectrum.  
This transesterification methodology proved to be a very efficient and high 
yielding route to diverse β-ketoester derivatives and also provided novel derivative 
9. 3-Nitrophenylboronic acid is an inexpensive, mild and environmentally friendly 
and catalyst which is desirable in the move towards greener organic synthesis. The 
ease of preparation of the β-ketoester products would subsequently lead to a 




number of diverse α-diazo-β-ketoester derivatives to be used as 1,3-dipoles in 
indazole synthesis. 
 
2.2.2 Synthesis of p-toluenesulfonyl azide 14 
Diazo transfer to compounds containing reactive methylene groups such 
as β-ketoesters, β-diketones, β-ketophosphonates and β-ketosulfones is readily 
achieved using the Regitz8,9 methodology for diazo transfer. This involves initial 
deprotonation of the α-hydrogen using a base of sufficient strength (e.g. 
triethylamine) followed by addition of the diazo transfer reagent. Diazo transfer 
reagents have been reviewed,10,11 most notably a review of their utility, safety and 
stability carried out by Bollinger and co-workers.12,13 
p-Toluenesulfonyl azide (tosyl azide) 13 is the most commonly used diazo 
transfer reagent and was chosen as a key reagent for this research. Previous work 
within the group have also found this to be the most consistent and high yielding 
diazo transfer reagent available. It was prepared following a literature procedure 







 Tosyl azide 13 is an extremely dangerous transfer reagent. Care must be 
taken when handling it and it should never be scraped out of its container because 
of its high impact sensitivity (50 kg.cm). The tosyl azide prepared during the 
course of this research was stored in a glass jar in the freezer in an isolated 
container. It crystallises to a white solid on freezing and for safety reasons only 
one batch of the azide was prepared and used at any one time in the laboratory. 
When needed, the tosyl azide 13 was carefully melted by placing in a beaker 




containing luke warm water and the resulting clear oil was carefully removed from 
its container using a clean Pasteur pipette with no sharp edges. 
 
2.2.3 Diazo transfer reactions to β-ketoesters using Regitz methodology 
 The α-diazo-β-ketoesters synthesised in this research were prepared using 
Regitz methodology8,9,11,15 for diazo transfer. This involves the initial addition of 
triethylamine to the β-ketoester in acetonitrile followed by careful addition of tosyl 
azide. The side-product of the diazo transfer reaction is p-toluenesulfonamide 16. 
The standard reaction mechanism for Regitz diazo transfer is shown in Scheme 
2.6. This is the optimal method of diazo transfer established within the group for 
the preparation of α-diazo-β-ketoesters. 
 
Scheme 2.6 
 The reaction included room temperature addition of the tosyl azide 13 
which allows for a slight exothermic reaction, possibly facilitating faster diazo 
transfer from the azide to the β-ketoester 17. This diazo transfer could be seen 
visually by a rapid appearance of a yellow coloured solution, which is 
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After 18 h at room temperature the acetonitrile was removed under reduced 
pressure. The resulting cream residue was dissolved in diethyl ether and washed 
twice with 9% aq. potassium hydroxide and once with water and the desired 
diazocarbonyl product 18 was obtained as a bright yellow oil in 80% yield. The 
1H NMR spectrum showed the crude product with no p-toluenesulfonamide 
remaining. A range of α-diazo-β-ketoesters (22) required for this research were 
subsequently synthesised using this methodology.  
 
Outline of α-diazocarbonyl compounds synthesised 
The following is a brief summary of the wide range of α-diazo-β-ketoester 
compounds synthesised. The first series of α-diazocarbonyl compounds were 
synthesised from commercially available β-ketoesters and also provided 23 as a 
novel α-diazo-β-ketoester derivative. These were characterised by short ester side-
chains while maintaining the methyl ketone moiety as displayed in Figure 2.2. All 
the α-diazocarbonyl compounds were synthesised as bright yellow oils in excellent 
yields which were stable over prolonged periods of storage at room temperature. 
The yields shown in Figure 2.2 reflect the crude reaction material which was > 








   
Figure 2.2 Summary of initial α-diazo-β-ketoester compounds  
 The two most characteristic features in the 1H NMR spectra of the α-diazo-
β-ketoesters in Figure 2.2 are the disappearance of the 2H singlet in the region of 
δH 3.34-3.49 ppm assigned to the methylene protons between the ester and the 
ketone and the shift of the 3H singlet of the methyl ketone protons from δH 2.24-
2.27 ppm to δH 2.48-2.51 ppm. The α-diazo-β-ketoesters are also characterised by 
absorptions in the IR spectra at max 2136-2146 cm-1 (C=N2 stretch) due to 
extended conjugation involving the diazo group and carbonyl bonds. In the 13C 
NMR spectra the ketone group was seen to shift from the region of δC 200 ppm to 
δH 188.4-190.4 ppm. In all cases the quaternary carbon belonging to the C=N2 
group could not be observed in the 13C NMR spectra.  
Following on from these compounds diazo transfer was next achieved for 
a range of β-ketoesters prepared via transesterification as described in Section 
2.2.1, with the exception of 26 which was prepared from commercially available 
starting material. This series contained products with both increased ester side-
chain lengths 28-30 and 32 and functionalities (alkene groups, additional ester 




groups) 25-27 and 31 as illustrated in Figure 2.3, and included 5 novel derivatives 














Figure 2.3 Summary of series of alternative ester side-chain derivatives  
The yields of 29, 30 and 32 in Figure 2.3 reflect the crude reaction material 
which was pure by 1H NMR spectroscopy and the diazocarbonyl compounds could 
be used without further purification. In the cases of 25-28 and 31, further 
purification by column chromatography on silica gel was required. As with the 
compounds synthesised in Figure 2.2, the disappearance of the 2H singlet 
appearing at δH 3.34-3.49 ppm in the 1H NMR spectra as well as the shift in the 

















































aYield refers to product after purification by column chromatography on silica gel.




2.47-2.48 ppm were significant. The quaternary diazo carbon (C=N2) was not 
visible in any of the 13C NMR spectra.  
The final series of α-diazocarbonyl compounds synthesised (Figure 2.4) 
had a variety of ketone side-chains with longer aliphatic chains and aryl ketones. 
35-37 were prepared from β-ketoesters 7-9 via transesterification, while 33, 34, 38 
and 39 were prepared using commercially available starting materials. These 
compounds had similar stability to the previous diazocarbonyl derivatives 
synthesised and no noticeable deterioration was observed following prolonged 
periods of storage at room temperature. The yields reflect the crude products 
obtained with the exception of 35, 36 and 37 which required purification by 
column chromatography on silica gel due to the presence of unreacted starting 
















Figure 2.4 Summary of lengthened ketone side-chain α-diazo-β-ketoester 
derivatives 




 Evidence for diazo transfer was again characterised by the disappearance 
of the 2H singlet belonging to the methylene protons between the ester and the 
ketone in the range of δH 3.34-3.49 ppm. The methylene CH2 protons alpha to the 
ketone, in 33-37, appear as a triplet and shift up to the region of δH 2.81-2.85 ppm. 
The quaternary diazo carbon (C=N2) could be detected for three α-diazo-β-
ketoesters in this series (33, 35 and 39) in the 13C NMR spectra in the range δC 
60.9-75.8 ppm. 
 Overall, the range of α-diazo-β-ketoesters required for this research were 
successfully prepared using Regitz methodology for diazo transfer. The optimum 
conditions were found to be room temperature addition of the triethylamine 
followed by the tosyl azide 13. The p-toluenesulfonamide by-product, which can 
be problematic to remove from some diazocarbonyl products, was completely 
removed using a potassium hydroxide wash negating the need for purification by 
chromatography on silica gel in most cases. The only observed effect of increasing 
the alkyl side-chain length on the ketone moiety was the yield of these compounds 
were slightly lower.  
2.2.4 Diazo transfer reactions to β-diketones  
Following on from the successful synthesis of fifteen α-diazo-β-ketoesters, 
the substrate scope was broadened to include two α-diazo-β-diketones that would 
provide alternative 1,3-dipoles in the indazole-forming reactions. The α-diazo-β-
diketones synthesised in this research were prepared using Regitz methodology 
for diazo transfer.17,18  The only difference in reaction procedure in comparison to 
the α-diazo-β-ketoester derivatives is the use of dichloromethane as solvent in the 
preparation of 42. This allowed the reaction mixture to be worked up immediately 
using 9% potassium hydroxide (as the water miscible acetonitrile did not need to 
be removed first before the work-up is carried out using diethyl ether as in the α-
diazo-β-ketoester work-up procedure). The use of dichlormethane is a slight 
modification of literature procedures where good yields and fast reaction times are 
seen for this substrate in dichloromethane and where there is difficulty extracting 
the desired product with diethyl ether. 
 




Figure 2.5 Summary of α-diazo-β-diketone derivatives 
Acetylacetone 40 exists predominantly in the enol form and similarly, 1-
phenylbutane-1,3-dione 41 exists almost entirely in the enol form so the 
differences in the NMR spectra in comparison to the diazo product are evident. 
The most characteristic features in the 1H NMR spectra of the diazo-β-diketones 
in Figure 2.5 are that in the case of 42, the symmetrical product now shows only 
one signal in the 1H NMR spectrum for the methyl groups at δH  2.44 ppm while 
the methyl group is at δH 2.57 ppm for 43. In both cases the quaternary carbon 
belonging to the C=N2 group was observed in the 13C NMR spectra at δC 84.6 and 
83.7 ppm, respectively. Both derivatives show absorptions in the IR spectra at max 
2120 and 2130 cm-1 for the C=N2 stretch. Derivative 43 is the first solid diazo 
compound prepared so far and the melting point of 77-80 ºC obtained closely 
matches the literature value of 78-81 ºC,19 indicating high purity after work-up. 
Only two α-diazo-β-diketone substrates were used in this project so there is scope 









2.2.5 Diazo transfer reactions to β-ketoamides 
The preparation of α-diazo-β-ketoamides would provide additional, 
diverse 1,3-dipoles for the indazole-forming reactions. The α-diazo-β-ketoamides 
44-46 were prepared using the same method and workup used for the α-diazo-β-
ketoesters.20-22 More than one equivalent of base was employed for derivatives 47 
and 48, as there is more than one site of deprotonation, and the work-up involved 
the use of water and brine washes only with dichloromethane extraction. All α-
diazo-β-ketoamides required further purification by column chromatography on 
silica gel as the p-toluenesulfonamide 16 by-product was more difficult to separate 











Figure 2.6 Summary of α-diazo-β-ketoamide compounds synthesised 
 Evidence for diazo transfer was again characterised by the disappearance 
of the 2H singlet belonging to the methylene protons and the enol peaks in the case 
of 44 and 48. The quaternary diazo carbon (C=N2) could be detected for two α-
diazo-β-ketoamides in this series (45 and 46) in the 13C NMR spectra at δC 72.4 
and 73.5 ppm respectively. The derivatives show absorptions in the IR spectra in 




the range max 2106 to 2130 cm-1 for the C=N2 stretch and spectra in the range max 
1607 to 1676 cm-1 for the carbonyl of the amide. 
Overall, the α-diazo-β-ketoamide derivatives in Figure 2.6 were the most 
difficult to prepare and purify, however, five amide-containing substrates were 
successfully synthesised in sufficient yields, including one novel derivative 46.  
To summarise, the synthesis of 22 diazo dicarbonyl compounds in this 
section provides a diverse range of 1,3-dipoles for the cycloaddition reactions that 





















2.3 Synthesis of 2-trimethylsilyl aryl triflates/nonaflates as aryne 
precursors 
2.3.1 Synthesis of aryne precursors via triflation method 
To produce a range of structurally varied indazoles, the indazole core 
structure could be altered by synthesising substituted aryne precursors which 
would lead to different substitution patterns on the benzene ring fragment of the 
indazole ring. Treatment of commercially available o-silylaryl triflates 49 with a 
fluoride ion source (Scheme 2.8) is a commonly reported route to aryne generation 




The use of arynes as reagents in organic synthesis was revolutionised when 
this route for fluoride-ion-induced aryne formation was designed by Himeshima 
and co-workers in 1983. This method involved silylation of 2-chlorophenol 51 
using molten sodium and trimethylsilylchloride in refluxing toluene to form 52 
initially before treatment with n-butyllithium and triflic anhydride to form 49 in 
good yields (Scheme 2.9).29 The ease of preparation from phenol derivatives and 
the mild reaction conditions make this an attractive route for these derivatives to 
be used as aryne precursors in organic synthesis.  
 
Scheme 2.9  




Some difficulties encountered with these aryl triflates, however, is their 
low hydrolytic stability during chemical transformations and the triflating reagents 
used in their synthesis can be unstable and expensive.30 
An efficient, one-pot procedure for synthesising functionalised o-
(trialkylsilyl)aryl triflates for easy access to functionalised aryne precursors was  
published by Peña and co-workers in 2002.31 This was a modified version of 
Himeshima’s original version.  
Peña’s method involved silylation of 2-bromophenol 53 with 
hexamethyldisilazane (HMDS) in solvent-free conditions at 80 °C. The product of 
this step underwent lithium-halogen exchange in the presence of n-butyllithium at 
-100 °C, followed by silyl migration from oxygen to carbon in a Retro-Brook 










Scheme 2.10  
Temperature must be strictly controlled during these reactions as higher 
temperatures can favour nucleophilic attack by the base on the silicon atom of the 
(2-bromophenoxy)trimethylsilane compound 54 and also may promote 
polymerisation of tetrahydrofuran where triflic acid is present in trace amounts.  




 Another modification procedure put forward by Brimble and co-workers 
in 2010 uses 2-chlorophenols and eliminates the use organolithium reagents which 
could be useful for scaling-up the reaction (Scheme 2.11).32  
Scheme 2.11  
 The aryne precursor 49 is commercially available from a number of 
vendors at a reasonable cost but may alternatively be synthesised in a facile 
manner if required.33 
2.3.2 Bromination of phenol derivatives  
 For the synthesis of a range of substituted aryne precursors, the project 
required the preparation of the 2-bromophenol starting materials 60 and 62 as they 
were not commercially available. These were prepared using a well-established 
method where phenols are selectively ortho-halogenated using N-
halosuccinimides in polar solvents.34 Using NBS in acetonitrile at 0 ºC, multi-gram 
quantities of 60 and 62 could be prepared successfully from 59 and 61 respectively 







Scheme 2.12  




The 1H NMR spectra for compounds 60 and 62 are very straightforward 
with two aromatic CH singlet signals in the range between δH 6.59-7.18 ppm and 
broad OH signals at δH 5.23 ppm (62) and δH 5.28 ppm (60).  
A difficulty encountered in the preparation of 62 was that the reaction 
would not reach 100% conversion, even after attempting the reaction with up to 2 
equivalents of NBS and increasing reaction times. The 1H NMR spectrum showed 
the presence of up to 5% starting material after repeated column chromatography 
on silica gel.  
Other methods in the literature report using bromine35 or tetra-N-
butylammonium tribromide36 to give the desired product cleanly but it was 
decided to bring the 95% pure compound through to the next stages of the 
synthesis where the starting material could be removed.  
2.3.3 Silylation of ortho-bromophenol derivatives 
With these two bromophenol compounds 60 and 62 and four commercially 
available bromophenol derivatives in hand, the silylation step using HMDS could 
be explored. Using Peña’s modified procedure,31 the first step in aryne precursor 
generation was silylation of the 2-bromophenol derivatives using HMDS at 80 ºC 
to give the desired products in quantitative yield (Figure 2.7). (The only exception 
to this was the dimethyl derivative 66 which contained 5% starting material carried 
forward from the previous step). No solvent is required if the starting bromophenol 
is an oil, but for solid starting materials THF is used as solvent. 






Figure 2.7 2-Bromophenoxytrimethylsilane derivatives 
Derivative 63 can be used to synthesise the unsubstituted aryne precursor 
in lieu of purchasing expensive 2-trimethylsilylphenyltriflate 49 for the 
preparation of unsubstituted indazole derivatives.   
The two aryne precursor starting materials 64 and 65 were chosen as they 
would generate unsymmetrical arynes which could possibly lead to mixtures of 
regioisomeric indazoles. The substituent effects could also have an effect on the 
regiochemistry of the product. Comparison of the electron donating methyl group 
attached to 64 and electron withdrawing chlorine atom on 65 could show that these 
opposing substituent effects could influence the regiochemistry of the 
cycloaddition. 
Phenoxytrimethylsilane derivatives 63 and 66-68 were then chosen as 
symmetrical aryne intermediates would be formed. Many drug compounds on the 
market (e.g. Paroxetine 69 and Tadalafil 70, Figure 2.8) and other drugs exerting 
biological effects (e.g. MDMA 71, Figure 2.8) contain the methylenedioxy 
benzene moiety in 68. It was, therefore, of key importance to prepare indazole 




compounds with this structural feature to potentially provide favourable biological 
testing results, which will be discussed in Section 2.10.  
Figure 2.8 Drug compounds containing methylenedioxybenzene  
The most characteristic features for these compounds in the 1H NMR 
spectra is the disappearance of the OH signals and appearance of the trimethylsilyl 
signals between δH 0.23-0.37 ppm. In the 13C NMR spectrum, the signal for the 
trimethylsilyl group appears between δC 0.3-0.4 ppm.   
The 2-bromophenoxytrimethylsilane derivatives were unstable and 
converted back to the 2-bromophenol starting materials within a few days, 
therefore, were used almost immediately after 1H NMR analysis confirmed their 
formation. 
The project branched into two directions from here: the first followed the 
initial route to prepare aryltriflate derivatives in a one-pot, two-step reaction 
(Route 1); the second route involved preparation of trimethylsilylphenols which 
could be used to generate arylnonaflate derivatives (Route 2)37 (Scheme 2.13). 




Scheme 2.13 Routes 1 and 2 used to access arynes in this project 
2.3.4 Synthesis of aryne precursors via triflation method (Route 1) 
At the outset of this project, 2-trimethylsilylaryltriflate derivatives were 
synthesised as the reagents of choice for aryne generation. Before Route 2 was 
explored, three aryltriflate aryne precursors 73-75 were prepared using Peña’s 
methodology. The 2-bromotrimethylphenoxysilane derivatives 64, 65 and 68 are 
treated with n-butyllithium at -100 °C, followed by triflic anhydride. Quenching 
at low temperatures gives the crude triflate product which could then be isolated 








Figure 2.9 2-Trimethylsilylaryltriflate derivatives 
The most characteristic features for these compounds in the 1H NMR 
spectra is the slight downfield shift of the trimethylsilyl signals from between δH 




0.23-0.30 ppm when the TMS group is on oxygen to δH 0.33-0.37 ppm when it is 
on carbon. In the 13C NMR spectra, the signals for the trimethylsilyl group appears 
between δC -0.35-0.4 ppm and the CF3 signal of the triflate group appears between 
δC 116.3 and 117.6 ppm.  
2.3.5 Synthesis of aryne precursors via nonaflation methods (Route 2) 
Route 2 involves the use of a relatively new method which was published 
by Ikawa and co-workers in 2011 and replaces the trifyl group (–SO2CF3) with the 
C4 homologue nonafyl group (–SO2C4F9). This route does not require the isolation 
of the unstable 2-trimethylsilylarylnonaflate derivatives.  The isolation of the 2-
trimethylsilylphenol derivative 58, after the Retro-Brook rearrangement, using n-
butyllithium is required instead. Formation of 2-trimethylsilylarylnonaflate 
derivative 72, in a one-pot, domino reaction subsequently generates benzyne 50 in 







This method replaces the use of triflating reagents with nonafyl fluoride 
(perfluoro-1-butanesulfonyl fluoride or nonafluorobutanesulfonyl fluoride or NfF) 
as they are more expensive, less stable and have a lower atom economy than 
nonafyl fluoride. Nonafyl fluoride has a dual function as it is used to nonaflate the 
hydroxyl group and then as a fluoride ion carrier for desilylation and aryne 



































Figure 2.10 2-Trimethylsilylphenol derivatives 
Five 2-trimethylsilylphenol derivatives were prepared as illustrated in 
Figure 2.10. The most characteristic features for these compounds in the 1H NMR 
spectra is the trimethylsilyl signals between δH 0.30-0.36 ppm and the broad OH 
signals in the range δH 4.63-5.56 ppm. In the 13C NMR spectra, the signals for the 
trimethylsilyl group appears in the range δC -1.2-0.35 ppm. The derivatives show 
a broad absorption in the IR spectra in the range max 3521-3603 cm-1 for the OH 
stretch. As well as lithium-halogen exchange occurring in these reactions they can 
also undergo 1,2-elimination reactions of halides/hydrogens.  
The yields for 58, 76 and 79 are good, however, there is a considerable 
difference with the halide-containing derivatives. Most notable is the chloro-
derivative 77 with a poor yield of 12%, most likely due to the choice of 1,2-
elimination pathways it can undergo; however, the yield obtained is an almost 
fivefold improvement of the literature yield of 2.6%.37 It is possibly the lower 
temperature of -100 ºC rather than the standard -78 ºC used for these type of 
alkyllithium reactions and preferential elimination of bromine rather than fluorine 
or chlorine which promotes the formation of the required product.  




2.3.5.1 Synthesis of nonafyl aryne prescursor 
To gain familiarity with the use of nonafyl fluoride, one nonafyl aryne 
precursor 7237 was isolated and fully characterised from those shown in Figure 
2.10. Sodium hydride was used to deprotonate the phenol 58 and nonaflation 






The most characteristic feature for this compound in the 1H NMR spectrum 
is the trimethylsilyl signal which shifts from δH 0.31 ppm to δH 0.37 ppm and the 
disappearance of the OH signal. In the 13C NMR spectrum, the signal for the 
trimethylsilyl group shifts upfield from δC 0.35 ppm to δC -0.9 ppm and the 
multiplet signals for the nonafluorobutane portion are too close to the baseline to 
report. 
2.3.6 Attempted synthesis of 6-(trimethylsilyl)benzo[d][1,3]dioxol-5-ol 
Formation of 2-trimethylsilylphenol derivative 80 from 2-
bromotrimethylsilylphenoxy derivative 68 was attempted using the same 
procedure (Route 2),37 however, this was unsuccessful with a complex mixture of 
unidentifiable material observed in the 1H NMR spectrum and no material 
resembling the desired compound was recovered from the reaction (Scheme 2.16). 









In 2005, Tambar and Stoltz reported a route towards aryne precursor 75 
that involves 80 as an intermediate as shown in Scheme 2.17. Benzyl-protected 
bromosesamol 81 undergoes lithium-bromine exchange with n-butyllithium 
followed by silylation with trimethylsilylchloride to form 82. On deprotecting the 
benzyl ether using palladium-catalysed hydrogenation,38 80 was prepared but is 
not isolated and is instead immediately trapped with triflic anhydride to form 75.  
 
Scheme 2.17  
In a recent report by Chen et al. 80 is used as a starting material to prepare 
a 2-trimethylsilylarylfluorosulfate, presumably by isolating it initially.39 No 
experimental or spectroscopic details are described in either paper.  
 The Tambar and Stoltz route was explored beginning from sesamol 59. 
Protection using benzyl bromide provides 83 and selective ortho-bromination with 
NBS forms 81. Unfortunately, in our hands, attempts to prepare 82 using n-




























  These reactions were attempted in the absence of organolithium reagents 
using Brimble’s32 procedure (Scheme 2.11, Section 2.3.1) but again with no 
success. In future work of this project, use of freshly distilled trimethylsilyl 
chloride could facilitate an improvement in this reaction. Nevertheless, sufficient 















2.3.7 Synthesis of pyridyne precursors 
 In search of an even more diverse range of arynes for the cycloaddition 
reactions it was decided to include pyridyne precursors as additional aryne 
precursors to be prepared in this project. 3,4-Pyridynes 84 have been shown to be 
useful synthetic intermediates in the synthesis of natural products such as 
ellipticine 85 and (S)-macrostomine 86 (Figure 2.11).40 Recent research work in 
Larock’s group has also shown the utility of of the 2,3-pyridyne intermediate 87 
in the synthesis of benzonaphthyridinones 88 in reasonable yields with high 
nucleophilic  regioselectivity observed (Figure 2.11).41 
 
Figure 2.11 Use of pyridyne intermediate in organic synthesis 
A literature procedure by Díaz and co-workers42 reports that for transferral 
of the trimethylsilyl group from oxygen to carbon (Retro-Brook rearrangement) in 
the preparation of the precursors does not require a bromine group for the 
elimination step. The pyridine oxygen interacts with the lithium cation allowing 
directed ortho-deprotonation and lithiation to occur. The first derivative that was 




investigated was 2-hydroxypyridine (2-pyridone) 89, using the silylation 
procedure as used previously31 to provide 90 in quantitative yield (Scheme 2.19). 
The most characteristic feature for this compound in the 1H NMR spectrum is the 
trimethylsilyl signal at δH 0.29 ppm and loss of the NH broad singlet (2-pyridone 
tautomer) at δH 13.7 ppm.  
Scheme 2.19 
Efforts to replicate the reaction conditions applied in the synthesis of the 
benzyne precursors were attempted using with n-butyllithium but did not result in 
formation of any desired product in going from 90 to 91. This is presumably due 
to the fact that organolithium bases can alkylate the nitrogen in the pyridine ring. 
Instead, freshly prepared LDA was used successfully to form 91, following a 
publication from Diaz et al.42 The most characteristic feature for this compound in 
the 1H NMR spectrum are the trimethylsilyl signal, which changes very little from 
the precursor, at δH 0.28 ppm and the appearance of a broad OH singlet at δH 13.0 
ppm. The IR spectrum shows an absorption at max 3074 cm-1 for the OH stretch. 
Using sodium hydride and nonafyl fluoride, we are delighted to report 3-
(trimethylsilyl)pyridin-2-yl-nonaflate 92 was isolated in 89% yield as a novel 2,3-
pyridyne precursor. Characteristic features for this compound in the 1H NMR 
spectrum is the trimethylsilyl signal at δH 0.38 ppm and the disappearance of the 
broad OH singlet at δH 13.0 ppm (Figure 2.12).  





Figure 2.12 1H NMR spectrum of 92 
In the 13C NMR spectrum, the signal for the trimethylsilyl group shifts 
upfield to δC -1.2 ppm and a 4C multiplet between δC 110.7 and 119.0 ppm is 
observed. In the 19F NMR spectrum four signals are observed, confirming the 
presence of the nonafluorobutane group (Figure 2.13). 
 
Figure 2.13 19F NMR spectrum of 92 
 Pleasingly, another novel 3,4-pyridyne precursor, 2-chloro-4-
(trimethylsilyl)pyridin-3-yl nonaflate, 96 was prepared similarly in three steps 
from 2-chloro-3-hydroxypyridine 93. The first step was silylation using HMDS 
which provided 94 in quantitative yield. The most characteristic feature for this 
3F 
2F 2F 2F 




compound in the 1H NMR spectrum is the trimethylsilyl signal at δH 0.28 ppm and 
loss of the OH broad singlet at δH 10.75 ppm.  
 
Scheme 2.20 
Using freshly prepared LDA, 95 was formed in moderate yield. The 1H 
NMR spectra shows the trimethylsilyl signal at δH 0.33 ppm and the appearance 
of a broad OH singlet at δH 5.79 ppm. The IR spectrum shows an absorption at 
max 3060 cm-1 for the OH stretch. 
Using sodium hydride and nonafyl fluoride, 96 was isolated in an excellent 
yield of 91% as another novel pyridyne precursor (Scheme 2.20). The 1H NMR 
spectrum of this compound displays just three signals, one at δH 0.43 ppm for the 
trimethylsilyl signal and two aromatic doublets. The disappearance of the broad 
OH singlet is also distinctive (Figure 2.14). 
 
Figure 2.14 1H NMR spectrum of 96 




In the 13C NMR spectrum, the signal for the trimethylsilyl group shifts 
upfield to δC -0.29 ppm and a 4C multiplet is seen between δC 109.6 and 118.7 
ppm. In the 19F NMR spectrum, four signals are present confirming the presence 
of a nonafluorobutane group again. 
To summarise, in this section three aryne precursors were prepared in the 
form of 2-trimethylsilylaryltriflates using Peña’s methodology.31 Five aryne 
precursors were prepared using Ikawa’s methodology37 in the form of 2-
trimethylsilylphenol derivatives, which could be used to generate arynes in situ 
via 2-trimethylsilylarylnonaflates and two novel pyridyne precursors were 
synthesised, using Ikawa’s methodology again, while also isolating the pyridine-
nonaflates. 
In total this provided 10 dipolarophiles for the cycloaddition reactions with 


















2.4 Synthesis of 1-acyl-1H-indazole compounds using Method 1 
This section describes the initial [3+2] cycloaddition reactions performed 
to prepare indazole derivatives using diazo dicarbonyl derivatives and aryne 
derivatives. A procedure reported by Larock and co-workers was initially used to 
generate arynes in situ and react them with diazo derivatives to form indazole 
compounds.5  
2.4.1 Generation of aryne and trapping with furan 
To gain familiarity with the methodology put forward by Larock for aryne 
generation, a Diels-Alder trapping reaction with furan 97 was performed5 with the 
aryne precursor 2-trimethylsilylphenyltriflate 49 and caesium fluoride in 





Following column chromatography on silica gel, the symmetrical 
cycloadduct product 98 was isolated. This derivative showed four characteristic 
signals in the 1H NMR spectrum including the alkenyl proton singlet at δH 5.71 
ppm. All analysis is consistent with literature data,43 verifying initial formation of 
an aryne under these conditions and isolation of a cycloaddition product in a 
moderate yield of 67%. Confident in using this methodology, initial indazole 












2.4.2 Synthesis of 1-acyl-1H-indazole compounds  
Larock had investigated [3+2] cycloaddition reactions of arynes with just 
one α-diazo β-ketoester 19 and they reported the formation of product 99, 
exclusively and in good yield after the initial cycloadduct 100 had undergone acyl 
migration (Scheme 2.22).5  
 
Scheme 2.22 
2.4.2.1 1-Acyl-1H-indazole-3-carboxylate derivatives 
 In the mechanism postulated by Larock (Scheme 2.23), the fluoride ion 
displaces the trimethylsilyl group on 49, forming the aryne 50 as the triflate 
leaving group is lost.  The aryne 50 and diazo 1,3-dipole 101 then undergo 
cycloaddition in a concerted fashion to form the initial 3,3 disubstituted 
intermediate 102.5 
 The acyl migration step has been suggested to proceed by a “dissociation-
ion pair intermediate-recombination” process where 102 dissociates to an ion pair, 
which can recombine to form the desired product 103. The driving force for 
formation of the acyl-migration product is probably re-aromatisation of the 




































Scheme 2.23  
 
Following on from Larock’s initial work,5 a series of novel indazole 
products were prepared in this project from the wide-range of α-diazo-β-
ketoesters, α-diazo-β-ketoamides and β-diketones previously synthesised within 
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Figure 2.15 Initial series of indazole compounds prepared 
 The initial indazole derivatives prepared (Figure 2.15) have an N-acetyl 
group in the 1-position and the variable component was the ester functionality. 
The spectral details of 104 and 100 were consistent with those reported in the 
literature.5,45 105-110 are novel derivatives, some of which show interesting 
biological activity (will be discussed in Section 2.10). Figure 2.16 shows the 
following series where the ester side chain was extended in length to provide novel 
indazole derivatives 111-113. 




Figure 2.16 Extending the length of the ester side chains 
The reaction conditions were mild and proceeded at room temperature 
stirring for 24 h. Although the literature procedure reported a hexane-ethyl acetate 
solvent system for column chromatography on silica gel purification, it was found 
that by changing the eluent to 95:5 dichloromethane-ethyl acetate, the solvent 
volume was reduced from ca. 1.5 L to less than 200 mL and the time required for 
purification decreased greatly.   
The indazole compounds were visible under UV light on TLC silica gel 
plates as bright purple spots while the starting material diazo compounds showed 
up as dark red spots which eluted after the desired products were isolated. For the 
t-butyl derivative 106, the desired product was obtained in high purity after the 
workup.  
1H NMR analysis showed a downfield shift of signals of ca. 0.2 ppm for 
substituents in close proximity to the indazole heterocyclic core but for bulkier 
substituents, this effect decreased the further away the group is from the indazole 
core. The aryl region contained four distinctive signals from δH 7.45-8.47 ppm in 
all compounds and was similar to the peaks observed by Larock for ethyl 1-acetyl-
1H-indazole-3-carboxylate 100.5  All N-acetyl derivatives contained a distinct 3H 
singlet in the 1H NMR spectra at δH 2.87 or 2.88 ppm for the acetyl group. 




Characteristic absorption bands in the IR spectra were observed between 
max 1716 -1736 cm-1 and max 1618-1670 cm-1 for the ester carbonyl and amide 
carbonyl functional groups respectively. Figure 2.17 shows the 1H NMR spectra 
of the t-butyl 2-diazo-3-oxobutanoate 21 in comparison to t-butyl 1-acetyl-1H-
indazole-3-carboxylate 106. There is a notable downfield shift of the t-butyl 
substituent of the diazo compound in comparison to the t-butyl substituent of the 
indazole and of the the acyl group which is now in the N-1 position of the indazole. 
The four aromatic signals are also distinctive. 
 
 
Figure. 2.17   1H NMR spectra of diazo 21 and indazole 106 
 
 As indicated in Figure 2.15 and Figure 2.16, the presence of an N-aryl by-
product was detected for some reactions that had distinctive signals in the aromatic 
region of the 1H NMR spectra. Following the procedure reported by Larock,5 
eleven 1,3-disubstituted indazole deriatives were isolated in high purity and good 




yields. However, for six derivatives, 99, 105, 111, 112, 125 and 126 (125 and 126 
seen later), the aromatic region of the 1H NMR spectra contained peaks belonging 
to an N-aryl by-product which is present in amounts from 4-10%. An example of 
the 1H NMR of 111 contaminated with by-product 114 is shown in Figure 2.18. 
Unfortunately, the by-product could not be separated from the N-acyl products but 
they were isolated and characterised at a later stage (Section 2.7). 
 
Figure 2.18 Evidence of N-aryl by product being present (in red) 
 These N-aryl compounds were reported by Larock on use of mono-
substituted diazo carbonyl derivatives (Scheme 2.24).5 Changing the equivalents 
of the aryne precursor could influence the formation of the products formed.  
Scheme 2.24 
Evidence for this N-aryl product 117 could be seen in small amounts in the 

























publication for their diazo dicarbonyl cycloadditions.5 In comparison to some 
spectra obtained in this work, however, the by-product is present in amounts 
varying from  4 to 10% and 20% for one example, was seen in 1H NMR analysis, 
even though the procedure was carried out using the exact same stoichiometry. 
The formation of the by-product is most likely due to the reaction of the ion pair 
with excess free benzyne (Scheme 2.25), generated during the acyl migration step 






 Separation of the N-aryl compounds from the N-acyl derivatives proved 
unsuccessful for these 6 derivatives by column chromatography on silica gel at 
this stage in the synthesis. Modifying the stoichiometric amounts using excess 
diazo dicarbonyl starting material resulted in a limit to the formation of the N-aryl 
by-product. This excess diazo material could be recovered after the reaction had 
gone to completion.  
 The mechanism proposed does not account for how the N-2 position does 
not lead to arylation in this pathway. If one of the intermediate anions formed has 
the negative charge on the N-1 position, the electrons could delocalise onto the N-
2 position leading to arylation of the 2-position (Figure 2.19).46-48 The lack of 
evidence of any N-2 reactivity could possibly be accounted for by the higher 
stability of the benzenoid N-1 tautomer over the quinonoid N-2 tautomer and fast 
arylation of the intermediate. 
 
 
Figure 2.19 Indazole tautomeric forms 




 From work in this project it is thought that the use of excess fluoride ion 
as the desilylating aryne generator may possibly be involved in the by-product 
formation by deacylating the N-1 position. Due to the low solubility of caesium 
fluoride in acetonitrile it was preferred to keep it in excess along with the diazo 
dicarbonyl derivative and to have the aryne precursor as the limiting reagent.  
The next series of indazoles were prepared using α-diazo β-ketoester 
derivatives containing extended ketone side-chains. This was an important part of 
the project as it was not known in advance if the initial cycloadduct would undergo 
acyl migration as efficiently (or at all) as with the acetyl group to provide N-acyl 
indazoles with longer N-acyl side chains. Pleasingly, the cycloaddition reactions 
successfully provided five novel N-acyl indazoles 118-122 in moderate to good 
yields (Figure 2.20). 
Figure 2.20 Extending the length of the N-1 amide side chains 
The 1H NMR spectra for this series showed the derivatives in high purity 
with no observable by-product signals. This may be due to the decision taken to 
alter the stoichiometry of the reagents keeping the aryne precursor as the limiting 
reagent or perhaps the lengthened N-acylium ions are stronger electrophiles than 
N-acetylium ions. A common structural feature evident in the 1H NMR spectra for 
these derivatives includes a distinct 2H triplet in the narrow range between δH 3.30-
3.32 ppm for the CH2 adjacent to the amide carbonyl. The aromatic region for 122 
is completely clear of any signs of the N-arylated by-product (Figure 2.21). 
 
 





Figure 2.21 1H NMR spectrum of 122 
  Similarly, the cycloaddition reactions with aryl ketone diazo derivatives 
successfully prepared two benzamide indazole derivatives, novel 123 and 124 
(Figure 2.22). Though there are more aromatic protons to describe, the aromatic 
region is free from any evidence of the N-aryl by-product (Figure 2.23). Spectral 






























Figure 2.23 1H NMR spectrum of 124 
 The next series prepared incorporated functionalised ester side chains 
(Figure 2.24). It was thought that problems with these derivatives may be 
encountered as the alkene functionality could also potentially participate in ene 
reactions or a [2+2] cycloaddition reaction with the aryne species. The first two 
derivatives 125 and 126 did not present any problems except for the N-aryl by-
product formation in both cases.  
 The 1H NMR spectrum of the crude material of the next two derivatives 
127 and 128, however, showed the presence of a complex mixture of 
unidentifiable material along with some desired product characteristic to the N-
acetyl indazole derivatives. Purification by column chromatography on silica gel 
and preparative thin-layer chromatography on silica gel was unsuccessful in 











Figure 2.24 Further indazole derivatives prepared 
 A total of 17 novel indazoles were isolated in high purity and good yields 
from this series of cycloadditions. The last two derivatives 127 and 128 will be 
discussed again in Section 2.5.2 using “Method 2” of aryne generation.  
 Future work here could involve increasing the equivalents of aryne 
precursor to selectively form the N-aryl compound as the major product. N-Aryl 
heterocycles are found in many bioactive compounds and natural products but 
conventional methods for their preparation such as nucleophilic substitution of 
aryl halides have limitations for their general application.50,51 Some N-aryl 
indazole derivatives were isolated and characterised at a later stage (Section 2.7). 
2.4.2.2 1-Acyl-1H-indazole-3-one derivatives 
 Two cycloaddition reactions using α-diazo-β-diketones and aryne 
precursor were also performed during this project and are now described. The 
investigation into using α-diazo-β-diketones substrates in cycloaddition reactions 
is interesting as with the α-diazo-β-ketoesters, the sole ketone group of the initial 




























*by-product detected **unable to isolate in a pure state




 The first reaction explored uses α-diazo-β-diketone 42 and is also reported 
in the literature.5 The 3,3-disubstituted cycloadduct 129 was the expected product 
before the acyl migration step was shown to be a common pathway. On analysis 
of 130 it was quickly seen to be a 1,3-disubstituted adduct as the 1H NMR 
spectrum contains two inequivalent CH3 signals at δH 2.77 and 2.87 ppm and the 
13C NMR spectra has two distinct carbonyl signals at δC 171.3 and 195.1 ppm for 
an amide and ketone functional group. The compound also showed two 
characteristic absorptions in the IR spectra at max 1727 and 1686 cm-1 for both 
ketone and amide carbonyl groups. This reaction proceeded smoothly to give 130 
in 62% yield (Scheme 2.26).  
Scheme 2.26 
 The use of diazo compound 43 in the cycloaddition reaction however, 
resulted in a mixture of inseparable isomers (Scheme 2.27).  As already stated, 
ketone groups have been shown to migrate preferentially in comparison to ester 
groups, but when two inequivalent ketone groups are present, either can migrate.5 
For this reaction, the mixture could not be separated and the acyl group chemical 
shift value was used to try to assign which compounds are present. Two possible 
products would be expected from this reaction: 131 and 132, but three distinct CH3 
signals are present in the 1H NMR spectrum. The acyl peak at δH 2.87 is attributed 
to 131 and the one at δH 2.77 is assigned to 132 from comparing the values to 130 
which had those exact numbers for similar signals. The third acyl signal at δH 2.70 
ppm is assigned to an N-2-acyl indazole 133 on comparison to amide derivatives 
that will be described in a later section (Section 2.4.2.3). 2-Acyl 2H-indazole 
derivatives have been mentioned in the literature previously using the zwitterion 
of anthranilic acid to generate an aryne, and a diazo group bearing an acyl group 
to give both 1-acyl and 2-acyl migration products depending on the substrate.44 







The fact that there is no evidence of a dibenzoyl indazole 135 or diacetyl 
indazole 130 being formed (Scheme 2.28) suggests that perhaps there is more to 
the postulated mechanism of acyl migration described earlier where ion pairs 
dissociate and recombine.  
Scheme 2.28 
Evidence for the ion-pair pathway includes where cross-over products 
were reported in the literature when a mixture of 2-acyl indazoles 136 and 137 are 
heated to form 1-acyl indazole derivatives 138 and 139 (Scheme 2.29), however, 
this only shows nitrogen to nitrogen migration.44  











Scheme 2.29 Cross-over products formed on heating 
Possibly, for the substrates in this project, the mechanism could involve an 
intramolecular [1,3]-acyl carbon to nitrogen shift (Scheme 2.30) or possibly two 





Scheme 2.30 Postulated [1,3]-sigmatropic rearrangement 
 
Scheme 2.31 Postulated two successive [1,2]-sigmatropic rearrangements 
 




2.4.2.3 1-Acyl-N,N-disubstituted-1H-indazole-carboxamide derivatives 
This section describes the use of α-diazo-β-ketoamides in the 
cycloaddition reactions with the arynes. Amides are abundant in nature and are 
also present in a number of well-known drug compounds such as penicillin, LSD 
and atorvastatin. It was thought that the replacement of the ester group with an 
amide moiety in the indazole would increase the anti-cancer activity of the 
indazole derivatives (will be discussed further in Section 2.10). It was also of 
interest to investigate the migratory aptitude of the amide group in comparison to 
the ester group as there is one example in the literature where the amide group was 
reported to migrate in a similar fashion to ester groups.5  
The initial reactions of the aryne precursor 49 with the α-diazo-β-
ketoamides 44 and 45 under the optimised conditions yielded 1,3-disubstituted 
indazole products 140 and 141 as expected (Scheme 2.32).  
 
Scheme 2.32 
The 1H NMR spectra contains the characteristic aromatic hydrogen signals 
from δH 7.41-8.44 ppm as well as the N-acyl group CH3 at δH 2.78 and 2.79 ppm 
for the dimethyl and diethyl derivatives respectively (Figure 2.25).  
 





Figure 2.25 1H NMR spectrum of 141 
 The absence of a ketone carbonyl signal in the 13C NMR spectra and the 
observation of similar derivatives in the literature,5,45 prepared by alternative 
synthetic routes, to give 1-acyl-3-carboxamide indazole derivatives with similar 
N-acetyl chemical shifts (at δH 2.78 ppm) confirmed the formation of 1-acyl-3-
carboxamide derivatives 140 and 141 (Figure 2.26). Another characteristic set of 
signals in the 1H NMR spectrum of 140 are at δH 3.23 and 3.36 ppm for the 








Figure 2.26 Carboxamide indazole derivatives prepared 
 Interestingly, these N-acyl CH3 chemical shift values are quite similar to 
the value of the ketone CH3 group in the 1-acyl-1H-indazole-3-one example 141. 
This information, coupled with the observation of sharp absorptions in the infrared 
spectra at max 1724-1726 and 1631-1634 cm-1, initially suggested that for these 




derivatives migration was not occurring to form the cycloadduct 142 or perhaps 
the amide group was migrating in preference to the ketone to form 143 (Figure 
2.27), however, we now know this is not the case. The N-acyl amide carbonyl can 
be described as an ‘unexpressed amide’ where the nitrogen is part of a heterocyclic 
ring and therefore the lone pair is not involved in energy resonance to the 
carbonyl.55  
 
Figure 2.27 Comparison of 130 to potential products 142 and 143 
   
 The next derivative to undergo the cycloaddition reaction was N-benzyl-2-
diazo-N-methyl-3-oxobutanamide 46, where some interesting results were 
observed, as shown in Scheme 2.33. Firstly, there was a doubling up of signals in 
the aliphatic region of the 1H NMR spectra for the N-acyl CH3 and NCH3 groups 
and the aromatic CH signals integrated for two protons rather than one. In the 13C 
NMR spectra this duplication was repeated.  






 Initially it was thought that the compound had only partially undergone 
acyl migration but the absence of a ketone carbonyl signal in the 13C NMR 
spectrum suggests that the derivative may have undergone a 1,2-acyl migration in 
addition to a 1,3-acyl migration rearrangement. The major isomer is tentatively 
assigned as the 1,2-product 145, as deduced from the integration of the 1H NMR 
spectra signals (the mixture was inseparable) as well as the acyl CH3 chemical 
shift appearing at δH 2.78 ppm for the minor isomer, attributed to the 1-acyl 













Figure 2.28 1H NMR spectrum of inseparable mixture of 145/146 
 It was reasoned that it might be possible to induce the formation of the 1,3-
acyl migration product 146 by heating the mixture, after reviewing a paper 
published by Baum  which revealed that heating 2-acyl-indazole 147 led to 









 Efforts to force the migration of the acyl group by heating the mixture of 
145 and 146, however, were unsuccessful and even over a period of many months 
the ratio of products stayed consistent. As a result of this, more research into this 
compound was undertaken and it is now believed that the duplication of signals 
may actually be due to the presence of rotamers. The amide bond has sufficient 
double bond character between the carbonyl and nitrogen that restricts rotation 











relatively high and rotation will be slow enough for two distinct sets of signals to 
be observed. The more upfield signals in the 1H NMR spectra usually corresponds 
to the cis-rotamer and the relative proportion of each rotamer is determined by 
both electronic factors and the relative sizes of the attached groups.56 
 
 
Structure 2.1 Partial double bond character of 3° amide leads to exhibition of 
two rotameric forms 
 A fraction isolated during column chromatography on silica gel was a 1:1 
mixture of the N-aryl by-products 149 and 150 (4%) of these derivatives (Figure 
2.29) or indeed, the N-aryl by-product of both rotameric forms of 149.  This was 
interesting as the N-aryl by-products of the indazole carboxylate derivatives were 









Figure 2.29 N-aryl by-products 149 and 150  
 The next substrate investigated was α-diazo-β-ketoamide 47 that gave 
another interesting result. The acetyl group shifts downfield by the standard 
distance of ~0.2 ppm from δH 2.42 in 47 to 2.65 ppm in 151, seen previously for 
1-acyl indazole derivatives, although it is a lower value than expected. Most 
noticeably, however, is the upfield shift of the aromatic signals in comparison to 
























Figure 2.30 1H NMR  spectra comparison of 47 and 151 
 Signals for a quaternary carbon at δC 96.9 ppm and a ketone signal at δC 
191.1 ppm were observed in the 13C NMR spectrum, confirming that acyl 
migration had not taken place for this derivative and instead cycloadduct 151 was, 
in fact, the product of this reaction. Further support for structure 151 comes from 
the lack of evidence of the N-aryl by-product or 2-acyl indazole product observed 
when α-diazo-β-ketoamide 46 is utilised. These products are accounted for when 
the initial cycloadduct dissociates into ion pairs and recombine to form more 
stable, fully aromatic 1H- or 2H-indazoles. Hydrogen bonding between oxygen of 
the ketone and hydrogen of the 2º amide may be playing a part in the stability of 


























 For the final α-diazo-β-ketoamide 48 used in the cycloaddition reactions, 
initially it was thought that the 3,3-disubstituted derivative 152 was isolated 
(Scheme 2.35).  
Scheme 2.35 
 The aromatic signals in the 1H NMR spectra (Figure 2.32) are upfield in 
comparison to the 1-acyl indazole, similar to 3H-indazole 151 seen in the previous 








Figure 2.32 1H NMR spectrum of 152 and/or 153 
 Also, the 13C NMR spectrum contains a signal at δC 70.3 ppm that could 
potentially belong to the quaternary C-3 of 152. However, the structure is 
tentatively assigned as the carbonyl carbons both show up in the range for amides 
at δC 145.4 and 149.3 ppm which argues that 153 is the product. The formation of 
153 can be rationalised by noting that hydrogen bonding may be occurring 
between the oxygen of the benzoyl group and hydrogen of the 2º amide but the 
steric hindrance involved in 152 can be relieved by migration of the benzoyl group 
to the N-2 position to form 153 (Figure 2.33). 




Figure 2.33 Possible products 152 and/or 153 
This section has provided us with interesting results and 8 novel indazole 
carboxamide derivatives with the most useful results in terms of compounds that 
were sent for biological testing being the formation of the N,N-dimethyl- and N,N-
diethyl-carboxamide derivatives (will be discussed further in Section 2.10). Future 
work here could involve confirmation of structure for the final two derivatives and 
observing their reaction with arynes generated by different methods to see if 
similar results are obtained. 
2.4.2.4 1-Acyl-1H-[1,3]dioxolo[4,5-f]indazole-3-carboxylate derivatives 
This section outlines the use of substituted aryne precursors to form 
indazole compounds. The first derivatives to be formed have a methylenedioxy 
bridge on the indazole core structure. It was envisioned that the anti-cancer activity 
of these derivatives might be increased in comparison to the unsubstituted aryl 
ring derivatives considering this methylenedioxyphenyl moiety is a precursor to 
quite a number of pharmaceuticals, as mentioned previously.57  
 These indazole compounds were prepared following the modified 
procedure disclosed in Section 2.4.2.1 using the 2-trimethylsilyl-
methylenedioxyphenyltriflate aryne precursor 75 and maintaining the diazo 
compound in excess for all derivatives. All reactions and purification went 
smoothly to produce the desired products 154-159 cleanly and in good yields with 
no evidence of the N-aryl by-product observed (Figure 2.34). 




Figure 2.34 Range of 1-acyl-1H-[1,3]dioxolo[4,5-f]indazole-3-carboxylate 
derivatives prepared 
1H NMR spectra analysis showed that all the derivatives had very similar 
chemical shift values except for signals due to the ester side chain. The aryl region 
contained two distinctive singlet signals between the narrow ranges of δH 7.44-
7.47 ppm and 7.88-7.89 ppm, the methylene protons of the methylenedioxy moiety 
was at δH 6.11 ppm in all spectra and the N-acetyl 3H singlet appears at δH 2.84 or 
2.87 ppm. In the 13C NMR spectra the acetyl group CH3 is at δC 22.9 or 23.0 ppm, 
the methylene group appeared at δC 102.3 ppm and the aromatic CH signals moved 
upfield to δC 95.7 and 99.3-99.4 ppm in all cases. 




Assignment of the quaternary carbon signals for these derivatives was 
aided by HMBC (Heteronuclear Multiple Bond Correlation) 2D (two-
dimensional) NMR experiments as the chemical shift values of the quaternary 
carbons attached to the nitrogens were too similar to differentiate. 
Characteristic absorption bands in the IR spectra were seen between max 
1720-1731 cm-1 and max 1644-1651 cm-1 for the ester and amide carbonyl groups 
respectively. Figure 2.35 shows an NMR spectrum of 157 after column 
chromatography on silica gel. 
  
Figure 2.35 1H NMR spectrum of 157  
These six compounds were isolated in good yields and purities and were 
sent forward for biological testing (will be discussed in Section 2.10). The 
protocol designed in this project requiring excess diazo compound was successful 
in eliminating the formation of the by-product and the excess diazo could be 
recovered after the reaction reaches completion by column chromatography on 
silica gel. In future work, by increasing the equivalents of aryne precursor the N-
aryl derivatives could be selectively formed.  
 
 




2.5 Synthesis of 1-acyl-1H-indazole compounds using Method 2 
 This section describes the use of the nonaflation of 2-trimethylsilylphenol 
derivatives to generate arynes which then undergo cycloaddition reactions to form 
indazole heterocycles. This method of aryne generation was published by Ikawa 
and co-workers in 2011 but has not yet received a lot of attention (Scheme 2.36).37 
This method has the appeal that the nonaflating reagent is much cheaper and more 
bench stable than the triflating reagent. It does not require the low temperatures 
required for triflation or the isolation of the immediate aryne precursor which was 





 The authors demonstrated the applicability of their aryne generation 
method using standard Diels Alder trapping experiments with furan derivatives 
160 to form epoxynaphthalene derivatives such as 163, a [3+2]-cycloaddition 
reaction with benzylazide 161 to form benzotriazole 164 and a nucleophilic 
addition reaction with isopropylamine 162 to form  aniline derivative 165 
(Scheme 2.37). 





2.5.1 Generation of aryne and trapping with furan  
 Process familiarisation was carried out again using a furan trapping test 
reaction and the characteristic peaks of the cycloadduct 98 could be identified in 
the 1H NMR spectrum of the crude material.  This technique was modified slightly 
by reducing the amount of nonafyl fluoride added to 1.5 equivalents and by 
excluding 18-crown-6 as an additive (to ensure the activation of the fluoride anion 
from NfF), and the introduction instead of 0.5 equivalents of caesium fluoride. 
This combined 2.0 equivalents amount of fluoride ion ensured complete 
generation of aryne from the precursors without requiring the expensive crown 





   




2.5.2 1-Acyl-1H-indazole-3-carboxylate derivatives 
 The first cycloaddition reaction performed using this nonaflation 
methodology prepared 108 in excellent yield (Scheme 2.39). It was initially 
thought that some diazo decomposition products might be observed in the 1H 
NMR spectra of the crude reaction mixtures as the reactions were heated to 60 °C, 
however, those concerns were unfounded as the only compounds observed in the 
1H NMR spectra were the desired indazole and unreacted excess diazo compound 
23. An increase in yield (79 to 87%) was observed using this nonaflation 
methodology (Method 2) in comparison to the triflate methodology (Method 1, 
Section 2.4.2.1) due to the facile isolation of the pure derivative and recovery of 
the excess diazo compound which could be recycled. Method 2 was found to be 







 After successful preparation of 108, this method was used in the synthesis 
of 128 and 127 which could not be isolated in high purity using the previous 
procedure (Method 1, Section 2.4.2.1). These reactions proved more successful, 
with isolation of pure (>98%) material for 128 (Figure 2.36) and semi-pure 
(>94%) material for 127 (contaminated with 6% unknown impurities after 
repeated column chromatography on silica gel) (Figure 2.37). A pure sample of 
125 was also obtained as the Method 1 procedure provided a product contaminated 
by 10% N-aryl by-product (Figure 2.37). 
 
 





Figure 2.36 1H NMR spectrum of 128 
 These results suggest that the conditions used to generate the aryne may 
affect the subsequent cycloaddition reactions. The yields for these particular 
reactions are quite low which may be related to the extra alkene functionality 
present which may be participating in a [2+2]-cycloaddition reaction itself with 
the aryne. These substrates did not work well regardless and further research is 
required that may optimise these reaction conditions to suit these functionalised 
substrates.  
 






























2.5.3 1-Acyl-substituted-1H-indazole-3-carboxylate compounds 
 This section describes efforts to further diversify the range of indazole 
derivatives being synthesised in this project by introducing a range of substituted 
aryne precursors with. Symmetrical disubstituted arynes were chosen so that one 
regioisomeric indazole derivative would be formed (Figure 2.38). As the aryne 
species can be classified as electrophilic, aryne precursors were chosen to 
investigate the efficiency of the cycloaddition reactions, e.g. dimethyl aryne 166 
may reduce the electrophilic nature of the aryne by donating electron-density into 
the ring and difluoro aryne 167 may increase the electrophilic behaviour of the 
aryne. The biological effect of having two electron donating groups in comparison 





Figure 2.38 Symmetrical aryne precursors with EDG and EWG 
2.5.3.1 1-Acyl 5,6-dimethyl-1H-indazole-3-carboxylate compounds 
 First the dimethyl aryne precursor 79 was used and reacted with three diazo 
1,3-dipoles to give the three indazole products (Figure 2.39). The first 
cycloaddition reaction was high yielding and isolated derivative 168 in high purity. 
The other derivatives, 169 and 170, however, were prepared using an impure 
sample of aryne precursor 79 (contained 15% starting material) and were difficult 
to purify. A reduction in yield was observed for 169 because of the need for 
repeated purification using preparative thin-layer-chromatography on silica gel. 










Figure 2.39  1-Acyl 5,6-dimethyl-1H-indazole-3-carboxylate compounds 
1H NMR analysis showed that the ester derivatives 168 and 169 had very 
similar chemical shift values, except of course for signals due to the ester side 
chain. The aryl region contained two distinctive singlet signals between the narrow 
ranges of δH 7.90-7.92 ppm and 8.23-8.25 ppm, the aryl-CH3 groups  were singlets 
between δH 2.40-2.44 ppm and the N-acetyl 3H singlet was at δH 2.85 ppm for both 
derivatives. In the 13C NMR spectra the aryl-CH3 groups appeared at δC 20.3 and 
20.9 ppm and the aromatic CH signals are at δC 115.5 and 121.6 ppm in both cases. 
Assignment of the quaternary carbon signals for these derivatives was 
aided by HMBC 2D NMR experiments as the chemical shift values of the 
quaternary carbons attached to the nitrogens were too similar to differentiate. 
  
 Characteristic absorption bands in the IR spectra for the ester and amide 
carbonyl functionalities were seen at the exact same wavelength for these 
derivatives at max 1716 cm-1 and max 1644 cm-1 respectively. Figure 2.40 shows 
the 1H NMR spectrum of 168 after column chromatography on silica gel. 
  





Figure 2.40 1H NMR spectrum of 168 
 1H NMR analysis of the carboxamide indazole derivative 170 shows the 
aryl region contains two singlets at δH 7.79 ppm and 8.21 ppm, the aryl-CH3 
groups at δH 2.37 and 2.43 ppm and the N-acetyl group at δH 2.75 ppm. In the 13C 
NMR spectra the aryl-CH3 groups appeared at δC 20.1 and 20.9 ppm with the 
aromatic CH signals are at δC 115.2 and 121.7 ppm. A characteristic absorption 












2.5.3.2  1-Acyl 5,6-difluoro-1H-indazole-3-carboxylate compounds 
 The role of fluorine in drug design and development is growing quickly as 
more unique properties of the element are discovered. The addition of fluorine into 
a molecule can positively influence a range of effects including intrinsic potency, 
membrane permeability and pharmacokinetic properties.58  
 Some fluorine-containing drug compounds are shown in Figure 2.41 that 
demonstrate the broad therapeutic effects caused by, but not limited to, the 
addition of fluorine to a drug molecule. Voriconazole 171 is a medication used to 
treat serious fungal infections. Fluorouracil 172 is a pyrimidine analogue used in 
the treatment of cancer. Atorvastatin (Lipitor®) 173 is a cholesterol-lowering 
drug. Fluoxetine (Prozac®) 174 is one of the most prescribed anti-depressants and 
maraviroc 175 is an anti-retroviral drug used in the treatment of HIV.  
Figure 2.41 Fluorine-containing pharmaceuticals 
 Currently, pharmaceutical compounds containing at least one fluorine 
account for >18% of the market share and >30% of the agrochemicals market; of 
















































 Larock reported unsuccessful reactions of the triflate aryne precursor 176 
with diazo compounds due to the electron poor nature of the aryne (Scheme 2.40). 
For reactions with ethyl 2-diazo-3-oxobutanoate 19, they reported a complex 
reaction mixture with poor yields of contaminated material 177.5   
Scheme 2.40 Larock’s only example of a difluoro indazole 
However, in this project, possibly due to the use of the nonaflate aryne 
precursor 78, we are pleased to report successful cycloaddition reactions of the 
difluoro aryne 167 with a range of diazo derivatives were successful (Figure 2.42). 
These 11 novel difluoro-indazole derivatives were isolated in high purity, albeit in 
moderate yields. There is scope to optimise the conditions further to increase 
yields as both starting materials (aryne precursor and diazo dipole) were recovered 
even after extending the reaction times to 24 h. Seven derivatives contain an ester 
side chain and 185 incorporates an amide group in the side chain. All contain an 
N-acetyl group except for 186 which includes an N-benzoyl group. The fluorinated 
indazole derivatives synthesised in this project were strong candidates for 
biological testing, and subsequently turned out to be some of our most active 
compounds in the anti-cancer testing with the NCI, which will be discussed in 
Section 2.10. 
 




Figure 2.42 Range of difluorosubstituted indazole deriatives 
 The aromatic regions of the 1H NMR spectra of the N-acetyl ester 
derivatives 178-184, 187 and 188 are very similar with almost identical chemical 




shift values. This region contained two distinctive doublet of doublet signals 
between the narrow ranges of δH 7.90-7.98 ppm and 8.30-8.31 ppm due to fluorine 
coupling, the N-acetyl 3H singlet was between δH 2.85-2.87 ppm for all 
derivatives. Figure 2.43 shows a representative 1H NMR spectrum of 179 where 
the high purity after column chromatography on silica gel and characteristic 
aromatic signalling of the derivative is observed. 
 
Figure 2.43 1H NMR spectrum of 179 
 There is extensive coupling in the 13C NMR spectra due to the two aromatic 
fluorines-the aromatic CH signals are doublets (unresolved coupling) or doublets 
of doublets at δC 104.0-104.1 and 108.9-109.1 ppm. In some cases the signals are 
too close to the baseline to analyse the C-F coupling constants and were 
consequently reported as a multiplet range.  
  
 Figure 2.44 shows a representative 13C NMR spectrum of the same 
derivative 179 where the multiplet signals from 19F coupling can be seen for the 
indazolic carbons between δC 103 and 154 ppm. 




Figure 2.44 13C NMR spectrum of 179 
Figure 2.45 contains an expansion of the C-F coupling region and its 







Figure 2.45 13C NMR spectrum splitting diagram for C-F signals in 179 
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Absorption bands in the IR spectra are seen between max 1643-1737 cm-1 for the 
carbonyl groups.  
 The aryl region in the 1H NMR spectrum of benzoyl derivative 186 was 
more complex than those derivatives described above. The CH signals shift upfield 
in comparison to the N-acetyl compounds, one is a multiplet between δH 7.55-7.61 
ppm and the other is a doublet of doublets at δH 8.07 ppm. In the 13C NMR spectra 
the aromatic CH signals are doublets (unresolved coupling) or doublets of doublets 
at δC 98.4 (upfield shift) and 109.2 ppm. Absorption bands in the IR spectra are 
seen at max 1726 cm-1 for the ester carbonyl and at max 1645 cm-1 for the amide 
carbonyl. 
 In amide derivative 185 the CH signals are doublets of doublets at δH 7.94 
ppm and δH 8.25 ppm. In the 13C NMR spectra the aromatic CH signals are 
doublets of doublets at δC 103.6 and 109.6 ppm. Absorption bands in the IR spectra 
are seen at max 1734 for the N-acyl carbonyl and at 1629 cm-1 for the amide 
carbonyl. 
11 novel difluoro substituted indazoles were prepared using this 
methodology which was of particular note as previous research groups reported 
trouble with synthesising derivatives of this nature.5 This was a significant 
advancement in methodology for synthesising a series of these difluoro indazole 
derivatives which are very difficult to access. These compounds are compared to 












2.5.3.3 1-Acyl 5/6-substituted 1H-indazole compounds 
The use of unsymmetrical aryne precursors in the indazole cycloaddition 
reaction is described in this section. The arynes were generated using the 
methodology optimised in this research as described in Section 2.5.3 that 
employed a nonaflate aryne precursor.37 The intention was to investigate the effect 
of the substituent on the formation of regioisomers, to see if the isomers were 
separable and subsequently send the novel derivatives for biological testing. 
The initial unsymmetrical aryne precursor used was 4-chloro-2-
(trimethylsilyl)phenol 77 which underwent a cycloaddition reaction with sec-butyl 
2-diazo-3-oxobutanoate 32 (Scheme 2.41) to give a mixture of inseparable 
regioisomers 189 and 190 in a 70:30 ratio. The major isomer was determined by 









1H NMR analysis of the mixture showed some overlapping of signals for 
the two isomers in the aliphatic region but the aryl region contained three 
distinctive signals for each of the two isomers which could be used to differentiate 
between the two. Each isomer is characterised by a doublet of doublets signal and 




two doublet signals. The N-acetyl 3H singlets were almost identical at δH 2.86 
(major) and 2.87 (minor) ppm (Figure 2.46). 
Figure 2.46 1H NMR spectrum of 189/190 
 Assignment of the major isomer as the 6-substituted 189 was carried out 
by examination of the aromatic J values of both isomers and analogy to 5- and 6-
substituted-1H-indazole derivatives including 5-chloro-substituted indazole 191 
(Figure 2.47).63-65  
 Analysis of the 1H NMR spectrum of 190, reveals that at δH 8.16 ppm the 
1H doublet (J 2, due to meta coupling to H6) can be compared to the singlet at δH 
8.28 ppm in 191.  The doublet of doublets signal at δH 7.55 ppm (J 8.9, 2) couples 
to ortho H7 and meta H4 and the doublet signal at δH 8.40 (J 8.9) couples to ortho 
H6. In the same way, the aromatic signals in the 1H NMR spectrum of the minor 









Figure 2.47 Chemical shifts of aromatic protons in 1H NMR spectra 
 The 13C NMR spectra was tentatively assigned for each isomer. Although 
the integration of carbon signal intensities may not be an accurate correlation 
between major/minor isomer and signal strength, the larger peak signals were 
tentatively assigned to the major isomer. 
 The formation of the major isomer could be rationalised by observing the 
contributing electronic and steric factors. The dominant electronic interaction 
governing regioselectivity is between the atoms bearing the largest HOMO and 
LUMO coefficients (Scheme 2.42). The carbon of the diazo carbonyl bears the 
largest HOMO and the carbon para to the chlorine substituent in the aryne 192 is 
the most electrophilic, therefore, the cycloaddition yields 189 as the major 
regioisomer. Steric effects are probably contributing very little to the 
regioselectivity of the cycloaddition reaction as the chlorine substituent is possibly 
too far from the reactive site to have much influence. 












 For the methyl aryne precursor 76 it was thought that extending the length 
of the ketone side chain of the diazo compound 33/34 could influence the reaction 
outcome but no effect was observed on the formation of a particular isomer, with 
a 1:1 mixture of inseparable regioisomers 193/194 and 195/196 being formed 
under these conditions (Scheme 2.43).  
Scheme 2.43 
 By analogy to similar compounds in the literature (Figure 2.48) 63-66 and 
using coupling constants, the 1H NMR spectra for the aromatic protons was 
tentatively assigned (Figure 2.49). The chemical shift values in the 1H NMR 
spectra of 197 and 193 are in similar ranges with comparable splitting patterns and 



























Figure 2.48 Aromatic chemical shift values assigned by analogy to 197 
However, for the most part the isomers could not be described separately. 









Figure 2.49 1H NMR spectra of 195/196 
 The method for the synthesis of 5/6-substituted indazole derivatives shows 
some selectivity with a chlorine substituent on the aryne precursor but no 




selectivity for a methyl group. Using unsymmetrical arynes, therefore, in the 
synthesis of 5/6-substituted indazole derivatives is not synthetically useful at this 
stage as the products are inseparable and, therefore, other routes, such as the 
Jacobsen Modification (described in Section 1.3.3.1) to 5- and 6-substituted 
indazoles are recommended. 
 Literature precedence has shown that when a methoxy group is present in 
the 3-position of the aryne, complete regioselectivity is observed. Larock 
demonstrated the cycloaddition of aryne precursor 198 with diazo 199 exclusively 
formed 7-methoxy indazole 200 (Scheme 2.44).5 Indazole formation using arynes 
in such cases are useful, so future work could involve using a 3-methoxy aryne 













2.6 Attempted Syntheses of Aza-Indazole Derivatives 
Attempts to use the novel pyridyne precursors in the domino reaction37 to 
form novel aza-indazole derivatives are discussed below. 
Although pyridyne intermediates have previously been generated from 
triflate precursors, they have not yet been used in aza-indazole synthesis or have 
not been generated using the nonaflate method so this would be an exciting new 
aspect to the project and would potentially provide excellent candidates for 
biological testing. Pyridyne intermediates are known to be very reactive and as a 
result they dimerise, decompose and form more impurities than their benzyne 
equivalent.41,42,67,68 Consequently, they also tend towards low yielding reactions. 
The initial attempted pyridyne reaction (Scheme 2.45) was unsuccessful, with no 
evidence of the cycloadduct 201 being formed and only starting material was 
recovered after 8 hours. 
 
 
Scheme 2.45  
 In spite of this, it was decided to pursue the aza-indazole forming reaction 
with the diazo dipoles. Unfortunately, these reactions were also unsuccessful, and 
only starting material was recovered in both cases Scheme 2.46 and Scheme 2.47. 
 It was hoped that incorporating a chloro-substituent into the pyridine 
precursor could influence formation of one regioisomer over another as seen in 
comparable pyridyne derivatives generated from trimethylsilylpyridyltriflates. If 
two products are formed, separation by column chromatography on silica gel may 
be easier than separation of indazole regioisomers as similar aza-indole 
regioisomers can be isolated from each other during the synthesis of ellipticine.42 












 The lack of success with this methodology so far proved disappointing. 
However, as these were initial reactions there is much scope for improvement of 
this work to achieve pyridyne generation using nonaflation. The inclusion of 18-
crown-6 as an additive to ensure fluoride activation may be a potential aid in a 
successful reaction outcome by ensuring fluoride reactivity and aryne generation. 
The use of a stronger base instead of caesium carbonate is also an aspect to be 
considered as the pKa of the pyridinol hydrogen is higher than that of phenolic 
hydrogens. 
Scheme 2.47 
 The cycloaddition reactions of the range of diazo dicarbonyl compounds 
with the range of aryne precursors provided a pool of over 50 novel N-acyl-




indazole derivatives, with much scope for the synthesis of analogues in future 
work, and over 40 derivatives which were prepared for biological testing (21 novel 
indazoles evaluated to date) and which were further derivatised as described in the 
























2.7 N-Deacylation of 1-acyl indazoles 
1H-Indazoles are biologically interesting compounds in their own right 
with many compounds showing biological activity such as 206 and 207 (Figure 
2.50) which are undergoing investigation as pain management drugs due to their 
ability to block the vanilloid receptor which causes burning pain upon activation.69  
 
Figure 2.50 Biologically active 1H-indazole derivatives 
 N-Deacylation was beneficial to the project as the novel 1H-indazoles 
prepared constituted another library of candidates to be submitted for biological 
testing and the free nitrogen could be further derivatised to provide additional 
novel compounds. The next aim, therefore, was to adopt an approach to deacylate 
the N-1 position of the N-acyl indazoles prepared in Section 2.6. A general method 
to deacylate all derivatives that would not affect the ester side chain is desirable. 
Initially, a method using thionyl chloride in methanol was employed after Wang 
et al. reported a mild deacylation method of arylacetamides that tolerated ester, 
aminosulfonyl or benzyloxyamide functionalities.70 In Wang’s research a methyl 
ester group was present, which was not affected by the acidic conditions in 
methanol. The proposed mechanism proceeds by generating HCl from the alcohol 
and thionyl chloride (Scheme 2.48). 












Scheme 2.48  
 This process employed cheap reagents, reported good yields and a short 
reaction time. However, when applied to indazole compound 106, although 
deacetylation does occur, transesterification of the t-butyl ester side chain to a 
methyl ester 208 also occurs (Scheme 2.49). Rather than using Wang’s conditions 
that required matching the ester side chains to the alcohol solvent, an alternative 
deacylation method was investigated.  
Scheme 2.49 
2.7.1 N-Deacylation of aryl unsubstituted 1-acyl indazoles 
  Use of tetra-n-butylammonium fluoride (TBAF) in THF was investigated 
after Carato et al. researched protection and deprotection methods for compounds 
bearing a reactive free nitrogen. For example, the authors reported the facile 




deacylation of benzooxazolone 209 after treatment with TBAF in THF at room 






 In this project, the procedure was slightly altered by using 4 equivalents of 
TBAF as some starting material N-acyl indazole derivatives were observed after 1 
hour with 3 equivalents of TBAF. 
 This method efficiently deacylated all the N-acyl indazole compounds in 
short reaction times at room temperature, followed by an aqueous work up to 
isolate pure compounds in high yields. This is a general method that is suitable for 
all derivatives and tolerates all ester functional groups. It was initially applied to 
twelve 1-acyl indazole carboxylate derivatives (Figure 2.51) and provided eight 
novel 1H-indazoles 214-216 and 218-222. 




Figure 2.51 First series of N-deacetylated compounds 
 An example of 1H NMR analysis for this work is shown in Figure 2.52. 
Characteristic peaks in the 1H NMR spectra is the appearance of the broad NH 
singlet between δH 10.61-12.51 ppm, the upfield shift of an aromatic proton signal 
and the disappearance of the acetyl CH3 peak in the region of δH 2.87 or 2.88 ppm 







































































































Figure 2.52 1H NMR spectra comparison 1-acetyl-indazole 107 vs 1H-indazole 
214  
  In the 13C NMR spectra, the most noticeable difference is the loss of the 
amide carbonyl between δC 171.3 and 171.6 ppm. The IR spectra for the 
compounds contain broad bands in the region of max 3000-3430 cm-1 for the amine 
NH and those 1-acyl-1H-indazole compounds that had two carbonyl stretches as 
N-acyl derivatives now have one sharp band at max 1715 and 1730 cm-1.  
The next derivatives deacylated included a 1-pentanoyl derivative 120 
which showed that this approach works well for acyl groups in general and not 
just acetyl groups (Scheme 2.51). This product 223 required a slightly extended 
period of time under vacuum to fully remove the side product 224. In the 1H NMR 
spectrum, the broad NH singlet is at δH 12.50 ppm and the disappearance of all 
signals from the pentanoyl group is observed. In the 13C NMR spectrum, the most 
characteristic differences is the loss of four aliphatic carbon signals as well as the 
amide carbonyl at δC 174.4 ppm. The IR spectrum contains a broad amine band 




















 The proposed mechanism suggests the initial nucleophilic attack of 
fluoride ion on the amide carbonyl. The stable indazolic anion formed can 
delocalise the negative charge extensively until the reaction is quenched to give 
the 1H-indazole derivative (Scheme 2.52).71,72  
 
 
Scheme 2.52  
 
2.7.2 Isolation of N-aryl by-product 
 As alluded to in Section 2.4, the N-aryl by-products, which could not be 
separated from the 1-acyl derivatives at that stage, were isolated from these 
reactions. Their production is due to excess benzyne in the reaction (Scheme 
2.53).  





 Three derivatives 225-227 were isolated (Figure 2.53) but as the amount 
of material was minimal, full characterisation was only obtained for 225 which 
has previously been reported in the literature.5 The separation of the 1H- and 1-
acyl-indazole compounds from each other was relatively easy using column 
chromatography on silica gel.  
Figure 2.53 N-aryl by-products isolated 




 Figure 2.54 show the differences in the aromatic region of the 1H- and 1-
phenyl-derivatives; the aliphatic regions for both compounds are almost identical. 
The aryl region of the N-phenyl derivatives show characteristic signals: a 1H 









Figure 2.54 1H NMR spectra of aryl region of 225 vs 211 
Insufficient sample meant that 13C analysis on these derivatives could not detect 
the quaternary carbon signals. 
 An apparent triplet of triplets is observed between δH 8.28-8.35 ppm for 
derivative 226 instead of the expected doublet (Figure 2.55). However, the 
intensities of the signals are not consistent with a true triplet of triplet. The signal 
is assigned here as a multiplet as there may possibly be unresolved 5J coupling to 











Figure 2.55 NMR spectra comparison of 221 vs 226 
 
2.7.3 N-Deacylation of 1H-indazole carboxamide derivatives 
 The deacylation method described above also worked efficiently to furnish 
the two known 1H-indazole carboxamide derivatives 228 and 229 (Figure 2.56) 
as confirmed by their comparison to literature data.73,74 The only difference in 
characteristic signals from the 1H-indazole carboxylate derivatives is the IR 
spectra for these compounds shows the amide carbonyl stretch is between max 





Figure 2.56 1H-indazole carboxamide derivatives 
The 1H NMR spectra of 228 is shown in Figure 2.57 and characteristic peaks 
include: appearance of the broad NH singlet at δH 10.23 ppm, the upfield shift of 
the aromatic proton signals from δH 8.44-7.41 ppm to δH 8.16-7.26 ppm and the 
























signals in the 1H NMR spectrum are at δH 3.21 and 3.41 ppm for the inequivalent 






Figure 2.57 1H NMR spectrum of 228 
2.7.4 N-Deacylation of substituted 1-acyl indazoles 
 The next series of reactions involve the use of substituted 1-acyl indazole 
derivatives. These compounds had been prepared using the optimised procedure 
that utilised excess diazo starting material, to limit the formation of the N-aryl by-
product. The optimised deacylation procedure that used increased equivalents (4 
equiv. instead of 3 equiv.) of TBAF was also in place for these derivatives. For 
these reasons, the pure products could be isolated after the water work-up without 
further purification and with no evidence of starting material or by-products being 
present.   
 The first series of deacylation derivatives prepared have the 
methylenedioxy bridge on the indazole ring, an N-acetyl group and all contain 
ester side chains in the 3-position (Figure 2.58).  
















Figure 2.58 First series of substituted N-deacetylated compounds 
 All reactions proceeded smoothly to provide 6 novel methylenedioxy-
containing indazole compounds in good yields and high purity. In the 1H NMR 
spectrum, characteristic signals include the appearance of the broad NH singlet 
between δH 11.41-12.11 ppm (except in the cases of 232 and 235 where the NH 
signal was not visible), the upfield shift of the aromatic proton signals of about 0.4 
ppm in both cases from δH 7.44-7.47 ppm and 7.88-7.89 ppm to δH 6.99-7.12 ppm 
and 7.42-7.46 ppm respectively and the disappearance of the acetyl CH3 peak in 
the region of δH 2.84-2.87 ppm. The methylene protons of the methylenedioxy 
moiety are observed at δH 6.05-6.06 ppm in all spectra (Figure 2.59).  
 In the 13C NMR spectrum, the most characteristic difference is the loss of 
the amide carbonyl at δC 171.6 ppm and the acetyl group CH3 at δC 22.9 or 23.0 
ppm, methylene group appeared at δC 101.7 or 101.8 ppm and the aromatic CH 




signals shift upfield from the N-acyl compounds from δC 95.7 and 99.3 or 99.4 
ppm to 90.5-90.8 and 98.3-98.5 ppm in all cases. 
 The IR spectra for the compounds contain broad bands in the region of max 
3193-3455 cm-1 for the amine NH and the two carbonyl stretches for the ester and 
amide now appear as one sharp band between max 1727 and 1736 cm-1. Six of 
these derivatives were prepared (Figure 2.58).  
Figure 2.59 1H NMR spectra comparison N-acyl 155 vs deacylated 230  
 The next series described are the derivatives prepared from deacylation of 
our difluoro- and dimethyl-indazole compounds described earlier. As encouraging 
biological testing results on the N-acyl versions of these compounds were obtained 
(which will be discussed further is Section 2.10), using the core structure for 
derivatisation was seen to be advantageous. Four disubstituted deacylated 
derivatives were prepared in good yields as white solids (Figure 2.60). In addition 
to being candidates for biological testing in their own right, further derivatisation 
of these compounds would provide excellent substrates also to be tested which 
will be discussed in Section 2.8. 
   




Figure 2.60 Disubstituted deacylated indazole derivatives 
 The 1H NMR spectra of the dimethyl derivatives 236 and 237 show 
characteristic signal differences from the N-acyl derivatives include that the 
methyl groups attached to the aryl ring now appear as a 6H singlet at δH 2.40 ppm 
rather than two separate signals and the acetyl CH3 signal has disappeared from 
δH 2.85 ppm (Figure 2.61). The amide carbonyl signal at δC 171.5 ppm and the 
acetyl CH3 at δC 23.0 ppm from the starting material are not present in the 13C 
NMR spectra. The IR spectra for the compounds contain broad bands in the region 
of max 3267-3382 cm-1 for the amine NH and the amide carbonyl stretches are no 









Figure 2.61 1H NMR spectrum of 236 
Similarly, for the difluoro-derivatives, characteristic features in the 1H 
NMR spectra (Figure 2.62) include the disappearance of the acetyl CH3 signal 
from δH 2.86 ppm and two doublet of doublets for the aromatic protons in the aryl 
region. In the 13C NMR spectra, the amide carbonyl signal at δC 171.2 ppm and 
the acetyl CH3 at δC 22.7 or 22.8 ppm are not present. Again in the IR spectra, a 
stretch from max 3212-3647cm-1 for the amine NH is observed, the amide carbonyl 
stretches are no longer present and only ester carbonyl stretches at max 1726 and 
1733 cm-1 can be observed. 













Figure 2.62 1H NMR spectrum of 238 
For 239 rather than 2 separate aryl doublet of doublets signals, usually 
observed as shown in Figure 2.62, an apparent triplet of doublets signal is 
observed (due to unresolved coupling) and is assigned as a multiplet (Figure 2.63). 
 
Figure 2.63 1H NMR spectrum of 239 
The last two reactions described in this deacylation section involve the 1:1 
mixture of 5/6-methyl N-butyryl- and N-pentanoyl indazole derivatives 193/194 
and 195/196. Successful deacylation of these compounds was also achieved to 
provide a mixture of regioisomers (Scheme 2.54). This was confirmed again by 
1H NMR and 13C NMR spectra where the characteristic disappearance of signals 




for the N-acyl groups as well as the appearance of amide carbonyl signal at δC 
174.1/174.2 ppm are observed. Again in the IR, a stretch from max 3269-3281cm-
1 for the amine NH is observed and the amide carbonyl stretches are no longer 
present leaving just ester carbonyl stretches at max 1713 and 1722 cm-1. 
 
Scheme 2.54 
This deacylation section described the chemistry that provided access to 
22 novel and useful 1H-indazole derivatives which were prepared for biological 
testing. Alkylation of these derivatives will be described in the next section (2.8). 
It is a mild method that can be used with a range of substrates with varying 














2.8 Benzylation of 1H-indazole derivatives  
 A major aim in this project was to synthesis N-benzyl indazole derivatives 
as many indazole drugs on the market or in late stage clinical trials for therapeutic 
activities contain a benzyl group in the structure including those shown in Figure 
2.64. Benzydamine 244 is marketed as Difflam™ and is a locally acting analgesic 
and anti-inflammatory used in treatment of painful inflammatory conditions of the 
mouth and throat. Bendazac 245 is an NSAID used topically for joint and muscular 
pain. Bindarit 246 is being investigated for its anti-inflammatory effects against a 
variety of conditions such as arthritis and lonidamine 247 is an anti-cancer 
therapeutic agent.75 
  
Figure 2.64 Benzylated indazole derivatives displaying therapeutic activities 
 In general, 1-alkyl isomers are thermodynamically more stable whereas the 
2-alkyl derivatives are kinetically favoured. Benzylation under basic conditions is 
less selective and usually provides equimolar regioisomeric products, however, 
the ratio of the isomers is influenced by electronic and steric effects. 
 Indazole benzylation proceeds under basic conditions via an ambident 
indazolyl anion to provide a mixture of two distinct isomeric products to a mixture 
of 1-benzyl-1H- and 1-benzyl-2H-indazoles (Scheme 2.55). 















This section describes the synthetic routes utilised to provide a range of novel 
benzylated derivatives to send for biological evaluation. 
 
2.8.1 Initial benzylation reactions65,76 
 The 1H-indazole derivatives prepared in Section 2.7 were used as 
substrates in the alkylation reaction as illustrated in Figure 2.65. A mixture of N-
1 and N-2 products were separated to provide a range of novel benzylated 
compounds in combined yields of 44-59% after column chromatography on silica 
gel.  
 


















Figure 2.65 First series of benzylation products 
 In all cases the N-2 isomer was eluted first followed by the N-1 isomer in 
combined yields of 44-59%.  The separate structures of the N-1 and N-2 
derivatives are confirmed by analogy to similar derivatives in the literature 
(Figure 2.66).66,65  For example, the N-1 isomer, H-7 in the 1H NMR spectra of 
both derivatives 256 and 248 are doublet signals at δH 8.21 ppm with the same J 
value coupling constant and the benzyl CH2 singlet is ca. δH 5.7 ppm for both 
compounds. For the N-2 isomer, H-7 in the 1H NMR spectra of both derivatives 
257 and 249 are doublet-type signals in the range δH 7.81-7.93 ppm with similar J 




value coupling constants and the benzyl CH2 singlet is between δH 6.11-6.20 ppm 
for both compounds. 
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 The isomers are easily differentiated by their 1H NMR spectra in the 
aromatic region where the N-1-isomer always has a 1H doublet between δH 8.18-
8.21 ppm and an 8H multiplet more upfield between δH 7.20-7.38 ppm; the N-2-
isomer always has two doublet-type signals at δH 8.02-8.03 ppm, δH 7.81-7.82 ppm 
and a 7H multiplet between δH 7.23-7.45 ppm. The benzyl CH2 group appears at 
δH 5.71/5.72 ppm in the N-1 isomer and at δH 6.12/6.13 ppm in the N-2 isomer. 
Representative examples of the 1H NMR of N-1 isomer 252 and N-2 isomer 253 
are shown in Figure 2.67. 
 Figure 2.67 1H NMR spectra comparison N-1 vs N-2 isomers 
 In the 13C NMR spectra the benzyl CH2 of the N-1 isomer appears at δC 
54.1 ppm in all cases and at δC 56.5 or 56.6 ppm for the N-2 isomer. In the IR 
spectrum, broad stretches from max 3269-3281cm-1 for the primary amine NH 
starting material are not present and the ester carbonyl stretches are in the very 
narrow range of max 1707-1709 cm-1 for these eight derivatives. 
 The ratios of the N-1:N-2 isomers can be influenced by the ester side chains 
slightly preferentially forming the less sterically hindered product and there are 
methods reported in the literature to induce the formation of one isomer over 
another.77,78 For example, performing the reaction under phase transfer conditions 
at different temperatures considerably affects the ratio of isomers formed (Scheme 
2.56). 





 Chromatographic separation on silica gel was used in this project to isolate 
both isomers as investigation of biological activity of both derivatives was desired. 
However, methods to form exclusively one isomer over the other were not applied 
here but could be looked at in the future as a more attractive route to the 
compounds. The yields of these reactions could be improved upon and future work 
will involve using microwave conditions in the alkylation reactions as a reported 
method in the literature shows similar reactions forming product in up to 82% 









 No correlation in melting point values were observed across our range of 
isomers although literature precedence indicates the N-1 isomers usually melt at a 
lower point than their N-2 counterparts. For example, N-1 isomer 252 is a yellow 
oil while N-2 isomer 253 is a white solid with a melting point of 69-70°C. 
 
2.8.2 Benzylation reactions of substituted indazole derivatives 
 The following series of compounds prepared have difluoro- and dimethyl-
substitution on the indazole core structure and incorporate an isopropyl ester side 
chain. These compounds were chosen as their N-acyl precursors (2 steps previous 
in Section 2.5.3.2) gave encouraging biological results which will be discussed in 
Section 2.10. By introducing a benzyl group in the 1-or 2-positions it was hoped 
to increase this observed activity based on compounds currently on the market. 
Again, for these derivatives the N-2 isomer was eluted first followed by the N-1 
















Figure 2.68 Substituted N-benzyl derivatives 
 
 





 The substituted N-1 and N-2 benzylated isomers 264 and 265 were easily 
differentiated by their 1H NMR spectra in the aromatic region where the N-1-
isomer contains two 1H singlets at δH 7.08 and 7.94 ppm and 2H and 3H multiplets 
in between those signals; the N-2-isomer has two singlets at δH 7.55 and 7.75 ppm 
and a 5H multiplet upfield of those. The benzyl CH2 group appears at δH 5.66 ppm 







Figure 2.69 1H NMR spectra comparison N-1 vs N-2 isomers 
 In the 13C NMR spectra, the benzyl CH2 of the N-1 isomer appears at δC 
53.9 ppm and at δC 56.4 ppm for the N-2 isomer. In the IR spectrum, the broad 
stretches from max 3269-3281 cm-1 for the amine NH starting material are not 
present and the ester carbonyl stretches are observed at max 1709 and 1726 cm-1 
for the N-1 and N-2 derivatives respectively. 
Difluoro derivatives 
 These N-1 and N-2 isomers are also easily differentiated by their 1H NMR 
spectra in the aromatic region where the N-1-isomer has two 1H doublet of doublet 
signals at δH 7.05 and 7.94 ppm and then a 2H and 3H multiplet in between those 
signals and the N-2-isomer has two 1H doublet of doublet signals at δH 7.50 and 
7.71 ppm, then a 5H multiplet upfield of those. The benzyl CH2 groups appear at 




the same chemical shift values as the dimethyl derivatives at δH 5.66 ppm for the 
N-1 isomer and at δH 6.06 ppm for the N-2 isomer (Figure 2.70). 
  
 
Figure 2.70 1H NMR spectra of 266 and 267 
 In the 13C NMR spectra, the benzyl CH2 of the N-1 isomer appears at δC 



















 In the IR spectrum, broad stretches from max 3269-3281 cm-1 for the amine 
NH starting material are not present and the ester carbonyl stretches appear at max 
1720 and 1711 cm-1 for the N-1 and N-2 derivatives respectively. 
 Access to 12 novel N-1 and N-2 indazole compounds was described herein. 
Most notable is the further scope for the preparation of a wide range of novel 
indazole derivatives, made possible merely by changing the alkylating reagent. 
Substituted benzyl groups, long alkyl chain derivatives and long chain alkyl 
halides will be the next alkyl groups to be targeted as their involvement in similar 



























2.9 Side-chain transformations  
 Following on from the long side-chained and functionalised α-diazo-β-
ketoesters in Section 2.2.3, the preparation of a range of novel β-ketoesters and 
their diazocarbonyl derivatives is described in the following section. Performing 
side chain transformations on the functionalisable esters to give more diverse side 
chains in the range of indazoles is an attractive route to explore. Focus was placed 
on the synthesis of tertiary amine compounds synthesised via epoxide and 
aldehyde derivatives as shown in Scheme 2.58.  
Scheme 2.58 
These derivatives were chosen as the side-chain of the citronellol ester 2 is 
similar to the side-chain of lanosterol-type steroids 268 and the geraniol ester 3 is 
similar to the side-chain of furanolipid-type derivatives 269 .These compounds 
have previously been transformed to tertiary amines and investigated within the 




























potential in U937 model cell lines79 and positive growth inhibition across the NCI 
60 cell line panel at both one- and five-dose testing levels.   
 The alkene present in the side chain of the esters enables the formation of 
epoxide derivatives which in turn allow oxidative cleavage to an aldehyde 
intermediate which can then be used to introduce amine functionality via reductive 
amination under mild conditions. Using the methodology towards the preparation 
of tertiary amine derivatives also provides interesting novel epoxide and aldehyde 
derivatives. 
 For the above transformations three potential options for introducing the 
various functional groups were available: after the ester formation, diazo transfer 
or indazole formation stage. The results of these transformations and reactions are 
discussed below. 
 
2.9.1 Epoxidations of alkene-containing derivatives  
  Epoxides are versatile building blocks in organic synthesis and are present 
in several bioactive compounds. Epoxide formation was successfully achieved in 
this project using commercially available m-CPBA as the oxidising agent and the 
standard associated reaction conditions to convert the alkene moiety to an oxirane 
ring.80 Use of m-CPBA in laboratories is preferred over other peroxy acids due to 
its ease of handling (present as a powder and can be stored in a refrigerator), 
versatile applicability (such as epoxidation of alkenes, oxidation of sulphides to 
sulfoxides and sulfones, Baeyer Villiger oxidation of aldehydes and ketones to 
esters, etc.), higher reactivity (due to the oxygen-oxygen bond being quite weak) 
and selectivity (stereochemistry is always retained). 
The reaction proceeds via what is commonly known as the ‘Butterfly 
mechanism’ as the transition state in which oxygen is added and proton shifted 
simultaneously resembles a butterfly. The peroxide is viewed as an electrophile, 
and the alkene a nucleophile (Scheme 2.59). 






 The initial reaction was carried out on the citronellol ester 3 in the presence 
of 1.2 equivalents of m-CPBA. This reaction involved the addition of the first half 
of the m-CPBA at 0 ºC (using an ice bath) and the second half was added as the 
reaction was allowed to warm to room temperature.81 The epoxide was obtained 
as an orange oil in 91% yield, which was pure by 1H NMR spectroscopy (Scheme 
2.60). 
 Scheme 2.60 
 The most distinctive feature for the epoxide in the 1H NMR spectrum is 
the disappearance of the 1H triplet at δH 5.03 ppm corresponding to the 1H of the 
alkene and the appearance of a 1H triplet at δH 2.69 ppm (J 6.0) for the oxirane 
CH. In the 13C NMR spectrum, the alkene peaks at δC 124.7 ppm for the alkene 
CH and δC 131.9 ppm for the quaternary alkene carbon were absent with the 
appearance of a new signal at δC 64.4 ppm corresponding to the oxirane CH. The 
IR spectra of both compounds shows ester and ketone carbonyl group bands which 
appeared at max 1739 and 1736 cm-1. Although not visible in the 1H NMR 
spectrum, the 13C NMR spectrum of 270 contained a duplication of signals for 




















Similar to its β-ketoester precursor 3, this epoxide derivative 270 also 
exhibited keto-enol tautomerisation which was visible in the 13C NMR spectrum. 
From NMR analysis, both enol forms are believed to be present here. 
 
Figure 2.72 Evidence of both enol forms in 13C NMR spectrum 
The enol-form of 271 is characterised by the enolic CH and COH signals 
at δC 89.7 and 175.4 ppm respectively and also the ester carbonyl signal at δC 172.6 
ppm in the 13C NMR spectrum. The trace amount of the more unusual enol-form 
272 is characterised by the alkenyl CH2 signal at δC 78.2 ppm and also the α-CH2 
at δC 39.5/39.8 ppm (Figure 2.72).  
 With the epoxide 270 in hand, the next step was the diazo transfer reaction. 
It was initially thought that this reaction involving triethylamine base and 
potassium hydroxide work-up could be problematic due to the labile nature of 
epoxides, however, successful diazo transfer to the epoxide was achieved in 77% 
yield with no adverse effects to the epoxide product isolated 273 (Scheme 2.61). 
 
Scheme 2.61 
 Similar to the other diazocarbonyl compounds synthesised in this project, 
the disappearance of the 2H singlet at δH 3.45 ppm was evidence for successful 
diazo transfer. The methyl ketone CH3 singlet was seen to shift from δH 2.27 ppm 




to δH 2.47 ppm and the IR spectrum shows absorptions at max 2149 cm-1 for the 
diazo (C=N2) group. The carbonyl group of the ketone was seen to shift from δC 
200.5 ppm to δC 190.1 ppm in the 13C NMR spectrum.  
 Previous work on the above investigations explored the possibility of 
carrying out an epoxidation on the citronellol diazocarbonyl compound 27 as 
shown in Scheme 2.62. However, no identifiable products were recovered from 
the reaction. It is thought that reaction with the m-CPBA led to decomposition of 
the diazocarbonyl compound as the 1H NMR spectrum showed no evidence of any 





 Because of this, it was decided to bring the ester epoxide derivative 270 
through the side chain transformation reactions to form the aldehyde and then 
tertiary amine derivatives and then subsequently prepare the diazo derivatives of 
each of those steps, as described in the following pages.   
 Another epoxide derivative 274 and diazo compound 275 were prepared 
in the same way as above using a geraniol ester 2 as illustrated in Scheme 2.63. 
The more sterically accessible alkene was selectively epoxidised to provide 274 in 

















 Again, the most distinctive feature for the epoxide in the 1H NMR 
spectrum is the disappearance of the 1H triplet at δH 5.07 ppm corresponding to 
the 1H of the alkene and the appearance of a 1H triplet at δH 2.70 ppm for the 
oxirane CH. In the 13C NMR spectrum, the alkene peaks at δC 123.6 ppm for the 
alkene CH and δC 131.8 ppm for the quaternary alkene carbon are absent with the 
appearance of a new signal at δC 63.7 ppm corresponding to the oxirane CH. The 
IR spectra of both compounds show ester and ketone carbonyl group bands which 
appear at max 1725 and 1743 cm-1.  
 As with the citronellol derivative, evidence of the enol form is observed in 
the 13C NMR spectra, but in this case, only the more substituted enol. Some 
characteristic signals of the enol form include the enolic CH and COH signals at 
δC 89.7 and 175.5 ppm respectively and also the ester carbonyl signal at δC 172.5 
ppm in the 13C NMR spectrum. The disappearance of the 2H singlet for 275 at δH 
3.45 ppm was evidence for successful diazo transfer. The methyl ketone CH3 
singlet was seen to shift from δH 2.26 ppm to δH 2.48 ppm and the IR spectrum 
showed absorptions at max 2141 cm-1 for the diazo (C=N2) group. The carbonyl 
group of the ketone was seen to shift from δC 200.5 ppm to δC 190.1 ppm in the 
13C NMR spectrum also. The epoxides were stable in storage at room temperature 
over a period of many months and would be used in a cycloaddition reaction with 
benzyne 50 which will be described in Section 2.9.4. 




2.9.2 Oxidative cleavage of epoxide derivatives 
 The next transformations investigated involved novel aldehyde 
derivatives, synthesised via the epoxide esters 270 and 274. Oxidative cleavage of 
the C-C bond in epoxides serves as a chemoselective alternative to ozonolysis, a 
process that can be dangerous on larger scales. This method was used in this 
project to access novel aldehyde derivatives which could subsequently be used in 
the synthesis of tertiary amines. The aldehydes themselves were not necessarily 
designed to be biologically evaluated as derivatives synthesised within the 
research group previously containing aldehyde functionality were not accepted as 
candidates for biological testing, implying that the aldehyde group may be an 
unfavourable feature when submitting compounds to be screened. Rather, the 
formation of the aldehyde derivatives were used as a route to tertiary amines via 
reductive amination which will be discussed further in Section 2.9.3.  
 Due to the apparent instability of diazo 27 in the epoxidation reactions 
using m-CPBA, it was decided to carry out the initial oxidative cleavage reaction 
on the ester derivative 270 and perform diazo transfer on the aldehyde derivative 
276 subsequently. The aldehydes were prepared using periodic acid in diethyl 








 Mechanistically, this reaction proceeds via initial acid ring opening of the 
epoxide 278 to form a vicinal diol 279. The periodic acid then forms a five 
membered cyclic periodate intermediate with the diol 280, and the concerted 
collapse of this intermediate leads to the formation of the aldehyde product 281 






 There are a few points to note for this reaction. The first is that the reaction 
must be stirred vigorously to ensure the periodic acid, which is insoluble in diethyl 
ether, is sufficiently mixed in the solution. The second is that the temperature must 
be maintained at 25 ºC using an oil bath and reflux condenser to facilitate 100% 
conversion to the aldehyde. The aldehydes are characterised in the 1H NMR 
spectrum by a 1H triplet at δH 9.77-9.79 ppm as well as the disappearance of the 
1H triplet of the oxirane at δH 2.69 or 2.70 ppm and the presence of the carbonyl 
CH of the aldehyde at δC 201.6 or 202.3 ppm in the 13C NMR spectrum. In contrast 
to the epoxides, the aldehydes are found to be very unstable unless used 
immediately, even when stored in the freezer under nitrogen. Successful diazo 
transfer to the aldehyde 276 was achieved as illustrated in Scheme 2.66 to provide 
283 in good yield. 









The diazocarbonyl product was obtained as a bright yellow oil and again 
the characteristic signals included the disappearance of the CH2 singlet at δH 3.45 
ppm and the methyl ketone CH3 singlet was seen to shift from δH 2.27 ppm to δH 
2.47 ppm. The IR spectrum showed the diazo group (C=N2) absorption at max 
2143 cm-1 and the carbonyl group of the aldehyde was seen to shift from δC 202.3 
ppm to δC 190.0 ppm in the 13C NMR spectrum also. 
For the geraniol derived aldehyde 277 an interesting result was obtained. 
The reaction was carried out using the standard reaction conditions and the 1H 
NMR spectrum of the crude reaction mixture showed the formation of the desired 
compound. However the major product obtained after the work-up and 
purification was acyl cleavage product 284 which was obtained as a bright yellow 




 α-Diazo β-ketoesters have been known to undergo alkaline acyl cleavage 
in aqueous conditions as reported in the literature84-86 but acyl cleavage was not 
expected using the routine 9% potassium hydroxide wash as it was not previously 
observed, even for similar substrates. This compound was characterised by the 1H 
singlet at δH 4.74 ppm for the proton attached to the diazo carbon and the lack of 




a full methyl ketone CH3 singlet at δH 2.48 ppm (Figure 2.73). 13C NMR analysis 
also showed the absence of the ketone carbonyl and methyl ketone CH3 at ca. δC 
30 and 190 ppm. 
 
 




















2.9.3  Reductive amination of aldehyde derivatives 
 The final derivatives investigated in this project were tertiary amines which 
were formed via the aldehyde. Collins reported recently on the synthesis and 
evaluation of a range of novel lanostane derivatives in U937 cell lines for their 
cytotoxic and apoptotic potential.79 Excellent IC50 values were observed for the 
tertiary amine functionalised derivatives 285 and 286 as shown in Figure 2.74. 
Since an important part of this project involves structural derivatisation of indazole 
compounds, reductive amination seemed like a fantastic avenue to explore in the 
development of novel compounds for biological testing. 
Figure 2.74 Aminolanostane derivatives showing low IC50 values 
 The amine group is one of the most frequently found functional groups in 
today’s armoury of commercially available drugs. Amine based pharmaceutical 
drugs are used therapeutically for a range of causes such as allergies 
(diphenhydramine 287), pain (codeine 288), malaria (quinine 289), bacterial 
infections (tetracycline 290) and in tissue numbing for certain procedures 
(lidocaine 291), to name a few (Figure 2.75). The amine functionality is the most 
common functional group found in drug molecules (>85%). The primary 
physicochemical property of importance in the drug chemistry of the amino group 
is its basicity. Because most amines are basic, salt forms can be generated to 
facilitate water solubility or solubility in other vehicles for drug administration. 
 
 
















Figure 2.75 Pharmaceutical drugs containing an amine group 
 Reductive amination is an important tool in organic synthesis for 
introducing amine functionality into an organic compound containing an aldehyde 
or ketone. These carbonyl compounds react with ammonia, primary or secondary 
amines to form primary, secondary or tertiary amines respectively.87-90   
 The first reaction undertaken in this project, was carried out following an 
established protocol, comprehensively cited in the literature, by Abdel and co-
workers. Citronellol derived aldehyde 276 was converted into its corresponding 
novel amine 293 in 76% yield following treatment with 1 equivalent of 
thiomorpholine 292 in the presence of sodium triacetoxyborohydride in dry 1,2-
dichlorethane at room temperature under an inert nitrogen atmosphere as shown 
in Scheme 2.68. The reducing agent exhibits remarkable selectivity, as no 
reduction of the aldehyde to form an alcohol is observed. The steric and electron-
withdrawing effects of the three acetoxy groups stabilise the boron-hydrogen bond 
resulting in the mild reducing properties of the substance. 






The ester was characterised in the 1H NMR spectrum by the disappearance 
of the aldehyde triplet at δH 9.78 ppm and the distinctive peaks of the 
thiomorpholine ring which appeared between δH 2.66-2.72 ppm as an 8H multiplet 
corresponding to the four CH2 groups in the ring. The 13C NMR spectrum showed 
the two SCH2 groups at δC 27.4 ppm and the two NCH2 groups at δC 54.7 ppm of 
the thiomorpholine ring. The IR spectrum showed the usual ester and ketone 
carbonyl absorptions at max 1743 and 1715 cm-1. 
Successful diazo transfer to the ester 293 gave the novel diazocarbonyl 294 
as a bright yellow oil in 71% yield (Scheme 2.69). Again the characteristic signals 
included the disappearance of the CH2 singlet at δH 3.44 ppm and the methyl 
ketone CH3 singlet was seen to shift from δH 2.27 ppm to δH 2.48 ppm. The IR 
spectrum showed the diazo group (C=N2) absorption at max 2141 cm-1 and the 
carbonyl group of the ketone was seen to shift from δC 200.5 ppm to δC 190.1 ppm 
in the 13C NMR spectrum.  
Scheme 2.69 
 The next reaction was carried out with the geraniol derived aldehyde 277 
using 2-(piperazin-1-yl)ethan-1-ol 295 as the tertiary amine yielding the novel 
amine 296 in 76% yield as shown in Scheme 2.70. 
















The ester was characterised in the 1H NMR spectrum by the disappearance 
of the aldehyde triplet at δH 9.77 ppm and the distinctive peaks of the piperazine 
ring which appeared between δH 2.48 and 2.62 ppm as an 11H multiplet 
corresponding to the four NCH2 groups in the ring along with the NCH2 and OH 
of the ethanol group. The 13C NMR spectrum showed the NCH2 groups of the ring 
at δC 52.8 and 53.2 ppm.  
The diazo transfer reaction took place using ester 296 to give another 
interesting result where the acyl cleavage derivative 297 was obtained as the major 
product (Scheme 2.71) similar to the diazo aldehyde with the same geraniol 
scaffold 284.  
This compound was characterised in the same way as 284 by the 1H singlet 
at δH 4.67 ppm for the proton attached to the diazo carbon and the lack of a “full” 
methyl ketone CH3 singlet at δH 2.40 ppm. 
The 1H NMR spectrum showed the presence of impurities which were not 
removed by repeated column chromatography on silica gel and the 1H and 13C 
NMR spectra were assigned with the presence of these impurities.  













 In total, 2 epoxide 273 and 275, 2 aldehyde 283 and 284, and 2 tertiary 
amine 294 and 297 derivatised diazo dipole compounds were synthesised and 
brought forward to the cycloaddition stage with the benzyne precursor 49 which 














2.9.4 Indazole cycloaddition reactions with diazo dipoles of epoxide, 
aldehyde and tertiary amine derivatives  
 Aryne cycloaddition reactions were performed with the epoxide diazo 
derivatives 273 and 275, and attempted with aldehydes 283 and 284 and tertiary 




 With two novel epoxide-containing diazo derivatives 273 and 275 in hand, 
work could begin on the cycloaddition reactions with the aryne to generate novel 
epoxide-containing indazole compounds. Although apprehensive about these 
diazo dipoles not performing well (as the alkene-containing diazo of the starting 
material ester 25 and 27 derivatives had not given pure product in the reactions 
with the triflate aryne precursor in Section 2.4.2.1), we are delighted to report that 
indazole derivatives with an epoxide moiety in the side chain were successfully 
isolated in good yields and high purity (Scheme 2.73).  












Comparative 1H NMR spectra for diazo 273 and indazole 298 are shown in Figure 
2.76. 
Figure 2.76 1H NMR spectra of diazo 273 and corresponding indazole 298 





In the aldehyde forming reactions, initial attempts were made to form 
indazole 300 using the diazo 1,3-dipoles of the aldehyde derivative 283 (Scheme 




The epoxide derivatives of the indazole 298 and 299 were brought through the 






















 It was found that the reactions in Scheme 2.75 did not go to completion; 
even when excess periodic acid was used and when the reaction times were 
extended. A pure sample of the aldehydes 300 and 301 were not isolated despite 
repeated purification attempts using column chromatography on silica gel so the 
impure aldehyde derivatives 300 and 301 were brought forward to the reductive 
amination step.  
Reductive amination 
 Initial attempts were made to form the indazole cycloadduct using the 
diazo 1,3-dipoles of the tertiary amine derivatives with no success (Scheme 2.76).  
Scheme 2.76 
 A subsequent search of the literature showed that arynes can also react 
readily with tertiary amines. One example reported in 2013 by Bhogude and co-
workers is shown in Scheme 2.77 where N-arylation of aromatic tertiary amines 
occurs readily in high yields. The authors proposed a plausible mechanistic route 
whereby the reaction is initiated by fluoride-induced aryne generation from 49 and 
then nucleophilic addition of dimethylaniline 303 to the aryne 50, generating a 









ammonium salt 305. Demethylation induced by the fluoride ion or the basic 
reaction medium provides N-aryl product 306.91,92  
Scheme 2.77 
 Instead, the aldehyde derivative of the indazole 300 was carried through 
the synthesis (Scheme 2.78). These reactions were less than ideal as the aldehyde 
starting materials contained irremovable starting material and the sodium 
triacetoxyborohydride was also involved in cleaving the acetyl group (preferable 
in the one-pot preparation of 1H-indazoles). Although pleased to report successful 
reductive amination of the aldehyde 300 with thiomorpholine 292, the major 
product was the deacylated 306. However, after repeated column chromatography 
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 The key characteristic signal in the 1H NMR spectra to show the 
incorporated thiomorpholine ring was the 8H multiplet at δH 2.64-2.75 ppm. In the 
13C NMR spectra, the thiomorpholine CH2 signals appeared at δC 27.8 and 54.9 
ppm and evidence of deacylation was that the amide carbonyl signal and methyl 
ketone CH3 were not present.  
 
 Next the aldehyde 301 was used in a reductive amination reaction with 
piperazine ethanol 295 (Scheme 2.79), however no evidence of product formation 
in the 1H NMR spectra of the crude material was observed. After purification 
attempts using column chromatography on silica gel, only the aldehyde starting 









 Throughout the project, derivatives of geraniol were found to be poor 
substrates in a range of indazole reactions. Increasing the equivalents of piperazine 
ethanol 295 in this reaction may aid in the future success of this reaction as 295 is 
a viscous liquid that is difficult to handle and measure accurately.  
It is also possible that for this compound, when the N-1 position is 
deacylated by the reducing agent it would be possible that the aldehyde side chain 
and the newly formed secondary amine of the indazole would react to further 



































 Overall, the side-chain transformations performed in this project were 
successful in that a range of novel ester and diazo derivatives could be prepared 
with epoxide, aldehyde and tertiary amine functionality. Although the initial 
indazole forming reactions with the epoxide side chain worked well, as a whole, 
the aldehyde and tertiary amine indazoles were not as successful. The synthesis of 
tertiary amine indazole derivative 306 was a notable result and further work on 
optimisation of this route and alteration of the secondary amine starting material 
should isolate more novel tertiary amine indazole derivatives. Future work in this 
area will involve the investigation other reductive amination routes, using simpler 
tertiary amines and perhaps using a shorter isopent-2-ene side-chain ester for the 
transformations. In general, the geraniol side chain has proven problematic 














2.10 Biological Evaluation 
2.10.1 Introduction 
 The 1H-indazole nucleus is an effective pharmocophore in medicinal 
chemistry and shows diverse biological and pharmacological activity.75 A major 
aim in this project was to synthesise a range of novel indazole compounds 
containing varying functionalisation throughout the structure and then to evaluate 
these for their biological activity. 
By making modifications to the indazole core it was hoped to first identify 
the structural features that enhance or diminish the biological action of the 
indazole derivative and then use this knowledge to direct synthesis to particular 
structural features of compounds that might return promising biological results.  
Collaboration with the National Cancer Institute (NCI) allowed assessment 
of the chemotherapeutic potential of synthesised novel indazole derivatives. Over 
four rounds of testing so far, 40 novel derivatives have been sent forward to be 
tested and 21 of those were accepted and screened for one-dose testing.  
Participation in an open global initiative for discovery and development of 
new drugs against superbugs with the Community for Antimicrobial Drug 
Discovery (CO-ADD) was undertaken. 19 novel indazole compounds have been 
sent to the Queensland University Bioscience Precinct in New Zealand for these 












2.10.2 National Cancer Institute Testing 
2.10.2.1 Development Therapeutic Programme 
The U.S. NCI’s Developmental Therapeutics Programme (DTP) is the 
drug discovery and developmental arm of the NCI. It plans, conducts and 
facilitates development of therapeutic agents for the treatment of cancer and 
AIDS.93 In 1955, the NCI set up the DTP, originally known as the Cancer 
Chemotherapy National Service Center (CCNSC), to act as a public screening 
centre for anticancer activity in compounds submitted by external institutions and 
companies. It operates a series of in vitro and in vivo anticancer compound 
screening programmes with the aim of identifying novel compound leads and their 
biological mechanisms of action.94  
Since its establishment, the DTP has been involved in the discovery or 
development of more than 40 U.S. licenced chemotherapeutic agents, which 
translates to >70% of the anticancer drugs on the market today.95-97  Some 
examples of anti-cancer agents developed with DTP involvement are shown in 
Table 2.1. 
Table 2.1: Anti-cancer agents developed with DTP involvement* 
Year Drug Year Drug Year Drug 
2015 Dinutuximab 1989 Carboplatin 1973 Bleomycin 
2010 Eribulin 1988 Ifosamide 1970 Mitramycin 
2009 Romidepsin 1987 Mitoxantrone 1969 Procarbazine 
2004 Erbitux 1983 Etoposide 1967 Hydroxyurea 
2003 Velcade 1982 Streptozotocin 1966 Thioguanine 
1998 Ontax 1979 Daunorubicin 1964 Actinomycin 
1996 Topotecan 1978 Cisplatin 1963 Vincristine 
1995 All-t-retinoic acid 1977 Carmustine 1962 Fluorouracil 
1992 Taxol 1976 Lomustine 1961 Vinblastine 
1991 Pentostatin 1975 Dacarbazine 1959 Cyclophosphamide 
1990 Hevamisole 1974 Adriamycin 1957 Chloroambucil 
*Table adapted from NCI website  




Notably, the above list contains Paclitaxel (Taxol®) 308 is one of the most 
widely prescribed anti-cancer drugs on the market (Table 2.1). It is a natural 
product isolated from the bark of the Pacific yew tree. It was first discovered by 
researchers working under a joint U.S. Department of Agriculture-National 
Cancer Institute grant and a DTP contractor formulated the drug for clinical trials. 
Paclitaxel is a mitotic inhibitor and is used today in cancer chemotherapy for the 
treatment of lung, ovarian, breast, head and neck cancer, and advanced forms of 








Figure 2.77 Paclitaxel (Taxol®) 308 
Bortezomib 309 is another DTP success story which was screened and 
formulated by the DTP in cooperation with its commercial sponsor. It was 
approved by the Food and Drug Administration (FDA) in 2003 and was the first 
treatment in more than a decade to be approved for patients with multiple 
myeloma. It took only 8 years from initial NCI-60 hit identification of the novel 





Figure 2.78 Bortezomib (Velcade®) 309 




The DTP functions as a valuable service that aids the academic and private 
sectors in overcoming various financial and technical barriers associated with drug 
discovery and that consequently keep the delivery of promising therapeutic agents 
from reaching patients. Particularly, the DTP has been a vital service in its support 
of high risk projects and therapeutic development for rare cancers.98,99 
2.10.2.2 Introduction to NCI-60 Cancer Cell-line Screen Programme 
The NCI-DTP is a 60 human tumour cell line service, developed in the late 
1980s as a strategic high-throughput screening tool for in vitro anti-cancer drug 
activity.99 Cytotoxicity data for more than 100,000 compounds across diverse 
cancer lines have been classified following this approach. The project is designed 
to screen up to 3,000 compounds per year for potential anticancer activity using 
60 different human tumour cell lines representing nine human cancers: leukaemia, 
melanoma, and cancers of the lung, colon, brain, ovaries, breast, prostate and 
kidney. The aim is to identify synthetic compounds or natural product samples 
showing selective growth inhibition or cell killing of particular tumour cell lines 
for further evaluation. 
The screening is a two-stage process beginning with an initial evaluation 
involving a single dose of 10 µM cytotoxicity screen of the compound with the 60 
cell line assay, known as a one-dose NCI-60 screen. In vitro activity of each 
compound in the human tumour cell line is displayed as a ‘mean graph’ (Figure 
2.79), consisting of a series of horizontal bar graphs representing units of nominal 
growth percent, deviating from the arithmetic mean growth for the entire 60 cell 
line panel (‘0’). The value reported is growth relative to the no-drug control, and 
relative to the time zero number of cells. This allows detection of both growth 
inhibition and lethality. 
In each case, graphs which extend to the right (values less than 0) signify 
more selective cytotoxicity or positive growth inhibition while those which extend 
to the left of centre line (values between 0 and 100) indicate a chemotherapeutic 
or non-cytotoxic effect on individual cell lines. For example, a value of 100 means 
no growth inhibition. A value of 40 would mean 60% growth inhibition. A value 
of 0 means no net growth over the course of the experiment. A value of -40 would 
mean 40% lethality. A value of -100 means all cells are dead.  






Figure 2.79 NCI-60 One-dose ‘mean graph’ 
Compounds that exhibit significant growth inhibition and satisfy the 
threshold inhibition criteria mean value of  50% across all 60 cell lines fit the 
necessary NCI-60 criteria for five dose screening and are then evaluated at five 
concentration levels, known as a 5-dose NCI-60 screen. Patterns of total panel 
activity can be correlated with those of over 100,000 compounds within an NCI-
60 database to reveal key mechanisms of action using the COMPARE programme.  
 
Following initial NCI-60 screening, compounds exhibiting interesting 
patterns of inhibition are evaluated by the Data Review Committee, prior to a five-
dose investigation. This screen is performed by a 5 × 10 fold serial dilution of a 




100µM stock solution at the same time as the one-dose sample. The results are 
displayed on a graph (Figure 2.80) showing the three response parameters; GI50, 
TGI and LC50.  
 
 
Figure 2.80 NCI-60 ‘five-dose graph/dose response curve’ for all cancer cell lines 
 
Following recommendation by the Biological Review Committee, 
compounds which exhibit useful activity profiles may progress to in vivo hollow-
fibre testing in mouse models and further xenograft assays, with successful drug 














2.10.2.3 NCI-60 one-dose screen results 
 An initial selection of novel 1,3-disubstituted indazole compounds 
prepared in this project were submitted for biological evaluation to the NCI as the 
indazole core structure is present in a range of anti-cancer therapeutic agents on 
the market. The first round of compounds evaluated were unsubstituted on the 
benzene ring of the indazole and had a variety of acyl groups in the N-1 position 
and the 3-position contained a range of alkyl ester side chain lengths and 
functionality as shown in Figure 2.81. It was envisioned that the selection of novel 
derivatives would provide alternative types of binding and steric interactions that 
could enhance or alter the biological activity by varying the ester side chain to 
include groups such as a bulky t-butyl group in 106, a lipophilic decyl group in 
113 and an extra aromatic ring in 110 Also, it was thought that altering the N-
acetyl side chain to a longer N-acyl group such as in 119 or having a fluorinated 







Figure 2.81 Initial series of N-acyl indazole derivatives submitted to DTP for NCI-
60 cell line screening 
 The indazole derivatives in Figure 2.81 were investigated for initial NCI-
60 one-dose tumour cell line activity and the one-dose mean graphs for each of the 










































growth inhibition of these agents on the NCI-60 human cell line panel is outlined 
below. Evaluation of these one-dose mean graphs revealed that compound 123 
(contains a p-fluorobenzoyl group in the N-1 position) showed the greatest overall 
biological activity when compared to the other compounds tested in this series. 
Figure 2.82 Illustration of NCI-60 mean growth percent for our initial derivatives 
 While none of the initial indazole derivatives exhibited the necessary 
biological activity across the 60 cell lines required for five-dose screening by the 
NCI (<50% mean growth), an interesting trend could be seen to emerge in activity 
against non-small cell lung cancer cell lines by altering the length or bulkiness of 




Figure 2.83 Altering ester side-chain length/bulkiness 
 The indazole derivative containing the t-butyl ester group 106 exhibits 
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squamous cell carcinoma and mesothelioma cancers) in comparison to the slightly 
less bulky isopentyl containing ester group 109 (90.16%) and activity against this 
particular cell line is completely switched off when the ester alkyl side chain 
contains the straight chain decyl group 113, showing no measurable growth 
inhibition on this cell line (100.36%).  
 
Figure 2.84 Activity against particular lung cancer cell lines 
Contrastingly, on analysis of the HOP-92 lung cancer cell line (represents 
undifferentiated large cell lung cancers), as the ester side chain increases in length, 
the growth inhibition increases from 90.61% for t-butyl 106 to 71.7% for isopentyl 
109 to 63.07% for the decyl group containing derivative 113 (Figure 2.84).  
 The indazole derivative containing the t-butyl ester side chain 106 also 
shows most inhibition against some particular renal cancer cell lines including the 
CAKI-1 cell line (71.19%) (clear cell carcinoma) and UO-31 cell line (81.78%) 
(carcinoma) in comparison to the isopentyl containing indazole analogue 109 
which showed its highest growth inhibition against the 786-O cell line (88.91%) 
(renal cell adenocarcinoma). The decyl ester-containing indazole derivative 113 

























Figure 2.85 Activity against particular renal cancer cell lines 
Analysis of the more functionalised indazoles 110, 119 and 123 provided 
information on the biological activity of derivatives incorporating a benzyl ester 
side chain and modified N-acyl groups (Figure 2.86).  
 
Figure 2.86 Indazoles containing other functionality 
In comparison to aliphatic side chain ester containing indazoles in Figure 
2.83, benzyl containing indazole 110 exhibited some increased activity against 
similar cell lines discussed above, such as lung cancer cell line NCI-H226 
(80.51%), renal cancer cell lines CAKI-1 (79.63%) and UO-31 (78.33%). 
Increased activity against breast cancer cell line MCF7 (adenocarcinoma) is 
observed for 110 (75.35%) in comparison to 86-97% for aliphatic ester side chain 
indazoles 106, 109 and 113. Interestingly, the elongation of the N-acyl group in 
119 did not provide any increase in activity against any of the cell lines in 
comparison to N-acetyl derivatives 106, 109, 110 and 113 and, in fact, it can be 
said that this derivative is biologically inactive across the 60 cell lines. The greatest 











































MCF7, slightly better than the previously mentioned N-acetyl aliphatic side chain 
ester-containing indazoles which showed 91.52-96.95% growth inhibition on the 
same cell line. 
The most active indazole derivative across the 60 cell lines in the initial 
round of testing was 123. Contrary to the most active derivatives in this section, 
123 contains the shortest ester side chain so the fluorinated benzoyl N-acyl group 
could be playing a significant role in increasing its activity. Elevated selective 
activity against the HOP-92 non-small cell lung cancer cell line (61.38%) and UO-
31 renal cancer cell line (77.19%) is observed in comparison to the other initial 
indazole derivatives 106, 109, 110, 113 and 119.  Selective activity is also seen 
against the PC-3 prostate cancer cell line (represents grade 4 adenocarcinoma) at 
72.53% growth inhibition. 
 Surprisingly, none of the 1H-indazole derivatives as described in Section 
2.7 were selected to be screened by the NCI, as a search of their database can 
identify a number of in vivo biologically active indazole derivatives with a 
hydrogen in the 1-position. However, they may be accepted on resubmission in 
the future following favourable results for similar compounds.   
 The next indazole derivatives selected to be assessed were disubstituted on 
the aryl ring with a methylenedioxy group 154 and 158, and methyl groups 168 
and 169 (Figure 2.87).  These compounds were targeted as the previous NCI-60 
results seemed to suggest indazole derivatives containing bulkier/longer side chain 
ester groups in the 3-position would return more favourable results. All derivatives 
contain an acetyl group in the 1-position. Assessment of the effect of having two 
resonance electron-donating groups of the methylenedioxy group versus the effect 
of two inductively electron-donating methyl groups on the aryl ring was also 
possible.  
 These compounds were investigated for initial NCI-60 one-dose tumour 
cell line activity and evaluation of the one-dose mean graphs revealed a number 
of interesting and distinctive patterns. The activity of the methylene-dioxy bridge-
containing indazoles was of particular interest as this moiety is present in a wide 




range of biologically active compounds.57 The one-dose mean graphs for each of 
the compounds depicted in Figure 2.87 are presented in Appendix II. 
 
Figure 2.87 Series of substituted indazole derivatives submitted to DTP for NCI-
60 testing   
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 In comparison to the unsubstituted aryl ring indazole derivatives, the 
activity of these compounds is increased across the 60 cell lines (Figure 2.88) and 
further analysis of the one-dose mean graphs revealed some excellent selective 
inhibition of certain cell lines.  
 These substituted derivatives can be observed to give an increased 
growth inhibition across the lung (HOP-92 cell line), renal (TK-10, UO-31, A498 
and 786-O cell lines, representing renal cell and spindle cell carcinomas) and 
prostate (PC-3 cell line) cancer cell lines, in particular, in comparison to the 
unsubstituted indazoles (Figure 2.89). The methylenedioxy-substituted indazole 
154 shows more selective growth inhibition (41.1%) on the HOP-92 lung cancer 
cell line in comparison to when the isopentyl ester in the 3-position is changed to 
a decyl group 158 (27.2%). However, on analysis of renal cancer lines, it is the 
decyl derivative 158 that shows more inhibition (27.1%) in comparison to 
isopentyl derivative 154 (19.1%), albeit on different cell lines: A498 which 
represents adenocarcinoma and 786-D which represents renal cell adenocarcinoma 
respectively. 

























Some moderate selective inhibition is also observed against breast cancer 
cell lines, in particular the T-47D cell line, as observed in Figure 2.90. The 
inhibitory effect is most pronounced when the cell line is treated with 
methylenedioxy-containing indazole derivatives 154 and 158, producing a growth 
inhibition of 22 and 18% respectively. 
Figure 2.90 % Selective Growth Observed in Breast Cancer cell lines 
We are delighted to report our most significant selective growth inhibition 
up until this point for these derivatives which was found in the dimethyl indazole 
analogues, and for the first time with an ovarian cancer cell line. When treated 
with the dimethyl substituted indazole derivatives 169 and 168, a particular 
ovarian cancer cell line, OVCAR-4, exhibited just 0.47 and 2.77 growth percent, 
respectively (Figure 2.91). The OVCAR-4 cell line was developed from an 
























































Figure 2.91 Illustration of mean growth % in ovarian cancer cell lines 
There is a considerable difference observed on the activity against the 
OVCAR-4 cell line on comparison of unsubstituted decyl indazole 113 (106.19% 
growth) and dimethyl substituted indazole analogue 169 (0.47%), suggesting the 
presence of the methyl groups on the aryl ring enhances the biological activity of 
the indazole derivatives.  
The next derivatives selected for biological evaluation contained two 
fluorine substitutents on the aryl ring of the indazole. A total of seven of these 
analogues were tested, five compounds contain a long or bulky aliphatic ester 
group, one contains a benzyl group and one derivative incorporates an amide in 
the 3-position, all analogues include an N-acetyl group in the 1-position (Figure 
2.92). Assessment of the effect of having two electron-withdrawing fluorine atoms 









Figure 2.92 Selection of difluoro substituted indazoles evaluated 
These compounds were investigated for initial NCI-60 one-dose tumour 
cell line activity but the activity profile required for five-dose testing across all 60 
cell lines was not present. Again, however, some interesting and characteristic 
selective growth inhibitory effects can be observed on evaluation of the one-dose 
mean graphs. The distinctive pattern of growth inhibition for these agents is 
outlined below (Figure 2.93) and the one-dose mean graphs for each of the 
compounds depicted in Figure 2.92 are presented in Appendix II. 




Figure 2.93 Mean growth% for difluoro substituted indazoles 
The isopropyl ester-containing indazole 179 shows the most selective 
growth inhibition 42.43% observed for these compounds on the HOP-92 lung 
cancer cell line and 179 also shows activity against the CNS SNB-75 cell line 
(72.14%), which is an in vitro model for astrocytoma-type brain cancer. The t-
butyl derivative 180 shows slightly decreased similar selective inhibition against 
the same CNS cell line (80.16%) and the melanoma UACC-62 cell line (80.34%). 
The bulky 2-ethylbutyl ester-containing indazole 183 shows an elevated 
mean growth % inhibition in comparison to aryl unsubstituted indazoles 
containing a bulky ester side chain while also showing an impressive 43.1% 
growth inhibition on the T-47D breast cancer cell line. The amide-containing 
derivative 185 exhibits the most active mean growth percent while also showing 
higher selective activity against the lung (68.03%), renal (67.7%) and prostate 
(68.93%) cell lines in comparison to its ester analogues. The benzyl ester-
containing indazole 181 shows some selectivity against the colon cancer KM12 
cell line (87.73%) and the breast cancer MDA-MB-231 cell line (85.5%). All 
derivatives show some selective activity against lung, renal, prostate and breast 

























Figure 2.94 Altering side chain of difluoro derivatives 
 On comparison of the dimethyl-substituted indazole derivatives 168 and 
169 to difluoro-substituted indazole derivatives 179 and 187, it is clear that the 
methyl groups on the aryl ring have a dramatic effect on the growth inhibition of 
the OVCAR-4 ovarian cancer cell line but when the methyl groups are replaced 
by fluorines, the effect on the OVCAR-4 cell line is completely switched off 
(Figure 2.95).  
 The difluoro indazole 179 has a more potent effect on the HOP-92 lung 
cancer cell line (42.43%) than its dimethyl analogue 168 (67.06%) suggesting that 
the isopropyl group is beneficial to activity against this particular cell line and that 
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also has a favourable effect on the activity against the SNB-75 CNS cancer cell 









Figure 2.95 Comparison of dimethyl and difluoro indazoles 
 With previous results in mind, the next series of compounds sent for 
biological evaluation consisted of methyl- and fluoro-disubstituted indazole rings, 
containing isopropyl side chain esters in the 3-position. We were keen to evaluate 
our novel derivatives benzylated in the N-1 position due to their similarity to drug 
compounds on the market and compare them to their or N-2 analogues (Figure 
2.96). These compounds 264-267 were successfully investigated for initial NCI-
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Figure 2.96 N-Benzyl indazole derivatives 
 An account of the growth inhibition for these agents is outlined below and 
the one-dose mean graphs for each of the compounds depicted in Figure 2.96 are 
presented in Appendix II. The highest mean % growth across all 60 cancer cell 
lines in this project was observed for N-1 benzylated difluoro-indazole 266 
(Figure 2.97). 
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 On examination of the one-dose mean graphs, some interesting selectivity 
for inhibition of particular cell lines could be observed. It was found that by 
altering the benzyl substitution position from the 1-position to the 2-position of 
the indazole results in contrasting activity and selectivity across the 60 cell line 
panel.  
 For difluoro derivatives 266 and 267 the N-1 benzyl indazole 266 
performed best in terms of activity across the 60 cell line panel and also in 
selectivity and growth inhibition against certain cell lines in comparison to N-2 
benzyl indazole 267. As shown in Figure 2.98, N-1 benzyl derivative 266 is a 
much more potent agent for inhibition of a number of cell lines in comparison to 
the N-2 analogue. Other selective activity not shown below includes growth 
inhibition of the K-562 leukaemia cell line (68.09%), the NCI-H522 lung cancer 
cell line (51.91%), the HT29 colon cancer cell line (58.88%), the CAKI-1 renal 
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 In contrast to the difluoro derivatives 266 and 267, the N-2 dimethyl 
indazole 265 exhibits slightly increased activity across the 60 cell lines in 
comparison to the N-1 indazole 264. However, the N-1 benzyl indazole displays a 
more selective growth inhibition profile.   
On inspection of the one-dose mean graphs, we can see that when treated 
with 264, the growth of the RPM-8228 leukaemia cell line (in vitro model of 
plasmacytoma and myeloma) is inhibited to 27.73% growth, a significant 
difference when compared to the N-2 analogue 265 (85.4%). The N-2 analogue, 
however, displays an increased activity profile against lung, colon and breast 
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2.10.2.3 COMPARE analysis 
The NCI COMPARE programme is an online database and comparison 
tool which can analyse one-dose and five-dose cytotoxicity data for the 60 cell line 
panel for similar activity profiles with compounds screened previously by the 
DTP. The COMPARE algorithm was developed by the NCI to help predict a 
biochemical mechanism of action from the in vitro anti-tumour screen.100 
Comparison of the mean graph cytotoxicity profile for a certain anti-cancer agent 
having a known mechanism of action with those of single compounds not 
previously characterised allows the identification of new agents with similar 
cytotoxicity profiles to that of the ‘seed’ compound, which may share the same 
mechanism of action.101 A high correlation of cytotoxicity with compounds of 
known biological activity can predict the compounds mechanism of action. It can 
also tell if the compound has any unique response of the drug in comparison to the 
known compounds.  
COMPARE analysis was carried out for a number of our most active 
derivatives 168, 169, 265 and 267 to see if their mechanisms of action were 
similar, even after changing substitution patterns. Derivatives 168 and 169 were 
investigated initially as they were observed to show the greatest activity on the 
OVCAR-4 ovarian cancer cell line at one-dose levels, exhibiting selective growth 
inhibition of 97.23 and 99.53% respectively. 
It was found that derivatives 168 and 169 have a definite correlation value 
of 0.81 at the one-dose concentration level, indicating the existence of a similar 
biological mode of action despite alteration of the alkyl group of the ester in the 
3-position from an isopropyl group to a decyl group as would be expected (Figure 
2.100). 
Figure 2.100 Derivatives with high correlation value possibly sharing mechanism 
of action 




The N-2 benzyl substituted dimethyl 265 and difluoro indazoles 267 were 
found to have a high correlation between the analogues of 0.74, again indicating a 
similar biological mechanism of action in spite of 265 containing two electron 
donating methyl groups on the aryl ring and 267 having two electron withdrawing 





Figure 2.101 Derivatives possibly sharing mechanism of action 
Both derivatives had been found to be highly potent against a number of cell lines 
as illustrated in Figure 2.102. The difluoro analogue 267 exhibits an increased 
inhibitory effect against the particular cell lines in comparison to dimethyl 
derivative 265.  
 






























2.10.3 Introduction to CO-ADD antimicrobial testing 
 A new not-for-profit initiative was launched in March 2015 where 
compounds could be screened for antibiotic activity by “The Community for 
Antimicrobial Drug Discovery” (CO-ADD) in a worldwide search for the next big 
antibiotic.102 The CO-ADD reached out to chemists in academia and research 
organisations who have synthesised novel compounds for other projects and would 
not otherwise be screened for antimicrobial activity. They believe there is 
untapped diversity in the scale of >36 million compounds contained in the 
laboratories of academic and small biotech companies, with thousands of chemists 
discovering and synthesising more every day.  
 These compounds are screened at no cost against a key panel of drug-
resistant bacterial strains and researchers who get positive results from initial 
screening have the option to proceed to further development using the CO-ADD’s 
resources. Samples are screened primarily against 5-7 ESKAPE bacterial 
pathogens and two fungal/yeast pathogens and if active, will be brought further 
through the screening stages.103 
This organisation’s integrated capabilities can help fast track hit 
compounds from the early stages to identification of a new drug candidate.  
This unique opportunity allows the worldwide community of researchers 
to submit novel compounds for free and readily accessible antimicrobial testing of 
compounds that otherwise would not have been investigated for their antibiotic 
activity.  
 Figure 2.103 shows the range of indazole deriatives sent for antimicrobial 
testing. By sending a large range of diverse compounds it was hoped to see a trend 
emerge to direct the project towards altering the structures so that antibiotic 
activity would be increased.  


















Figure 2.103 19 compounds submitted to CO-ADD for antimicrobial screening 




2.10.4 Conclusion to biological testing 
 From the 40 compounds submitted to the NCI for biological screening to 
date, 21 were accepted and assessed for their anticancer activity. The initial one-
dose screening was extremely useful in identifying which structural features to 
target in future submissions and in future synthesis of novel indazole compounds 
in this project. Future synthetic studies within the research group will look at 
further exploring the N-alkyl derivatives by using substituted benzyl groups and 
long chain alkyl halides as potential alkylating agents for these compounds.  
 Derivatives having undergone side-chain transformations like the epoxide 
and tertiary amine indazole derivatives will be sent for testing in the future. 
Previously, a 1H-indazole with the epoxide side chain was not accepted for testing 
but perhaps substitution in the 1-position would increase the chances of being 
accepted. Surprisingly, no N-1 unsubstituted indazole derivatives were accepted 
for testing. Work within the group has also discovered that structures containing 
aldehydes are not usually accepted to the NCI for assessment. 
 The one-dose screening results have shown that the initial aryl-
unsubstituted indazole deriatives do not show significant biological action against 
the NCI-60 cell array but increased selectivity was seen in growth inhibition of 
particular cancer cell lines in the presence of our substituted derivatives. For 
example, our most active derivatives showed remarkable inhibition across ovarian 
cancer cell lines (168 and 169), lung cancer cell lines (179), leukaemia cell lines 
(264) and breast cancer cell lines (266) (Figure 2.104). 
  
 





Figure 2.104 Most active compounds in NCI evaluation 
 To conclude, it is evident from these investigations that indazole-
containing derivatives are an important class of heterocyclic compounds which, 
through some structural modification and biological evaluation, possess unique 
bioactivity and much potential for the development of novel anticancer agents. 









2.11 Concluding remarks 
The overall synthetic achievement of this project was the successful 
synthesis of a range of novel compounds (>160) and specifically, indazole 
derivatives (>100), through a number of tailored and modified synthetic routes in 
high purities and good yields. This initial project has great potential for expansion 
as most routes explored so far have more novelty to be further investigated. 
Following on from the synthetic strategies put in place during the course of this 
work, a number of potential target molecules could be identified for future 
synthesis. 
The initial indazole formation cycloaddition reactions were accomplished 
using an established method that uses aryne precursors as the dipolarophile and 
diazocarbonyl compounds as the 1,3-dipole, both of which were prepared in the 
laboratory. We were able to easily diversify the indazole derivatives formed by 
altering the diazo and/or aryne precursor starting materials. This method used 2-
trimethylsilylphenyltriflate derivatives and caesium fluoride to generate the aryne 
in situ. 
During the project, a newer and less exploited method of aryne generation 
was discovered that had not been fully taken advantage of yet in indazole 
formation before our research. Tailoring this method to suit our chemical 
syntheses provided a new method that was more cost effective and limited the 
formation of by-products in comparison to the more established method used 
previously. This method generated a 2-trimethylsilylphenylnonaflate which 
subsequently formed the aryne in situ in a one-pot reaction. 
Initial studies into using the nonaflate method for the generation of 
pyridyne intermediates were initially investigated. Two novel pyridyne precursors 
were prepared in the laboratory but unfortunately with no success with these in 
cycloaddition reactions so far. There is much scope for the expansion and 
improvement of this foundation work.  
 A route to a mild and general deacylation method of N-acyl indazoles was 
established in this project. This gave rise to a number of novel indazoles being 
synthesised and the potential for derivatisation at the N-1 position. 




A method for successful alkylation of the 1H-indazoles was identified that 
gave rise to the formation of both N-1- and N-2-benzylated isomers which were 
separable by column chromatography on silica gel producing compounds similar 
in structure to some indazole derivatives on the market.  
Initial investigations into side chain transformations of the functionalisable 
ester group of some indazole derivatives were performed, giving rise to even more 
structurally varied indazole derivatives and a range of novel functionalised 
derivatives. 
 Four rounds of biological testing involving 21 novel derivatives took place 
at the NCI where some structural-activity patterns were identified and encouraging 
anti-cancer activity was observed for some derivatives. 
An antimicrobial screen was performed by CO-ADD on 19 novel indazole 
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3.1 General Procedures 
Solvents were distilled prior to use as follows: dichloromethane (DCM) 
was distilled from phosphorus pentoxide,1 ethyl acetate was distilled from 
potassium carbonate,2,3 hexane was stored and distilled prior to use, 
tetrahydrofuran (THF) was distilled from sodium benzophenone ketyl, 
dimethylformamide (DMF) was stored for 24 h over calcium hydride then distilled 
under reduced pressure and stored over 4Å molecular sieves. 3-
Chloroperoxybenzoic acid (70%) was supplied by Aldrich and used without 
purification. Caesium fluoride was supplied by Aldrich and stored in a desiccator. 
Organic phases were dried using anhydrous magnesium sulphate. All commercial 
reagents were used without further purification unless otherwise stated. 
 
Proton (300 MHz) and carbon (75.5 MHz) NMR spectra were recorded on 
a Bruker Avance 300 MHz NMR spectrometer. Proton (400 MHz), carbon (100 
MHz) and fluorine (376 MHz) NMR spectra were recorded on a Bruker Avance 
400 MHz NMR spectrometer. All spectra were recorded at room temperature (~20 
ºC) in deuterated chloroform (CDCl3) unless otherwise stated using 
tetramethylsilane (TMS) as internal standard. Chemical shifts (δH and δC) are 
reported in parts per million (ppm) relative to TMS and coupling constants are 
expressed in Hertz (Hz). Splitting patterns in 1H spectra are designated as s 
(singlet), br s (broad singlet), d (doublet), t (triplet), q (quartet), dd (doublet of 
doublets), ddd (doublet of doublets of doublets), dt (doublet of triplets), dq 
(doublet of quartets) and m (multiplet). 13C NMR spectra were assigned with the 
aid of DEPT experiments. Compounds which were assigned with the aid of DEPT 
experiments were assigned by identifying the carbon type (CH3, CH2, CH or C). 
 
Infra red spectra were recorded as thin films on sodium chloride (NaCl) 
plates, as potassium bromide (KBr) discs for solids or as solution spectra in CDCl3 
on a Perkin Elmer Paragon 1000 FT-IR spectrometer. Melting points were 
measured on a Uni-Melt Thomas Hoover capillary melting point apptus and are 
uncorrected. Flash chromatography was performed using Kieselgel silica gel 60, 
0.040-0.063 mm (Merck). Thin layer chromatography (TLC) was carried out on 
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pre-coated silica gel plates (Merck 60 PF254). Visualisation was achieved by UV 
(254 nm) light detection and vanillin staining. 
 
Elemental analyses were performed by the Microanalysis Laboratory, 
National University Ireland, Cork using Perkin-Elmer 240 and Exeter Analytical 
CE440 elemental analysers. Nominal mass spectra were recorded on a Waters 
Quattro Micro triple quadrupole spectrometer in electrospray ionisation (ESI) 
mode using 50% water/acetonitrile containing 0.1% formic acid as eluent; samples 
were made up in acetonitrile. High resolution mass spectra (HRMS) were recorded 
on a Waters LCT Premier Time of Flight spectrometer in electrospray ionisation 
(ESI) mode using 50% water/acetonitrile containing 0.1% formic acid as eluent; 
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3.2 Synthesis of α-diazocarbonyl compounds 
3.2.1 Preparation of ester derivatives by transesterification4 
3,7-Dimethylocta-2,6-dienyl 3-oxobutanoate 2  
Geraniol 310 (1.54 g, 10.0 mmol, 1.0 equiv.) was added to a stirred solution 
of ethyl acetoacetate 311 (1.30 g, 10.0 mmol, 1.0 equiv.) in toluene (40 mL). 3-
nitrophenylboranic acid 1 (42 mg, 250 μmol, 2.5 mol%) was then added as 
catalyst. The reaction was heated under reflux (150 °C) with the toluene-ethanol 
azetrope continuously removed from the reaction using a Dean-stark distillation 
apptus. TLC analysis after 5 h indicated complete consumption of the ethyl 
acetoacetate 311 starting material and, after cooling, the toluene was removed 
under reduced pressure to yield 3,7-dimethylocta-2,6-dienyl 3-oxobutanoate 2 as 
a yellow oil (0.78 g, 66%), which was used without further purification. The 13C 
NMR spectra were assigned to the keto and enol forms as listed below.  Keto 
form: δH(CDCl3, 300 MHz): 1.61 (3H, s, CH3), 1.68 (3H, s, CH3), 1.71 (3H, s, 
CH3), 2.01-2.13 (4H, m, 2 × CH2), 2.27 [3H, s, C(O)CH3], 3.46 [2H, s, 
C(O)CH2C(O)], 4.65 (2H, d, J 7.2, OCH2), 5.07 [1H, t, J 7.2, CH=C(CH3)2], 5.35 
[1H, t, J 7.2, OCH2CH=C(CH3)]; δC(CDCl3, 100 MHz): 16.4 (CH3), 17.6 (CH3), 
25.6 (CH3), 26.2 (CH2), 30.0 [C(O)CH3], 39.5 (CH2), 50.1 [C(O)CH2C(O)], 62.2 
(OCH2), 117.7 (CH) alkene, 123.6 (CH) alkene, 131.8 [Cq(CH3)2], 143.0 (Cq) 
alkene, 167.1 (C=O) ester, 200.5 (C=O) ketone; max (film)/cm-1 1742, 1719, 1649, 
1152; m/z (ESI+) 238 [M]+ (10%) 162 (100).  
 
Enol form: δC(CDCl3, 100 MHz): 14.0 (CH3), 16.2 (CH3), 21.1 (CH3COH), 26.4 
(CH2), 30.0 (CH3), 39.5 (CH2), 59.3 (OCH2), 89.7 (CH) alkene, 123.5 (CH) 
alkene, 123.9 (CH) alkene, 139.4 [Cq(CH3)2], 142.3 (Cq) alkene, 172.5 (C=O), 
175.3 (COH). Spectral details are in agreement with those reported in the 
literature.5 
 
    Chapter 3: Experimental 
234 
 
3,7-Dimethyloct-6-enyl 3-oxobutanoate 3   
The title compound was prepared following the same procedure as 3,7-
dimethylocta-2,6-dienyl 3-oxobutanoate 2 using citronellol 312 (2.39 g, 15.4 
mmol), ethyl acetoacetate 311 (2.01 g, 15.4 mmol) in toluene (50 mL) and 3-
nitrophenylboranic acid 1  (64 mg, 384 µmmol, 2.5 mol%). After 5 h the toluene 
was removed under reduced pressure to yield 3,7-dimethyloct-6-enyl 3-
oxobutanoate 3 as a yellow oil (3.48 g, 94%) as a mixture of diastereoisomers 
which were indistinguishable in the 1H NMR spectrum and was used without 
further purification. δH(CDCl3, 400 MHz): 0.91 (3H, d, J 6.3, CHCH3), 1.12-1.79 
[11H, m, containing CH, 2 × CH2, 1.61 (3H, s, CH3) and 1.68 (3H, s, CH3)], 1.92-
2.15 (2H, m, OCH2CH2), 2.27 [3H, s, C(O)CH3], 3.45 [2H, s, C(O)CH2C(O)], 
4.12-4.30 (2H, m, OCH2), 5.08 [1H, t, J 7.1, CH=C(CH3)2]; δC(CDCl3, 100 MHz): 
17.6 (CH3), 19.3 (CH3), 25.3 (CH2), 25.7 (CH3), 29.4 [C(O)CH3], 30.1 (CH), 35.3 
(CH2), 36.9 (CH2), 50.2 [C(O)CH2C(O)], 64.0 (OCH2), 124.5 (CH) alkene, 131.4 
(Cq) alkene, 167.2 (C=O) ester, 200.5 (C=O) ketone. max (film)/cm-1 1749, 1718, 
1654; m/z (ESI+) 241 [M + H]+ (7%); HRMS (ESI+): exact mass calculated for 
C14H25O3 [M + H]+ 241.1804. Found 241.1803. 
 
Note: Trace amount of enol form visible in 13C NMR spectrum with characteristic 
peaks at δC(ppm) 21.2 (CH3COH), 89.8 (CH) alkene, 172.5 (C=O) ester, 175.4 
(COH). Spectral details are in agreement with those reported in the literature.6 
 




The title compound was prepared following the procedure described for 3,7-
dimethyloct-6-enyl 3-oxobutanoate 2 using butan-2-ol 313 (1.79 g, 23.1 mmol), 
ethyl acetoacetate 311 (2.00 g, 23.1 mmol) and 3-nitrophenylboranic acid 1  (95 
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mg, 576 µmmol, 2.5 mol%) in toluene (50 mL). After 5 h the toluene was removed 
under reduced pressure to yield the reaction mixture as a pale yellow oil. 
Following purification of the crude product by column chromatography on silica 
gel using hexane:ethyl acetate (95:5) as eluent, sec-butyl 3-oxobutanoate 4 was 
isolated as a pale orange oil (1.97 g, 54%). δH(CDCl3, 400 MHz): 0.91 (3H, t, J 
7.4, CH2CH3), 1.23 (3H, d, J 6.3, CHCH3), 1.48-1.70 (2H, m, CH2CH3), 2.26 [3H, 
s, C(O)CH3], 3.43 [2H, s, C(O)CH2C(O)], 4.85-4.95 (1H, m, OCH); δC(CDCl3, 
100 MHz): 9.5 (CH2CH3), 19.3 (CHCH3), 28.6 (CH2CH3), 30.0 [C(O)CH3], 50.4 
[C(O)CH2C(O)], 73.5 (OCH), 166.7 (C=O) ester, 200.6 (C=O) ketone; max 
(film)/cm-1 1741, 1716; HRMS (ESI+): exact mass calculated for C8H15O3 [M + 
H]+  159.1021. Found 159.1023.  
 
Note: Trace amount of enol form visible in 13C NMR spectrum with characteristic 
peaks at δC(ppm) 21.1 (CH3COH), 90.1 (CH) alkene, 172.4 (C=O) ester, 175.2 
(COH). Spectral details are in agreement with those reported in the literature.7 
 




The title compound was prepared following the procedure described for 
3,7-dimethyloct-6-enyl 3-oxobutanoate 2 using 2-ethylbutan-1-ol 314 (2.35 g, 
15.4 mmol), ethyl acetoacetate 311 (3.01 g, 15.4 mmol) and 3-nitrophenylboranic 
acid 1  (64 mg, 384 µmmol, 2.5 mol%) in toluene (50 mL). After 5 h the toluene 
was removed under reduced pressure to yield 2-ethylbutyl 3-oxobutanoate 5 as a 
colourless oil (2.68 g, 95%), which was used without further purification. 
δH(CDCl3, 300 MHz): 0.89 (6H, t, J 7.5, 2 × CH3), 1.31-1.41 (4H, m, 2 × CH2CH3), 
1.47-1.60 (1H, m, CH), 2.27 [3H, s, C(O)CH3], 3.47 [2H, s, C(O)CH2C(O)], 4.07 
(2H, d, J 6.0, OCH2); δC(CDCl3, 100 MHz): 10.8 (2 × CH3), 22.8 (2 × CH2), 30.0 
[C(O)CH3], 40.2 (CH), 50.2 [C(O)CH2C(O)], 67.5 (OCH2), 167.2 (C=O) ester, 
200.5 (C=O) ketone; max (film)/cm-1 1745, 1716; m/z (ESI+) 186 [M]+ (100%).  
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Note: Trace amount of enol form visible in 13C NMR spectrum with characteristic 
peaks at δC(ppm) 21.1 (CH3COH), 89.7 (CH) alkene, 172.8 (C=O) ester, 175.3 
(COH). Spectral details are in agreement with those reported in the literature.8 
 




The title compound was prepared following the procedure described for 
3,7-dimethyloct-6-enyl 3-oxobutanoate 2 using 2-ethyl-1-hexanol 315 (2.40 g, 
15.4 mmol), ethyl acetoacetate 311 (2.04 g, 15.4 mmol) and 3-nitrophenylboranic 
acid 1  (64 mg, 384 µmmol, 2.5 mol%) in toluene (50 mL). After 5 h the toluene 
removed under reduced pressure to yield 2-ethylhexyl 3-oxobutanoate 6 as a 
colourless oil (3.09 g, 94%), which was used without further purification. 
δH(CDCl3, 300 MHz): 0.86-0.91 (6H, m, 2 × CH3), 1.20-1.45 (8H, m, 4 × CH2), 
1.52-1.62 (1H, m, CH), 2.27 [3H, s, C(O)CH3], 3.43 [2H, s, C(O)CH2C(O)], 4.07 
(2H, d, J 5.8, OCH2); δC(CDCl3, 100 MHz): 10.9 (CH3), 14.1 (CH3), 22.7 (CH2), 
23.1 (CH2), 28.8 (CH2), [C(O)CH3], 30.3 (CH2), 38.7 (CH), 50.0 [C(O)CH2C(O)], 
67.7 (OCH2), 167.3 (C=O) ester, 200.5 (C=O) ketone; max (film)/cm-1 1742, 1717; 
m/z (ESI+) 215 [M + H]+ (5%); HRMS (ESI+): exact mass calculated for C12H23O3 
[M + H]+ 215.1647. Found 215.1645. 
 
Note: Trace amount of enol form visible in 13C NMR spectrum with characteristic 
peaks at δC(ppm) 21.1 (CH3COH), 89.7 (CH) alkene, 172.8 (C=O) ester, 175.3 
(COH). Spectral details are in agreement with those reported in the literature.9 
 




The title compound was prepared following the procedure described for 
3,7-dimethyloct-6-enyl 3-oxobutanoate 2 using isopropanol 316 (0.75 g, 12.6 
mmol), methyl 3-oxoheptanoate 317 (2.03 g, 12.6 mmol) and 3-
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nitrophenylboronic acid (52 mg, 316 μmol, 2.5 mol%) in toluene (50 mL). After 
5 h the toluene was removed to give the reaction mixture as a yellow oil. Following 
purification of the crude product by chromatography on silica gel, using 
hexane:ethyl acetate (80:20) as eluent, isopropyl 3-oxoheptanoate 7 (1.65 g, 70%) 
was isolated as an orange oil. δH(CDCl3, 400 MHz): 0.92 (3H, t, J 7.3, CH3), 1.27-
1.39 {8H, m containing [1.27 (6H, d, J 6.3, 2 × CH3) and CH2]}, 1.52-1.61 (2H, 
m, CH2), 2.51 [2H, t, J 7.4, C(O)CH2], 3.49 [2H, s, C(O)CH2C(O)], 5.06 (1H, 
septet, J 6.2, OCH); δC(CDCl3, 100 MHz): 13.7 (CH3), 21.7 (2 × CH3), 22.1 (CH2), 
25.5 (CH2), 42.6 (CH2), 49.6 [C(O)CH2C(O)], 68.9 (OCH), 166.8 (C=O) ester, 
203.0 (C=O) ketone.  max (film)/cm-1 1734, 1718. m/z (ESI+) 187 [M + H]+ (22%), 
185 (100); HRMS (ESI+): exact mass calculated for C10H19O3 [M + H]+ 187.1334. 
Found 187.1308. Spectral details are in agreement with those reported in the 
literature.10 
 
Note: Trace amount of enol form visible in 13C NMR spectrum with characteristic 
peaks at δC(ppm) 89.3 (CH) alkene, 172.4 (C=O) ester, 178.8 (COH).  
 
t-Butyl 3-oxoheptanoate 8 
The title compound was prepared following the 
procedure described for 3,7-dimethyloct-6-enyl 3-
oxobutanoate 2 using t-butanol 318 (0.94 g, 12.7 
mmol), methyl 3-oxoheptanoate 317 (2.01 g, 12.7 mmol) and 3-
nitrophenylboranic acid 1  (52 mg, 316 μmol, 2.5 mol%) in toluene (40 mL). After 
5 h the toluene was removed to give the reaction mixture as a yellow oil. Following 
purification of the crude product by chromatography on silica gel using 
hexane:ethyl acetate (70:30) as eluent, t-butyl 3-oxoheptanoate 8 was isolated as 
a light brown oil (1.45 g, 57%). δH(CDCl3, 400 MHz): 0.91 (3H, t, J 7.2, CH2CH3), 
1.29-1.37 (2H, m, CH2), 1.47 (9H, s, 3 × CH3), 1.52-1.62 (2H, m, CH2), 2.53 [2H, 
t, J 7.2, C(O)CH2CH2], 3.34 [2H, s, C(O)CH2C(O)]; δC(CDCl3, 100 MHz): 13.8 
(CH3), 22.2 (CH2), 25.6 (CH2), 27.9 (3 × CH3), 42.6 [C(O)CH2CH2], 50.7 
[C(O)CH2C(O)], 81.8 (OCq), 166.6 (C=O) ester, 203.5 (C=O) ketone; max 
(film)/cm-1 1747, 1720, 1323; m/z (ESI-) 200 M+ (5%), 241 (100); HRMS (ESI+): 
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exact mass calculated for C11H21O3 [M + H]+ 201.1491. Found 201.1477. Spectral 
details are in agreement with those reported in the literature.11 
 
Propyl 3-oxoheptanoate 9 
The title compound was prepared following the 
procedure described for 3,7-dimethyloct-6-enyl 3-
oxobutanoate 2 using n-propanol 319 (0.76 g, 12.7 
mmol), methyl 3-oxoheptanoate 317 (2.02 g, 12.7 mmol) and 3-
nitrophenylboronic acid 1 (52 mg, 316 μmol, 2.5 mol%) in toluene (50 mL). After 
5 h the toluene was removed to give the reaction mixture as a yellow oil. Following 
purification of the crude product by chromatography on silica gel, using 
hexane:ethyl acetate (80:20) as eluent, propyl 3-oxoheptanoate 9 was isolated as 
an orange oil (1.98 g, 84%). δH(CDCl3, 300 MHz): 0.91-0.99 [6H, m, containing 
0.91 (3H, t, J 7.2, CH3) and 0.94 (3H, t, J 7.2, CH3)], 1.26-1.38 (2H, m, CH2), 
1.52-1.72 (4H, m, 2 × CH2), 2.53 [2H, t, J 7.2, C(O)CH2CH2], 3.44 [2H, s, 
C(O)CH2C(O)], 4.09 (2H, t, J 6.8, OCH2); δC(CDCl3, 100 MHz): 10.3 (CH3), 13.8 
(CH3), 21.9 (CH2), 22.1 (CH2), 25.5 (CH2), 42.7 [C(O)CH2CH2], 49.3 
[C(O)CH2C(O)], 66.9 (OCH2), 167.4 (C=O) ester, 202.9 (C=O) ketone; max 
(film)/cm-1 1748, 1717; m/z (ESI+) 187 [M + H]+ (100%), 209 (88); HRMS (ESI+): 
exact mass calculated for C10H19O3 [M + H]+ 187.1326. Found 187.1334.  
 
Decyl 3-oxobutanoate 10   
 
The title compound was prepared following the procedure described for 
3,7-dimethyloct-6-enyl 3-oxobutanoate 2 using decanol 320 (2.92 g, 15.4 mmol), 
ethyl acetoacetate 311 (2.01 g, 15.4 mmol) and 3-nitrophenylboranic acid 1  (64 
mg, 384 µmmol, 2.5 mol%) in toluene (45 mL). After 5 h the toluene was removed 
under reduced pressure and decyl 3-oxobutanoate 10 was isolated as colourless oil 
(3.32 g, 89%) and was used without further purification. The 13C NMR spectra 
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were assigned to the keto and enol forms as listed below. δH(CDCl3, 300 MHz): 
0.86 (3H, t, J 7.2, CH3), 1.15-1.45 (14H, m, 7 × CH2), 1.50-1.73 (2H, m, CH2), 
2.27 [3H, s, C(O)CH3], 3.45 [2H, s, C(O)CH2C(O)], 4.13 (2H, t, J 7.2, OCH2); 
δC(CDCl3, 100 MHz): 14.0 (CH3), 22.6 (CH2), 25.7 (CH2), 28.4 (CH2), 29.1 (CH2), 
29.2 (CH2), 29.45 (CH2), 29.47 (CH2), 30.0 [C(O)CH3], 31.8 (CH2), 50.1 
[C(O)CH2C(O)], 65.5 (OCH2), 167.2 (C=O) ester, 200.5 (C=O) ketone; max 
(film)/cm-1 1734, 1718; m/z (ESI-) 241 [M - H]- (50%); HRMS (ESI+): exact mass 
calculated for C14H27O3 [M + H]+ 243.1960. Found 243.1956. 
 
Enol form: δC(CDCl3, 100 MHz): 14.0 (CH3), 21.1 (CH3COH), 25.7 (CH2), 28.9 
(CH2), 29.2 (CH2), 29.3 (CH2), 29.4 (CH2), 29.5 (CH2), 29.6 (CH3), 30.1 (CH2), 
63.0 [CH2C(O)], 64.1 (OCH2), 89.8 (CH) alkene, 172.5 (C=O) ester, 175.3 (COH). 
Spectral details are in agreement with those reported in the literature.12 
 
Undec-10-en-1-yl 3-oxobutanoate 11  
The title compound was prepared following the procedure described for 
3,7-dimethyloct-6-enyl 3-oxobutanoate 2 using undec-10-en-1-ol 321 (2.41 g, 
15.4 mmol), ethyl acetoacetate 311 (2.00 g, 15.4 mmol)  and 3-nitrophenylboranic 
acid 1  (64 mg, 384 µmmol, 2.5 mol%) in toluene (50 mL). After 5 h the toluene 
was removed under reduced pressure to yield undec-10-en-1-yl 3-oxobutanoate 11 
as a colourless oil (3.78 g, 97%), which was used without further purification. The 
13C NMR spectra were assigned to the keto and enol forms as listed below. 
δH(CDCl3, 400 MHz): 1.21-1.45 (12H, m, 6 × CH2), 1.59-1.70 (2H, m, CH2), 2.01-
2.07 (2H, m, CH2), 2.26 [3H, s, C(O)CH3], 3.45 [2H, s, C(O)CH2C(O)], 4.13 (2H, 
t, J  6.7, OCH2), 4.90-5.02 (2H, m, CH=CH2), 5.74-5.87 (1H, m, CH=CH2); 
δC(CDCl3, 100 MHz): 25.7 (CH2), 28.4 (CH2), 28.8 (CH2), 29.0 (CH2), 29.1 (CH2), 
29.3 (CH2), 29.3 [C(O)CH3], 33.7 (CH2), 50.0 [C(O)CH2C(O)], 65.4 (OCH2), 
114.1 (CH2) alkene, 139.0 (CH) alkene, 167.1 (C=O) ester, 200.5 (C=O) ketone; 
max (film)/cm-1 1734, 1718, 1640; m/z (ESI+) 255 [M + H]+ (8%); HRMS (ESI+): 
exact mass calculated for C15H27O3 [M + H]+ 255.1960. Found 255.1962. 




Enol form: δC(CDCl3, 100 MHz): 21.1 (CH3COH), 25.9 (CH2), 28.7 (CH2), 29.0 
(CH2), 29.1 (CH2), 29.2 (CH2), 29.3 (CH2), 32.8 (CH2), 63.0 [CH2C(O)], 64.1 
(OCH2), 89.7 (CH) alkene, 172.7 (C=O) ester, 175.3 (COH). Spectral details are 
in agreement with those reported in the literature.13 
 
3.2.2 Preparation of diazo transfer reagent 
Caution: Diazo transfer reagents are potentially hazardous reagents and 
extreme care should be taken in their use14-16. They are shock sensitive and in the 
case of p-toluenesulfonyl azide 13 (tosyl azide 13), which is a solid below room 
temperature, it should not be scraped out of its container as it may explode. Instead, 
tosyl azide 13 should be allowed to warm to its melting point (ca. 20 °C) and then 
be pipetted from its container using a clean Pasteur pipette which has no sharp 
edges. The preparation or concentration of solutions containing diazo transfer 
reagents was carried out in a well-ventilated fumehood behind a safety shield.  For 
safety reasons only one batch of tosyl azide 13 was made and stored in the 
laboratory at any one time. Tosyl azide 13 was stored in a freezer. 
  
4-Toluenesulfonyl azide 13  
A solution of p-toluenesulfonyl chloride 14 (13.00 g, 63.0 
mmol) in acetone (30 mL) was added dropwise over 15 
min to a stirred solution of sodium azide 15 (4.34 g, 67.0 
mmol) in water (15 mL) and acetone (30 mL) in an ice bath at 0°C. Once the 
addition was complete, the reaction mixture was stirred at ambient temperature for 
2 h after which time the acetone was removed under reduced pressure. The 
aqueous solution was extracted with DCM (30 mL) and the organic layer was then 
washed with water (2 × 20 mL) and brine (2 × 20 mL). The organic layer was dried 
with MgSO4 and concentrated under reduced pressure without heating the water 
bath, to yield pure p-toluenesulfonyl azide 13 as a colourless oil which crystallised 
to a white solid on refrigeration (12.22 g, 98%). δH(CDCl3, 400 MHz) 2.48 (3H, 
s, CH3), 7.41 (2H, d, J 8.0, 2 × ArCH), 7.82-7.85 (2H, m, 2 × ArCH); max 
    Chapter 3: Experimental 
241 
 
(film)/cm-1 2129, 1595, 1371, 1172. Spectral details are in agreement with those 
reported in the literature.17 
3.2.3 Diazo transfer reactions to β-ketoesters 
Room temperature addition of tosyl azide 13 and work-up as described by 
Regitz18-21 
Variation of ester side-chain 
Methyl 2-diazo-3-oxobutanoate 18 
Triethylamine (1.45 mL, 10.4 mmol) was added to a stirred 
solution of methyl acetoacetate 17 (2.07 g, 10.4 mmol) in 
acetonitrile (25 mL). After 2 min a solution of p-
toluenesulfonyl azide 13 (2.05 g, 10.4 mmol) in acetonitrile (25 mL) was added 
dropwise at room temperature over 15 min to yield a bright yellow solution.  The 
reaction was stirred for 18 h under a nitrogen atmosphere. After 18 h, TLC analysis 
showed complete consumption of the ester starting material and the reaction 
mixture was concentrated under reduced pressure. The resulting cream residue 
was dissolved in diethyl ether (40 mL) and washed with 9% KOH (2 × 50 mL) 
followed by water (50 mL). The organic layer was dried with MgSO4 and 
concentrated under reduced pressure to yield methyl 2-diazo-3-oxobutanoate 18 
as a bright yellow oil (1.93 g, 80%), which was used without further purification. 
δH(CDCl3, 300 MHz): 2.49 [3H, s, C(O)CH3], 3.85 (3H, s, OCH3); δC(CDCl3, 100 
MHz): 28.1 [C(O)CH3], 52.2 (OCH3), 161.8 (C=O) ester, 190.0 (C=O) ketone, no 
signal observed for (C=N2); m/z (ESI+) 143 [M + H]+ (26%), 74 (100), 144 (12); 
max (film)/cm-1 2144, 1726, 1660, 1317. Spectral details are in agreement with 
those reported in the literature.22 
 
Ethyl 2-diazo-3-oxobutanoate 19  
The title compound was prepared following the procedure 
described for methyl 2-diazo-3-oxobutanoate 18 using 
triethylamine (2.15 mL, 15.4 mmol), ethyl acetoacetate 311 
(2.01 g, 15.4 mmol) in acetonitrile (25 mL) and p-toluenesulfonyl azide 13 (3.03 
g, 15.4 mmol) dissolved in acetonitrile (25 mL).  The reaction was stirred at room 
temperature under a nitrogen atmosphere for 18 h. Following the work-up,ethyl 2-
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diazo-3-oxobutanoate 19 was obtained as a bright yellow oil (2.06 g, 86%), which 
was used without further purification. δH(CDCl3, 300 MHz): 1.33 (3H, t, J 7.2 
OCH2CH3), 2.48 [3H, s, C(O)CH3], 4.32 (2H, q, J 7.2, OCH2CH3); δC(CDCl3, 75.5 
MHz): 14.3 (CH3), 28.3 [C(O)CH3], 61.5 (OCH2), 161.4 (C=O) ester, 190.3 (C=O) 
ketone, no signal observed for (C=N2); max (film)/cm-1 2141, 1723, 1661; m/z 
(ESI+) 157 [M + H]+ (5%), 64 (100). Spectral details are in agreement with those 
reported in the literature.23 
 
Isopropyl 2-diazo-3-oxobutanoate 20  
The title compound was prepared following the procedure 
described for methyl 2-diazo-3-oxobutanoate 18 using 
triethylamine (1.91 mL, 13.89 mmol), isopropyl acetoacetate 
322 (2.00 g, 13.89 mmol) in acetonitrile (25 mL) and p-toluenesulfonyl azide 13 
(2.74 g, 13.89 mmol) dissolved in acetonitrile (25 mL). The reaction was stirred 
at room temperature under a nitrogen atmosphere for 18 h. Following the work-
up, isopropyl 2-diazo-3-oxobutanoate 20 was obtained as a bright yellow oil (1.99 
g, 84%), which was used without further purification. δH(CDCl3, 300 MHz): 1.31 
(6H, d, J 6.3, 2 × CH3), 2.49 [3H, s, C(O)CH3], 5.18 (1H, septet, J 6.3, CH); 
δC(CDCl3, 100 MHz): 21.9 (2 × CH3), 28.5 [C(O)CH3], 69.7 (CH), 161.3 (C=O) 
ester, 190.6 (C=O) ketone, no signal observed for (C=N2); max (film)/cm-1 2142, 
1715, 1660, 1368; m/z (ESI+)171 [M + H]+ (5%), 102 (100). Spectral details are 
in agreement with those reported in the literature.24 
 
Note: The 1H NMR spectrum showed 3% unreacted tosyl azide 13 starting 
material after work-up. 
 
t-Butyl 2-diazo-3-oxobutanoate 21 
The title compound was prepared following the procedure 
described for methyl 2-diazo-3-oxobutanoate 18 using 
triethylamine (1.82 mL, 12.64 mmol), t-butyl acetoacetate 
323 (2.00 g, 12.64 mmol) in acetonitrile (25 mL), p-toluenesulfonyl azide 13 (2.51 
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h under a nitrogen atmosphere. Following the work-up, t-butyl 2-diazo-3-
oxobutanoate 21 was obtained as a bright yellow oil (2.21 g, 95%), which was 
used without further purification. δH(CDCl3, 400 MHz): 1.52 (9H, s, 3 × CH3 of t-
butyl), 2.45 [3H, s, C(O)CH3]; δC(CDCl3, 100 MHz): 27.9 [C(O)CH3],  28.2 (3 
×CH3), 83.1 (Cq), 160.5 (C=O) ester, 190.5 (C=O) ketone, no signal observed for 
C=N2; max (film)/cm-1 2134, 1715, 1660, 1311; m/z (ESI+) 185 [M + H]+ (40%), 
129 (100). Spectral details are in agreement with those reported in the literature.25 
 
Benzyl 2-diazo-3-oxobutanoate 22  
The title compound was prepared following the 
procedure described for methyl 2-diazo-3-
oxobutanoate 18 using triethylamine (1.45 mL, 10.4 
mmol), benzyl acetoacetate 326 (2.00 g, 10.4 mmol) in acetonitrile (25 mL) and 
p-toluenesulfonyl azide 13 (2.03 g, 10.4 mmol) dissolved in acetonitrile (25 mL). 
The reaction was stirred at room temperature under a nitrogen atmosphere for 18 
h. Following the work-up, benzyl 2-diazo-3-oxobutanoate 22 was obtained as a 
bright yellow oil (2.1 g, 93%), which was used without further purification. 
δH(CDCl3, 400 MHz): 2.48 [3H, s, C(O)CH3], 5.29 (2H, s, OCH2C6H5), 7.32-7.44 
(5H, m, 5 × ArCH); δC(CDCl3, 100 MHz): 28.3 [C(O)CH3], 67.0 (OCH2), 128.4 
(ArCH), 128.7 (2 × ArCH), 128.8 (2 × ArCH), 161.3 (C=O) ester, 190.1 (C=O) 
ketone, no signal observed for (C=N2); max (film)/cm-1 2144, 1712, 1651, 1328; 
m/z (ESI+) 219 [M + H]+ (10%), 459 (100). Spectral details are in agreement with 
those reported in the literature.26 
 
Pentyl 2-diazo-3-oxobutanoate 23  
The title compound was prepared following the 
procedure described for methyl 2-diazo-3-
oxobutanoate 18 using triethylamine (1.62 mL, 11.6 
mmol), pentyl 3-oxobutanoate 324 (2.05 g, 11.6 mmol) in acetonitrile (25 mL) and 
p-toluenesulfonyl azide 13 (2.28 g, 11.6 mmol) dissolved in acetonitrile (25 mL). 
The reaction was stirred at room temperature under a nitrogen atmosphere for 18 
h. Following the work-up, pentyl 2-diazo-3-oxobutanoate 23 was obtained as a 
bright yellow oil (2.1 g, 92%), which was used without further purification. 
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δH(CDCl3, 400 MHz): 0.92 (3H, t, J 6.9, CH2CH3), 1.31-1.39 (4H, m, 2 × CH2), 
1.65-1.74 (2H, m, CH2), 2.48 [3H, s, C(O)CH3], 4.24 (2H, t, J 6.9, OCH2CH2); 
δC(CDCl3, 100 MHz): 13.9 (CH3), 22.2 (CH2), 27.9 (CH2), 28.4 (CH2), 28.3 
[C(O)CH3], 65.5 (OCH2), 161.5 (C=O) ester, 190.2 (C=O) ketone, no signal 
observed for (C=N2); max (film)/cm-1 2141, 1719, 1663, 1365; m/z (ESI+) 199 [M 
+ H]+ (30%), 116 (100); HRMS (ESI+): exact mass calculated for C9H14O3N2 [M 
+ H]+ 199.1083. Found 199.1088. 
 
Isopentyl 2-diazo-3-oxobutanoate 24   
The title compound was prepared following the 
procedure described for methyl 2-diazo-3-
oxobutanoate 18 using triethylamine (1.65 mL, 11.61 
mmol), isopentyl 3-oxobutanoate 325 (2.00 g, 11.61 mmol) in acetonitrile (25 mL) 
and p-toluenesulfonyl azide 13 (2.31 g, 11.62 mmol) dissolved in acetonitrile (25 
mL). The reaction was stirred at room temperature under a nitrogen atmosphere 
for 18 h. Following the work-up, isopentyl 2-diazo-3-oxobutanoate 24 was 
obtained as a bright yellow oil (2.02 g, 88%), which was used without further 
purification. δH(CDCl3, 400 MHz): 0.94 (6H, d, J 6.6, 2 × CH3), 1.54-1.76 [3H, 
m, OCH2CH2 and CH(CH3)2], 2.48 [3H, s, C(O)CH3], 4.27 (2H, t, J 6.6, 
OCH2CH2); δC(CDCl3, 100 MHz): 22.4 (2 × CH3), 25.1 (CH), 28.2 [C(O)CH3], 
37.3 (CH2), 64.1 (OCH2), 161.5 (C=O) ester, 190.2 (C=O) ketone, no signal 
observed for (C=N2); max (film)/cm-1 2141, 1716, 1662, 1316; m/z (ESI+) 199 [M 
+ H]+ (5%), 102 (100). Spectral details are in agreement with those reported in the 
literature.24 
 
3,7-Dimethylocta-2,6-dienyl 2-diazo-3-oxobutanoate 25 
The title compound was prepared following 
the procedure described for methyl 2-diazo-
3-oxobutanoate 18 using triethylamine 
(1.17 mL, 8.4 mmol), 3,7-dimethylocta-2,6-dienyl 3-oxobutanoate 2 (2.12 g, 8.4 
mmol)  in acetonitrile (25 mL) and p-toluenesulfonyl azide 13 (1.65 g, 8.4 mmol) 
dissolved in acetonitrile (25 mL). The reaction was stirred at room temperature 
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under a nitrogen atmosphere for 18 h. Following the work-up, the residue was 
purified by column chromatography on silica gel using hexane:ethyl acetate 
(90:10) as eluent to yield 3,7-dimethylocta-2,6-dienyl 2-diazo-3-oxobutanoate 25 
as a yellow oil (1.91 g, 86%). δH(CDCl3, 400 MHz): 1.58 (3H, s, CH3), 1.66 (3H, 
s, CH3), 1.71 (3H, s, CH3), 2.02-2.13 (4H, td, J 12.1, 6.4, 2 × CH2), 2.46 [3H, s, 
C(O)CH3], 4.73 (2H, d, J 7.2, OCH2), 5.05 [1H, t, J 5.9, CH=C(CH3)2], 5.34 [1H, 
t, J 7.0, OCH2CH=C(CH3)]; δC(CDCl3, 100 MHz): 16.5 (CH3), 17.7 (CH3), 25.6 
(CH3), 26.2 (CH2), 28.2 [C(O)CH3], 39.5 (CH2), 62.1 (OCH2), 117.6 (CH) alkene, 
123.5 (CH) alkene, 131.9 (Cq) alkene, 143.4 (Cq) alkene, 161.4 (C=O) ester, 190.2 
(C=O) ketone, no signal observed for (C=N2); max (film)/cm-1 2141, 1719, 1660, 
1312; m/z (ESI+) 264 [M]+ 238 (100); HRMS (ESI+): exact mass calculated for 
C14H21O3N2 [M + H]+ 265.1552. Found 265.1556. Spectral details are in 
agreement with those reported in the literature.27 
 
 
2-(Methacryloyloxy) ethyl 2-diazo-3-oxobutanoate 26  
The title compound was prepared following the 
procedure described for methyl 2-diazo-3-
oxobutanoate 18 using triethylamine (0.94 mL, 
9.33 mmol), 2-(methacryloyloxy)ethyl 3-oxobutanoate 327 (2.01 g, 9.33 mmol) in 
acetonitrile (25 mL) and p-toluenesulfonyl azide 13 (1.84 g, 9.33 mmol) dissolved 
in acetonitrile (25 mL). The reaction was stirred at room temperature under a 
nitrogen atmosphere for 18 h. Following the work-up, the residue was purified by 
column chromatography on silica gel using hexane:ethyl acetate (90:10) as eluent 
to yield 2-(methacryloyloxy) ethyl 2-diazo-3-oxobutanoate 26 as a yellow oil 
(1.78 g, 79%). δH(CDCl3, 400 MHz): 1.95 (3H, dd, J 1.5, 1.0, CH3), 2.48 [3H, s, 
C(O)CH3], 4.40-4.44 (2H, m, OCH2), 4.48-4.53 (2H, m, OCH2), 5.61-5.64 (1H, 
m, one of alkene CH2), 6.12-6.14 (1H, m, one of alkene CH2); δC(CDCl3, 100 
MHz): 18.2 (CH3), 28.2 [C(O)CH3], 62.0 (OCH2), 62.9 (OCH2), 126.2 (CH2) 
alkene, 135.8 (Cq) alkene, 161.1 (C=O) α-diazo ester, 166.9 (C=O) methacrylate 
ester, 189.7 (C=O) ketone, no signal observed for (C=N2); ѵmax (film)/cm-1 2144, 
1719, 1656, 1313; HRMS (ESI+): exact mass calculated for C10H13O5N2 [M + H]+ 
241.0824. Found 241.0829.  
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3,7-Dimethyloct-6-enyl 2-diazo-3-oxobutanoate 27  
The title compound was prepared following 
the procedure described for methyl 2-diazo-
3-oxobutanoate 18 using triethylamine (1.21 
mL, 8.37 mmol), 3,7-dimethyloct-6-enyl 3-oxobutanoate 3 (2.01 g, 8.37 mmol)  in 
acetonitrile (25 mL) and p-toluenesulfonyl azide 13 (1.64 g, 8.37 mmol) dissolved 
in acetonitrile (25 mL). The reaction was stirred at room temperature under a 
nitrogen atmosphere for 18 h. Following the work-up, the residue was purified by 
column chromatography on silica gel using hexane:ethyl acetate (90:10) as eluent 
to yield 3,7-dimethylocta-6-enyl 2-diazo-3-oxobutanoate 27 as a yellow oil (1.52 
g, 68%). δH(CDCl3, 400 MHz): 0.93 (3H, d, J 6.3, CHCH3), 1.14-1.82 [11H, m, 
containing CH2CH, (2 × CH2), 1.61 (3H, s, CH3) and 1.68 (3H, s, CH3)], 1.89-2.08 
(2H, m, CH2), 2.47 [3H, s, C(O)CH3], 4.02-4.34 (2H, m, OCH2), 5.07 [1H, t, J 6.9, 
CH=C(CH3)2]; δC(CDCl3, 100 MHz): 17.6 (CH3), 19.3 (CH3), 25.3 (CH2), 25.6 
(CH3), 28.1 [C(O)CH3], 29.4 (CH), 35.4 (CH2), 36.8 (CH2), 63.9 (OCH2), 124.3 
(CH) alkene, 131.5 (Cq) alkene, 161.4 (C=O) ester, 190.2 (C=O) ketone, no signal 
observed for (C=N2); max (film)/cm-1 2141, 1721, 1662, 1316; HRMS (ESI+): 
exact mass calculated for C14H23O3N2 [M + H]+ 267.1709. Found 267.1712.  
 
2-Ethylhexyl 2-diazo-3-oxobutanoate 28  
The title compound was prepared following the 
procedure described for methyl 2-diazo-3-
oxobutanoate 18 using triethylamine (1.34 mL, 9.3 
mmol), 2-ethylhexyl 3-oxobutanoate 6 (2.06 g, 9.3 
mmol) in acetonitrile (25 mL) and p-toluenesulfonyl azide 13 (1.84 g, 9.3 mmol) 
dissolved in acetonitrile (25 mL). The reaction was stirred at room temperature 
under a nitrogen atmosphere for 18 h. Following the work-up, the residue was 
purified using column chromatography on silica gel using hexane:ethyl acetate 
(95:5) to yield 2-ethylhexyl 2-diazo-3-oxobutanoate 28 as a bright yellow oil (1.60 
g, 78%. δH(CDCl3, 300 MHz): 0.90 (6H, m, 2 × CH3), 1.25-1.43 (8H, m, 4 × CH2), 
1.59-1.68 (1H, m, CH), 2.47 [3H, s, C(O)CH3], 4.17 (2H, d, J 5.6, OCH2); 
δC(CDCl3, 100 MHz): 10.9 (CH3), 14.0 (CH3), 22.9 (CH2), 23.1 (CH2), 28.9 (CH2), 
30.1 (CH2), 30.3 [C(O)CH3], 38.7 (CH), 67.7 (OCH2), 161.5 (C=O), 190.1 (C=O), 
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no signal observed for (C=N2); ѵmax (film)/cm-1 2960, 2143, 1711, 1656, 1315; m/z 
(ESI+) 241 [M + H]+ (8%), 118 (100).  
 
Decyl 2-diazo-3-oxobutanoate 29 
The title compound was prepared 
following the procedure described 
for methyl 2-diazo-3-oxobutanoate 
18 using triethylamine (0.42 mL, 4.1 mmol), decyl 3-oxobutanoate 10 (1.01 g, 4.1 
mmol) in acetonitrile (25 mL) and p-toluenesulfonyl azide 13 (0.81 g, 4.1 mmol) 
dissolved in acetonitrile (25 mL). The reaction was stirred at room temperature 
under a nitrogen atmosphere for 18 h. Following the work-up, decyl 2-diazo-3-
oxobutanoate 29 (0.88 g, 80%) was isolated as a bright yellow oil which was used 
without further purification. δH(CDCl3, 400 MHz): 0.88 (3H, t, J 6.9, CH3), 1.20-
1.41 (14H, m, 7 × CH2), 1.62-1.72 (2H, m, CH2), 2.48 [3H, s, C(O)CH3], 4.23 (2H, 
t, J 6.7, OCH2); δC(CDCl3, 100 MHz): 14.1 (CH3), 22.7 (CH2), 25.8 (CH2), 28.2 
(CH2), 28.6 [C(O)CH3], 29.2 (CH2), 29.3 (CH2), 29.5 (CH2), 29.5 (CH2), 31.9 
(CH2), 65.6 (OCH2), 161.5 (C=O) ester, 190.2 (C=O) ketone, no signal observed 
for (C=N2); ѵmax (film)/cm-1 2139, 1721, 1664, 1314; HRMS (ESI+): exact mass 
calculated for C14H25O3N2 [M + H]+ 269.1865. Found 269.1871. Spectral details 
are in agreement with those reported in the literature.27 
 
 
2-Ethylbutyl 2-diazo-3-oxobutanoate 30 
The title compound was prepared following the 
procedure described for methyl 2-diazo-3-oxobutanoate 
18 using triethylamine (1.84 mL, 9.3 mmol), 2-
ethylbutyl 3-oxobutanoate 5 (2.01 g, 9.3 mmol) in acetonitrile (25 mL) and p-
toluenesulfonyl azide 13 (1.84 g, 9.3 mmol) dissolved in acetonitrile (25 mL). The 
reaction was stirred at room temperature under a nitrogen atmosphere for 18 h. 
Following the work-up, 2-ethylbutyl 2-diazo-3oxobutanoate 30 was isolated as a 
bright yellow oil (1.54 g, 78%), which was used without further purification. 
δH(CDCl3, 400 MHz): 0.92 (6H, t, J 7.5, 2 × CH3), 1.31-1.43 (4H, m, 2 × CH2), 
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δC(CDCl3, 100 MHz): 10.7 (2 × CH3), 22.8 (2 × CH2), 28.1 [C(O)CH3], 40.4 (CH), 
67.3 (OCH2), 161.5 (C=O) ester, 190.0 (C=O) ketone, no signal observed for 
(C=N2); ѵmax (film)/cm-1 2140, 1717, 1662, 1312;  m/z (ESI+) 213 [M + H]+ (30%), 
102 (100), 118 (80).  
 
Undec-10-en-1-yl 2-diazo-3-oxobutanoate 31  
The title compound was prepared 
following the procedure described 
for methyl 2-diazo-3-oxobutanoate 
18 using triethylamine (1.20 mL, 11.8 mmol), dodec-11-en-1-yl 3-oxobutanoate 
11 (3.06 g, 11.5 mmol) in acetonitrile (30 mL) and p-toluenesulfonyl azide 13 
(2.33 g, 11.8 mmol) dissolved in acetonitrile (30 mL). The reaction was stirred at 
room temperature under a nitrogen atmosphere for 18 h. Following the work-up, 
the residue was purified by column chromatography on silica gel using 
hexane:ethyl acetate (90:10) as eluent to yield undec-10-en-1-yl 2-diazo-3-
oxobutanoate 31 as a yellow oil (1.78 g, 78%). δH(CDCl3, 400 MHz): 1.22-1.43 
(12H, m, 6 × CH2), 1.64-1.75 (2H, m, CH2), 1.99-2.09 (2H, m, CH2), 2.47 [3H, s, 
C(O)CH3], 4.23 (2H, t, J 6.6, OCH2), 4.90-5.01 (2H, m, CH=CH2), 5.74-5.87 (1H, 
m, CH=CH2); δC(CDCl3, 100 MHz): 25.7 (CH2), 28.2 [C(O)CH3], 28.6 (CH2), 
28.8 (CH2), 29.0 (CH2), 29.1 (CH2), 29.3 (CH2), 29.4 (CH2), 33.7 (CH2), 65.5 
(OCH2), 114.1 (CH2) alkene, 139.1 (CH) alkene, 161.5 (C=O) ester, 190.2 (C=O) 
ketone, no signal observed for (C=N2); ѵmax (film)/cm-1 2140, 1721, 1660, 1315; 
HRMS (ESI+): exact mass calculated for C15H25O3N2 [M + H]+ 281.1865. Found 
281.1867.  
 
sec-Butyl 2-diazo-3-oxobutanoate 32  
The title compound was prepared following the procedure described for methyl 2-
diazo-3-oxobutanoate 18 using triethylamine (0.29 mL, 
2.05 mmol), sec-butyl 3-oxobutanoate 4 (0.320 g, 2.05 
mmol) in acetonitrile (10 mL) and p-toluenesulfonyl azide 
13 (0.401 g, 2.05 mmol) dissolved in acetonitrile (10 mL). The reaction was stirred 
at room temperature under a nitrogen atmosphere for 18 h. Following the work-
up, sec-butyl 2-diazo-3-oxoanoate 32 was isolated as a bright yellow oil (0.293 g, 
    Chapter 3: Experimental 
249 
 
78%), which was used without further purification. δH(CDCl3, 400 MHz): 0.94 
(3H, t, J 7.5, CH3), 1.29 (3H, d, J 6.3, CH3), 1.56-1.73 (2H, m, CH2CH3), 2.48 
[3H, s, C(O)CH3], 4.96-5.04 (1H, m, OCH); δC(CDCl3, 100 MHz): 9.5 (CH3), 19.5 
(CH3), 28.2 [C(O)CH3], 28.8 (CH2), 73.9 (OCH), 161.1 (C=O) ketone, 190.3 
(C=O) ester, no signal observed for C=N2; ѵmax (film)/cm-1 2141, 1725, 1719, 
1662;   m/z (ESI+) 185 [M + H]+ (10%), 255 (100). Spectral details are in agreement 
with those reported in the literature.24 
 
Variation of ketone side-chain 
Methyl 2-diazo-3-oxoheptanoate 33 
The title compound was prepared following the 
procedure described for methyl 2-diazo-3-oxobutanoate 
18 using triethylamine (0.91 mL, 6.32 mmol), methyl 3-
oxoheptanoate 317 (1.04 g, 6.32 mmol) in acetonitrile (25 mL) and p-
toluenesulfonyl azide 13 (1.26 g, 6.32 mmol) dissolved in acetonitrile (25 mL). 
The reaction was stirred at room temperature under a nitrogen atmosphere for 18 
h. Following the work-up, methyl 2-diazo-3-oxoheptanoate 33 was obtained as a 
bright yellow oil (0.84 g, 72%), which was used without further purification. 
δH(CDCl3, 400 MHz): 0.93 (3H, t, J 7.2, CH2CH3), 1.33-1.42 (2H, m, CH2), 1.58-
1.65 (2H, m, CH2), 2.85 [2H, t, J 7.6, C(O)CH2], 3.84 (3H, s, OCH3); δC(CDCl3, 
100 MHz): 13.6 (CH3), 22.2 (CH2), 26.3 (CH2), 39.7 [C(O)CH2], 51.9 (OCH3), 
75.4 (C=N2), 161.6 (C=O) ester, 192.6 (C=O) ketone; max (film)/cm-1 2137, 1726, 
1660, 1312; m/z (ESI+) 185 [M + H]+ (58%). HRMS (ESI+): exact mass calculated 
for C8H13O3N2 [M + H]+ 185.0926. Found 185.0918. Spectral details are in 
agreement with those reported in the literature.29 
 
Ethyl 2-diazo-3-oxohexanoate 34  
The title compound was prepared following the 
procedure described for methyl 2-diazo-3-oxobutanoate 
18 using triethylamine (1.28 mL, 12.66 mmol), ethyl 3-
oxohexanoate 327 (2.01 g, 12.66 mmol) in acetonitrile 
(25 mL) and p-toluenesulfonyl azide 13 (2.51 g, 12.66 mmol) dissolved in 
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acetonitrile (25 mL). The reaction was stirred at room temperature under a nitrogen 
atmosphere for 18 h. Following the work-up, ethyl 2-diazo-3-oxohexanoate 34 
was obtained as a bright yellow oil (2.22 g, 95%), which was used without further 
purification. δH(CDCl3, 400 MHz): 0.96 (3H, t, J 7.5, CH3), 1.34 (3H, t, J 7.2, 
OCH2CH3), 1.62-1.71 [2H, m, C(O)CH2CH2], 2.83 [2H, t, J 7.2, C(O)CH2CH2], 
4.31 (2H, q, J 7.2, OCH2CH3); δC(CDCl3, 100 MHz): 13.7 (CH3), 14.3 (CH3), 17.8 
(CH2), 42.0 [C(O)CH2], 61.3 (OCH2), 161.3 (C=O) ester, 192.8 (C=O) ketone, no 
signal observed for (C=N2); ѵmax (film)/cm-1 2135, 1721, 1659, 1302; m/z (ESI+) 
185 [M + H]+ (58%), 102 (100). HRMS (ESI+): exact mass calculated for 
C8H13O3N2 [M + H]+ 185.0926. Found 185.0903. Spectral details are in agreement 
with those reported in the literature.30 
 
Propyl 2-diazo-3-oxoheptanoate 35 
The title compound was prepared following the 
procedure described for methyl 2-diazo-3-
oxobutanoate 18 using triethylamine (0.54 mL, 
5.37 mmol), propyl 3-oxoheptanoate 9 (1.06 g, 5.37 mmol) in acetonitrile (25 mL) 
and p-toluenesulfonyl azide 13 (1.06 g, 5.37 mmol) dissolved in acetonitrile (25 
mL). The reaction was stirred at room temperature under a nitrogen atmosphere 
for 18 h. Following the work-up, the residue was purified by column 
chromatography on silica gel, using hexane:ethyl acetate (90:10) as eluent to yield 
propyl 2-diazo-3-oxoheptanoate 35 as a bright yellow oil (615 mg, 71%). 
δH(CDCl3, 400 MHz): 0.81-1.00 [6H, m, containing 0.94 (3H, t, J 7.3, CH3) and 
0.97 (3H, t, J 7.4, CH3)], 1.33-1.42 (2H, m, CH2), 1.58-1.70 (4H, m, 2 × CH2), 
2.82 [2H, t, J 7.8, C(O)CH2], 4.12 (2H, t, J 6.7, OCH2); δC(CDCl3, 100 MHz): 
10.2 (CH3), 13.8 (CH3), 21.8 (CH2), 22.3 (CH2), 26.6 (CH2), 39.9 [C(O)CH2], 66.8 
(OCH2), 75.8 (C=N2), 161.4 (C=O) ester, 192.9 (C=O) ketone; ѵmax (film)/cm-1 
2135, 1719, 1660, 1394; m/z (ESI+) 213 [M + H]+ (80%), 214 (13) 338 (100). 
HRMS (ESI+): exact mass calculated for C10H17O3N2 [M + H]+ 213.1239. Found 
213.1234. Spectral details are in agreement with those reported in the literature.24 
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Isopropyl 2-diazo-3-oxoheptanoate 36  
The title compound was prepared following the 
procedure described for methyl 2-diazo-3-
oxobutanoate 18 using triethylamine (0.31 mL, 2.15 
mmol), isopropyl 3-oxoheptanoate 7 (0.4 g, 2.15 mmol) in acetonitrile (10 mL) 
and p-toluenesulfonyl azide 13 (0.42 g, 2.15 mmol) dissolved in acetonitrile (5 
mL). The reaction was stirred at room temperature under a nitrogen atmosphere 
for 18 h. Following the work-up, the residue was purified by column 
chromatography on silica gel, using hexane:ethyl acetate (90:10) as eluent to yield 
isopropyl 2-diazo-3-oxoheptanoate 36 as a bright yellow oil (317 mg, 68%). 
δH(CDCl3, 400 MHz): 0.92 (3H, t, J 7.2, CH3), 1.25-1.45 [1.32 (6H, d, J 6.4, 2 × 
CH3) and CH2], 1.57-1.65 (2H, m, CH2), 2.81 (2H, t, J 7.2, C(O)CH2), 5.11-5.20 
(1H, m, CH). δC(CDCl3, 100 MHz): 13.8 (CH3), 21.9 (2 × CH3), 22.3 (CH3CH2), 
26.5 (CH3CH2CH2), 39.9 (COCH2), 69.2 (OCH(CH3)2), 161.0 (C=O) ester, 193.1 
(C=O) ketone, no signal observed for (C=N2); ѵmax (film)/cm-1 2135, 1716, 1660, 
1299; m/z (ESI+) 213 [M + H]+ (100%), 214 (10); HRMS (ESI+): exact mass 
calculated for C10H17O3N2 [M + H]+ 213.1239. Found 213.1239.  
 
Note: The 1H NMR spectrum showed the product was contaminated with 6% ethyl 
2-diazo-3-oxobutanoate 19 which was brought forward through the synthesis and 
removed completely at a later stage.  
 
t-Butyl 2-diazo-3-oxoheptanoate  37 
The title compound was prepared following the 
procedure described for methyl 2-diazo-3-
oxobutanoate 18 using triethylamine (1.44 mL, 9.98 
mmol), t-butyl 3-oxoheptanoate 8 (2.01 g, 9.98 mmol) in acetonitrile (25 mL) and 
p-toluenesulfonyl azide 13 (1.97 g, 9.98 mmol) dissolved in acetonitrile (25 mL). 
The reaction was stirred at room temperature under a nitrogen atmosphere for 18 
h. Following the work-up, the residue was purified by column chromatography on 
silica gel using hexane:ethyl acetate (95:5) to yield t-butyl 2-diazo-3-
oxoheptanoate 37 as a bright yellow oil (1.59 g, 69%). δH(CDCl3, 400 MHz): 0.92 
(3H, t, J 7.2, CH3), 1.28-1.41 (2H, m, CH2), [11H, m containing CH2 and 1.52 
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(9H, s, 3 × CH3 of t-butyl), 2.82 [2H, t, J 7.6, C(O)CH2]; δC(CDCl3, 100 MHz): 
13.9 (CH3), 22.3 (CH2), 26.4 (CH2), 28.3 (3 × CH3 of t-butyl), 39.9 [C(O)CH2], 
83.0 (Cq), 160.6 (C=O) ester, 193.3 (C=O) ketone, no signal observed for (C=N2);  
ѵmax (film)/cm-1 2960, 2131, 1713, 1652, 1313; m/z (ESI+) 213 [M + H]+ (100%), 
214 (10) HRMS (ESI+): exact mass calculated for C11H18O3N2 [M + H]+ 227.1396 
Found 227.1390. 
 
Methyl 2-diazo-3-(4-fluorophenyl)-3-oxopropanoate 38  
The title compound was prepared following the 
procedure described for methyl 2-diazo-3-
oxobutanoate 18 using triethylamine (0.06 mL, 0.41 
mmol), methyl 3-(4-fluorophenyl)-3-oxopropanoate 328 (0.08 g, 0.41 mmol) in 
acetonitrile (4 mL) and p-toluenesulfonyl azide 13 (0.16 g, 0.82 mmol) dissolved 
in acetonitrile (0.5 mL). The reaction was stirred at room temperature under a 
nitrogen atmosphere for 18 h. Following the work-up, methyl 2-diazo-3-(4-
fluorophenyl)-3-oxopropanoate 38 was obtained as a bright yellow oil (78 mg, 
85%), which was used without further purification. δH(CDCl3, 300 MHz): 3.79 
(3H, s, OCH3), 7.08-7.42 (2H, m, 2 × ArCH), 7.66-7.70 (2H, m, 2 × ArCH); 
δC(CDCl3, 100 MHz): 52.4 (OCH3), 115.1 (d, 2JCF 22.0, 2 × ArCH), 131.2 (d, 3JCF 
9.1, 2 × ArCH), 133.0 (d, 4JCF 3.2, ArCq), 161.3 (C=O) ester, 165.2 (d, 1JCF 251, 
ArCF), 185.4 (C=O) ketone, no signal observed for (C=N2); ѵmax (film)/cm-1 2985, 
2145, 1725, 1692, 1630, 1322; m/z (ESI+) 245.3 [M + Na]+(30%). Spectral details 
are in agreement with those reported in the literature.31 
 
Ethyl 2-diazo-3-oxo-3-phenylpropanoate 39 
The title compound was prepared following the 
procedure described for methyl 2-diazo-3-
oxobutanoate 18 using triethylamine (0.73 mL, 5.2 
mmol), ethyl 3-phenyl-3-oxopropanoate 329 (1.0 g, 5.2 mmol) in acetonitrile (15 
mL) and p-toluenesulfonyl azide 13 (1.03 g, 5.2 mmol) dissolved in acetonitrile 
(20 mL). The reaction was stirred at room temperature under a nitrogen 
atmosphere for 18 h. Following the work-up, methyl 2-diazo-3-phenyl-3-
oxopropanoate 39 was obtained as a bright yellow oil (0.7 g, 61%), which was 
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used without further purification. δH(CDCl3, 300 MHz): 1.25 (3H, t,  J 7.1, 
CH2CH3), 4.24 (2H, q, J 7.1, OCH2CH3), 7.41 (2H, ddd, J 6.7, 4.5, 1.2, 2 × ArCH), 
7.49-7.56 (1H, m, ArCH) 7.60-7.65 (2H, m, 2 × ArCH);  δC(CDCl3, 100 MHz): 
14.2 (CH3), 60.9 (C=N2); 61.6 (OCH2CH3), 127.9 (2 × ArCH), 128.4 (2 × ArCH), 
132.3 (ArCH), 137.1 (ArCq), 161.0 (C=O) ester, 186.9 (C=O) ketone; ѵmax 
(film)/cm-1 2145, 1726, 1630, 1308; m/z (ESI+) 218 [M]+, 223 (100%). Spectral 
details are in agreement with those reported in the literature.32 
 
3.2.4 Diazo transfer to β-diketones 
3-Diazopentane-2,4-dione 42  
The title compound was prepared following the procedure 
described for methyl 2-diazo-3-oxobutanoate 18 using 
triethylamine (1.4 mL, 10 mmol), acetylacetone 40 (1 g, 10 
mmol) in DCM (15 mL) and p-toluenesulfonyl azide 13 (1.97 g, 10 mmol) in DCM 
(25 mL). The reaction was stirred at room temperature for 18 h under a 
atmosphere. The reaction mixture was washed with 9% KOH (2 × 50 mL) 
followed by water (1 × 50 mL). The organic layer was dried with MgSO4 and 
concentrated under reduced pressure Following the work-up, 3-diazopentane-2,4-
dione 42 was obtained as a yellow oil and used without further purification (0.99 
g, 79%). δH(CDCl3, 400 MHz): 2.44 (6H, s, 2 × CH3); δC(CDCl3, 100 MHz): 28.4 
(2 × CH3), 84.6 (C=N2), 188.2 (2 × C=O); m/z (ESI+) 127 [M + H]+ (10%) 141 
(100); HRMS (ESI+): exact mass calculated for C5H7O2N2 [M + H]+ 127.0508. 
Found 127.0511; ѵmax (film)/cm-1 2130, 1666, 1308. Spectral details are in 
agreement with those reported in the literature.33 
 
2-Diazo-1-phenylbutane-1,3-dione 43 
The title compound was prepared following the procedure 
described for methyl 2-diazo-3-oxobutanoate 18 using 
triethylamine (1.4 mL, 10 mmol), 1-phenylbutane-1,3-
dione 41 (1 g, 10 mmol) in acetonitrile (15 mL) and p-toluenesulfonyl azide 13 
(1.97 g, 10 mmol) in acetonitrile (25 mL). The reaction was stirred at room 
temperature for 18 h under a atmosphere.  Following the work-up, 2-diazo-1-
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phenylbutane-1,3-dione 43 was obtained as a yellow solid and used without further 
purification (1.54 g, 82%), m.p. 77-80 ºC, (Lit.34 78-81 ºC). δH (400 MHz, CDCl3): 
2.57 [3H, s, C(O)CH3], 7.46-7.52 (2H, m, 2 × ArCH), 7.55-7.61 (1H, m, ArCH), 
7.62-7.66 (2H, m, ArCH); δC(CDCl3, 100 MHz): 29.1 [C(O)CH3], 83.7 (C=N2), 
127.3 (2 × ArCH), 128.9 (2 × ArCH), 132.7 (ArCH), 137.3 (ArCq), 185.0 (PhCO), 
190.7 (CH3CO); (Found: C 63.52; H 4.30; N 14.82; C10H8O2N2 requires C 63.83; 
H 4.29; N 14.89%); m/z (ESI+) 161 [M + H – N2]+ (10%); HRMS (ESI+): exact 
mass calculated for C10H9O2N2 [M + H]+ 189.0664. Found 189.0661; ѵmax 
(KBr)/cm-1 2120, 1659, 1646, 1578, 1362. Spectral details are in agreement with 
those reported in the literature.34 
 
3.2.5 Diazo transfer reactions to β-ketoamides 
Note: The α-diazo-β-ketoamide derivatives were often difficult to yield in high 
purity even after repeated column chromatography on silica gel and were carried 
forward to the next stage. 
2-Diazo-N,N-dimethyl-3-oxobutanamide 44  
Triethylamine (0.7 mL, 5 mmol) was added to a stirred solution 
of N,N-dimethylacetoacetamide 330 (0.79 g, 5 mmol, 80% 
solution in water) in acetonitrile (15 mL). After 2 min a solution 
of p-toluenesulfonyl azide 13 (0.99 g, 5 mmol) in acetonitrile (10 mL) was added 
dropwise at room temperature over 15 min to yield a bright yellow solution.  The 
reaction was stirred for 18 h under a nitrogen atmosphere. After 18 h the 
acetonitrile was removed under reduced pressure. The resulting yellow residue 
was dissolved in DCM (40 mL), washed with brine (2 × 50 mL) and water (50 
mL). The organic layer was extracted, dried with MgSO4 and concentrated under 
reduced pressure and the residue obtained was purified by column 
chromatography on silica gel using chloroform as eluent to yield diazo-N,N-
dimethyl-3-oxobutanamide 44 as a bright yellow oil (0.65 g, 84%). δH(CDCl3, 400 
MHz): 2.36 [3H, s, C(O)CH3], 3.02 (6H, s, 2 × CH3); δC(CDCl3, 100 MHz): 27.3 
(CH3), 37.5 [N(CH3)2], 161.4 (C=O) amide, 201.6 (C=O) ketone, no signal 
observed for (C=N2); m/z (ESI+) 155 [M]+(100%); ѵmax (film)/cm-1 2931, 2108, 
1658, 1651. Spectral details are in agreement with those reported in the literature.35 




2-Diazo-N,N-diethyl-3-oxobutanamide 45  
The title compound was prepared following the procedure 
described for 2-diazo-N,N-dimethyl-3-oxobutanamide 44 
using triethylamine (0.7 mL, 5 mmol), N,N-
diethylacetoacetamide 331 (1.0 mL, 5 mmol) in acetonitrile (10 mL) and p-
toluenesulfonyl azide 13 (0.96 g, 5 mmol) in acetonitrile (25 mL).  The reaction 
was stirred under a nitrogen atmosphere for 18 h. Following the work-up, the 
residue was purified by column chromatography on silica gel using hexane:ethyl 
acetate (65:35) as eluent to yield 2-diazo-N,N-diethyl-3-oxobutanamide 45 as a 
bright yellow oil (0.60 g, 65%).  δH(CDCl3, 400 MHz): 1.15 (6H, t, J 7.1, 2 × 
CH2CH3), 2.29 [3H, s, C(O)CH3], 3.34 (4H, q, J 7.1, 2 × CH2CH3); δC(CDCl3, 100 
MHz): 13.1 (2 × CH3), 27.3 [C(O)CH3], 41.9 (2 × CH2), 72.4 (C=N2), 160.4 (C=O) 
amide, 190.1 (C=O) ketone; max (film)/cm-1 2106, 1652, 1607; m/z (ESI+) 184 [M 
+ H]+ (6%). Spectral details are in agreement with those reported in the literature.36 
N-Benzyl-2-diazo-N-methyl-3-oxobutanamide 46 
The title compound was prepared following the 
procedure described for 2-diazo-N,N-dimethyl-3-
oxobutanamide 44 using triethylamine (0.7 mL, 4.9 
mmol), N-benzyl-N-methyl-3-oxobutanamide 332 (1.0 g, 4.9 mmol) in acetonitrile 
(10 mL) and p-toluenesulfonyl azide 13 (0.97 g, 4.9 mmol) in acetonitrile (25 mL).  
The reaction was stirred under a nitrogen atmosphere for 18 h.  Following the 
work-up, the residue was purified by column chromatography on silica gel using 
hexane:ethyl acetate (65:35) as eluent to yield N-benzyl-2-diazo-N-methyl-3-
oxobutanamide 46 as a bright yellow oil (0.79 g, 70%).  δH(CDCl3, 400 MHz): 
2.41 [3H, s, C(O)CH3], 2.90 (3H, s, NCH3), 4.62 (2H, s, CH2), 7.20-7.41 (5H, m , 
5 × ArCH); δC(CDCl3, 100 MHz): 27.4 [C(O)CH3], 35.8 (NCH3), 52.9 (CH2), 73.5 
(C=N2), 127.7 (2 × ArCH), 127.8 (ArCH), 128.9 (2 × ArCH), 136.0 (ArCq), 161.7 
(C=O) amide, 189.4 (C=O) ketone; max (film)/cm-1 2925, 2108, 1657, 1641, 1631; 
m/z (ESI+) 231 [M]+ (10%), 212 (100). HRMS (ESI)+: Exact mass calculated for 
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2-Diazo-3-oxo-N-phenylbutanamide 47  
The title compound was prepared following the 
procedure described for 2-diazo-N,N-dimethyl-3-
oxobutanamide 44 using triethylamine (1.8 mL, 4.0 
mmol), 3-oxo-N-phenylbutanamide 333 (0.35 g, 2.0 
mmol) in acetonitrile (10 mL) and p-toluenesulfonyl azide 13 (0.43 g, 2.2 mmol, 
1.1 equiv.) in acetonitrile (20 mL).  The reaction was stirred under a nitrogen 
atmosphere for 18 h.  The acetonitrile was removed under reduced pressure.  The 
resulting yellow residue was dissolved in DCM (40 mL) and washed with water 
(3 × 50 mL), dried with MgSO4 and concentrated under reduced pressure.  The 
residue was purified by column chromatography on silica gel using hexane:ethyl 
acetate (85:15) as eluent to yield 2-diazo-3-oxo-N-phenylbutanamide 47 as a 
yellow solid (0.33 g, 82%), m.p. 117-120 ºC, (Lit.37 118-120 ºC). δH(CDCl3, 400 
MHz): 2.42 [3H, s, C(O)CH3], 7.10-7.14 (1H, m, ArCH), 7.31-7.35 (2H, m, 2 × 
ArCH), 7.58 (2H, dd, J 8.6, 1.0, 2 × ArCH) 10.17 (1H, br s, NH); δC(CDCl3, 100 
MHz): 26.8 [C(O)CH3], 120.1 (2 × ArCH), 124.5 (1 × ArCH), 129.1 (2 × ArCH), 
137.8 (ArCq), 158.2 (C=O) amide, 189.9 (C=O) ketone, no signal observed for 
(C=N2);. max (KBr)/cm-1 2130, 1676, 1598, 1553; m/z (ESI-) 202 [M - H]- (19%) 
201 (60), 324 (100). Spectral details are in agreement with those reported in the 
literature.37 
 
2-Diazo-3-oxo-N,3-diphenylpropanamide 48  
The title compound was prepared following the 
procedure described for 2-diazo-N,N-dimethyl-3-
oxobutanamide 44 using triethylamine (1.1 mL, 
8.0 mmol), 3-oxo-N,3-diphenylpropanamide 334 
(0.96 g, 4.0 mmol) in acetonitrile (10 mL) and p-toluenesulfonyl azide 13 (0.87 g, 
4.4 mmol) in acetonitrile (25 mL).  The reaction was stirred under a nitrogen 
atmosphere for 3 h.  The acetonitrile was removed under reduced pressure.  The 
resulting yellow residue was dissolved in DCM (40 mL) and washed with water 
(3 × 50 mL), dried with MgSO4 and concentrated under reduced pressure. The 
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residue was purified by column chromatography on silica gel using hexane:ethyl 
acetate (65:35) as eluent to yield 2-diazo-3-oxo-N,3-diphenylpropanamide 48 as a 
yellow solid (0.78 g, 74%),  m.p. 97-100 ºC, (Lit.38 95-98 ºC). δH(CDCl3, 400 
MHz): 7.13 (1H, t, J 7.4, ArCH), 7.35 (2H, t, J 8.0, 2 × ArCH ), 7.52 (2H, t, J 7.4, 
2 × ArCH), 7.57-7.74 (5H, m, 5 × ArCH), 10.45 (1H, br s, NH); δC(CDCl3, 100 
MHz): 120.2 (2 × ArCH), 124.5 (ArCH), 127.1 (2 × ArCH), 129.1 (4 × ArCH), 
132.8 (ArCH), 136.6 (ArCqNH), 137.9 (ArCqCO), 158.6 (C=O) amide, 188.1 
(C=O) ketone, no signal observed for (C=N2); max (KBr)/cm-1 3256, 2130, 1674, 
1594, 1542; m/z (ESI+) 266 [M + H]+ (100%); HRMS (ESI+): exact mass calculated 
for C15H12N3O2 [M + H]+ 266.0930. Found 266.0932. Spectral details are in 
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3.3 Synthesis of 2-trimethylsilyl aryl triflates/nonaflates as aryne precursors 
3.3.1 Bromination of phenol derivatives  
2-Bromo-4,5-dimethylphenol 62  
N-Bromosuccinimide 338 (1.46 g, 8.2 mmol) in acetonitrile 
(10 mL) was added to 3,4-dimethylphenol 61 (1 g, 8.2 mmol) 
in acetonitrile (10 mL) at 0 °C via an addition funnel.  After 
10 min the reaction was quenched with water and extracted with DCM which was 
then washed with water (3 × 50 mL), dried with magnesium sulfate and 
concentrated under reduced pressure. The residue obtained was purified by 
column chromatography on silica gel using hexane:ethyl acetate (98:2) as eluent 
to yield 2-bromo-4,5-dimethylphenol 62 as a white solid, (1.43 g, 90%),  m.p. 75-
78 ºC, (Lit.43 80 ºC). δH(CDCl3, 400 MHz): 2.15 (3H, s, CH3), 2.17 (3H, s, CH3), 
5.28 (1H, br s, OH), 6.80 (1H, s, ArCH), 7.18 (1H, s, ArCH); δC(CDCl3, 100 
MHz): 18.6 (ArCCH3), 19.5 (ArCCH3), 106.5 (ArCBr), 117.1 (ArCH), 130.2 
(ArCCH3), 132.2 (ArCH), 137.9 (ArCCH3), 150.0 (ArCOH); HRMS (ESI+): exact 
mass calculated for C8H1079BrO [M + H]+ 200.9915. Found 200.9908 
[(C8H1079BrO)]+; max (film)/cm-1 3319, 2944, 1604, 1406, 1193. Spectral details 
are in agreement with those reported in the literature.43 
 
Note: After repeated column chromatography the sample still contained 5% 
starting material visible in the 1H NMR spectrum that could not be removed and 
was carried forward through the synthesis where it was removed completely, at a 
later stage.  
6-Bromobenzo[d][1,3]dioxol-5-ol  60  
The title compound was prepared in the same manner as 
2-bromo-4,5-dimethylphenol 62 using N-
bromosuccinimide 338 (3.2 g, 18 mmol) in acetonitrile 
(20 mL), 5-benzodioxolol 59 (2.5 g, 18 mmol) in acetonitrile (20 mL). Following 
the work-up, the solvent was removed under reduced pressure to provide the 
product 6-bromobenzo[d][1,3]dioxol-5-ol 60 as a green/black solid (3.30 g, 85%)  
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m.p. 85-88 ºC, (Lit.45 87-88 ºC), which contained 10% starting material, was used 
without further purification. δH(CDCl3, 400 MHz): 5.23 (1H, br s, OH), 5.93 (2H, 
s, OCH2O), 6.59 (1H, s, ArCH), 6.89 (1H, s, ArCH); δC(CDCl3, 100 MHz):  98.1 
(ArCH), 99.2 (ArCBr), 101.7 (OCH2O), 110.6 (ArCH), 142.0 (ArCO), 147.4 
(ArCOH), 148.3 (ArCO);  m/z (ESI-) 215.9[(C7H5O279Br)+, 6%], 
217.9[(C7H5O281Br)+, 6%], 81 (100), 79 (95); max (KBr)/cm-1 3393, 2959, 1502, 
1486, 1253, 1184. Spectral details are in agreement with those reported in the 
literature.45 
 
3.3.2 Silylation of bromophenol derivatives 
 (2-Bromophenoxy)trimethylsilane 63  
A mixture of 2-bromophenol 53 (0.79 g, 3.64 mmol) and 
hexamethyldisilazane (HMDS) 334 (0.5 ml, 3.64 mmol) in 
THF (10 mL) was stirred under reflux for 2 h in a flask fitted 
with a condenser and a CaCl2 tube. Excess NH3 and unreacted HMDS were 
removed under reduced pressure to provide (2-bromophenoxy)trimethylsilane 63 
as a yellow oil (0.8 g, quantitative) which was used without further purification. 
δH(CDCl3, 400 MHz): 0.24 [9H, s, Si(CH3)3], 6.73-6.83 (2H, m, 2 × ArCH), 7.10 
(1H, ddd, J 8.0, 7.3, 1.6, ArCH), 7.45 (1H, dd, J 8.0, 1.6, ArCH); δC(CDCl3, 100 
MHz): 0.34 [Si(CH3)3], 115.6 (ArCBr), 120.7 (ArCH), 122.7 (ArCH), 128.3 
(ArCH), 133.3 (ArCH), 152.4 (ArCO); m/z (ESI+) 243[(C9H13OSi79Br)+, 50%], 
245[(C9H13OSi81Br)+, 50%]; max (film)/cm-1 2960, 1584, 1477, 1255. Spectral 
details are in agreement with those reported in the literature.39 
 
 (2-Bromo-4-methylphenoxy)trimethylsilane 64  
The title compound was prepared using the procedure 
described for (2-bromophenoxy)trimethylsilane  54 using 2-
bromo-4-methylphenol 335 (1.21 mL, 10 mmol) and HMDS 
334  (1.24 mL, 6.0 mmol) in the absence of solvent at 80 ºC for 45 min in a flask 
protected with a CaCl2 tube.  Excess NH3 and unreacted HMDS were removed under 
reduced pressure to provide (2-bromo-4-methylphenoxy)trimethylsilane 64 in high 
purity as a colourless oil (2.59 g, quantitative). δH(CDCl3, 400 MHz): 0.23 [9H, s, 
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Si(CH3)3], 2.20 (3H, s, CH3), 6.70 (1H, d, J 8.2, ArCH), 6.90 (1H, ddd, J 8.2, 2.1, 
0.6, ArCH), 7.28 (1H, d, J 1.6, ArCH); δC(CDCl3, 100 MHz):  0.4 [Si(CH3)3], 20.3 
(CH3), 115.1 (ArC-Br), 120.4 (ArCH),  128.9 (ArCH),  132.4 (ArCCH3), 133.6 
(ArCH), 150.1 [ArCOSi(CH3)3]; max (film)/cm-1 2958, 1599, 1486, 1247; m/z 
(ESI+) 258[(C9H12OSiCl79Br + H)+, 8%], 260[(C9H12OSiCl81Br + H)+, 4%]. 
Spectral details are in agreement with those reported in the literature.41 
 
(2-Bromo-4-chlorophenoxy)trimethylsilane 65  
The title compound was prepared using the procedure 
described for (2-bromophenoxy)trimethylsilane  54 using 2-
bromo-4-chlorophenol 336 (0.64 g, 3.08 mmol) and HMDS 
334  (0.7 ml, 3.39 mmol) in THF (10 mL). Excess NH3 and unreacted HMDS were 
removed under reduced pressure to provide (2-bromo-4-
chlorophenoxy)trimethylsilane 65 in high purity as a colourless oil (0.86 g, 
quantitative) which was used without further purification. δH(CDCl3, 400 MHz): 
0.30 [9H, s, Si(CH3)3], 6.74 (1H, d, J 8.6, ArCH), 7.09 (1H, d, J 8.6, ArCH), 7.46 
(1H, s, ArCH);  δC(CDCl3, 100 MHz): 0.4 [Si(CH3)3], 116.1 (ArCBr), 121.3 
(ArCH), 126.9 (ArC-Cl), 128.0 (ArCH), 132.8 (ArCH), 151.5 [ArCOSi(CH3)3]; 
max (film)/cm-1 2960, 1458, 1422, 1215; m/z (ESI+) 279[(C9H12OSi79BrCl)+, 4%], 
281[(C9H12OSi81BrCl)+, 5%],163 (12), 81 (22), 79 (20). Spectral details are in 
agreement with those reported in the literature.41 
 
(2-Bromo-4,5-difluorophenoxy)trimethylsilane 67  
The title compound was prepared using the procedure 
described for (2-bromophenoxy)trimethylsilane 54 using 2-
bromo-4,5-difluorophenol 337 (0.34 g, 3 mmol) and HMDS 
334 (0.68 ml, 3.3 mmol) in THF (10 mL). Excess NH3 and unreacted HMDS were 
removed under reduced pressure to provide (2-bromo-4,5-
difluorophenoxy)trimethylsilane 67 in high purity as a colourless oil (0.8 g, 
quantitative). δH(CDCl3, 400 MHz): 0.30 [9H, s, Si(CH3)3], 6.80-6.90 (1H, m, 
ArCH), 7.05-7.09 (1H, m, ArCH); δC(CDCl3, 100 MHz):  0.5 [Si(CH3)3], 109.3 
(dd, 3JCF 7.1, 4JCF 3.9, CBr), 109.7 (d, 2JCF 19.1, ArCH), 121.3 (d, 2JCF 20.7, 
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ArCH), 145.5 (dd. 1JCF 245.7, 2JCF 13.5, ArCF), 149.2 [dd, 2JCF 8.8, 3JCF 3.0, ArCO 
Si(CH3)3], 149.7 (dd, 1JCF 249.3, 2JCF 13.5, ArCF); max (film)/cm-1 2962, 1599, 
1499, 1105; m/z (ESI+) 281 {[(C9H11OSi79BrF2) + H]+, 12%}. Spectral details are 
in agreement with those reported in the literature.41 
 
(2-Bromo-4,5-dimethylphenoxy)trimethylsilane44 66  
The title compound was prepared using the procedure 
described for (2-bromophenoxy)trimethylsilane 54 using 2-
bromo-4,5-dimethylphenol 62 (1 g, 5.0 mmol) and HMDS 
334  (1.1 ml,  5.0 mmol) in THF (10 mL). Excess NH3 and unreacted HMDS were 
removed under reduced pressure to yield (2-bromo-4,5-
dimethylphenoxy)trimethylsilane 66 as a colourless oil (1.27 g, 94%). δH(CDCl3, 
400 MHz): 0.37 [9H, s, Si(CH3)3], 2.24 (6H, s, 2 × CH3), 6.75 (1H, s, ArCH), 7.34 
(1H, s, ArCH); δC(CDCl3, 100 MHz): 0.36 [Si(CH3)3], 18.6 (ArCH3), 19.5 
(ArCH3), 111.7 (ArCBr), 121.9 (ArCH), 131.1 (ArCCH3), 133.6 (ArCH), 136.7 
(ArCCH3), 150.1 (ArCOH); max (film)/cm-1 2960, 1491, 1288, 850; m/z (ESI+) 
272 [(C11H18SiO79Br)+, 5%], 274 [C11H18SiO81Br)+, 5%]. Spectral details are in 
agreement with those reported in the literature. 
 
Note: The sample contained 5% starting material carried forward from the 
previous step that could not be removed and was carried forward to the next step. 
 
 {(6-Bromobenzo[d][1,3]dioxol-5-yl)oxy}trimethylsilane 68  
The title compound was prepared using the procedure 
described for (2-bromophenoxy)trimethylsilane 54 using 
6-bromobenzo[d][1,3]dioxol-5-ol 60 (0.79 g, 3.64 
mmol) and HMDS 334 (0.5 ml, 3.64 mmol) in THF (10 
mL). Excess NH3 and unreacted HMDS were removed under reduced pressure to 
yield [(6-bromobenzo[d][1,3]dioxol-5-yl)oxy]trimethylsilane 68 in high purity as 
a dark oil (0.8 g, quantitative). δH(CDCl3, 400 MHz): 0.27 [9H, s, Si(CH3)3], 5.93 
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(2H, s, OCH2O), 6.44 (1H, s, ArCH), 6.95 (1H, s, ArCH); Spectral details are in 
agreement with those reported in the literature.46 
 
3.3.3 Preparation of 2-(trimethylsilyl)phenyltriflate derivatives 
4-Methyl-2-(trimethylsilyl)phenyl trifluoromethanesulfonate 73  
(2-Bromo-4-methylphenoxy)trimethylsilane 64 (2.59 g, 10 
mmol) was dissolved in THF (50 mL), the solution cooled to 
-100 ºC and n-BuLi (4.8 mL, 2.5M in hexanes, 12 mmol, 1.2 
equiv.) was added dropwise. The mixture was stirred for 20 min while the 
temperature reached -80 ºC. The mixture was again cooled to -100 ºC and triflic  
anhydride (2.1 mL, 12.5 mmol, 1.2 equiv.) was added dropwise and stirred was 
continued for 20 min while the temperature reached -80 ̊ C. Cold saturated sodium 
bicarbonate was added, the phases separated and the aqueous layer extracted with 
diethyl ether (3 × 20 mL). The combined organic layers dried with MgSO4, filtered 
and concentrated under reduced pressure. The residue obtained was purified by 
column chromatography on silica gel using hexane as eluent to provide 4-methyl-
2-(trimethylsilyl)phenyl trifluoromethanesulfonate 73 as a colourless oil (1.86 g, 
60%). δH(CDCl3, 400 MHz): 0.36 [9H, s, Si(CH3)3], 2.36 (3H, s, CH3), 7.21 (2H, 
d, J 1.6, 2 × ArCH), 7.30 (1H, s, ArCH); δC(CDCl3, 100 MHz): 0.4 [Si(CH3)3], 
22.0 (CH3), 117.6 (q, 1JCF 320.2, CF3) 120.5 (ArCH),  132.8, (ArCH),  133.4, 
(ArCCH3)3),  137.9 (ArCH), 138.4 (ArCCH3), 154.3 (ArCOTf); ѵmax (film)/cm-1 
2960, 1468, 1421, 1254, 1213.  Spectral details are in agreement with those 
reported in the literature.41 
 
4-Chloro-2-(trimethylsilyl)phenyl trifluoromethanesulfonate 74  
The title compound was prepared using the procedure 
described for 4-methyl-2-(trimethylsilyl)phenyl 
trifluoromethanesulfonate 73 using (2-bromo-4-
chlorophenoxy)trimethylsilane 65 (0.86 g, 3.1 mmol) in THF (10 mL), n-BuLi (1.5 
mL, 2.5M in hexanes, 3.7 mmol) and triflic  anhydride (0.67 mL, 4.0 mmol). 
Following the work-up, the residue was purified by column chromatography on silica 
gel and using hexane as eluent to afford 4-chloro-2-(trimethylsilyl)phenyl 
trifluoromethanesulfonate 74 as a colourless oil (0.78 g, 76%). δH(CDCl3, 400 
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MHz): 0.37 [9H, s, Si(CH3)3], 7.26 (1H, d, J 1.4, ArCH), 7.39 (1H, dd, J 8.8, 2.6, 
ArCH), 7.45 (1H, d, J 2.6, ArCH); δC(CDCl3, 100 MHz): -1.0 [Si(CH3)3], 116.3 
(q, 1JCF 320.1, CF3), 121.0 (ArCH), 131.0 (ArCH), 133.5 (ArCCl), 135.3 (ArCSi),  
135.8, (ArCH), 153.1 (ArCOTf); max (film)/cm-1 2959, 1580, 1474, 1278, 1184; 
m/z (ESI+) 332 [M+] (2%).  Spectral details are in agreement with those reported 
in the literature.41 
 
6-(Trimethylsilyl)benzo[d][1,3]dioxol-5-yl trifluoromethanesulfonate 75  
The title compound was prepared using the procedure 
described for 4-methyl-2-(trimethylsilyl)phenyl 
trifluoromethanesulfonate 68 using {(6-
bromobenzo[d][1,3]dioxol-5-yl)oxy}trimethylsilane 68 (0.80 g, 3.6 mmol), n-
BuLi (1.7 mL, 2.5M in hexanes, 4.3 mmol) and triflic  anhydride (0.7 mL, 4.3 mmol, 
1.2 equiv.) Following the work-up, the residue was purified by column 
chromatography on silica gel and using hexane as eluent to afford 6-
(trimethylsilyl)benzo[d][1,3]dioxol-5-yl trifluoromethanesulfonate 75 as a 
colourless oil (34%, 0.323 g). δH(CDCl3, 400 MHz): 0.33 [s, 9H, Si(CH3)3], 6.03 
(s, 1H, OCH2O), 6.86 (d, J  14.1, 2H, ArCH); δC(CDCl3, 100 MHz): -0.35 
[Si(CH3)3], 102.7 (OCH2O), 113.5 (ArCH), 116.7 (q, 1JCF 320.4,  CF3), 120.9 
(ArCSi), 125.3 (ArCH), 147.2 (ArCO), 149.0 (ArCO), 149.9 (ArCOTf); max 
(film)/cm-1 1217, 1248, 1507, 2960. Spectral details are in agreement with those 
reported in the literature.43 
 
3.3.4 Preparation of 2-(trimethylsilyl)phenol derivatives and nonaflated 
aryne precursor 
2-(Trimethylsilyl)phenol 58  
An oven dried flask was charged with (2-
bromophenoxy)trimethylsilane  63 (3.69 g, 11 mmol) and THF 
(15 mL) and the mixture was cooled to -78 ºC. n-BuLi (4.8 mL, 
2.5M in hexanes, 12 mmol) was added dropwise and the reaction was allowed to 
warm to room temperature. A saturated aqueous solution of ammonium chloride 
was added to the mixture to quench and the mixture was extracted with ethyl 
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acetate (3 × 20 mL). The combined organic extracts were dried with MgSO4, and 
concentrated under reduced pressure. The residue obtained was purified by 
column chromatography on silica gel hexane:ethyl acetate (10:1) to provide 2-
(trimethylsilyl)phenol 58 as a colourless oil (2.17 g, 77%). δH(CDCl3, 400 MHz): 
0.31 [1H, s, 9H, Si(CH3)], 4.80 (1H, br s, OH), 6.66 (1H, dd, J 8.0, 0.6, ArCH), 
6.91(1H, dt, J 7.3, 0.9, ArCH), 7.19-7.24 (1H, m, ArCH), 7.36 (dd, J 7.2, 1.7, 
ArCH). δC(CDCl3, 100 MHz):  0.35 [Si(CH3)3], 115.4 (ArCH), 121.5 (ArCH), 
126.3 (ArCSi), 131.6 (ArCH), 136.2 (ArCH), 161.3 (ArCOH); max (film)/cm-1 
3560, 2957, 1700, 1587, 1474, 1249. m/z (ESI+) 167 [M + H]+ (12%). Spectral 
details are in agreement with those reported in the literature.40 
 
4-Methyl-2-(trimethylsilyl)phenol 76  
The title compound was prepared using the procedure 
described for 2-(trimethylsilyl)phenol 58 using (2-bromo-4-
methylphenoxy)trimethylsilane 64 (7.54 g, 29 mmol) in THF 
(30 mL) and  n-BuLi (12.8 mL, 2.5M in hexanes, 32 mmol) Following the work-
up, the residue obtained was purified by column chromatography on silica gel 
using hexane:ethyl acetate (95:5) to yield 4-methyl-2-(trimethylsilyl)phenol 76 as 
a colourless oil (4.01 g, 76%). δH(CDCl3, 400 MHz): 0.30 [9H, s, Si(CH3)3], 2.27 
(3H, s, CH3),  4.63 (1H, br s, OH), 6.56 (1H, d, J 8.1, ArCH), 7.02 (1H, dd, J 8.1, 
1.8, ArCH), 7.14 (1H, d, J 1.8, ArCH); δC(CDCl3, 100 MHz): -0.93 [Si(CH3)3], 
20.5 (CH3), 114.4 (ArCH), 125.1 (ArCSi), 129.4 (ArCCH3), 131.1 (ArCH), 135.7 
(ArCH), 158.1 (ArCOH); m/z (ESI-) 179 [M - H]- (100%), 180 (20); HRMS (ESI+): 
exact mass calculated for C10H15OSi [M - H]- 179.0892. Found 179.0888; max 
(film)/cm-1 3540, 2958, 1486, 1247. Spectral details are in agreement with those 
reported in the literature.42 
 
Note: Sample contained 5% starting material and was carried forward to the next 
step where it was completely removed. 
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4-Chloro-2-(Trimethylsilyl)phenol 77  
The title compound was prepared using the procedure 
described for 2-(trimethylsilyl)phenol 58 using (2-bromo-4-
chlorophenoxy)trimethylsilane 65 (1.68 g, 6.0 mmol) in THF 
(20 mL) and n-BuLi (2.64 mL, 2.5M in hexanes, 6.6 mmol) Following the work-up, 
the residue was purified by column chromatography on silica gel using 
hexane:ethyl acetate (10:1) to yield 4-chloro-2-(trimethylsilyl)phenol 77 as a 
colourless solid (150 mg, 13%), m.p. 24-26 ºC, (Lit. 25-27 ºC). δH(CDCl3, 400 
MHz): 0.30 [9H, s, Si(CH3)3], 4.95 (1H, br s, OH), 6.61 (1H, d, J 8.5, ArCH), 7.16 
(1H, dd, J 8.5, 2.5, ArCH), 7.26 (1H, d, J 2.5, ArCH);  δC(CDCl3, 100 MHz): -1.2 
[Si(CH3)3], 115.8 (ArCH), 125.7 (ArCCl), 128.1 (ArCSi),   130.1 (ArCH),  134.7 
(ArCH), 158.7 (ArCOH); max (KBr)/cm-1 3562, 2957, 1382, 1249; m/z (ESI-) 199 
[M - H]- (60%), 201 (25). Spectral details are in agreement with those reported in 
the literature.40 
 
4,5-Difluoro-2-(trimethylsilyl)phenol 78  
The title compound was prepared using the procedure 
described for 2-(trimethylsilyl)phenol 58 using (2-bromo-
4,5-difluorophenoxy)trimethylsilane 74 (6.7 g, 24 mmol) in 
THF (20 mL) and n-BuLi (10.6 mL, 2.5M in hexanes, 26 mmol). Following the 
work-up, the residue was purified by column chromatography on silica gel 
hexane:ethyl acetate (16:1) to provide 4,5-difluoro-2-(trimethylsilyl)phenol 78 as 
a colourless oil (2.12 g, 44%). δH(CDCl3, 400 MHz): 0.30 [1H, s, 9H, Si(CH3)3], 
5.56 (1H, br s, OH), 6.54 (1H, dd, 2JHF 11.4, 3JHF 5.9, ArCH), 7.09 (1H, t, 2JHF 
10.1, ArCH); δC(CDCl3, 100 MHz): -1.2 [Si(CH3)3], 104.2 (d, 2JCF 18.9, ArCH), 
121.9 (dd, 3JCF 3.8, 4JCF 1.8, ArCSi), 122.6 (dd, 2JCF 16.3, 3JCF 1.5 ArCH), 145.0 
(dd. 1JCF 241.2, 2JCF 11.9, ArCF), 150.9 (dd, 1JCF 249.4, 2JCF 14.3, ArCF), 156.2 
(dd, 3JCF 8.0, 4JCF 2.0, ArCOH); max (film)/cm-1 3603, 3403, 2959, 1614, 1513, 
1436;  m/z (ESI-) 201 [M - H]- (100%), 202 (12). Spectral details are in agreement 
with those reported in the literature.40 
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4,5-Dimethyl-2-(trimethylsilyl)phenol 79  
The title compound was prepared using the procedure 
described for 2-(trimethylsilyl)phenol 58 using (2-bromo-
3,4-dimethylphenoxy)trimethylsilane 66 (1.15 g, 4.2 mmol) 
in THF and  n-BuLi (1.8 mL, 2.5 M in hexanes, 4.6 mmol). Following the work-
up, the residue was purified by column chromatography on silica gel hexane:ethyl 
acetate (10:1) to yield 4,5-dimethyl-2-(trimethylsilyl)phenol 79 as a colourless oil 
(0.64 mg, 79%). δH(CDCl3, 400 MHz): 0.36 [9H, s, Si(CH3)3], 2.25 (6H, s, 2 × 
CH3), 5.01 (1H, br s, OH) 6.54 (1H, s, ArCH), 7.15 (1H, s, ArCH); δC(CDCl3, 100 
MHz): -0.86 [Si(CH3)3], 18.6 (CH3), 19.7 (CH3), 115.9 (ArCH), 121.9 (ArCSi), 
128.0 (ArCCH3), 136.2 (ArCH), 139.2 (ArCCH3), 158.6 (ArCOH); max (film)/cm-
1 3521, 2954, 1607, 1498, 1192; m/z (ESI-) 193 [M - H]- (100%), 194 [M]+(20).  
Spectral details are in agreement with those reported in the literature.40 
 
2-(Trimethylsilyl)phenyl nonaflate 72 
A mixture of 2-trimethylsilyl phenol 58 (100 mg, 0.6 mmol), 
NfF (0.43 mL, 2.4 mmol) and NaH (55% in mineral oil, 79 
mg, 1.8 mmol) in acetonitrile (6.0 mL) were stirred under a 
nitrogen atmosphere for 4.5 h at 60 ºC. A saturated aqueous solution of ammonium 
chloride was added to the mixture to quench and the mixture was extracted with 
ethyl acetate (3 × 20 mL). The combined organic extracts were dried with MgSO4 
and concentrated under reduced pressure.  The residue obtained was purified by 
column chromatography on silica gel using hexane as eluent to provide 2-
(trimethylsilyl)phenyl nonaflate 72 as a colourless oil (239 mg, 89%). δH(CDCl3, 
400 MHz): 0.37 [9H, s, Si(CH3)3], 7.31-7.37 (2H, s, 2 × ArCH), 7.42-7.48 (1H, m, 
ArCH), 7.54 (1H, dd, J 7.6, 1.8,  ArCH); δC(CDCl3, 100 MHz): -0.9 [Si(CH3)3], 
119.7 (ArCH), 127.5 (ArCH), 131.3 (ArCH), 132.6 [ArCSi(CH3)3], 136.2 (ArCH), 
155.4 (ArCONf), signals for CF2CF2CF2CF3 not visible; m/z (ESI+) 448 M+ (12%). 
Spectral details are in agreement with those reported in the literature.40 
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3.3.5 Attempted synthesis of 6-(trimethylsilyl)benzo[d][1,3]dioxol-5-ol  
6-(Trimethylsilyl)benzo[d][1,3]dioxol-5-ol 80  
Using the procedure described for 2-(trimethylsilyl)phenol 
58, n-BuLi (1.0 mL, 2.5M in hexanes, 2.5 mmol, 1.1 
equiv.) was added to {(6-bromobenzo[d][1,3]dioxol-5-
yl)oxy}trimethylsilane 68 (665 mg, 2.3 mmol) in THF (10 mL). Following the 
work-up, purification was attempted using column chromatography on silica gel 
hexane:ethyl acetate (16:1) but the reaction was deemed unsuccessful and the 1H 
NMR spectrum showed a complex mixture of unidentifiable material. 
 
5-(Benzyloxy)benzo[d][1,3]dioxole 83  
5-Benzodioxolol (200 mg, 1.45 mmol), potassium 
carbonate (200 mg, 1.45 mmol) and benzylbromide 
339 (0.172 mL, 1.45 mmol) were stirred in acetone 
(50 mL) for 3 h at 60 ºC. The residue was purified 
using column chromatography in silica gel hexane:ethyl acetate (98:2) to yield 5-
(benzyloxy)benzo[d][1,3]dioxole 83 (230 mg, 70%).  δH(CDCl3, 400 MHz): 4.98 
(2H, s, CH2 benzyl), 5.90 (2H, s, OCH2O), 6.39 (1H, dd, J 8.5, 2.5, ArCH), 6.56 
(1H, d, J 2.5, ArCH), 6.69 (1H, d, J 8.5, ArCH), 7.28-7.42 (5H, m, 5 × ArCH 
benzyl). Spectral details are in agreement with those reported in the literature.47 
 
5-(Benzyloxy)-6-bromobenzo[d][1,3]dioxole 81  
The title compound was prepared in the same 
manner as 6-bromobenzo[d][1,3]dioxol-5-ol  60 
using N-bromosuccinimide 338 (93 mg, 0.52 
mmol) in 20 mL acetonitrile and 5-
(benzyloxy)benzo[d][1,3]dioxole  83 (119 mg, 0.52 mmol) in acetonitrile (20 mL). 
Following the work-up,5-(benzyloxy)-6-bromobenzo[d][1,3]dioxole 81 was 
obtained in high purity (159 mg, quantitative). δH(CDCl3, 400 MHz): 5.06 (1H, s, 
CH2), 5.92 (2H, s, OCH2O), 6.56 (1H, s, ArCH), 7.00 (1H, s, ArCH), 7.27-7.54 
(5H, m, 5 × ArCH benzyl). Spectral details are in agreement with those reported 
in the literature.48 
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Attempted synthesis of {6-(Benzyloxy)benzo[d][1,3]dioxol-5-
yl}trimethylsilane 82  
n-BuLi (0.31 mL, 2.5M in hexanes, 0.77 mmol) was 
added to a solution of 5-(benzyloxy)-6-
bromobenzo[d][1,3]dioxole (215 mg, 0.7 mmol) 340 
in dry THF (5 mL) at -78 ºC. After 15 min 
trimethylsilylchloride (0.1 mL, 0.77 mmol) was added dropwise. After 5 minutes, 
the cold bath was removed and the reaction mixture was allowed to warm to room 
temperature. After 15 minutes, the mixture was quenched with saturated aqueous 
ammonium chloride (5 mL). The aqueous layer was extracted with Et2O (3 × 5 
mL). The organic layers were combined, dried with MgSO4 andconcentrated under 
reduced pressure. Following the work-up, purification was attempted with column 
chromatography on silica gel using hexane:ethyl acetate (10:1) as eluent but the 
reaction was deemed to be unsuccessful and the 1H NMR spectrum showed a 
complex mixture of unidentifiable material.43  
 
 
3.3.6 Synthesis of pyridyne precursors 
2-[(Trimethylsilyl)oxy]pyridine 90  
The title compound was prepared using the procedure 
described for (2-bromophenoxy)trimethylsilane  54 using 2-
hydroxypyridine 89 (1.0 g, 10.4 mmol) and HMDS 334  (2.2 
ml, 10.4 mmol) in THF (10 mL). Excess NH3 and unreacted HMDS were removed 
under reduced pressure to yield 2-[(trimethylsilyl)oxy]pyridine 90 in high purity as 
a colourless oil (1.75 g, quantitative). δH(CDCl3, 400 MHz): 0.29 [9H, s, Si(CH3)3], 
6.61 (1H, d, J 8.2, ArCH), 6.78 (1H, dd, J 6.6, 5.4, ArCH), 7.45-7.51 (1H, m, 
ArCH), 8.04 (1H, dd, J 4.8, 1.5, ArCH); δC(CDCl3, 100 MHz): 0.46 [Si(CH3)3], 
112.8 (ArCH), 116.7 (ArCH), 138.8 (ArCH), 147.3 (ArCH), 162.6 
[ArCOSi(CH3)3]; max (film)/cm-1 2964, 1642, 1496, 1274; m/z (ESI+) 191 [M + H 
+ Na]+ (26%); Spectral details are in agreement with those reported in the 
literature.49 
 




A solution of n-BuLi (4.2 mL, 2.5M in hexanes, 10.5 mmol) 
was added to freshly distilled diisopropylamine 341 (1.54 mL, 
10.5 mmol) in dry THF (5 mL) at -78 ºC and stirred for 15 
mins under a nitrogen atmosphere. A solution of 2-[(trimethylsilyl)oxy]pyridine 
90 (1.75 g, 10.4 mmol) in dry THF (10 mL) was added to the flask at -78 ºC and 
the temperature was then allowed to increase slowly to room temperature. The 
mixture was poured into a 5% sodium bicarbonate solution (20 mL), extracted 
with DCM (3 × 20 mL) and dried with anhydrous MgSO4 and concentrated under 
reduced pressure. The residue obtained was purified by chromatography 
hexane:ethyl acetate (70:30-50:50) to yield 3-(trimethylsilyl)pyridin-2-ol 91 as a 
white solid (0.65 g, 37%), m.p. 99-102 ºC, (Lit.50 101-102 ºC).  δH(CDCl3, 400 
MHz): 0.28 [9H, s, Si(CH3)3], 6.23 (1H, t, J 6.4, ArCH), 7.36 (1H, dd, J 6.4, 2.2, 
ArCH), 7.55 (1H, dd, J 6.4, 2.1, ArCH), 13.01 (1H, br s, OH); δC(CDCl3, 100 
MHz): -1.8 [Si(CH3)3], 106.5 (ArCH), 131.5 (ArCSi), 135.6 (ArCH), 147.3 
(ArCH), 167.9 (ArCOH); max (KBr)/cm-1 3074, 2956, 1630, 1465, 1244; m/z 
(ESI+) 168 [M + H]+ (100%) 169 (10); HRMS (ESI+): exact mass calculated for 
C8H14NOSi [M + H]+ 168.0845. Found 168.0839. Spectral details are in agreement 
with those reported in the literature.50 
 
3-(Trimethylsilyl)pyridin-2-yl-nonaflate 92  
A mixture of 3-(trimethylsilyl)pyridin-2-ol 91 (60 mg,  0.36 
mmol), NfF (0.26 mL, 1.44 mmol) and NaH (55% in mineral 
oil, 47 mg, 1.1 mmol) in acetonitrile (4.0 mL) were stirred 
under a nitrogen atmosphere for 6.5 h. A saturated aqueous solution of ammonium 
chloride was added to the reaction and it was extracted with DCM (3 × 10 mL). 
The crude product was purified by column chromatography on silica gel using 
hexane:ethyl acetate (98:2) as eluent to provide 3-(trimethylsilyl)pyridin-2-yl 
nonaflate 92 as a colourless oil (239 mg, 89%). δH(CDCl3, 400 MHz): 0.38 [9H, 
s, Si(CH3)3], 7.32  (1H, dd, J 6.8, 5.1, ArCH), 7.93 (1H, d, J 7.0, ArCH), 8.34 (1H, 
d, J 3.5,  ArCH); δC(CDCl3, 100 MHz): -1.2 [Si(CH3)3], 110.7-119.0 (4C, m, 
SO2CF2CF2CF2CF3) 123.7 (ArCH), 125.9 (ArCSi), 147.2 (ArCH), 149.2 (ArCH), 
161.3 (ArCONf); δF(CDCl3, 376.5 MHz): -125.72 (2F, ddd, J 14.5, 6.1, 3.1, CF2), 
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-120.94 (2F, d, J 6.5, CF2), -107.93 (2F, t, J 13.8, CF2), -80.70 (3F, t, J 9.7, 
CF3);max (film)/cm-1 2908, 1571, 1508, 1417; m/z (ESI)+ 450 [M + H]+ (20%) 305 
(100), 323 (90). HRMS (ESI+): exact mass calculated for C12H13F9NO3SSi [M + 
H]+ 450.0242. Found 450.0234. 
 
2-Chloro-3-[(trimethylsilyl)oxy]pyridine 94 
The title compound was prepared using the procedure described 
for (2-bromophenoxy)trimethylsilane 54 using 2-chloro-3-
hydroxypyridine 93 (1.42 g, 11 mmol) and HMDS 334 (1.4 
ml, 6.59 mmol) in THF (10 mL). Excess NH3 and unreacted HMDS were removed 
under reduced pressure to yield 2-chloro-3-[(trimethylsilyl)oxy]pyridine 94 in high 
purity as an orange oil (2.22 g, quantitative). δH(CDCl3, 400 MHz): 0.28 [9H, s, 
Si(CH3)3], 7.10 (1H, dd, J 8.2, 4.5, ArCH), 7.15 (1H, dd, J 7.9, 1.5, ArCH), 7.98 
(1H, dd, J 4.4, 1.5, ArCH); δC(CDCl3, 100 MHz): 0.16 [Si(CH3)3], 123.0 (ArCH), 
128.1 (ArCH), 141.7 (ArCH), 143.8 (ArCCl), 147.9 (ArCOSi); m/z (ESI+) 202 [M 
+ H]+ (100%) 204 (30); HRMS (ESI+): exact mass calculated for C8H13NOSiCl 
[M + H]+ 202.0455. Found 202.0453; max (film)/cm-1 1657, 1568, 1312. Spectral 
details are in agreement with those reported in the literature.51 
 
2-Chloro-4-(trimethylsilyl)pyridin-3-ol 95  
A solution of n-BuLi (4.3 mL, 2.5M in hexanes, 10.7 mmol) 
was added to freshly distilled diisopropylamine 341 (1.7 mL, 
11.6 mmol) in dry THF (5 mL) at -78 ºC and stirred for 15 mins 
under a nitrogen atmosphere. A solution of 2-chloro-3-
[(trimethylsilyl)oxy]pyridine 94 (1.66 g, 10.4 mmol) in dry THF (20 mL) was 
added to the flask at -78 ºC and the temperature was then allowed to increase 
slowly to room temperature. The mixture was poured into a 5% sodium 
bicarbonate solution (20 mL), extracted with DCM (3 × 20 mL), dried with 
anhydrous MgSO4 and concentrated under reduced pressure. The residue obtained 
was purified by column chromatography on silica gel using hexane:ethyl acetate 
(70:30-50:50) as eluent to yield 2-chloro-4-(trimethylsilyl)pyridin-3-ol 95 as a 
white solid (1.20 g, 56%), m.p. 103-106 ºC, (Lit. 104-106 ºC). δH(CDCl3, 400 
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MHz): 0.33 [9H, s, Si(CH3)3], 5.79 (1H, br s, OH), 7.19 (1H, d, J 4.5, ArCH), 7.93 
(1H, d, J 4.5, ArCH); δC(CDCl3, 100 MHz): -1.4 [Si(CH3)3], 129.1 (ArCH), 137.1 
(ArCCl), 137.9 (ArCSi), 140.9 (ArCH), 152.2 (ArCOH); max (KBr)/cm-1 3526, 
3060, 1572, 1392, 1125; m/z (ESI+) 202 [M + H]+ (45%); HRMS (ESI+): exact 
mass calculated for C8H13NOSiCl [M + H]+ 202.0455. Found 202.0446. Spectral 
details are in agreement with those reported in the literature.51  
 
2-Chloro-4-(trimethylsilyl)pyridin-3-yl nonaflate 96  
The title compound was prepared using the procedure 
described for 3-(trimethylsilyl)pyridin-2-yl nonaflate 92 
using  2-chloro-4-(trimethylsilyl)pyridin-3-ol 95 (100 mg,  
0.5 mmol), NfF (604 mg, 2 mmol) and NaH (55% in mineral 
oil, 36 mg,  1.5 mmol) in acetonitrile (6 mL) were stirred under a nitrogen 
atmosphere for 6.5 h. Following the work-up, crude product was purified by 
column chromatography on silica gel using hexane:ethyl acetate (98:2) as eluent 
to provide 2-chloro-4-(trimethylsilyl)pyridin-3-yl nonaflate 96 as a colourless oil 
(220 mg, 91%). δH(CDCl3, 400 MHz): 0.43 [9H, s, Si(CH3)3], 7.40  (1H, d, J 4.6, 
ArCH), 8.36 (1H, d, J 4.6, ArCH); δC(CDCl3, 100 MHz): -0.29 [Si(CH3)3], 109.6-
118.7 (4C, m, SO2CF2CF2CF2CF3), 129.8 (ArCH), 145.2 (ArCCl), 145.4 (ArCSi), 
148.0 (ArCH), 149.0 (ArCONf); δF(CDCl3, 376.5 MHz): -125.7 (2F, ddd, J 14.5, 
5.9, 3.0, CF2), -120.5 (2F, dd, J 8.0, 4.5, CF2), -107.3 (2F, t, J 14.0, CF2), -80.7 
(3F, t, J 9.7, CF3); max (KBr)/cm-1 2962, 1417, 1357, 1205, 1144;  m/z (ESI)+ 484 
[M + H]+ (80%), 454 (60), 413 (50), 102 (100); HRMS (ESI+): exact mass 
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3.4 Synthesis of 1-acyl-1H-indazole compounds Method 1 
3.4.1 Generation of aryne and trapping with furan 






1,4-Dihydro-1,4-epoxynaphthalene 98  
Caesium fluoride (102 mg, 0.68 mmol) was added to 2-
(trimethylsilyl)phenyl-trifluoromethanesulfonate 49 (100 mg, 
0.34 mmol), furan 97 (18 mg, 0.27 mmol) and acetonitrile (4 mL).  The reaction 
mixture was stirred at reflux for 24 h, under a nitrogen atmosphere.  The mixture 
was diluted with brine (4 mL) and the organic layer was extracted with diethyl 
ether (3 × 5 mL).  The combined organic extracts were dried with MgSO4, 
concentrated under reduced pressure and purified by column chromatography on 
silica gel using hexane:ethyl acetate (70:30) as eluent, to yield 1,4-dihydro-1,4-
epoxynaphthalene 98 as a white solid (26 mg, 67%),  m.p. 53-56 ºC, (Lit.54 54-56 
ºC). δH(CDCl3, 400 MHz): 5.71 (2H, s, 2 × C=CH), 6.96 [2H, dd, J 5.0, 3.0, 2 × 
C(O)H], 7.03 (2H, s, 2 × ArCH), 7.25 (2H, dd, J 4.8, 2.8, 2 × ArCH); δC(CDCl3, 
100 MHz): 82.33 (2 × CO), 120.26 (2 × ArCH), 125.00 (2 × ArCH), 143.02 (C=C), 
149.00 (2 × Cq); max (KBr)/cm-1 2924, 2342, 1457; m/z (ESI-) 143 [M - H]- 
(100%). Spectral details are in agreement with those reported in the literature.54 
 
O
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3.4.2  Synthesis of 1-acyl-1H-indazole-3-carboxylate compounds 
Method 152,53:  
 
Methyl 1-acetyl-1H-indazole-3-carboxylate 104  
Caesium fluoride (91 mg, 0.6 mmol) was added to a stirred 
solution of 2-(trimethylsilyl)phenyl-
trifluoromethanesulfonate 49 (104 mg, 0.35 mmol), and 
methyl 2-diazo-3-oxo-butanoate 18 (43 mg, 0.3 mmol) in 
acetonitrile (4 mL).  The reaction was stirred at room 
temperature under a nitrogen atmosphere for 24 h.  The solution obtained was 
diluted with brine (20 mL) and extracted with ethyl acetate (3 × 20 mL). The 
residue obtained was purified by column chromatography on silica gel using 
DCM:ethyl acetate eluent (95:5) to yield methyl 1-acetyl-1H-indazole-3-
carboxylate 104 as light pink crystals (45 mg, 69%), m.p. 106-109 ºC, (Lit.55 111-
112 ºC).  δH(CDCl3, 300 MHz): 2.88 [3H, s, C(O)CH3], 4.07 (3H, s, OCH3), 7.47 
(1H, ddd, J 8.0, 7.0, 1.0, ArCH), 7.61 (1H, ddd, J 8.0, 7.0, 1.0, ArCH), 8.23 (1H, 
td, J 8.0, 1.0, ArCH), 8.47 (1H, td, J 8.5, 1.0, ArCH).  δC(CDCl3, 100 MHz): 23.1 
[C(O)CH3], 52.7 (OCH3), 115.6 (ArCH), 122.2 (ArCH), 124.7 (ArCq) 125.8 
(ArCH), 130.0 (ArCH), 140.3 (C=N), 145.5 (ArCN), 162.3 (C=O) ester, 171.3 
(C=O) amide;max (KBr)/cm-1 1727, 1505, 1324; m/z (ESI+) 219 [M + H]+ (5%), 
141 (100); HRMS (ESI)+: Exact mass calculated for C11H11N2O3 [M + H]+ 
219.0770.  Found 219.0763. Spectral details are in agreement with those reported 
in the literature.55 
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Ethyl 1-acetyl-1H-indazole-3-carboxylate 99 
The title compound was prepared following the 
procedure described for methyl 1-acetyl-1H-indazole-
3-carboxylate 104 using caesium fluoride (91 mg, 0.6 
mmol), 2-(trimethylsilyl)phenyl-
trifluoromethanesulfonate 49 (104 mg, 0.35 mmol) and 
ethyl 2-diazo-3-oxo-butanoate 19 (47 mg, 0.3 mmol) in acetonitrile (4 mL).  
Following the work-up, the crude 1H NMR showed the presence of ethyl 1-phenyl-
1H-indazole-3-carboxylate 117 which could not be separated from ethyl 1-acetyl-
1H-indazole-3-carboxylate 99 after chromatography. The residue was purified by 
column chromatography on silica gel using DCM:ethyl acetate eluent (95:5) to 
yield ethyl 1-acetyl-1H-indazole-3-carboxylate 99 and ethyl 1-phenyl-1H-
indazole-3-carboxylate 117 as a white solid in a 5:1 ratio (65 mg, 91%), m.p. 93-
96 ºC, (Lit.52 93 ºC). δH(CDCl3, 400 MHz): 1.49 (3H, t, J 7.1, OCH2CH3), 2.88 
[3H, s, C(O)CH3], 4.56 (2H, q,  J 7.2, OCH2CH3), 7.45 (1H, td, J 7.1, 0.9, ArCH), 
7.60 (1H, td, J 8.4, 1.2, ArCH,), 8.15 (1H, dt, J 8.1, 0.9, ArCH), 8.48 (1H, dt, J  
8.1, 0.9, ArCH);  δC(CDCl3, 100 MHz): 14.3 (CH2CH3), 23.1 [C(O)CH3], 61.9 
(CH2CH3), 115.6 (ArCH), 122.3 (ArCH), 124.7 (ArCq), 125.7 (ArCH), 129.9 
(ArCH), 140.9 (C=N), 141.7 (ArCN), 161.8 (C=O) ester, 171.5 (C=O) ketone; 
max (KBr)/cm-1: 2859, 1726, 1622; HRMS (ESI+): exact mass calculated for 
C12H13N2O3 [M + H]+ 233.0926. Found 233.0917. Spectral details are in 
agreement with those reported in the literature.52 
 
Ethyl 1-phenyl-1H-indazole-3-carboxylate 117 
Note: Characteristic signals of the N-arylated by-product 
observed in the 1H NMR spectrum occurred at δH(ppm): 
7.70-7.79 (3H, m, 3 × ArCH) and  8.32 (1H, d, J 8.1, 
ArCH). 
A sample of ethyl 1-phenyl-1H-indazole-3-carboxylate 
117 could be isolated after deacylation of ethyl 1-acetyl-
1H-indazole-3-carboxylate and subsequent purification of the 1-phenyl- and 1-H-
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derivatives by column chromatography on silica gel. See N-Deacylation 
experimental on page 87 for more information.52 
 
Isopropyl 1-acetyl-1H-indazole-3-carboxylate 105 
The title compound was prepared following the procedure 
described for methyl 1-acetyl-1H-indazole-3-carboxylate 
104 using 2-(trimethylsilyl)phenyl-
trifluoromethanesulfonate 49 (104 mg, 0.35 mmol), 
isopropyl 2-diazo-3-oxo-butanoate 20 (51 mg, 0.3 mmol) 
in acetonitrile (4 mL) and caesium fluoride (91 mg, 0.6 mmol).  Following the 
work-up, isopropyl 1-acetyl-1H-indazole-3-carboxylate 105 was obtained as light 
pink crystals (68 mg, 92%).  δH(CDCl3, 400 MHz): 1.49 (6H, d, J 6.3, 2 × CH3), 
2.88 [3H, s, C(O)CH3], 5.43 (1H, septet, J 6.3, CH), 7.46 (1H, ddd, J 8.1, 7.2, 0.9, 
ArCH), 7.60 (1H, ddd, J 8.4, 7.1, 1.2, ArCH), 8.19 (1H, td, J 8.1, 1.0, ArCH), 8.46 
(1H, dd, J 4.7, 3.8, ArCH).  δC(CDCl3, 100 MHz): 22.9 (2 × CH3), 24.0 [C(O)CH3], 
70.6 (OCH), 116.4 (ArCH), 123.1 (ArCH), 125.4 (ArCq), 126.5 (ArCH), 130.7 
(ArCH), 141.1 (C=N), 142.1 (ArCN), 160.8 (C=O) ester, 171.6 (C=O) amide;  
max (KBr)/cm-1 1716, 1644, 1378; HRMS (ESI)+: Exact mass calculated for 
C13H15N2O3 [M + H]+ 247.1083.  Found 247.1071; (Found C, 63.5; H, 5.71; N 
10.91. C14H16O3N2 requires C, 63.4; H, 5.73; N, 11.38%). 
 
Note: 4% of the N-arylated by-product was observed in the 1H NMR spectrum 
which could not be separated from the 1-acyl compound after column 
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t-Butyl 1-acetyl-1H-indazole-3-carboxylate 106 
The title compound was prepared following the 
procedure described for methyl 1-acetyl-1H-indazole-3-
carboxylate 104 using 2-(trimethylsilyl)phenyl-
trifluoromethanesulfonate 49 (100 mg, 0.34 mmol), t-
butyl 2-diazo-3-oxo-butanoate 21 (66 mg, 0.36 mmol, 
1.1 equiv.) in acetonitrile (4 mL) and caesium fluoride (91 mg, 0.6 mmol).  The 
reaction was stirred at room temperature under a nitrogen atmosphere for 24 h.  
Following the work-up, t-butyl 1-acetyl-1H-indazole-3-carboxylate 106 was 
obtained as light pink crystals (75.7 mg, 97%).  δH(CDCl3, 300 MHz): 1.72 (9H, 
s, 3 × CH3 of t-butyl), 2.87 [3H, s, C(O)CH3], 7.44 (1H, ddd, J 8.1, 7.2, 0.9, ArCH), 
7.59 (1H, ddd, J 8.4, 7.1, 1.2, ArCH), 8.15 (1H, td, J 8.1, 1.0, ArCH), 8.47 (1H, 
td, J 8.5, 0.8, ArCH); δC(CDCl3, 100 MHz): 23.1 [C(O)CH3], 28.3 (3 × CH3 of t-
butyl), 83.3 [C(CH3)3], 115.5 (ArCH), 122.3 (ArCH), 124.5 (ArCq), 125.5 
(ArCH), 129.7 (ArCH), 140.4 (C=N), 142.1 (ArCN), 160.8 (C=O) ester, 171.6 
(C=O) amide; max (KBr)/cm-1 1713, 1501 1141; HRMS (ESI)+: Exact mass 
calculated for C14H17N2O3 [M + H]+ 261.1239.  Found 261.1232. 
 
sec-Butyl 1-acetyl-1H-indazole-3-carboxylate 107  
The title compound was prepared following the 
procedure described for methyl 1-acetyl-1H-indazole-
3-carboxylate 104 using 2-(trimethylsilyl)phenyl-
trifluoromethanesulfonate 49 (100 mg, 0.34 mmol), 
sec-butyl 2-diazo-3-oxobutanoate 32 (66 mg, 0.36 
mmol, 1.1 equiv.) in acetonitrile (4 mL) and caesium 
fluoride (91 mg, 0.6 mmol). Following the work-up, the residue was purified by 
column chromatography on silica gel using DCM:ethyl acetate eluent (95:5) to 
yield pure sec-butyl 1-acetyl-1H-indazole-3-carboxylate 107 as a yellow oil. (57 
mg, 73%). δH(CDCl3, 400 MHz): 1.04 (3H, t, , J 7.5, CH3),  1.46 (3H, d, J 6.3, 
CH3), 1.74-1.94 (2H, m, CH2), 2.88 [3H, s, C(O)CH3], 5.24-5.32 (1H, m, OCH), 
7.43-7.48 (1H, m, ArCH), 7.57-7.63 (1H, m, ArCH), 8.19 (1H, d, J 8.1, ArCH), 
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8.47 (1H, d, J 8.5, ArCH); δC(CDCl3, 100 MHz): 9.8 (CH2CH3), 19.6 (CHCH3), 
23.1 [C(O)CH3], 28.9 (CH2), 74.3 (OCH), 115.6 (ArCH), 122.2 (ArCH), 124.6 
(ArCq), 125.6 (ArCH), 129.8 (ArCH), 140.3 (C=N), 141.2 (ArCN), 161.5 (C=O) 
ester, 171.6 (C=O) amide; max (film)/cm-1 1732, 1501, 1194; HRMS (ESI+): exact 
mass calculated for C14H17N2O3 [M + H]+ 261.1239. Found 261.1237.  
 
Pentyl 1-acetyl-1H-indazole-3-carboxylate 108 
The title compound was prepared following the 
procedure described for methyl 1-acetyl-1H-
indazole-3-carboxylate 104 using 2-
(trimethylsilyl)phenyl-trifluoromethanesulfonate 
49 (100 mg, 0.34 mmol), pentyl 2-diazo-3-oxo-
butanoate 23 (71 mg, 0.36 mmol, 1.1 equiv.) in 
acetonitrile (4 mL) and caesium fluoride (91 mg, 0.6 mmol) was added.  The 
reaction was stirred at room temperature under a nitrogen atmosphere for 24 h.  
Following the work-up, the residue was purified by column chromatography on 
silica gel using DCM:ethyl acetate eluent (95:5) and to yield pentyl 1-acetyl-1H-
indazole-3-carboxylate 108 (65 mg, 79%) as a yellow oil.  δH(CDCl3, 400 MHz): 
0.93 (3H, t, J 7.1, CH2CH3), 1.36-1.48 (4H, m, 2 × CH2), 1.85-1.92 (2H, m, CH2), 
2.88 (3H, s, C(O)CH3), 4.50 (2H, t, J 6.8, OCH2), 7.44-7.49 (1H, m, ArCH), 7.55-
7.65 (1H, ddd, J 8.4, 7.1, 1.1, ArCH), 8.20 (1H, d, J 8.1, ArCH), 8.47 (1H, d, J 
8.5, ArCH); δC(CDCl3, 100 MHz): 14.0 (CH3), 22.3 (CH2), 23.1 [C(O)CH3], 28.1 
(CH2), 28.3 (CH2), 66.0 (OCH2), 115.6 (ArCH), 122.2 (ArCH), 124.6 (ArCq), 
125.7 (ArCH), 129.9 (ArCH), 140.3 (C=N), 140.9 (ArCN), 161.9 (C=O) ester, 
171.6 (C=O) amide; max (film)/cm-1 1722, 1644; HRMS (ESI+): exact mass 
calculated for C15H19N2O3 [M + H]+ 273.1396. Found 273.1388; (Found C, 65.77; 
H, 6.67; N 8.14. C15H18O3N2 requires C, 65.68; H, 6.61; N, 10.21%). 
 




The title compound was prepared following the 
procedure described for methyl 1-acetyl-1H-
indazole-3-carboxylate 104 using 2-
(trimethylsilyl)phenyl-trifluoromethanesulfonate 49 
(100 mg, 0.34 mmol), isopentyl 2-diazo-3-oxo-
butanoate 24 (71 mg, 0.36 mmol, 1.1 equiv.) in acetonitrile (4 mL) and caesium 
fluoride (91 mg, 0.6 mmol).  The reaction was stirred at room temperature under 
a nitrogen atmosphere for 24 h.  Following the work-up, the residue was purified 
by column chromatography on silica gel using DCM: ethyl acetate eluent (95:5) 
and isopentyl-1H-indazole-3-carboxylate 109 was obtained as light pink crystals 
(62 mg, 76%).  δH(CDCl3, 400 MHz): 1.00 (6H, d, J 6.4, 2 × CH3), 1.70-1.89 [3H, 
m, containing OCH2CH2 and CH(CH3)2], 2.87 [3H, s, C(O)CH3], 4.53 (2H, t, J 
6.8, OCH2), 7.46 (1H, ddd, J 8.1, 0.9, ArCH), 7.60 (1H, ddd, J 7.1, 1.2, ArCH), 
8.20 (1H, td, J 8.1, 1.0, ArCH), 8.47 (1H, td, J 8.5, 0.9, ArCH); δC(CDCl3, 100 
MHz): 22.5 (2 × CH3), 23.1 (CH), 25.3 [C(O)CH3], 37.3 (CH2), 64.6 (OCH2), 
115.6 (ArCH), 122.2 (ArCH), 124.6 (ArCq), 125.7 (ArCH), 129.9 (ArCH), 140.3 
(C=N), 140.8 (ArCN), 161.9 (C=O) ester, 171.5 (C=O) amide; max (KBr)/cm-1 
2959, 1722, 1646, 1124; m/z (ESI+) 274 [M]+; HRMS (ESI)+: Exact mass 
calculated for C15H19N2O3 [M + H]+ 275.1396.  Found 275.1388. 
 
Benzyl 1-acetyl-1H-indazole-3-carboxylate 110 
The title compound was prepared following the 
procedure described for methyl 1-acetyl-1H-
indazole-3-carboxylate 104 using 2-
(trimethylsilyl)phenyl-trifluoromethanesulfonate 49 
(100 mg, 0.34 mmol), benzyl 2-diazo-3-oxo-
butanoate 22 (68 mg, 0.36 mmol, 1.1 equiv.) in 
acetonitrile (4 mL) and caesium fluoride (91 mg, 0.6 mmol).  The reaction was 
stirred at room temperature under a nitrogen atmosphere for 24 h.  Following the 
work-up, the residue was purified by column chromatography on silica gel using 
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DCM:ethyl acetate eluent (95:5) to yield benzyl-1H-indazole-3-carboxylate 110 
as light pink crystals (64.7 mg, 73%).  δH(CDCl3, 400 MHz): 2.88 (3H, s, 
C(O)CH3), 5.53 (2H, s, OCH2C6H5), 7.34-7.46 (4H, m, 3 × ArCH benzyl and 1 × 
ArCH indazole), 7.51-7.55 (2H, m, 2 × ArCH benzyl), 7.60 (1H, ddd, J 8.4, 7.1, 
1.1, ArCH), 8.18 (1H, d, J 8.1, ArCH), 8.47 (1H, d, J 8.48, ArCH);  δC(CDCl3, 
100 MHz): 23.1 [C(O)CH3], 67.4 (OCH2C6H5), 115.6 (ArCH indazole), 122.2 
(ArCH indazole), 123.8 (ArCq benzyl), 123.9 (ArCq indazole), 125.8 (ArCH 
indazole), 128.6 (2 × ArCH benzyl), 128.6 (ArCH benzyl), 128.8 (2 × ArCH 
benzyl), 129.9 (ArCH indazole), 135.3 (Cq benzyl), 140.3 (C=N), 140.5 (ArCN), 
161.7 (C=O) ester, 171.5 (C=O) amide; max (KBr)/cm-1 1718, 1646, 1498, 1324; 
HRMS (ESI)+: Exact mass calculated for C17H15N2O3 [M + H]+ 295.1083.  Found 
295.1082. 
 
2-Ethylbutyl 1-acetyl-1H-indazole-3-carboxylate 111  
The title compound was prepared following the 
procedure described for methyl 1-acetyl-1H-
indazole-3-carboxylate 104 using 2-
(trimethylsilyl)phenyl-trifluoromethanesulfonate 49 
(104 mg, 0.35 mmol), 2-ethylbutyl 2-diazo-
3oxobutanoate 30 (0.0636 g, 0.3 mmol) in 
acetonitrile (4 mL) and caesium fluoride (91 mg, 0.6 mmol). Following the work-
up, the residue was purified by column chromatography on silica gel using 
DCM:ethyl acetate eluent (95:5) to yield 2-ethylbutyl 1-acetyl-1H-indazole-3-
carboxylate 111 as a yellow oil (58.8 mg, 68%). δH(CDCl3, 400 MHz): 0.99 (6H, 
t, J 7.5, 2 × CH3), 1.46-1.57 (4H, m, 2 × CH2), 1.78 (td, J 12.5, 6.2, CH), 2.87 [3H, 
s, C(O)CH3], 4.44 (2H, d, J 5.8, OCH2), 7.46 (1H, ddd,  J 8.1, 7.1, 1.0, ArCH), 
7.60 (1H, ddd, J 8.4, 7.1, 1.2, ArCH), 8.18 (1H, td, J 8.1, 1.0, ArCH), 8.47 (1H, 
td, J 8.5, 0.9, ArCH); δC(CDCl3, 100 MHz): 11.1 (2 × CH3), 23.1 [C(O)CH3], 23.5 
(2 × CH2), 40.5 (CH), 67.8 (OCH2), 115.6 (ArCH), 122.1 (ArCH), 124.6 (ArCq), 
125.7 (ArCH), 129.8 (ArCH), 140.3 (C=N), 140.9 (ArCN), 162.0 (C=O) ester, 
171.5 (C=O) amide; max (film)/cm-1 2964, 1733, 1500, 1325;  m/z (ESI-) 245 
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[M - COCH3]- (60%), 262 (100), 263 (12), 246 (10); HRMS (ESI+): exact mass 
calculated for C16H21N2O3 [M + H]+ 289.1552. Found 289.1548.  
 
Note: 4% of the N-arylated by-product was observed in the 1H NMR spectrum 
which could not be separated from the 1-acyl compound after column 
chromatography on silica gel.  
 
2-Ethylhexyl 1-acetyl-1H-indazole-3-carboxylate 112  
The title compound was prepared following the 
procedure described for methyl 1-acetyl-1H-
indazole-3-carboxylate 104 using 2-
(trimethylsilyl)phenyl-trifluoromethanesulfonate 
49 (104 mg, 0.35 mmol), 2-ethylhexyl 2-diazo-3-
oxobutanoate 28 (0.072 g, 0.3 mmol) in 
acetonitrile (4 mL) and caesium fluoride (91 mg, 
0.6 mmol). Following the work-up, the residue was purified by column 
chromatography on silica gel using DCM:ethyl acetate eluent (95:5) to yield 2-
ethylhexyl 1-acetyl-1H-indazole-3-carboxylate 112 as a yellow oil (63.6 mg, 
67%). δH(CDCl3, 400 MHz): 0.88-1.03 [6H, m, containing 0.91 (3H, t, J 7.1, CH3) 
and 0.99 (3H, t, J 7.5, CH3)], 1.21-1.56 (8H, m, 4 × CH2), 1.83 (1H, td, J 12.3, 6.1, 
CH), 2.87 [3H, s, C(O)CH3], 4.42 (2H, d, J 5.8, OCH2), 7.46 (1H, ddd, J 8.1, 7.1, 
0.9, ArCH), 7.62 (1H, ddd, J 8.4, 7.1, 1.1, ArCH), 8.17-8.21 (1H, m,  ArCH), 8.47 
(1H, td, J 8.5, 0.8, ArCH); δC(CDCl3, 100 MHz): 11.1 (CH3), 14.0 (CH3), 23.0 
(CH2), 23.0 [C(O)CH3], 24.0 (CH2), 29.0 (CH2), 30.6 (CH2), 38.9 (CH), 68.2 
(OCH2), 115.6 (ArCH), 122.1 (ArCH), 124.6 (ArCq), 125.7 (ArCH), 129.8 
(ArCH), 140.3 (C=N), 140.9 (ArCN), 162.0 (C=O) ester, 171.5 (C=O) amide. max 
(film)/cm-1 2955, 1735, 1730, 1670, 1254; m/z (ESI-) 316 [M]+ (18%), 113 (100). 
HRMS (ESI+): exact mass calculated for C18H25N2O3 [M + H]+ 317.1865. Found 
317.1855. 
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Note: 8% of the N-arylated by-product was observed in the 1H NMR spectrum 
which could not be separated from the 1-acyl compound after column 
chromatography on silica gel.  
 
Decyl 1-acetyl-1H-indazole-3-carboxylate 113  
The title compound was prepared 
following the procedure described 
for methyl 1-acetyl-1H-indazole-3-
carboxylate 104 using 2-
(trimethylsilyl)phenyltrifluoromethanesulfonate 49 (100 mg, 0.34 mmol), decyl 2-
diazo-3-oxobutanoate 29 (67 mg, 0.34 mmol) in acetonitrile (4 mL) and caesium 
fluoride (91 mg, 0.6 mmol).  The reaction was stirred at room temperature under 
a nitrogen atmosphere for 24 h.  Following the work-up, the residue was purified 
by column chromatography on silica gel using DCM:ethyl acetate eluent (95:5) to 
yield decyl 1-acetyl-1H-indazole-3-carboxylate 113 as light pink crystals (89 mg, 
86%),  m.p. 47-49 ºC. δH(CDCl3, 400 MHz): 0.93 (3H, t, J 6.7, CH3), 1.20-1.47 
(14H, m, 7 × CH2), 1.84-1.91 (2H, m, OCH2CH2 ), 2.88 [3H, s, C(O)CH3], 4.49 
(2H, t, J 6.9, OCH2), 7.43 (1H, t, J 8.3, ArCH), 7.60 (1H, t, J 8.3, ArCH), 8.20 
(1H, d, J 8.3, ArCH), 8.47 (1H, d, J 8.3, ArCH); δC(CDCl3, 100 MHz): 14.1 
(CH2CH3), 22.7 [C(O)CH3], 23.1 (CH2), 25.9 (CH2), 28.7 (CH2), 29.2 (CH2), 29.3 
(CH2), 29.5 (2 × CH2), 31.9 (OCH2CH2), 65.9 (OCH2), 115.6 (ArCH), 122.2 
(ArCH), 124.7 (Cq), 125.7 (ArCH), 129.8 (ArCH), 140.3 (C=N), 140.9 (ArCN), 
161.9 (C=O) ester, 171.5 (C=O) amide; m/z (ESI+) 345 [M + H]+ (38%), 346 (10), 
42 (100). Exact mass calculated for C20H29N2O3 [M + H]+ 345.2178. Found 
345.2179; max (KBr)/cm-1 2926, 1736, 1501, 1195; (Found: C, 70.61; H, 8.36; N, 
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Methyl 1-pentanoyl-1H-indazole-3-carboxylate 118  
The title compound was prepared following the procedure 
described for methyl 1-acetyl-1H-indazole-3-carboxylate 104 
using 2-(trimethylsilyl)phenyl-trifluoromethanesulfonate 49 
(100 mg, 0.34 mmol), methyl 2-diazo-3-oxoheptanoate 33 (67 
mg, 0.36 mmol) in acetonitrile (4 mL) and caesium fluoride 
(91 mg, 0.6 mmol).  The reaction was stirred at room 
temperature under a nitrogen atmosphere for 24 h.  Following 
the work-up, the residue was purified by column chromatography on silica gel 
using DCM:ethyl acetate eluent (95:5) to yield methyl 1-pentanoyl-1H-indazole-
3-carboxylate 118 as light pink crystals (65 mg, 83%).  δH(CDCl3, 400 MHz): 0.99 
(3H, t, J 7.3, CH2CH3), 1.43-1.55 (2H, m, CH2), 1.79-1.89 (2H, m, CH2), 3.31 (2H, 
t, J 7.5, C(O)CH2), 4.1 (3H, s, OCH3), 7.44 (1H, ddd,  J 8.04, 7.2, 0.9, ArCH), 
7.59 (1H, ddd, J 8.4, 7.1, 1.2, ArCH), 8.22 (1H, td, J 8.1, 1.0, 1.0, ArCH), 8.46 
(1H, td, J 8.5, 0.8, 0.8, ArCH); δC(CDCl3, 100 MHz): 14.7 (CH3), 23.1 (CH2CH3), 
27.2 (CH2CH2CH3), 35.5 [C(O)CH2], 53.4 (OCH3), 116.4 (ArCH), 123.0 (ArCH), 
125.5 (ArCq), 126.5 (ArCH), 130.7 (ArCH), 141.1 (C=N), 141.2 (ArCN), 163.1 
(C=O) ester, 175.1 (C=O) amide;max (KBr)/cm-1 1722, 1645;  m/z (ESI+) 261 [M 
+ H]+ (60%), 262 (8), 177 (100); HRMS (ESI)+: Exact mass calculated for 
C14H17N2O3 [M + H]+, 261.1239.  Found 261.1229; (Found: C, 64.93; H, 6.36; N, 
10.45.  C14H16N2O3 requires C, 64.60; H, 6.2; N, 10.76%).  
 
 
Ethyl 1-butyryl-1H-indazole-3-carboxylate 119 
The title compound was prepared following the procedure 
described for methyl 1-acetyl-1H-indazole-3-carboxylate 
104 using 2-(trimethylsilyl)phenyl-
trifluoromethanesulfonate 49 (100 mg, 0.34 mmol), ethyl 2-
diazo-3-oxohexanoate 34, (67 mg, 0.36 mmol) in 
acetonitrile (4 mL) and caesium fluoride (91 mg, 0.6 mmol).  
The reaction was stirred at room temperature under a nitrogen atmosphere for 24 
h.  Following the work-up, the residue was purified by column chromatography 
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on silica gel using DCM:ethyl acetate eluent (95:5) to yield ethyl 1-butyryl-1H-
indazole-3-carboxylate 119 as light pink crystals (72 mg, 92%).  δH(CDCl3, 400 
MHz): 1.08 (3H, t, J 7.4, CH2CH3), 1.51 (3H, t, J 7.1, OCH2CH3), 1.84-1.94 (2H, 
m, CH2CH2CH3), 3.30 (2H, t, J 7.4, C(O)CH2), 4.56 (2H, q, J 7.1, OCH2CH3), 
7.42-7.47 (1H, m, ArCH), 7.59 (1H, ddd, J 8.4, 7.1, 1.1, ArCH), 8.21 (1H, d, J 
8.1, ArCH), 8.48 (1H, d, J 8.5, ArCH);  δC(CDCl3, 100 MHz): 14.3 (CH3CH2CH2), 
14.5 (CH3CH2O), 17.8 (CH3CH2CH2), 36.7  [CH3CH2CH2C(O)],  61.8 
(OCH2CH3), 115.5 (ArCH), 122.2 (ArCH), 124.0 (ArCq), 125.6 (ArCH), 129.8 
(ArCH, 140.4 (C=N), 140.6 (ArCN), 161.9 (C=O) ester, 174.2 (C=O) amide; max 
(KBr)/cm-1 1652, 1646, 1373; m/z (ESI+) 261 [M + H]+ (100%), 191 (100); HRMS 




Propyl 1-pentanoyl-1H-indazole-3-carboxylate 120  
The title compound was prepared following the 
procedure described for methyl 1-acetyl-1H-indazole-3-
carboxylate 104 using 2-(trimethylsilyl)phenyl-
trifluoromethanesulfonate 49 (100 mg, 0.34 mmol), 
propyl 2-diazo-3-oxoheptanoate butanoate 35 (67 mg, 
0.36 mmol) in acetonitrile (4 mL) and caesium fluoride 
(91 mg, 0.6 mmol).  The reaction was stirred at room 
temperature under a nitrogen atmosphere for 24 h.  Following the work-up, the 
crude residue was purified by column chromatography on silica gel using 
DCM:ethyl acetate eluent (95:5) to isolate propyl 1-pentanoyl-1H-indazole-3-
carboxylate 120 as a yellow solid (58 mg, 67%) m.p. 40-42 ̊ C.  δH(CDCl3, 400 
MHz): 0.99 (3H, t, J 7.3, CH3), 1.09 (3H, t, J 7.4, CH3), 1.44-1.52 (2H, m, CH2), 
1.58-1.84 (4H, m, 2 × CH2), 3.32 [2H, t, J 7.8, C(O)CH2], 4.46 (2H, t, J 6.7, 
OCH2), 7.45 (1H, t, J 8.0, ArCH), 7.59 (1H, t, J 8.0, ArCH), 8.19 (1H, d, J 8.0, 
ArCH), 8.48 (1H, d, J 8.0, ArCH); δC(CDCl3, 100 MHz): 10.5 (CH3 ester), 13.9 
(CH3) amide, 22.1 (CH2), 22.3 (CH2), 26.5 (CH2), 34.7 (CH2), 67.3 (OCH2), 115.6 
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140.6 (ArCN), 162.0 (C=O) ester, 174.4 (C=O) amide; max (KBr)/cm-1 2919, 
1734, 1718, 1507; m/z (ESI+) 289 [M + H]+ (100%), 290 (42), 287 (10); HRMS 
(ESI)+: Exact mass calculated for C16H21N2O3 [M + H]+ 289.1552;  Found 
289.1546; (Found: C, 66.65; H, 6.99; N, 9.72.  C16H20N2O3 requires C, 66.65; H, 
6.99; N, 9.52%). 
 
Isopropyl 1-pentanoyl-1H-indazole-3-carboxylate 121 
The title compound was prepared following the 
procedure described for methyl 1-acetyl-1H-indazole-3-
carboxylate 104 using 2-(trimethylsilyl)phenyl-
trifluoromethanesulfonate 49 (100 mg, 0.34 mmol), 
isopropyl 2-diazo-3-oxoheptanoate 36 (67 mg, 0.36 
mmol) in acetonitrile (4 mL) and caesium fluoride (91 
mg, 0.6 mmol).  The reaction was stirred at room 
temperature under a nitrogen atmosphere for 24 h. Following the work-up, the 
crude residue was purified by column chromatography on silica gel using 
DCM:ethyl acetate eluent (95:5) to isolate isopropyl 1-pentanoyl-1H-indazole-3-
carboxylate 121 as a yellow oil (55.4 mg, 64%). δH(CDCl3, 400 MHz): 0.99 (3H, 
t, J 7.3, CH3), 1.44-1.56 (8H, m, J 6.3, 2 × CH3 and CH2), 1.84 (2H, td, J 15.1, 7.5, 
CH2), 3.32 (2H, t, J 7.5, CH2), 5.42 (1H, sept, J 6.3, CH of isopropyl), 7.42-7.47 
(1H, m, ArCH), 7.59 (1H, ddd, J 8.4, 7.1, 1.1, ArCH), 8.18 (1H, d, J 8.1, ArCH), 
8.48 (1H, d, J 8.5, ArCH); δC(CDCl3, 100 MHz): 13.9 (CH3), 22.2 (2 × CH3), 22.3 
(CH2), 26.4 (CH2), 34.6 (CH2), 69.7 [CH(CH3)2], 115.5 (ArCH), 122.2 (ArCH), 
124.5 (ArCq), 125.5 (ArCH), 129.7 (ArCH), 140.4 (C=N), 141.0 (ArCN), 161.4 
(C=O) ester, 174.4 (C=O) amide. max (film)/cm-1 2934, 2131, 1777, 1728, 1693, 
1163; m/z (ESI+) 289 [M + H]+ (10%), 493 (100); HRMS (ESI+): exact mass 
calculated for C16H21O3N2 [M + H]+ 289.1552. Found 289.1542; (Found: C, 67.07; 
H, 7.18.  C16H20N2O3 requires C, 66.65; H, 6.99%). 
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t-Butyl 1-pentanoyl-1H-indazole-3-carboxylate 122  
The title compound was prepared following the procedure 
described for methyl 1-acetyl-1H-indazole-3-carboxylate 
104 using 2-(trimethylsilyl)phenyl-
trifluoromethanesulfonate 49 (100 mg, 0.34 mmol), t-
butyl 2-diazo-3-oxoheptanoate 37 (67 mg, 0.36 mmol) in 
acetonitrile (4 mL) and caesium fluoride (91 mg, 0.6 
mmol).  The reaction was stirred at room temperature 
under a nitrogen atmosphere for 24 h.  Following the work-up, the residue was 
purified by column chromatography on silica gel using DCM:ethyl acetate eluent 
(95:5) to yield t-butyl 1-pentanoyl-1H-indazole-3-carboxylate 122 as light pink 
crystals (41 mg, 72%).   δH(CDCl3, 400 MHz): 0.99 (3H, t, CH3, J 7.3), 1.42-1.55 
(2H, m, CH2), 1.72 (9H, s, 3 × CH3), 1.83 (2H, ddd, CH2, J 13.2, 8.5, 6.5), 3.32 
[2H, t, J 7.5, C(O)CH2], 7.44 (1H, ddd, J 8.0, 7.2, 0.9, ArCH), 7.59 (1H, ddd, J 
8.4, 7.1, 1.2, ArCH), 8.15 (1H, td, J 8.1, 0.9, ArCH), 8.46 (1H, d, J 8.5, ArCH).  
δC(CDCl3, 100 MHz): 13.9 (CH3), 22.3 (CH2), 26.5 (CH2), 28.3 (3 × CH3), 34.7 
[C(O)CH2], 83.2 [C(CH3)3], 115.6 (ArCH), 122.3 (ArCH), 124.0 (ArCq), 125.4 
(ArCH), 129.6 (ArCH), 140.5 (C=N), 141.9 (ArCN), 165.0 (C=O) ester, 174.5 
(C=O) amide; max (KBr)/cm-1 1737, 1710, 1611. m/z (ESI+) 303 [M + H]+ (100%), 
302 (4), 57 (52); HRMS (ESI+): exact mass calculated for C17H23O3N2 [M + H]+ 
303.1709. Found 303.1711.  
 
Aryl ketone side chain 
Methyl 1-(4-fluorobenzoyl)-1H-indazole-3-carboxylate 123  
The title compound was prepared following the 
procedure described for methyl 1-acetyl-1H-indazole-3-
carboxylate 104 using 2-(trimethylsilyl)phenyl-
trifluoromethanesulfonate 49 (100 mg, 0.34 mmol), 
methyl 2-diazo-3-(4-fluorophenyl)-3-oxopropanoate 38 
(80 mg, 0.36 mmol) in acetonitrile (4 mL) and caesium 
fluoride (91 mg, 0.6 mmol).  The reaction was stirred at 
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room temperature under a nitrogen atmosphere for 24 h.  Following the work-up, 
the residue was purified by column chromatography on silica gel using DCM:ethyl 
acetate eluent (95:5) to provide methyl 1-(4-fluorobenzoyl)-1H-indazole-3-
carboxylate 123  as a yellow solid (69 mg, 68%), m.p. 96-99 ̊ C. δH(CDCl3, 400 
MHz): 4.06 (3H, s, OCH3), 7.20-7.25 (2H, m, 2 × ArCH phenyl), 7.52 (1H, ddd, 
J 8.0, 7.2, 0.9, ArCH indazole), 7.67 (1H, ddd J 8.4, 7.1, 1.2, ArCH indazole) 8.20-
8.26 (2H, m, 2 × ArCH phenyl), 8.30 (1H, td, J 8.1, 0.9, ArCH indazole), 8.56 
(1H, d, J 8.5, ArCH indazole);  δC(CDCl3, 100 MHz): 52.61 (OCH3), 115.7 (ArCH 
indazole), 115.6 (d, 2JCF, 31.8, 2 × ArCH phenyl), 122.2 (ArCH indazole), 124.5 
(ArCq indazole), 126.1 (ArCH), 129.5 (d, 4JCF, 4.0, ArCq), 130.0 (ArCH), 134.5 
(d, 3JCF, 9.3, 2 × ArCH phenyl), 140.9 (C=N), 141.5 (ArCN), 162.2 (C=O) amide, 
165.4 (CF, d, 1JCF 214.9), 167.4 (C=O) ester; max (KBr)/cm-1 1720, 1602, 1499; 
m/z (ESI+) 299 [M + H]+ (80%); HRMS (ESI+): exact mass calculated for 
C16H12O3N2F [M + H]+ 299.0832. Found 299.0829.  
 
Ethyl 1-benzoyl-1H-indazole-3-carboxylate 124  
The title compound was prepared following the procedure 
described for methyl 1-acetyl-1H-indazole-3-carboxylate 
104 using 2-(trimethylsilyl)phenyl-
trifluoromethanesulfonate 49 (100 mg, 0.34 mmol), ethyl 
2-diazo-3-oxo-3-phenylpropanoate  (74 mg, 0.36 mmol) 
in acetonitrile (4 mL) and caesium fluoride (91 mg, 0.6 
mmol).  The reaction was stirred at room temperature 
under a nitrogen atmosphere for 24 h.  Following the work-up, the residue was 
purified by column chromatography on silica gel using DCM:ethyl acetate eluent 
(95:5) to yield ethyl 1-phenyl-1H-indazole-3-carboxylate 124 as a light pink solid 
(62.4 mg, 71%), m.p. 118-121 ºC, (Lit.56 123 ºC). δH(CDCl3, 400 MHz): 1.48 (3H, 
t, J 7.13, CH3), 4.53 (2H, q, J 7.13, OCH2), 7.48-7.56 (3H, m, containing ArCH 
indazole and 2 × ArCH phenyl), 7.60-7.69 (2H, m, containing ArCH indazole and 
ArCH phenyl), 8.14-8.18 (2H, m, 2 × ArCH phenyl), 8.27 (1H, td, J 8.18, 1.0, 
ArCH indazole), 8.57 (1H, td, J 8.5, 1.0, ArCH indazole); δC(CDCl3, 100 MHz): 
14.3 (CH3), 61.8 (CH2), 115.8 (ArCH indazole), 122.2 (ArCH indazole), 124.5 
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(ArCq indazole), 125.9 (ArCH indazole), 128.1 (2 × ArCH phenyl), 129.8 (ArCH 
indazole), 131.7 (2 × ArCH phenyl),  132.2 (ArCq phenyl), 133.0 (ArCH phenyl), 
141.5 (C=N), 141.5 (ArCN), 161.8 (C=O) ester, 168.2 (C=O) amide; max 
(KBr)/cm-1 1734, 1717, 1700, 1684, 1328, 1151; m/z (ESI+) 294 M+ (5%), 276 
(50), 219 (100), 163 (65), 46 (100). Spectral details not reported in literature.56 
 
Functionalisable ester side chain 
Undec-10-en-1-yl 1-acetyl-1H-indazole-3-carboxylate 126 
The title compound was prepared 
following the procedure described 
for methyl 1-acetyl-1H-indazole-3-
carboxylate 104 using 2-
(trimethylsilyl)phenyl-
trifluoromethanesulfonate 49 (100 mg, 0.34 mmol), undec-10-en-1-yl 2-diazo-3-
oxobutanoate butanoate 31 (71 mg, 0.36 mmol) in acetonitrile (4 mL) and caesium 
fluoride (91 mg, 0.6 mmol).  The reaction was stirred at room temperature under 
a nitrogen atmosphere for 24 h.  Following the work-up, the residue was purified 
by column chromatography on silica gel using DCM:ethyl acetate eluent (95:5) to 
yield undec-10-en-1-yl 1-acetyl-1H-indazole-3-carboxylate 126 as light pink 
crystals (84 mg, 79%).  δH(CDCl3, 400 MHz): 1.31-1.65 (12H, m, 6 × CH2), 1.84-
1.91 (2H, m, CH2), 1.91-2.06 (2H, m, CH2), 2.88 [3H, s, C(O)CH3], 4.49 (2H, t, J 
7.0, OCH2), 4.91-5.01 (2H, m, CH=CH2), 5.75-5.86 (1H, m, CH=CH2), 7.46 (1H, 
t, J 8.0, ArCH), 7.60 (1H, t, J 8.0, ArCH), 8.21 (1H, d, J 8.0, ArCH), 8.47 (1H, d, 
J 8.0, ArCH);  max (KBr)/cm-1 2928, 1934, 1919, 1507; m/z (ESI+) 357 [M + H]+ 
(22%), 267 (100); HRMS (ESI)+: Exact mass calculated for C21H29N2O3 [M + H]+ 
357.2178.  Found 357.2176.  
 
Note: 13C NMR analysis was run on an impure sample and contained some peaks 
belonging to impurities. δC(CDCl3, 100 MHz): 23.1 (CH2), 26.0 [C(O)CH3], 28.6 
(CH2), 28.9 (CH2), 29.1 (CH2), 29.2 (CH2), 29.4 (CH2), 29.4 (CH2), 33.7 (CH2), 
66.0 (OCH2), 114.2 (CH2) alkene, 115.6 (ArCH), 122.2 (ArCH), 123.9 
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(ArCq),125.5 (ArCH), 129.8 (ArCH), 139.2 (CH) alkene, 140.3 (C=N), 140.6 
(ArCN), 161.8 (C=O) ester, 171.5 (C=O) amide. 
 
2-(Methacryloyloxy)ethyl 1-acetyl-1H-indazole-3-carboxylate 125  
The title compound was prepared following the 
procedure described for methyl 1-acetyl-1H-
indazole-3-carboxylate 104 using 2-
(trimethylsilyl)phenyl-trifluoromethanesulfonate 
49 (104 mg, 0.35 mmol), 
2-(methacryloyloxy)ethyl 2-diazo-3-oxo-3-
phenylpropanoate  26 (65 mg, 0.3 mmol) in 
acetonitrile (4 mL) and caesium fluoride (91 mg, 0.6 mmol).  The reaction was 
stirred at room temperature under a nitrogen atmosphere for 24 h.  Following the 
work-up, the crude 1H NMR showed the presence of the N-arylated by-product 2-
(methacryloyloxy)ethyl 1-phenyl-1H-indazole-3-carboxylate 227 which could not 
be separated from 2-(methacryloyloxy)ethyl 1-acetyl-1H-indazole-3-carboxylate 
125 after column chromatography on silica gel. The residue was purified by 
column chromatography on silica gel using DCM:ethyl acetate eluent (95:5) to 
yield 2-(methacryloyloxy)ethyl 1-acetyl-1H-indazole-3-carboxylate 125 as a 
brown oil (62 mg, 65%). δH(CDCl3, 400 MHz): 1.96 (3H, d, CH3, J 1.5), 2.88 [3H, 
s, C(O)CH3], 4.57-4.61 (2H, m, OCH2), 4.74-4.77 (2H, m, OCH2), 5.61 (1H, d, J 
1.4, one of alkene CH2), 6.18 (1H, s, one of alkene CH2), 7.42-7.48 (1H, m, ArCH), 
7.61 (1H, ddd, J 8.5, 7.2, 1.1, ArCH), 8.18 (1H, dd, J 8.5, 0.9, ArCH), 8.47 (1H, 
dd, J 8.5, 0.9, ArCH); δC(CDCl3, 100 MHz): 18.3 (CH3), 23.1 [C(O)CH3], 62.2 
(OCH2), 63.2 (OCH2), 115.6 (ArCH), 122.1 (ArCH), 123.9 (Cq) alkene, 124.6 
(ArCq), 125.8 (ArCH), 126.3 (CH2 alkene), 130.0 (ArCH), 135.9 (C=N), 140.3 
(ArCN), 161.5 (C=O) ester, 167.1 (C=O) ester, 171.5 (C=O) amide; max 
(film)/cm-1 2999, 1723, 1498, 1323, 1146; m/z (ESI+) 317 [M + H]+ (5%), 339 
(10), 196 (60); HRMS (ESI+): exact mass calculated for C16H17O5N2 [M + H]+ 
317.1137. Found 317.1135. 
 
Note: 10% of the N-arylated by-product was observed in the 1H NMR spectrum 
which could not be separated from the 1-acyl compound after chromatography.  
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3,7-Dimethyloct-6-en-1-yl 1-acetyl-1H-indazole-3-carboxylate 128 
The title compound was prepared 
following the procedure described for 
methyl 1-acetyl-1H-indazole-
3-carboxylate 104 using 2-
(trimethylsilyl)phenyl-
trifluoromethanesulfonate 49 (104 mg, 
0.35 mmol), 3,7-dimethyloct-6-enyl 2-
diazo-3-oxobutanoate 27 (59 mg, 0.3 mmol) in acetonitrile (4 mL) and caesium 
fluoride (91 mg, 0.6 mmol).  The reaction was stirred at room temperature under 
a nitrogen atmosphere for 24 h. The 1H NMR spectrum of the crude reaction 
mixture showed the presence of the desired compound along with other impurities 
and by-products. Attempts to purify the residue by column chromatography on 
silica gel using DCM:ethyl acetate eluent (95:5) and by preparative TLC were 
unsuccessful in isolating the desired compound from this mixture.  
1H NMR peaks for 3,7-dimethyloct-6-en-1-yl 1-acetyl-1H-indazole-3-carboxylate 
128 were extracted as follows: δH(CDCl3, 300 MHz): 1.01 (3H, d, J 6.3, CHCH3), 
1.14-1.26 (1H, m, CH3CH), 1.30-1.42 (2H, m, CH2), 1.44-1.57 (2H, m, CH2), 1.61 
(3H, s, CH3), 1.68 (3H, s, CH3), 2.08-2.38 (2H, m, CH2), 2.87 [3H, s, C(O)CH3], 
4.42-4.53 (2H, m, OCH2), 5.78 [1H, t, J 6.9, CH=C(CH3)2], 7.46 (1H, t, J 7.5, 
ArCH), 7.60 (1H, t, J 7.5, ArCH), 8.20 (1H, d, J 8.1, ArCH), 8.47 (1H, d, J 8.1, 
ArCH). 
 
3,7-Dimethylocta-2,6-dien-1-yl 1-acetyl-1H-indazole-3-carboxylate 127  
The title compound was prepared 
following the procedure described for 
methyl 1-acetyl-1H-indazole-3-
carboxylate 104 using 2-
(trimethylsilyl)phenyl-
trifluoromethanesulfonate 49 (104 mg, 
0.35 mmol), 3,7-dimethylocta-2,6-dienyl 
2-diazo-3-oxobutanoate 25 (59 mg, 0.3 mmol) in acetonitrile (4 mL) and caesium 
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fluoride (91 mg, 0.6 mmol).  The reaction was stirred at room temperature under 
a nitrogen atmosphere for 24 h. The 1H NMR spectrum of the crude reaction 
mixture showed the presence of the desired compound along with other impurities 
and by-products. Attempts to purify the residue by column chromatography on 
silica gel using DCM:ethyl acetate eluent (95:5) and by preparative TLC were 
unsuccessful in isolating the desired compound from this mixture. 
1H NMR peaks for 3,7-dimethylocta-2,6-dien-1-yl 1-acetyl-1H-indazole-3-
carboxylate 127 were extracted as follows: δH(CDCl3, 300 MHz): 1.61 (3H, s, 
CH3), 1.68 (3H, s, CH3), 1.73 (3H, s, CH3), 2.02-2.13 (4H, m, 2 × CH2), 2.88 [3H, 
s, C(O)CH3], 5.01 (2H, d, J 7.2, OCH2), 5.07 [1H, t, J 7.2, CH=C(CH3)2], 5.56 
[1H, m, OCH2CH=C(CH3)], 7.46 (1H, t, J 8.1, ArCH), 7.56 (1H, t, J 7.5, ArCH), 
8.20 (1H, d, J 8.1, ArCH), 8.47 (1H, d, J 8.1, ArCH). 
 
3.4.3 Synthesis of β-diketone indazole derivatives 
1,1'-(1H-Indazole-1,3-diyl)bis(ethan-1-one) 130  
The title compound was prepared following the procedure 
described for methyl 1-acetyl-1H-indazole-3-carboxylate 
104 using 2-(trimethylsilyl)phenyl-
trifluoromethanesulfonate 49 (100 mg, 0.3 mmol), 2-diazo 
acetylacetone 42 (65 mg, 0.3 mmol) in acetonitrile (4 mL) 
and caesium fluoride (91 mg, 0.6 mmol).  The reaction was stirred at room 
temperature under a nitrogen atmosphere for 24 h.  Following the work-up, the 
residue was purified by column chromatography on silica gel using hexane:ethyl 
acetate eluent (95:5) to yield 1,1'-(1H-indazole-1,3-diyl)bis(ethan-1-one) 130 as 
an off white solid (38 mg, 62%), m.p. 114-117ºC, (Lit.52 114-117 ºC). δH(CDCl3, 
400 MHz): 2.77 [3H, s, C(O)CH3 ketone], 2.87 [3H, s, C(O)CH3 amide], 7.46 (1H, 
t, J 7.6, ArCH), 7.59 (1H, t, J 7.8  ArCH), 8.36 (1H, d, J 8.0, ArCH), 8.44 (1H, d, 
J 8.5, ArCH); δC(CDCl3, 100 MHz): 22.9 [C(O)CH3] ketone, 26.9 [C(O)CH3] 
amide, 115.3 (ArCH), 122.9 (ArCH), 123.9 (ArCq), 126.1 (ArCH), 129.9 (ArCH), 
140.4 (C=N), 146.3 (ArCN), 171.3 (C=O) ester, 195.1 (C=O) amide. max 
(KBr)/cm-1 1727, 1686, 1485, 1320, 1166, 1139; HRMS (ESI+): exact mass 
calculated for C11H11O2N2 [M + H]+ 203.0821. Found 203.0812. Spectral details 
are in agreement with those reported in the literature.52 




yl)ethan-1-one 132 and 1-(3-benzoyl-2H-indazol-2-yl)ethan-1-one 133  
Following the procedure described for methyl 1-acetyl-1H-indazole-3-
carboxylate 104, 2-(trimethylsilyl)phenyl-trifluoromethanesulfonate 49 (100 mg, 
0.34 mmol), 2-diazo-1-phenylbutane-1,3-dione 43 (63 mg, 0.34 mmol) in 
acetonitrile (4 mL) and caesium fluoride (103 mg, 0.6 mmol). The reaction was 
stirred at room temperature under a nitrogen atmosphere for 24 h.  Following the 
work-up, the 1H NMR spectrum of the crude reaction mixture showed the presence 
of three distinct products. The residue was purified by column chromatography on 
silica gel using hexane:ethyl acetate eluent (95:5). The 1H NMR spectrum showed 
an inseparable mixture of 3 products from the reaction in a 1:1:1 ratio. Acyl peaks 
that could be identified with the compounds are assigned as follows: 
1-(1-Benzoyl-1H-indazol-3-yl)ethan-1-one 131: δH(CDCl3, 400 MHz): 2.87 
[3H, s, C(O)CH3 amide]. 
1-(3-Benzoyl-1H-indazol-1-yl)ethan-1-one 132: δH(CDCl3, 400 MHz): 2.77 
[3H, s, C(O)CH3 ketone]. 
1-(3-Benzoyl-2H-indazol-2-yl)ethan-1-one 133: δH(CDCl3, 400 MHz): 2.70 
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3.4.4 Synthesis of 1-acetyl-N,N-disubstituted-1H-indazole-3-carboxamide 
derivatives 
1-Acetyl-N,N-dimethyl-1H-indazole-3-carboxamide 140  
Caesium fluoride (91 mg, 0.6 mmol) was added to a stirred 
solution of 2-(trimethylsilyl)phenyl-
trifluoromethanesulfonate 49 (100 mg, 0.34 mmol), and 2-
diazo-N,N-dimethyl-3-oxobutanamide 44 (56 mg, 0.36 
mmol)  in acetonitrile (4 mL).  The reaction was stirred at 
room temperature under a nitrogen atmosphere for 24 h.  
The solution obtained was diluted with brine (20 mL) and extracted with ethyl 
acetate (3 × 20 mL). The residue obtained was purified by column chromatography 
on silica gel using DCM:ethyl acetate eluent (95:5) followed by chloroform-
methanol (99:1) and 1-acetyl-N,N-dimethyl-1H-indazole-3-carboxamide 140 was 
obtained as yellow crystals (66 mg, 84%).  δH(CDCl3, 400 MHz): 2.78 [3H, s, 
C(O)CH3], 3.23 (3H, s, NCH3), 3.36 (3H, s, NCH3), 7.41 (1H, ddd, J 8.1, 7.2, 0.9, 
ArCH), 7.59 (1H, ddd, J 8.1, 7.2, 1.2, ArCH), 8.06 (1H, td, J 8.1, 1.0, ArCH), 8.44 
(1H, td, J 8.4, 0.8, ArCH); δC(CDCl3, 100 MHz): 23.0 [CO(CH3)], 36.0 (NCH3), 
38.9 (NCH3), 115.3 (ArCH),  122.3 (ArCH). 125.3 (ArCH), 125.6 (ArCq), 129.9 
(ArCH), 139.5 (C=N), 144.4 (ArCN), 162.8 [(CH3)2NCO], 171.1 (C=O) N-acyl; 
max (KBr)/cm-1 2934, 1724, 1634, 1500; m/z (ESI+) 255 [M + H + Na]+ (21%); 
HRMS (ESI+): exact mass calculated for C12H14N3O2 [M + H]+ 232.1086. Found 
232.1076. 
 
1-Acetyl-N,N-diethyl-1H-indazole-3-carboxamide 141  
The title compound was prepared following the procedure 
described for 1-acetyl-N,N-dimethyl-1H-indazole-3-
carboxamide 140 using 2-(trimethylsilyl)phenyl-
trifluoromethanesulfonate 49 (100 mg, 0.34 mmol), 2-
diazo-N,N-diethyl-3-oxobutanamide 45 (71 mg, 0.36 
mmol) in acetonitrile (4 mL) and caesium fluoride (91 mg, 0.6 mmol).  The 
reaction was stirred at room temperature under a nitrogen atmosphere for 24 h. 
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Following the work-up, the residue was purified by column chromatography on 
silica gel using DCM:ethyl acetate eluent (95:5) followed by chloroform-methanol 
(99:1) to yield 1-acetyl-N,N-diethyl-1H-indazole-3-carboxamide 141 as yellow 
crystals (84 mg, 95%).   δH(CDCl3, 400 MHz): 1.29 [6H, t (overlapping), J 8.1, 2 
× CH3CH2], 2.79 [3H, s, C(O)CH3], 3.65 [4H, q × 2 (overlapping), J 8.1, 2 × 
CH3CH2], 7.46 (1H, t, J 8.1, ArCH), 7.56 (1H, t, J 8.1, ArCH), 8.06 (1H, d, J 8.1, 
ArCH), 8.44 (1H, d, J 8.1, ArCH); δC(CDCl3, 100 MHz): 12.9 (CH3), 14.7 (CH3), 
23.0 [CO(CH3)], 40.9 (NCH2), 43.5 (NCH2), 115.2 (ArCH),  122.3 (ArCH). 125.2 
(ArCH), 125.8 (ArCq), 129.9 (ArCH), 139.5 (C=N), 144.7 (ArCN), 162.2 
[(CH3CH2)2NCO], 171.1 (C=O) N-acyl; max (KBr)/cm-1 2978, 1726, 1631, 1381, 
1137; m/z (ESI+) 260 [M + H]+ (30%); HRMS (ESI+): exact mass calculated for 
C14H18O2N3 [M + H]+ 260.1399. Found 260.1395. 
 
 3-Acetyl-N-phenyl-3H-indazole-3-carboxamide 151  
The title compound was prepared following the 
procedure described for 1-acetyl-N,N-dimethyl-1H-
indazole-3-carboxamide 140 using 2-
(trimethylsilyl)phenyl-trifluoromethanesulfonate 
49 (100 mg, 0.33 mmol), 2-diazo-3-oxo-N-
phenylbutanamide 47  (61 mg, 0.3 mmol) in acetonitrile (4 mL) and caesium 
fluoride (91 mg, 0.6 mmol).  The reaction was stirred at room temperature under 
a nitrogen atmosphere for 24 h.  Following the work-up, the residue was purified 
by column chromatography on silica gel using DCM:ethyl acetate eluent (95:5) 
followed by chloroform-methanol (99:1) to yield 1-acetyl-N,N-diethyl-1H-
indazole-3-carboxamide 151 as yellow crystals (27 mg, 32%), m.p. 134-136 ºC. 
δH(CDCl3, 400 MHz): 2.65 [3H, s, C(O)CH3], 6.89-6.93 (2H, m, 2 × ArCH 
phenyl), 7.10-7.16 (1H, m, ArCH phenyl), 7.28-7.34 (2H, m, 2 × ArCH indazole), 
7.46-7.54 (3H, m, containing 2 × ArCH and NH), 7.67 (2H, dd, J 8.3, 1.6, 2 × 
ArCH phenyl); δC(CDCl3, 100 MHz): 27.7 [CO(CH3)], 96.9 [(CO)2C], 115.9 
(ArCH),  123.2 (ArCH). 124.5 (ArCH), 126.5 (ArCq indazole) 129.6 (ArCH), 
129.6 (2 × ArCH), 129.8 (ArCH), 129.9 (2 × ArCH), 134.2 (Cq phenyl), 151.5 
(tentative ArCN), 156.1 (C=O) amide, 191.1 (C=O) ketone;max (KBr)/cm-1: 
    Chapter 3: Experimental 
294 
 
2144, 1724, 1692, 1298; m/z (ESI+) 279 M+ (8%), 46 (100); HRMS (ESI+): exact 
mass calculated for C16H14O2N3 [M + H]+ 280.1086. Found 280.1088.  
 
1-Acetyl-N-benzyl-N-methyl-1H-indazole-3-carboxamide 146 and 2-acetyl-
N-benzyl-N-methyl-2H-indazole-3-carboxamide 145 (1:1.3)   
Following the procedure described for 1-acetyl-N,N-dimethyl-1H-
indazole-3-carboxamide 140, 2-(trimethylsilyl)phenyl-trifluoromethanesulfonate 
49 (100 mg, 0.34 mmol), N-benzyl-2-diazo-N-methyl-3-oxobutanamide 46 (90 
mg, 0.3 mmol) in acetonitrile (4 mL) and caesium fluoride (91 mg, 0.6 mmol) was 
allowed to stir at room temperature under a nitrogen atmosphere for 24 h.  
Following the work-up, the crude 1H NMR showed a mixture of products. The 
residue was purified by column chromatography on silica gel using DCM:ethyl 
acetate eluent (95:5) followed by chloroform:methanol (99:1) to yield the mixture 
of products 146 and 145 in a 1.3:1 ratio of 1,3-disubstituted regioisomers: 2,3-
disubstitued regioisomers as a brown oil (60 mg, 58%); and 149 and 150 N-
arylated by-products (4 mg, 3.9%), which were further separated using from the 
N-acyl products using column chromatography on silica gel using hexane:ethyl 
acetate eluent (80:20). max (film)/cm-1: 1726, 1637, 1375; m/z (ESI+) 330 [M + 
Na]+ (20%), 308 (8); HRMS (ESI+): exact mass calculated for C18H18O2N3 [M + 
H]+ 308.1399. Found 308.1394.  
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Major isomer: 2-Acetyl-N-benzyl-N-methyl-2H-indazole-3-carboxamide 145 
δH(CDCl3, 400 MHz): 2.53 [3H, s, C-C(O)CH3], 3.15 [3H, s, C(O)NCH3], 4.97 
(2H, s, CH2), 7.29-7.46 (6H, m, containing 5 × ArCH benzyl and ArCH indazole), 
7.56-7.62 (1H, m, ArCH indazole), 8.13 (1H, dd J 13.6, 8.1, ArCH indazole), 8.43 
(1H, dd J 12.4, 8.5, ArCH indazole); δC(CDCl3, 100 MHz): 22.8 [C(O)CH3], 33.8 
(NCH3), 54.7 (NCH2), 115.2 (ArCH), 122.4 (ArCH), 125.3 (ArCH), 125.8 (ArCq), 
127.2 (2 × ArCH), 127.6 (ArCH), 128.3 (ArCH), 128.7 (2 × ArCH), 136.8 (ArCq 
phenyl), 139.6 (C=N), 143.9 (ArCN), 163.2 [C(O)NMe], 171.1 [C(O)CH3]. 
Minor isomer: 1-Acetyl-N-benzyl-N-methyl-1H-indazole-3-carboxamide 146  
δH(CDCl3, 400 MHz): 2.78 (3H, s, NC(O)CH3), 3.28 (3H, s, NCH3), 4.87 (2H, s, 
CH2), 7.29-7.46 (6H, m, containing 5 × ArCH benzyl and ArCH indazole), 7.56-
7.62 (1H, m, ArCH indazole), 8.13 (1H, dd J 13.6, 8.1, ArCH indazole), 8.43 (1H, 
dd, J 12.4, 8.5, ArCH indazole); δC(CDCl3, 100 MHz): 23.0 [CO(CH3)], 36.5 
(NCH3), 51.6 (NCH2), 115.3 (ArCH),  122.3 (ArCH), 125.3 (ArCH), 125.8 (ArCq), 
127.2 (2 × ArCH), 127.7 (ArCH), 128.3 (ArCH), 128.8 (2 × ArCH), 136.6 (ArCq 
phenyl), 139.5 (ArCN), 144.4 (C=N), 162.9 [C(O)NMe], 171.1 (CH3C=O);  
 
N-benzyl-N-methyl-1-phenyl-1H-indazole-3-carboxamide 149 and N-benzyl-
N-methyl-2-phenyl-2H-indazole-3-carboxamide 150 
δH(CDCl3, 400 MHz): 3.13 and 
3.41 (2 × 3H, s, NCH3), 4.89 and 
5.20 (2 × 2H, s, CH2), 7.26-7.64 
(22H, m, 22 × ArCH), 7.74 (2 × 
2H, t, J 7.1, 4 × ArCH indazole), 
8.31 (2 × 1H, t, J 7.5, ArCH 
indazole). 
 
**Note: Further investigation into these compounds have suggested the 
duplication of signals is due to the presence of two rotameric forms of the 1,3-
disubstituted derivatives 146 and 149. 
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Tentative assignment of 2-benzoyl-N-phenyl-2H-indazole-3-carboxamide 153 








The title compounds were prepared following the procedure described for 
1-acetyl-N,N-dimethyl-1H-indazole-3-carboxamide 140 using 2-
(trimethylsilyl)phenyl-trifluoromethanesulfonate 49 (104 mg, 0.35 mmol), 2-
diazo-3-oxo-N,3-diphenylpropanamide 48 (59 mg, 0.3 mmol) in acetonitrile (4 
mL) and caesium fluoride (91 mg, 0.6 mmol).  The reaction was stirred at room 
temperature under a nitrogen atmosphere for 24 h. Following the work-up, the 
residue was purified by column chromatography on silica gel using hexane:ethyl 
acetate eluent (90:10-80:20) to yield 2-benzoyl-N-phenyl-2H-indazole-3-
carboxamide 153 and/or 3-benzoyl-N-phenyl-3H-indazole-3-carboxamide 152 as 
yellow crystals (74 mg, 95%), m.p. 157-160 ºC. δH(CDCl3, 400 MHz): 3.22 (1H, 
br s, NH), 7.20-7.25 (1H, m, ArCH), 7.27-7.39 (5H, m, 5 × ArCH), 7.45-7.39 (4H, 
m, 4 × ArCH), 7.60 (2H, t, J 7.8, 2 × ArCH), 7.93 (2H, dd, J 8.6, 1.2, 2 × ArCH); 
δC(CDCl3, 100 MHz: 70.3 [Cq(CO)2 of 152 tentative], 117.0 (ArCH indazole), 
121.5 (2 × ArCH), 125.7 (ArCH indazole), 126.5 (2 × ArCH), 127.5 (ArCH 
indazole),  128.2 (2 × ArCH phenyl), 128.8 (ArCH phenyl), 129.6  (ArCH 
indazole),  129.7 (2 × ArCH phenyl),  130.7 (ArCH phenyl), 133.8 (COCq phenyl), 
135.2 (ArCN), 145.4 (C=O) amide, 149.3 [N(CO)Ph of 153 tentative]; max 
(KBr)/cm-1: 3282, 2966, 1718, 1616, 1276; m/z (ESI+) 341 M+ (10%), 46 (100); 
HRMS (ESI+): exact mass calculated for C21H16O2N3 [M + H]+ 342.1243. Found 
342.1232. 
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3.4.5 Synthesis of 1-acyl-1H-[1,3]dioxolo[4,5-f]indazole-3-carboxylate 
compounds 
sec-Butyl 1-acetyl-1H-[1,3]dioxolo[4,5-f]indazole-3-carboxylate 155  
Caesium fluoride (91 mg, 0.6 mmol) was added to 
a stirred solution of 6-
(trimethylsilyl)benzo[d][1,3]dioxol-5-yl 
trifluoromethanesulfonate 75 (100 mg, 0.29 
mmol), and sec-butyl 2-diazo-3-oxobutanoate 32 
(80 mg, 0.44 mmol, 1.5 equiv.) in acetonitrile (4 
mL).  The reaction was stirred at room temperature under a nitrogen atmosphere 
for 24 h.  The solution obtained was diluted with brine (20 mL) and extracted with 
ethyl acetate (3 × 20 mL). The residue obtained was purified by column 
chromatography on silica gel using DCM:ethyl acetate eluent (95:5) to yield pure 
sec-butyl 1-acetyl-1H-[1,3]dioxolo[4,5-f]indazole-3-carboxylate 1565as a yellow 
solid (41 mg, 47%), m.p. 169-170C. δH(CDCl3, 400 MHz): 1.02 (3H, t, CH3, J 
7.5),  1.43 (3H, d, J 6.3, CH3), 1.70-1.91 (2H, m, CH2), 2.84 [3H, s, C(O)CH3], 
5.20-5.28 (1H, m, OCH), 6.11 (2H, s, OCH2O), 7.44 (1H, s, ArCH), 7.88 (1H, s, 
ArCH). δC(CDCl3, 100 MHz): 9.8 (CH2CH3), 19.6 (CHCH3), 23.0 [C(O)CH3], 
28.9 (CH2), 74.2 (OCH), 95.7 (ArCH), 99.4 (ArCH), 102.3 (OCH2O), 119.7 
(ArCq), 137.1 (C=N), 140.7 (ArCN), 147.3 (ArCOCH2), 150.9 (ArCOCH2), 161.6 
(C=O) ester, 171.6 (C=O) amide; max (KBr)/cm-1 2974, 1727, 1644, 1491, 1459; 
m/z (ESI+) 305 [M + H]+ (56%), 249 (8); HRMS (ESI+): exact mass calculated for 
C15H17N2O5 [M + H]+ 305.1137. Found 305.1124. 
 
Isopentyl 1-acetyl-1H-[1,3]dioxolo[4,5-f]indazole-3-carboxylate 154  
The title compound was prepared following the 
procedure described for sec-butyl 1-acetyl-1H-
[1,3]dioxolo[4,5-f]indazole-3-carboxylate 156 
using 6-(trimethylsilyl)benzo[d][1,3]dioxol-5-yl 
trifluoromethanesulfonate 75 (100 mg, 0.28 
mmol), isopentyl 2-diazo-3-oxo-butanoate 24 (59 mg, 0.3 mmol) in acetonitrile (4 
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mL) and caesium fluoride (91 mg, 0.6 mmol).  The reaction was stirred at room 
temperature under a nitrogen atmosphere for 24 h.  Following the work-up, the 
residue was purified by column chromatography on silica gel using DCM: ethyl 
acetate eluent (95:5) to yield isopentyl 1-acetyl-1H-[1,3]dioxolo[4,5-f]indazole-3-
carboxylate 154  as an orange oil (66 mg, 72%).  δH(CDCl3, 400 MHz): 1.00 (6H, 
d, J 6.4, 2 × CH3), 1.72-1.86 [3H, m, containing OCH2CH2 and CH(CH3)2], 2.87 
[3H, s, C(O)CH3], 4.49 (2H, t, J 6.8, OCH2), 6.11 (2H, s, OCH2O), 7.46 (1H, s, 
ArCH), 7.88 (1H, s, ArCH); δC(CDCl3, 100 MHz): 22.5 (2 × CH3), 23.0 
[C(O)CH3], 25.3 (CH), 37.3 (CH2), 64.5 (OCH2), 95.7 (ArCH), 99.3 (ArCH), 
102.3 (OCH2O), 119.8 (ArCq), 137.1 (C=N), 140.3 (ArCN), 147.3 (ArCOCH2), 
151.0 (ArCOCH2), 162.0 (C=O) ester, 171.6 (C=O) amide; max (film)/cm-1 2958, 
1730, 1478, 1210, 1149; m/z (ESI+) 319 [M + H]+ (10%);  HRMS (ESI)+: Exact 
mass calculated for C16H18N2O5 [M + H]+ 319.1294.  Found 319.1283. 
 
2-Ethylbutyl 1-acetyl-1H-[1,3]dioxolo[4,5-f]indazole-3-carboxylate 157  
The title compound was prepared following the 
procedure described for sec-butyl 1-acetyl-1H-
[1,3]dioxolo[4,5-f]indazole-3-carboxylate 156 
using 6-(trimethylsilyl)benzo[d][1,3]dioxol-5-yl 
trifluoromethanesulfonate 75 (100 mg, 0.29 
mmol), 2-ethylbutyl 2-diazo-3-oxo-butanoate 30 
(59 mg, 0.3 mmol) in acetonitrile (4 mL) and caesium fluoride (91 mg, 0.6 mmol).  
The reaction was stirred at room temperature under a nitrogen atmosphere for 24 
h.  Following the work-up, the residue was purified by column chromatography 
on silica gel using DCM: ethyl acetate eluent (95:5) to yield 2-ethylbutyl 1-acetyl-
1H-[1,3]dioxolo[4,5-f]indazole-3-carboxylate 157 as a white solid (65 mg, 68%), 
m.p. 105-107C. δH(CDCl3, 400 MHz): 0.98 (6H, t, J 7.5, 2 × CH3), 1.45-1.54 
(4H, m, 2 × CH2), 1.76 (1H, td, J 12.5, 6.3, CH), 2.84 (3H, s, C(O)CH3), 4.40 (2H, 
d, J 5.9, OCH2), 6.11 (2H, s, OCH2O), 7.44 (1H, s, ArCH), 7.88 (1H, s, ArCH); 
δC(CDCl3, 100 MHz): 11.1 (2 × CH3), 22.9 [C(O)CH3], 23.5 (2 × CH2), 40.4 (CH), 
67.8 (OCH2), 95.7 (ArCH), 99.3 (ArCH), 102.3 (OCH2O), 119.7 (ArCq), 137.1 
(C=N), 140.4 (ArCN), 147.3 (ArCOCH2), 150.9 (ArCOCH2), 162.1 (C=O) ester, 
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171.6 (C=O) amide; max (KBr)/cm-1 2963, 1729, 1648, 1462, 1388. m/z (ESI+) 
333 [M + H]+ (100%); HRMS (ESI)+: Exact mass calculated for C17H21N2O5 [M 
+ H]+ 333.1450. Found 333.1450; (Found: C, 60.03; H, 5.94; N, 7.78.  C17H20N2O5 
requires C, 61.44; H, 6.07; N, 8.43%). 
 
2-Ethylhexyl 1-acetyl-1H-[1,3]dioxolo[4,5-f]indazole-3-carboxylate 156  
The title compound was prepared following 
the procedure described for sec-butyl 1-
acetyl-1H-[1,3]dioxolo[4,5-f]indazole-3-
carboxylate 156 using 6-
(trimethylsilyl)benzo[d][1,3]dioxol-5-yl 
trifluoromethanesulfonate 75 (100 mg, 0.29 
mmol), 2-ethylhexyl 2-diazo-3-oxo-
butanoate 28 (80 mg, 0.3 mmol) in acetonitrile (4 mL) and caesium fluoride (91 
mg, 0.6 mmol).  The reaction was stirred at room temperature under a nitrogen 
atmosphere for 24 h.  Following the work-up, the residue was purified by column 
chromatography on silica gel using hexane:ethyl acetate eluent (90:10) to yield 2-
ethylhexyl 1-acetyl-1H-[1,3]dioxolo[4,5-f]indazole-3-carboxylate 156 as a white 
solid (58 mg, 56%),  m.p. 84-85C. δH(CDCl3, 400 MHz): 0.91 (3H, t, J 7.1, CH3), 
0.98 (3H, t, J 7.5, CH3)], 1.30-1.54 (8H, m, 4 × CH2), 1.70-1.90 (1H, m, CH), 2.84 
[3H, s, C(O)CH3], 4.39 (2H, d, J 5.8, OCH2), 6.11 (2H, s, OCH2O), 7.45 (1H, s, 
ArCH), 7.89 (1H, s, ArCH); δC(CDCl3, 100 MHz): 11.1 (CH3), 14.1 (CH3), 22.9 
(CH2), 23.0 [C(O)CH3], 24.0 (CH2), 28.9 (CH2), 30.6 (CH2), 38.9 (CH) 68.1 
(OCH2), 95.7 (ArCH), 99.3 (ArCH), 102.3 (OCH2O), 119.7 (ArCq), 137.1 (C=N), 
140.4 (ArCN), 147.3 (ArCOCH2), 150.9 (ArCOCH2), 162.1 (C=O) ester, 171.6 
(C=O) amide; max (KBr)/cm-1 2960, 1731, 1650, 1462, 1317, 1062; m/z (ESI+) 
361 [M + H]+ (100%), 249 (8). HRMS (ESI+): exact mass calculated for 
C19H25N2O5 [M + H]+ 361.1763. Found 361.1765; (Found: C, 62.97; H, 6.70; N, 
7.57.  C19H24N2O5 requires C, 63.32; H, 6.71; N, 7.77%). 
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Decyl 1-acetyl-1H-[1,3]dioxolo[4,5-f]indazole-3-carboxylate 158  
The title compound was prepared 
following the procedure 
described for sec-butyl 1-acetyl-
1H-[1,3]dioxolo[4,5-f]indazole-
3-carboxylate 156 using 6-
(trimethylsilyl)benzo[d][1,3]dioxol-5-yl trifluoromethanesulfonate 75 (95 mg, 
0.28 mmol), decyl 2-diazo-3-oxo-butanoate 29 (108 mg, 0.28 mmol) in 
acetonitrile (4 mL) and caesium fluoride (91 mg, 0.6 mmol).  The reaction was 
stirred at room temperature under a nitrogen atmosphere for 24 h.  Following the 
work-up, the residue was purified by column chromatography on silica gel using 
DCM:ethyl acetate eluent (95:5) and decyl 1-acetyl-1H-[1,3]dioxolo[4,5-
f]indazole-3-carboxylate 158 was obtained as a white solid (74 mg, 66%),  m.p. 
84-85C. δH(CDCl3, 400 MHz): 0.88 (3H, t, J 6.8, CH3), 1.20-1.51 (14H, m, 7 × 
CH2), 1.80-1.90 (2H, m, CH2), 2.84 [3H, s, C(O)CH3], 4.45 (2H, t, J 6.9, OCH2), 
6.11 (2H, s, OCH2O), 7.47 (1H, s, ArCH), 7.89 (1H, s, ArCH); δC(CDCl3, 100 
MHz): 14.1 (CH2CH3), 22.7 (CH2), 23.0 [C(O)CH3],  26.0 (CH2), 28.6 (CH2), 29.2 
(CH2), 29.3 (CH2), 29.5 (2 × CH2), 31.9 (OCH2CH2), 65.9 (OCH2), 95.7 (ArCH),  
99.4 (ArCH), 102.3 (OCH2O), 119.8 (ArCq), 137.1 (C=N), 140.3 (ArCN), 147.3 
(ArCOCH2), 151.0 (ArCOCH2), 162.0 (C=O) ester, 171.6 (C=O) amide; m/z 
(ESI+) 389 [M + H]+ (100%); HRMS (ESI)+: Exact mass calculated for 
C21H29N2O5 [M + H]+ 389.2076. Found 389.2069; max (KBr)/cm-1 2924, 1720, 
1651, 1295; (Found: C, 67.36; H, 7.55; N, 7.10.  C21H28N2O5 requires C, 64.93; 
H, 7.27; N, 7.21%). 
 
Undec-10-en-1-yl 1-acetyl-1H-[1,3]dioxolo[4,5-f]indazole-3-carboxylate 159 
The title compound was prepared 
following the procedure 
described for sec-butyl 1-acetyl-
1H-[1,3]dioxolo[4,5-f]indazole-
3-carboxylate 156 using 6-
(trimethylsilyl)benzo[d][1,3]dioxol-5-yl trifluoromethanesulfonate 75 (100 mg, 
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0.33 mmol), undec-10-en-1-yl 2-diazo-3-oxobutanoate 31 (59 mg, 0.3 mmol) in 
acetonitrile (4 mL) and caesium fluoride (91 mg, 0.6 mmol).  The reaction was 
stirred at room temperature under a nitrogen atmosphere for 24 h.  Following the 
work-up, the residue was purified by column chromatography on silica gel using 
hexane:ethyl acetate eluent (95:5) to yield undec-10-en-1-yl 1-acetyl-1H-
[1,3]dioxolo[4,5-f]indazole-3-carboxylate 159 as a white solid (80 mg, 67%),  
m.p. 75-76 C. δH(CDCl3, 400 MHz): 1.27-1.50 (12H, m, 6 × CH2), 1.80-1.90 (2H, 
m, CH2), 2.00-2.08 (2H, m, CH2), 2.84 [3H, s, C(O)CH3], 4.45 (2H, t, J 7.0, 
OCH2), 4.90-5.03 (2H, m, CH=CH2), 5.75-5.87 (1H, m, CH=CH2), 6.11 (2H, s, 
OCH2O), 7.47 (1H, s, ArCH), 7.89 (1H, s, ArCH);  δC(CDCl3, 100 MHz): 23.0 
(CH2), 25.9 (CH3), 28.6 (CH2), 28.9 (CH2), 29.1 (CH2), 29.2 (CH2), 29.4 (CH2), 
29.4 (CH2), 33.8 (CH2), 65.9 (OCH2), 95.7 (ArCH), 99.4 (ArCH), 102.3  
(OCH2O), 114.2 (CH2) alkene, 119.8 (ArCq), 137.1 (C=N), 139.2 (CH) alkene, 
139.2 (ArCN), 147.3 (ArCOCH2), 150.9 (ArCOCH2), 162.1 (C=O) ester, 171.6 
(C=O) amide; max (KBr)/cm-1 2926, 1721, 1493, 1475, 1296, 1159; HRMS (ESI)+: 
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3.5 Synthesis of 1-acyl-1H-indazole derivatives Method 2 
3.5.1 Generation of aryne and trapping with furan  
Method 2:  




1,4-Dihydro-1,4-epoxynaphthalene54 98  
2-(Trimethylsilyl)phenol 58 (0.05 g, 0.3 mmol) was added to a 
flask evacuated and filled with nitrogen followed by caesium 
carbonate (0.1466 g, 0.45 mmol) in acetonitrile (3 ml) and caesium fluoride (23 
mg, 0.15 mmol). Furan 97 (0.065 ml, 0.9 mmol) and nonafluorobutanesulfonyl 
fluoride (81 μL, 0.45 mmol) were added by syringe. The reaction was stirred at 60 
°C under a nitrogen atmosphere for 8 h. The reaction mixture was diluted with 
brine (20 mL) and extracted with ethyl acetate (20 mL). The organic layer was 
dried with MgSO4 and analysis of the crude residue identified the characteristic 
peaks of 1,4-dihydro-1,4-epoxynaphthalene 98 as assigned on page 46 (Section 
3.4.2). 
 
3.5.2 Synthesis of 1-acyl-1H-indazole derivatives using 2-
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Pentyl 1-acetyl-1H-indazole-3-carboxylate 108  
Caesium fluoride (45.6 mg, 0.3 mmol) and 
nonafluorobutanesulfonyl fluoride (0.272 g, 
0.9 mmol) was added to a stirred solution of 2-
(trimethylsilyl)phenol 58 (100 mg, 0.6 mmol), 
caesium carbonate (293 mg, 0.9 mmol) and n-
pentyl 2-diazo-3-oxobutanoate 23 (351 mg, 1.8 mmol) in acetonitrile (6 mL). The 
reaction was stirred at 60 °C under a nitrogen atmosphere for 8 h. The reaction 
mixture was diluted with brine (20 mL) and extracted with ethyl acetate (20 mL). 
The organic layer was dried with MgSO4 and concentrated under reduced pressure, 
the residue was purified by column chromatography on silica gel using DCM:ethyl 
acetate eluent (95:5) to yield n-pentyl 1-acetyl-1H-indazole-3-carboxylate 108 as 
a yellow oil (143 mg, 87%). δH(CDCl3, 400 MHz): 0.93 (3H, t, J 7.1, CH2CH3), 
1.36-1.48 (4H, m, 2 × CH2), 1.85-1.92 (2H, m, CH2), 2.88 [3H, s, C(O)CH3], 4.50 
(2H, t, J 6.8, OCH2), 7.44-7.49 (1H, m, ArCH), 7.55-7.65 (1H, ddd, J 8.4, 7.1, 1.1, 
ArCH), 8.20 (1H, d, J 8.1, ArCH), 8.47 (1H, d, J 8.5, ArCH). Spectral details as 
described previously on page 51 (Section 3.4.2.1). 
 
3,7-Dimethyloct-6-en-1-yl 1-acetyl-1H-indazole-3-carboxylate 128   
The title compound was prepared 
following the procedure described for 
pentyl 1-acetyl-1H-indazole-3-carboxylate 
108 using caesium fluoride (45.6 mg, 0.3 
mmol), nonafluorobutanesulfonyl fluoride 
(0.272 g, 0.9 mmol), 2 
(trimethylsilyl)phenol 58 (100 mg, 0.35 
mmol), 3 ,7-dimethyloct-6-enyl 2-diazo-3-oxobutanoate  (59 mg, 0.3 mmol) and 
caesium carbonate (293 mg, 0.9 mmol) in acetonitrile (6 mL). The reaction was 
stirred at 60 °C under a nitrogen atmosphere for 8 h. After work-up, the residue 
obtained was purified by column chromatography on silica gel using hexane:ethyl 
acetate (3:1) and then DCM:hexane (5:1) to yield 3,7-dimethyloct-6-en-1-yl 1-
acetyl-1H-indazole-3-carboxylate 128  as a colourless oil (48 mg, 40%). 
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δH(CDCl3, 400 MHz): 1.01 (3H, d, J 6.2, CHCH3), 1.22-1.50 (2H, m, CH2), 1.56-
1.75 [8H, m, containing 1.61 (3H, s, CH3), 1.66 (3H, s, CH3) and CH2], 1.85-2.11 
(3H, m, containing CH2 and CH3CH), 2.88 [3H, s, C(O)CH3], 4.50-4.59 (2H, m, 
OCH2), 5.10 [1H, t, J 6.8, CH=C(CH3)2], 7.46 (1H, t, J 7.6, ArCH), 7.60 (1H, t, J 
7.8, ArCH), 8.20 (1H, d, J 7.9, ArCH), 8.47 (1H, d, J 8.4, ArCH); δC(CDCl3, 100 
MHz): 17.7 (CH3), 19.5 (CH3), 23.1 (CH2), 25.4 (CH3), 25.7 (CH3), 29.7 (CH), 
35.5 (CH2), 37.0 (CH2), 64.5 (OCH2), 115.6 (ArCH), 122.2 (ArCH), 124.5 
(ArCH),  124.6 (ArCq),  125.7 (CH) alkene 129.9 (ArCH), 131.5 (Cq) alkene, 140.3 
(C=N), 142.9 (ArCN), 161.9 (C=O) ester, 171.5 (C=O) amide; max (KBr)/cm-1 
2960, 2924, 1731, 1499; m/z (ESI+) 365 [M + Na]+ (40%); HRMS (ESI+): exact 
mass calculated for C20H27N2O3 [M + H]+ 330.2022. Found 330.2020. 
 
3,7-Dimethylocta-2,6-dien-1-yl 1-acetyl-1H-indazole-3-carboxylate 127  
The title compound was prepared 
following the procedure described for 
pentyl 1-acetyl-1H-indazole-3-
carboxylate 108 using caesium fluoride 
(45.6 mg, 0.3 mmol), 
nonafluorobutanesulfonyl fluoride (0.272 
g, 0.9 mmol),  2-(trimethylsilyl)phenol 58 
(100 mg, 0.35 mmol), 3,7-dimethylocta-2,6-dienyl 2-diazo-3-oxobutanoate 25 
(177 mg, 1.1 mmol) in acetonitrile (4 mL) and caesium fluoride (91 mg, 0.6 
mmol).  The reaction was stirred at room temperature under a nitrogen atmosphere 
for 8 h. Following the work-up, attempts were made to purify the residue by 
column chromatography on silica gel using hexane:ethyl acetate (3:1) and then 
DCM: hexane (5:1) to yield 3,7-dimethylocta-2,6-dien-1-yl 1-acetyl-1H-indazole-
3-carboxylate 127 contaminated with 6% impurities which could not be removed 
by repeated column chromatography on silica gel (19 mg, 16%).  δH(CDCl3, 300 
MHz): 1.61 (3H, s, CH3), 1.68 (3H, s, CH3), 1.73 (3H, s, CH3), 2.02-2.13 (4H, m, 
2 × CH2), 2.88 [3H, s, C(O)CH3], 5.01 (2H, d, J 7.2, OCH2), 5.07 [1H, t, J 7.2, 
CH=C(CH3)2], 5.56 [1H, m, OCH2CH=C(CH3)], 7.46 (1H, t, J 8.1, ArCH), 7.56 
(1H, t, J 7.5, ArCH), 8.20 (1H, d, J 8.1, ArCH), 8.47 (1H, d, J 8.1, ArCH). 
 
    Chapter 3: Experimental 
305 
 
2-(Methacryloyloxy)ethyl 1-acetyl-1H-indazole-3-carboxylate 125  
The title compound was prepared following the 
procedure described for pentyl 1-acetyl-1H-
indazole-3-carboxylate 108 using caesium 
fluoride (45.6 mg, 0.3 mmol), 
nonafluorobutanesulfonyl fluoride (0.272 g, 0.9 
mmol), 2-(trimethylsilyl)phenol 58 (100 mg, 
0.35 mmol), 2-(methacryloyloxy)ethyl 2-diazo-
3-oxo-3-phenylpropanoate  26 (195 mg, 0.9 mmol) and caesium carbonate (293 
mg, 0.9 mmol) in acetonitrile (6 mL). The reaction was stirred at 60 °C under a 
nitrogen atmosphere for 8 h. Following the work-up, the residue obtained was 
purified by column chromatography on silica gel using DCM:ethyl acetate (3:1) 
and then preparative TLC using hexane:ethyl acetate (65:35) to yield 2-
(methacryloyloxy)ethyl 1-acetyl-1H-indazole-3-carboxylate 125  as a white solid 
(22 mg, 20%),  m.p. 295-299 ºC. δH(CDCl3, 400 MHz): 1.96 (3H, d, J 1.5, CH3), 
2.88 [3H, s, C(O)CH3], 4.57-4.61 (2H, m, OCH2), 4.74-4.77 (2H, m, OCH2), 5.60 
(1H, d, J 1.4, one of alkene CH2), 6.18 (1H, s, one of alkene CH2), 7.42-7.48 (1H, 
m, ArCH), 7.61 (1H, ddd, J 8.5, 7.2, 1.1, ArCH), 8.18 (1H, dd, J 8.5, 0.9, ArCH), 
8.47 (1H, dd, J 8.5, 0.9, ArCH); δC(CDCl3, 100 MHz): 18.3 (CH3), 23.1 
[C(O)CH3], 62.2 (OCH2), 63.2 (OCH2), 115.6 (ArCH), 122.1 (ArCH), 123.9 
(Cq)alkene, 124.6 (ArCq), 125.8 (ArCH), 126.3 (CH2 alkene), 130.0 (ArCH), 135.9 
(C=N), 140.3 (ArCN), 161.5 (C=O) ester, 167.1 (C=O) methacrylate ester, 171.5 
(C=O) amide;  Spectral details as described on page 61 (Section 3.4.2.1). 
 
3.5.3 Synthesis of 5,6-dimethyl-1H-indazole-3-carboxylate compounds 
Isopropyl 1-acetyl-5,6-dimethyl-1H-indazole-3-carboxylate 168  
Caesium fluoride (45.6 mg, 0.3 mmol) and 
nonafluorobutanesulfonyl fluoride (0.272 g, 0.9 mmol) 
were added to a stirred solution of 4,5-dimethyl-2-
(trimethylsilyl)phenol 79 (100 mg, 0.6 mmol), caesium 
carbonate (293 mg, 0.9 mmol) and isopropyl 2-diazo-3-






    Chapter 3: Experimental 
306 
 
stirred at 60 °C under a nitrogen atmosphere for 8 h. The solution obtained was 
diluted with brine (20 mL) and extracted with ethyl acetate (20 mL). The organic 
layer was dried with MgSO4 and concentrated. The residue was purified by 
column chromatography on silica gel using DCM:ethyl acetate eluent (95:5)  to 
yield isopropyl 1-acetyl-1H-indazole- 3-carboxylate 168 as a white solid (62 mg, 
76%), m.p. 78-83 ºC. δH(CDCl3, 400 MHz): 1.49 (6H, d, J 6.3, 2 × CH3),  2.40 
(3H, s, ArCH3), 2.43 (3H, s, ArCH3), 2.85 [3H, s, C(O)CH3], 5.41 (1H, sep, J 6.2, 
OCH), 7.90 (1H, s, ArCH), 8.23 (1H, s, ArCH); δC(CDCl3, 100 MHz): 20.3 
(ArCH3), 20.9 (ArCH3), 21.9 (2 × CH3), 23.0 [C(O)CH3], 69.6 (CH), 115.5 
(ArCH), 121.6 (ArCH), 123.3 (Cq), 135.1 (ArCCH3), 139.5 (C=N), 140.1 
(ArCCH3), 140.8  (ArCN), 161.6 (C=O) ester, 171.5 (C=O) amide; max (KBr)/cm-
1 2984, 1716, 1644,  1496, 1467, 1378;  HRMS (ESI+): exact mass calculated for 
C15H19N2O3 [M + H]+ 275.1396. Found 275.1393.  
 
Decyl 1-acetyl-5,6-dimethyl-1H-indazole-3-carboxylate 169  
The title compound was prepared 
using the procedure described for 
pentyl 1-acetyl-1H-indazole-3-
carboxylate 108 using caesium 
fluoride (38 mg, 0.25 mmol), 
nonafluorobutanesulfonyl fluoride (224 mg, 0.74 mmol), 4,5-dimethyl-2-
(trimethylsilyl)phenol 79 (100 mg, 0.5 mmol), caesium carbonate (293 mg, 0.74 
mmol) and decyl 2-diazo-3-oxobutanoate (314 mg, 1.5 mmol) in acetonitrile (6 
mL). The reaction was stirred at 60 °C under a nitrogen atmosphere for 8 h. 
Following the work-up, the residue was purified using column chromatography on 
silica gel using hexane:ethyl acetate eluent (98:2) and then preparative TLC using 
DCM as eluent to yield decyl 1-acetyl-5,6-dimethyl-1H-indazole-3-carboxylate 
169 as a yellow solid (38 mg, 41%), m.p. 54-59 ºC. δH(CDCl3, 400 MHz): 0.88 
(3H, t, J 6.6, CH3), 1.25-1.60 (14H, m, 7 × CH2), 1.81-1.91 (2H, m, CH2), 2.41 
(3H, s, ArCH3), 2.44 (3H, s, ArCH3), 2.85 [3H, s, C(O)CH3], 4.48 (2H, t, J 6.9, 
OCH2), 7.92 (1H, s, ArCH), 8.25 (1H, s, ArCH); max (KBr)/cm-1 2985, 2928, 
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1716, 1644, 1496, 1415, 1104; m/z (ESI+) 373 [M + H]+ (32%); HRMS (ESI+): 
exact mass calculated for C22H33N2O3 [M + H]+ 372.2491. Found 373.2480. 
 
Note: 13C analysis was run on an impure sample and contained some peaks 
belonging to impurities. δC(CDCl3, 100 MHz): 14.1 (CH2CH3), 20.3 (ArCH3), 20.9 
(ArCH3), 22.7 (CH2), 23.0 [C(O)CH3], 26.0 (CH2), 28.7 (CH2), 29.3 (2 × CH2), 
29.5 (2 × CH2), 31.9 (OCH2CH2), 65.9 (OCH2), 115.5 (ArCH), 121.6 (ArCH), 
123.3 (ArCq), 135.2 (ArCCH3), 139.5 (C=N), 140.2 (ArCCH3), 140.5  (ArCN), 
162.2 (C=O) ester, 171.5 (C=O) amide. 
 
1-Acetyl-N,N-diethyl-5,6-dimethyl-1H-indazole-3-carboxamide 170  
The title compound was prepared using the procedure 
described for pentyl 1-acetyl-1H-indazole-3-
carboxylate 108 using caesium fluoride (59 mg, 0.39 
mmol), nonafluorobutanesulfonyl fluoride (362 mg, 1.2 
mmol), 4,5-dimethyl-2-(trimethylsilyl)phenol 79 (150 
mg, 0.77 mmol), caesium carbonate (391 mg, 1.2 mmol) and 2-diazo-N,N-diethyl-
3-oxobutanamide 45 (421 mg, 2.3 mmol) in acetonitrile (8 mL). The reaction was 
stirred at 60 °C under a nitrogen atmosphere for 8 h. Following the work-up, the 
residue was purified using column chromatography on silica gel using 
hexane:ethyl acetate eluent (70:30) to yield 1-acetyl-N,N-diethyl-5,6-dimethyl-
1H-indazole-3-carboxamide 170 as an orange solid (68 mg, 30%), m.p. 67-69 ºC. 
δH(CDCl3, 400 MHz): δH(CDCl3, 400 MHz): 1.32 (6H, dt, J 2.3, 6.3, 2 × 
NCH2CH3),  2.37 (3H, s, ArCH3), 2.43 (3H, s, ArCH3), 2.75 (3H, s, C(O)CH3), 
3.59-3.70 (4H, m, 2 × NCH2), 7.79 (1H, s, ArCH), 8.21 (1H, s, ArCH). δC(CDCl3, 
100 MHz): 12.9 (CH3), 14.7 (CH3), 20.1 (ArCH3), 20.9 (ArCH3), 23.0 [CO(CH3)], 
40.9 (NCH2), 43.5 (NCH2), 115.2 (ArCH), 121.7 (ArCH), 124.3 (ArCq), 134.7 
(ArCCH3), 138.6 (C=N), 140.1 (ArCCH3), 144.3 (ArCN), 162.5 
[NC(O)(CH3CH2)2], 171.1 [NC(O)CH3]; max (KBr)/cm-1 2974, 1635, 1382, 1175; 
m/z (ESI+) 310 [M + Na]+ (100%), 288 [M + H]+(4); HRMS (ESI+): exact mass 







    Chapter 3: Experimental 
308 
 
3.5.4 Synthesis of 5,6-difluoro-1H-indazole-3-carboxylate compounds 
Ethyl 1-acetyl-5,6-difluoro-1H-indazole-3-carboxylate 178  
The title compound was prepared using the 
procedure described for pentyl 1-acetyl-1H-
indazole-3-carboxylate 108 using caesium fluoride 
(38 mg, 0.25 mmol), nonafluorobutanesulfonyl 
fluoride (224 mg, 0.74 mmol), 4,5-difluoro-2-
(trimethylsilyl)phenol 78 (100 mg, 0.5 mmol), 
caesium carbonate (241 mg, 0.74 mmol) and ethyl 2-diazo-3-oxobutanoate 19 
(222 mg, 1.5 mmol) in acetonitrile (6 mL). The reaction was stirred at 60 °C under 
a nitrogen atmosphere for 24 h. Following the work-up, the residue was purified 
using column chromatography on silica gel using DCM: hexane (80:20) to yield 
ethyl 1-acetyl-5,6-difluoro-1H-indazole-3-carboxylate 178 as a white solid (68 
mg, 51%), m.p. 116-118 ºC. δH (CDCl3, 400MHz): 1.51 (3H, t, J 7.1, CH2CH3),  
2.87 [3H, s, C(O)CH3], 4.56 (2H, q, J 7.1, OCH2), 7.98 (1H, dd, 3JHF 9.1, 4JHF 7.8, 
ArCH), 8.31 (1H, dd, 3JHF 9.9, 4JHF 6.8, ArCH); δC(CDCl3, 100 MHz): 14.3 
(CH2CH3), 22.8 [C(O)CH3], 62.2 (OCH2), 104.1 (d, 2JCF 24.1, ArCH), 109.1 (dd, 
2JCF 20.6, 3JCF 1.2, ArCH), 120.4 (dd, 3JCF 8.7, 4JCF 1.1, ArCq), 135.9 (d, 3JCF 10.6, 
ArCN), 140.4 (d, 4JCF 4.4, C=N), 149.6 (dd, 1JCF 249.5, 2JCF 15.3, ArCF), 152.6 
(dd, 1JCF 253.9, 2JCF 15.8, ArCF), 161.3 (C=O) ester, 171.2 (C=O) amide; max 
(KBr)/cm-1 2986, 1722, 1505, 1319, 1159; m/z (ESI+) 291 [M + Na]+ (5%); HRMS 
(ESI+): exact mass calculated for C12H11N2O3F2 [M + H]+ 269.0738. Found 
269.0747. 
Isopropyl 1-acetyl-5,6-difluoro-1H-indazole-3-carboxylate 179  
The title compound was prepared using the 
procedure described for pentyl 1-acetyl-1H-
indazole-3-carboxylate 108 using caesium fluoride 
(38 mg, 0.25 mmol), nonafluorobutanesulfonyl 
fluoride (224 mg, 0.74 mmol), 4,5-difluoro-2-
(trimethylsilyl)phenol 78 (100 mg, 0.5 mmol), 
caesium carbonate (241 mg, 0.74 mmol) and isopropyl 2-diazo-3-oxobutanoate 20 
(255 mg, 1.5 mmol) in acetonitrile (6 mL). The reaction was stirred at 60 °C under 
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a nitrogen atmosphere for 24 h. Following the work-up, the residue was purified 
using column chromatography on silica gel using DCM: hexane (80:20) to yield 
isopropyl 1-acetyl-5,6-difluoro-1H-indazole-3-carboxylate 179 as a white solid 
(80 mg, 57%), m.p. 134-139 ºC. δH (CDCl3, 400MHz): 1.49 (6H, d, J 6.3, 2 × 
CH3),  2.86 [3H, s, C(O)CH3], 5.35-5.46 (1H, m, OCH), 7.94 (1H, dd, 3JHF 9.3, 
4JHF 7.7, ArCH), 8.30 (1H, dd, 3JHF 10.0, 4JHF 6.8, ArCH); δC(CDCl3, 100 MHz): 
21.9 (2 × CH3), 22.8 [C(O)CH3], 70.2 (OCH), 104.0 (d, 2JCF 23.8, ArCH), 109.1 
(d, 2JCF 20.6, ArCH), 120.3 (d, 3JCF 8.8, Cq), 135.9 (d, 3JCF 11.1, ArCN), 140.8 
(dd, 4JCF 4.4, 5JCF 1.5, C=N), 149.6 (dd, 1JCF 249.7, 2JCF 14.8, ArCF), 152.5 (dd, 
1JCF 254.0, 2JCF 15.7, ArCF), 160.8 (C=O) ester, 171.2 (C=O) amide; max 
(KBr)/cm-1 2984, 1737, 1711, 1317, 1167; m/z (ESI+) 282 M+ (20%), 263 (60); 
HRMS (ESI+): exact mass calculated for C13H13F2N2O3 [M + H]+ 283.1083. Found 
283.1077. 
 
t-Butyl 1-acetyl-5,6-difluoro-1H-indazole-3-carboxylate 180  
The title compound was prepared using the 
procedure described for pentyl 1-acetyl-1H-
indazole-3-carboxylate 108 using caesium fluoride 
(38 mg, 0.25 mmol), nonafluorobutanesulfonyl 
fluoride (224 mg, 0.74 mmol), 4,5-difluoro-2-
(trimethylsilyl)phenol 78 (100 mg, 0.5 mmol), 
caesium carbonate (241 mg, 0.74 mmol) and t-butyl 2-diazo-3-oxobutanoate 21 
(276 mg, 1.5 mmol) in acetonitrile (6 mL). The reaction was stirred at 60 °C under 
a nitrogen atmosphere for 24 h. Following the work-up, the residue was purified 
using column chromatography on silica gel using DCM: hexane (80:20) to yield 
t-butyl 1-acetyl-5,6-difluoro-1H-indazole-3-carboxylate 180 as a white solid (68 
mg, 46%), m.p. 144-146 ̊ C. δH (CDCl3, 400MHz): 1.70 (9H, s, 3 × CH3),  2.85 
[3H, s, C(O)CH3], 7.90 (1H, dd, 3JHF 9.2, 4JHF 7.8, ArCH), 8.30 (1H, dd, 3JHF 10.0, 
4JHF 6.8, ArCH); δC(CDCl3, 100 MHz): 22.7 [C(O)CH3], 28.2 (3 × CH3 of t-butyl), 
83.8 [C(CH3)3], 104.0  (d, 2JCF 24.2, ArCH), 109.1 (dd, 2JCF 20.6, 3JCF 1.4, ArCH), 
120.2 (dd, 3JCF 5.3, 4JCF 1.5, ArCq), 136.0 (d, 3JCF 11.3, ArCN), 140.1 (C=N), 
141.6-152.1 (m, 2 × ArCF), 160.2 (C=O) ester, 171.3 (C=O) amide;max 
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(KBr)/cm-1 2935, 1723, 1499, 1146; m/z (ESI-) 318 [M - H + Na] +  (10%). HRMS 
(ESI-): exact mass calculated for C14H13N2O4F2 [M - H]- 295.0894. Found 
295.0883.  
 
Pentyl 1-acetyl-5,6-difluoro-1H-indazole-3-carboxylate  182  
The title compound was prepared using the 
procedure described for pentyl 1-acetyl-1H-
indazole-3-carboxylate 108 using caesium 
fluoride (38 mg, 0.25 mmol), 
nonafluorobutanesulfonyl fluoride (224 mg, 
0.74 mmol), 4,5-difluoro-2-
(trimethylsilyl)phenol 78 (100 mg, 0.5 mmol), 
caesium carbonate (293 mg, 0.74 mmol) and pentyl 2-diazo-3-oxobutanoate 23 
(297 mg, 1.5 mmol) in acetonitrile (6 mL). The reaction was stirred at 60 °C under 
a nitrogen atmosphere for 24 h. Following the work-up, the residue was purified 
using column chromatography on silica gel using DCM:hexane (80:20) to yield 
pentyl 1-acetyl-5,6-difluoro-1H-indazole-3-carboxylate 182 as a yellow oil (55 
mg, 35%). δH(CDCl3, 400 MHz): 0.95 (3H, t, J 7.0, CH3), 1.40-1.70 (4H, m, 2 × 
CH2), 1.83-1.91 (2H, m, CH2), 2.86 [3H, s, C(O)CH3], 4.48 (2H, t, J 6.8, OCH2), 
7.96 (1H, dd, 3JHF 9.2, 4JHF 7.7, ArCH), 8.31 (1H, dd, 3JHF 10.0, 4JHF 6.8, ArCH); 
δC(CDCl3, 100 MHz): 13.9 (CH3), 22.3 (CH2), 22.8 [C(O)CH3], 28.1 (CH2), 28.3 
(CH2), 66.2 (OCH2),  104.1 (d, 2JCF 23.9, ArCH), 109.0 (d, 2JCF 20.6, ArCH), 120.4 
(dd, 3JCF 6.5, 4JCF 3.8, ArCq), 135.9 (d, 3JCF 11.2, ArCN), 140.5 (d, 4JCF 3.1, C=N), 
148.3-157.7 (m, 2 × ArCF), 161.3 (C=O) ester, 171.2 (C=O) amide; max 
(film)/cm-1 2922, 1734, 1509, 1317, 1159; m/z (ESI-) 309 [M - H]- (25%), 311 
(25); HRMS (ESI+): exact mass calculated for C15H17N2O3F2 [M + H]+ 311.1207. 
Found 311.1198. 
 
Note: Significant amounts of 4,5-difluoro-2-(trimethylsilyl)phenol (20 mg) 78 
was recovered unreacted after column chromatography. 
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2-Ethylbutyl 1-acetyl-5,6-difluoro-1H-indazole-3-carboxylate 183  
The title compound was prepared using the 
procedure described for pentyl 1-acetyl-1H-
indazole-3-carboxylate 108 using caesium 
fluoride (38 mg, 0.25 mmol), 
nonafluorobutanesulfonyl fluoride (224 mg, 0.74 
mmol), 4,5-difluoro-2-(trimethylsilyl)phenol 78 
(100 mg, 0.5 mmol), caesium carbonate (293 mg, 0.74 mmol) and 2-ethylbutyl 2-
diazo-3-oxobutanoate 30 (314 mg, 1.5 mmol) in acetonitrile (6 mL). The reaction 
was stirred at 60 °C under a nitrogen atmosphere for 24 h. Following the work-up, 
the residue was purified using column chromatography on silica gel using 
DCM:hexane (80:20) to yield 2-ethylbutyl 1-acetyl-5,6-difluoro-1H-indazole-3-
carboxylate 183 as a white solid, (64 mg, 39%), m.p. 78-81 ºC.  δH(CDCl3, 400 
MHz): 0.99 (6H, t, J 7.5, 2 × CH3), 1.50 (4H, m, 2 × CH2), 1.77 [1H, td, J 12.5, 
6.2, CH(CH3)2], 2.86 [3H, s, C(O)CH3], 4.42 (2H, t, J 5.9, OCH2), 7.94 (1H, dd, 
3JHF 9.3, 4JHF 7.6, ArCH), 8.30 (1H, dd, 3JHF 10.0, 4JHF 6.8, ArCH); δC(CDCl3, 100 
MHz): 11.0 (2 × CH3), 22.7 [C(O)CH3], 23.5 (2 × CH2), 40.5 (CH), 68.1 (OCH2), 
104.1 (d, 2JCF 23.9, ArCH), 108.9 (dd, 2JCF 20.7, 3JCF 1.5, ArCH), 120.3 (dd, 3JCF 
20.7, 4JCF 1.5, ArCq), 135.9 (d, 3JCF 10.7, ArCN), 140.5 (dd, 4JCF 4.4, 5JCF 1.5, 
C=N), 149.6 (dd, 1JCF 249.3, 2JCF 5.2, ArCF), 152.5 (dd, 1JCF 254.1, 2JCF 15.7, 
ArCF), 161.4 (C=O) ester, 171.2 (C=O) amide; max (KBr)/cm-1 2962, 1733, 1507, 
1319, 1157; HRMS (ESI+): exact mass calculated for C16H19F2N2O3 [M + H]+ 
325.1364. Found 325.1367. 
 
2-Ethylhexyl 1-acetyl-5,6-difluoro-1H-indazole-3-carboxylate 184  
The title compound was prepared using the 
procedure described for pentyl 1-acetyl-1H-
indazole-3-carboxylate 108 using caesium 
fluoride (38 mg, 0.25 mmol), 
nonafluorobutanesulfonyl fluoride (224 mg, 
0.74 mmol), 4,5-difluoro-2-
(trimethylsilyl)phenol 78 (100 mg, 0.5 
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mmol), caesium carbonate (293 mg, 0.74 mmol) and 2-ethylhexyl 2-diazo-3-
oxobutanoate 28 (360 mg, 1.5 mmol) in acetonitrile (6 mL). The reaction was 
stirred at 60 °C under a nitrogen atmosphere for 24 h. Following the work-up, the 
residue was purified using column chromatography on silica gel using DCM: 
hexane (80:20) to yield 2-ethylhexyl 1-acetyl-5,6-difluoro-1H-indazole-3-
carboxylate 184 as a white solid (70 mg, 40%), m.p. 72-73 ºC. δH(CDCl3, 400 
MHz): 0.92 (3H, t, J 6.9, CH3), 0.99 (3H, t, J 7.5, CH3), 1.30-1.52 (8H, m, 4 × 
CH2), 1.82 (1H, td, J 12.3, 6.0, CH), 2.86 [3H, s, C(O)CH3], 4.41 (2H, d, J 5.9, 
OCH2), 7.94 (1H, dd, 3JHF 9.2, 4JHF 7.7, ArCH), 8.31 (1H, dd, 3JHF 10.0, 4JHF 6.8, 
ArCH); δC(CDCl3, 100 MHz): 11.0 (CH3), 14.0 (CH3), 22.7 (CH2), 22.9 
[C(O)CH3], 24.0 (CH2), 28.9 (CH2), 30.6 (CH2), 38.9 (CH), 68.5 (OCH2), 104.1 
(d, 2JCF 24.0, ArCH), 108.9 (dd, 2JCF 20.7, 3JCF 1.5, ArCH), 120.3 (d, 3JCF 8.9, 
ArCq), 135.9 (d, 3JCF 11.1, ArCN), 140.5 (dd, 4JCF 4.5, 5JCF 1.5, C=N), 149.6 (dd, 
1JCF 249.4, 2JCF 15.3, ArCF), 152.5 (dd, 1JCF 254.2, 2JCF 15.7, ArCF), 161.4 (C=O) 
ester, 171.2 (C=O) amide;max (KBr)/cm-1 2928, 1726, 1509, 1319, 1156; m/z 
(ESI-) 309 [M - H - COCH3]+ (20%), 315 (100); HRMS (ESI+): exact mass 
calculated for C18H23F2N2O3 [M + H]+ 353.1853. Found 353.1864. 
 
Benzyl 1-acetyl-5,6-difluoro-1H-indazole-3-carboxylate 181 
The title compound was prepared using the 
procedure described for pentyl 1-acetyl-1H-
indazole-3-carboxylate 108 using caesium 
fluoride (38 mg, 0.25 mmol), 
nonafluorobutanesulfonyl fluoride (224 mg, 
0.74 mmol), 4,5-difluoro-2-
(trimethylsilyl)phenol 78 (100 mg, 0.5 
mmol), caesium carbonate (241 mg, 0.74 mmol) and benzyl 2-diazo-3-
oxobutanoate 22 (327 mg, 1.5 mmol) in acetonitrile (6 mL). The reaction was 
stirred at 60 °C under a nitrogen atmosphere for 24 h. Following the work-up, the 
residue was purified using column chromatography on silica gel using DCM: 
hexane (80:20) to yield benzyl 1-acetyl-5,6-difluoro-1H-indazole-3-carboxylate 
181 as a white solid (65 mg, 39%), m.p. 119-121 ºC. δH (CDCl3, 400MHz): 2.85 
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[3H, s, C(O)CH3], 5.52 (2H, s, OCH2C6H5), 7.26-7.64 (5H, m, 5 × ArCH), 7.94 
(1H, dd, 3JHF 9.1, 4JHF 7.7, ArCH), 8.30 (1H, dd, 3JHF 9.8, 4JHF 6.7, ArCH); 
δC(CDCl3, 100 MHz): 22.8 [C(O)CH3], 67.6 (OCH2C6H5), 104.1 (d, 2JCF 24.2, 
ArCH), 109.0 (dd, 2JCF 21.2, 3JCF 1.6, ArCH), 120.1 (d, 3JCF 54.0, ArCq), 128.6 (2 
× ArCH benzyl), 128.8 (ArCH benzyl), 128.8 (2 × ArCH benzyl), 135.0 (ArCq 
benzyl), 161.1 (C=O) ester, 171.2 (C=O) amide, ArCN, C=N and 2 × CF too close 
to baseline to detect. max (KBr)/cm-1 2926, 1722, 1504, 1311, 1153; m/z (ESI+) 
330 [M ]+ (40%), 331 (10); HRMS (ESI+): exact mass calculated for C17H13F2N2O3 
[M + H]+ 331.0910. Found 331.0903. 
 
 
Decyl 1-acetyl-5,6-difluoro-1H-indazole-3-carboxylate 187  
The title compound was prepared 
using the procedure described for 
pentyl 1-acetyl-1H-indazole-3-
carboxylate 108 using caesium 
fluoride (38 mg, 0.25 mmol), 
nonafluorobutanesulfonyl fluoride 
(224 mg, 0.74 mmol), 4,5-difluoro-2-
(trimethylsilyl)phenol 78 (100 mg, 0.5 
mmol), caesium carbonate (241 mg, 0.74 mmol) and decyl 2-diazo-3-
oxobutanoate 29 (402 mg, 1.5 mmol) in acetonitrile (6 mL). The reaction was 
stirred at 60 °C under a nitrogen atmosphere for 24 h. Following the work-up, the 
residue was purified using column chromatography on silica gel using DCM: 
hexane (80:20) to yield decyl 1-acetyl-5,6-difluoro-1H-indazole-3-carboxylate 
187 as a yellow solid (60 mg, 32%), m.p. 59-61 ºC. δH (CDCl3, 400MHz): 0.88 
(3H, t, J 6.8, CH3), 1.22-1.37 (14H, m, 7 × CH2), 1.80-1.90 (2H, m, CH2 ), 2.86 
[3H, s, C(O)CH3], 4.48 (2H, t, J 6.8, OCH2), 7.96 (1H, dd, 3JHF 9.3, 4JHF 7.6, 
ArCH), 8.31 (1H, dd, 3JHF 10.0, 4JHF 6.8, ArCH);  δC(CDCl3, 100 MHz): 14.1 
(CH2CH3), 22.7 [C(O)CH3], 22.8 (CH2), 25.9 (CH2), 28.6 (CH2), 29.2 (CH2), 29.3 
(CH2), 29.5 (2 × CH2), 31.9 (OCH2CH2), 66.2 (OCH2), 104.1 (d, 2JCF 24.0, ArCH), 
109.0 (d, 2JCF 20.5, ArCH), 120.4 (d, 3JCF 8.8, ArCq), 135.9 (d, 3JCF 11.6, ArCN), 
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140.5 (d, 4JCF 4.2, C=N), 149.7 (dd, 1JCF 270.0, 2JCF 20.8, ArCF), 152.6 (dd, 1JCF 
243.3, 2JCF 7.6, ArCF), 161.3 (C=O) ester, 171.2 (C=O) amide; max (KBr)/cm-1 
2922, 2854, 1734, 1509, 1317, 1158; HRMS (ESI+): exact mass calculated for 
C20H27F2N2O3 [M + H]+ 381.1990. Found 381.2005. 
 
 
Ethyl 1-benzoyl-5,6-difluoro-1H-indazole-3-carboxylate 186  
The title compound was prepared using the 
procedure described for pentyl 1-acetyl-1H-
indazole-3-carboxylate 108 using caesium fluoride 
(38 mg, 0.25 mmol), nonafluorobutanesulfonyl 
fluoride (224 mg, 0.74 mmol), 4,5-difluoro-2-
(trimethylsilyl)phenol 78 (100 mg, 0.5 mmol), 
caesium carbonate (241 mg, 0.74 mmol) and ethyl 2-
diazo-3-oxo-3-phenylpropanoate 39 (327 mg, 1.5 mmol) in acetonitrile (6 mL). 
The reaction was stirred at 60 °C under a nitrogen atmosphere for 24 h. Following 
the work-up, the residue was purified using column chromatography on silica gel 
using DCM: hexane (80:20) to yield ethyl 1-benzoyl-5,6-difluoro-1H-indazole-3-
carboxylate 186 as a white solid, (45 mg, 27%), m.p. 119-120 ̊ C. δH (CDCl3, 
400MHz): 1.50 (3H, t, J 7.1, CH3), 4.55 (2H, q, J 7.1, CH2), 7.26-7.50 (5H, m, 5 
× ArCH), 7.55-7.61 (1H, m, ArCH), 8.07 (1H, dd, 3JHF 9.4, 4JHF 7.7, ArCH); 
δC(CDCl3, 100 MHz): 14.4 (CH2CH3), 61.7 (OCH2), 98.4 (d, 2JCF 23.5 ArCH 
indazole), 109.2 (dd, 2JCF 20.1, 3JCF 1.4, ArCH indazole), 113.6 (ArCH phenyl), 
113.8 (ArCH phenyl), 118.2 (ArCH phenyl), 118.4 (ArCH phenyl), 119.5 (ArCq 
phenyl), 119.6 (ArCH phenyl), 120.0 (d, 3JCF 8.2, ArCq indazole), 135.0 (d, 3JCF 
2.7, ArCN), 135.9 (C=N), 139.0-151.0 (m, 2 × ArCF), 161.8 (C=O) ester, 164.1 
(C=O) amide; max (KBr)/cm-1 1726, 1645, 1521, 1496, 115; m/z (ESI+) 331 [M + 
H]+ (10%), 330 (40); HRMS (ESI+): exact mass calculated for C17H13F2N2O3 [M 
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Undec-10-en-1-yl 1-acetyl-5,6-difluoro-1H-indazole-3-carboxylate 188  
The title compound was 
prepared using the procedure 
described for pentyl 1-acetyl-
1H-indazole-3-carboxylate 108 
using caesium fluoride (38 mg, 
0.25 mmol), 
nonafluorobutanesulfonyl 
fluoride (224 mg, 0.74 mmol), 4,5-difluoro-2-(trimethylsilyl)phenol 78 (100 mg, 
0.5 mmol), caesium carbonate (241 mg, 0.74 mmol) and undec-10-en-1-yl 2-
diazo-3-oxobutanoate 31 (420 mg, 1.5 mmol) in acetonitrile (6 mL). The reaction 
was stirred at 60 °C under a nitrogen atmosphere for 24 h. Following the work-up, 
the residue was purified using column chromatography on silica gel using DCM: 
hexane (80:20) to yield undec-10-en-1-yl 1-acetyl-5,6-difluoro-1H-indazole-3-
carboxylate 188 as an off white solid (45 mg, 23%), m.p. 59-61 ºC. δH (CDCl3, 
400MHz): 1.24-1.50 (12H, m, 6 × CH2), 1.80-1.91 (2H, m, CH2 ), 2.04 (2H, dd, J 
13.4, 6.3, CH2), 2.87 [3H, s, C(O)CH3], 4.48 (2H, t, J 6.3, OCH2), 4.96 (2H, dd, J 
23.7, 13.7, CH=CH2), 5.81 (1H, tdd, J 13.3, 10.1, 6.7, CH=CH2), 7.96 (1H, dd, 
3JHF 9.0, 4JHF 7.9, ArCH), 8.31 (1H, dd, 3JHF 9.9, 4JHF 6.8, ArCH);  δC(CDCl3, 100 
MHz): 22.8 [C(O)CH3], 25.9 (CH2), 28.6 (CH2), 28.9 (CH2), 29.1 (CH2), 29.2 
(CH2), 29.4 (CH2), 29.4 (CH2), 33.8 (CH2), 66.3 (OCH2), 104.1 (d, 2JCF 23.8, 
ArCH), 109.0 (d, 2JCF 20.8, ArCH), 114.2 (CH2) alkene, 120.4 (d, 3JCF 8.5, ArCq), 
135.9 (d, 3JCF 11.6, ArCN), 139.2 (CH) alkene, 140.5 (dd, 4JCF 4.1, 5JCF 1.4, C=N), 
149.6 (d, 1JCF 264.5, ArCF), 152.6 (d, 1JCF 254.0, ArCF), 161.3 (C=O) ester, 171.2 
(C=O) amide; max (KBr)/cm-1: 2928, 2849, 1716, 1643, 1317, 1148; HRMS 
(ESI+): exact mass calculated for C20H27F2N2O3 [M + H]+ 381.1051. Found 
330.1065. 
 
Note: The sample contained 3% starting material after column chromatography 
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1-Acetyl-N,N-diethyl-5,6-difluoro-1H-indazole-3-carboxamide 185  
The title compound was prepared using the 
procedure described for pentyl 1-acetyl-1H-
indazole-3-carboxylate 108 using caesium fluoride 
(38 mg, 0.25 mmol), nonafluorobutanesulfonyl 
fluoride (224 mg, 0.74 mmol), 4,5-difluoro-2-
(trimethylsilyl)phenol 78 (100 mg, 0.5 mmol), 
caesium carbonate (241 mg, 0.74 mmol) and 2-diazo-N,N-diethyl-3-
oxobutanamide 45 (275 mg, 1.5 mmol) in acetonitrile (6 mL). The reaction was 
stirred at 60 °C under a nitrogen atmosphere for 24 h. Following the work-up, the 
residue was purified using column chromatography on silica gel using DCM: 
hexane (80:20) to yield 1-acetyl-N,N-diethyl-5,6-difluoro-1H-indazole-3-
carboxamide 185 as a low melting brown solid (47 mg, 32%). δH (CDCl3, 
400MHz): 1.28-1.39 [6H, m, containing 1.31 (3H, t, J 7.1, CH3) and 1.36 (3H, t, 
J 7.0, CH3)], 2.77 [3H, s, C(O)CH3], 3.62 (2H, q, J 7.2, NCH2), 3.75 (2H, q, J 7.0, 
NCH2), 7.94 (1H, dd, 3JHF 9.3, 4JHF 7.8, ArCH), 8.25 (1H, dd, 3JHF 10.0, 4JHF 6.8, 
ArCH); δC(CDCl3, 100 MHz):12.8 (CH3), 14.7 (CH3), 22.6 [C(O)CH3], 41.3 
(CH2), 43.5 (CH2), 103.6 (d, 2JCF 23.9, ArCH), 109.6 (dd, 2JCF 20.5, 3JCF 1.5, 
ArCH), 122.7 (dd, 3JCF 8.5, 4JCF 1.1, ArCq), 135.1 (d, 3JCF 11.1, ArCN), 144.0 (dd, 
4JCF 4.3, 5JCF 1.4, C=N), 149.2 (dd, 1JCF 248.5, 2JCF 15.2, ArCF), 152.5 (dd, 1JCF 
253.5, 2JCF 15.7, ArCF), 161.3 (C=O) ester, 170.7 (C=O) amide;max (KBr)/cm-1 
2981, 1734, 1629, 1430; m/z (ESI+) 318 [M + Na]+ (70%), 296 (10); HRMS (ESI+): 
exact mass calculated for C14H16N3O2F2 [M + H]+ 296.1211. Found 296.1205.  
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3.5.5 Synthesis of 5/6-substituted indazole compounds using unsymmetrical 
aryne precursors 
sec-Butyl 1-acetyl-6-chloro-1H-indazole-3-carboxylate 189 and sec-butyl 1-
acetyl-5-chloro-1H-indazole-3-carboxylate 190 70:30  
Using the procedure described for pentyl 1-acetyl-1H-indazole-3-
carboxylate 108, caesium fluoride (46 mg, 0.3 mmol), nonafluorobutanesulfonyl 
fluoride (269 mg, 0.89 mmol), 4-chloro-2-(trimethylsilyl)phenol 77 (120 mg, 0.60 
mmol), caesium carbonate (289 mg, 0.89 mmol) and sec-butyl 2-diazo-3-
oxobutanoate 32 (331 mg, 1.8 mmol) in acetonitrile (6 mL) were stirred at 60 °C 
under a nitrogen atmosphere for 8 h. Following the work-up, the residue was 
purified using column chromatography on silica gel using DCM: hexane (80:20) 
to yield a 70:30 mixture of regioisomers as a colourless oil (83 mg, 47%). max 
(KBr)/cm-1 2975, 1736, 1497, 1162; m/z (ESI+) 317 [M + Na]+ (20%); HRMS 
(ESI+): exact mass calculated for C14H16ClN2O3 [M + H]+ 295.0849. Found 
295.0845. 
 
Major isomer: sec-Butyl 1-acetyl-6-chloro-1H-indazole-3-carboxylate 189 
δH(CDCl3, 400 MHz): 1.03 (3H, t, CH3, J 7.4),  
1.45 (3H, d, J 6.3, CH3), 1.70-1.93 (2H, m), 2.86 
[3H, s, C(O)CH3], 5.21-5.31 (1H, m, OCH), 7.42 
(1H, dd, J 8.6, 1.7, ArCH), 8.10 (1H, d, J 8.6, 
ArCH), 8.51 (1H, d, J 1.4, ArCH); 
Tentative 13C NMR assignment: δC(CDCl3, 100 
MHz): 9.8 (CH2CH3),  19.5 (CHCH3), 23.0 
[C(O)CH3], 28.9 (CH2), 74.5 (OCH), 115.6 (ArCH), 123.1 (ArCH), 123.2 (ArCq), 
126.7 (ArCH), 131.5 (ArC-Cl), 136.4 (C=N), 140.6 (ArCN), 161.1 (C=O) ester, 
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Minor isomer: sec-Butyl 1-acetyl-5-chloro-1H-indazole-3-carboxylate 190 
 δH(CDCl3, 400 MHz): 1.04 (3H, t, , J 7.4, CH3),  
1.46 (3H, d, J 6.3, CH3), 1.70-1.93 (2H, m), 2.87 
[3H, s, C(O)CH3], 5.21-5.31 (1H, m, OCH), 7.55 
(1H, dd, J 8.9, 2.0, ArCH), 8.16 (1H, d, J 1.7, 
ArCH), 8.40 (1H, d, J 8.9, ArCH); 
Tentative 13C NMR assignment: δC(CDCl3, 100 
MHz): 9.8, (CH2CH3)  19.6 (CHCH3), 22.9 [C(O)CH3], 28.9 (CH2), 74.6 (OCH), 
116.6 (ArCH), 121.7 (ArCH), 121.7 (ArCq), 125.7 (ArCq), 127.1 (ArC-Cl), 130.4 
(ArCH), 138.7 (C=N), 141.0 (ArCN), 161.1 (C=O) ester, 171.3 (C=O) amide. 
 
Methyl 5-methyl-1-pentanoyl-1H-indazole-3-carboxylate 193 and methyl 6-
methyl-1-pentanoyl-1H-indazole-3-carboxylate 194 1:1  
Using the procedure described for pentyl 1-acetyl-1H-indazole-3-
carboxylate 108 using caesium fluoride (43 mg, 0.28 mmol), 
nonafluorobutanesulfonyl fluoride (269 mg, 0.89 mmol), 4-methyl-2-
(trimethylsilyl)phenol 76 (100 mg, 0.55 mmol), caesium carbonate (290 mg, 0.89 
mmol) and methyl 2-diazo-3-oxobutanoate 33 (306 mg, 1.68 mmol) in acetonitrile 
(6 mL) were stirred at 60 °C under a nitrogen atmosphere for 8 h. Following the 
work-up, the residue was purified using column chromatography on silica gel 
using DCM: hexane (80:20) to yield a 50:50 mixture of regioisomers (99 mg, 65%) 
as a colourless oil. δC(CDCl3, 100 MHz): 13.9 (CH2CH3), 21.5 and 22.1 (ArCH3), 
22.3 and 26.4 (CH2CH3), 34.5 and 34.7 [C(O)CH2], 52.6 (OCH3), 115.1 and 115.3 
(ArCH), 121.3 and 121.6 (ArCH), 125.0 (ArCq), 127.6 (ArCH), 131.7 (ArCCH3), 
135.7 (C=N), 140.8 (ArCN), 162.4 (C=O) ester, 174.2 (C=O) amide. 
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Methyl 5-methyl-1-pentanoyl-1H-indazole-3-carboxylate 193 
δH (CDCl3, 400MHz): 0.99 (3H, t, J 7.3, CH2CH3), 
1.43-1.55 (2H, m, CH2), 1.77-1.87 (2H, m, CH2), 2.54 
(3H, s, ArCH3), 3.30 (2H, t, J 7.4, C(O)CH2), 4.08 (3H, 
s, OCH3), 7.42 (1H, d,  J 8.3, ArCH), 8.08 (1H, d, J 
8.3, ArCH), 8.30 (1H, s, ArCH).   
 
 
Methyl 6-methyl-1-pentanoyl-1H-indazole-3-carboxylate 194  
δH (CDCl3, 400MHz): 0.99 (3H, t, J 7.3, CH2CH3), 
1.43-1.55 (2H, m, CH2), 1.77-1.87 (2H, m, CH2), 2.52 
(3H, s, ArCH3), 3.30 [2H, t, J 7.4, C(O)CH2], 4.07 (3H, 
s, OCH3), 7.28 (1H, d, J 8.6, ArCH), 8.00 (1H, s, 
ArCH), 8.35 (1H, d, J 8.6, ArCH).  
 
 
Ethyl 5-ethyl-1-butyryl-1H-indazole-3-carboxylate 195 and ethyl 6-methyl-1-
butyryl-1H-indazole-3-carboxylate 196 1:1  
Using the procedure described for pentyl 1-acetyl-1H-indazole-3-
carboxylate 108, caesium fluoride (43 mg, 0.28 mmol), nonafluorobutanesulfonyl 
fluoride (251 mg, 0.83 mmol), 4-methyl-2-(trimethylsilyl)phenol 58 (100 mg, 0.56 
mmol), caesium carbonate (271 mg, 0.83 mmol) and ethyl 2-diazo-3-
oxohexanoate 34 (309 mg, 1.68 mmol) in acetonitrile (6 mL) were stirred at 60 ºC 
for 8 h. Following the work-up, the residue was purified using column 
chromatography on silica gel using DCM: hexane (80:20) to yield a 50:50 mixture 
of regioisomers as a yellow solid (65 mg, 66%), m.p. 104-107 ºC which could not 
be separated by column chromatography on silica gel. max (KBr)/cm-1 2924, 1712, 
1480, 1280; m/z (ESI-) 175 [M - H]- (100%), 176 [M+] (10); δC(CDCl3, 100 MHz): 
13.7 [CH3CH2CH2C(O)], 14.4 (CH3CH2O), 17.8 [CH3CH2CH2C(O)], 21.5 
(ArCH3), 22.1 (ArCH3), 36.6 and 36.8 [CH3CH2CH2C(O)],  61.8 (CH3CH2O), 
    Chapter 3: Experimental 
320 
 
115.5 and 115.3 (ArCH), 121.4 and 121.6 (ArCH), 122.7 and 125.0 (ArCq), 127.5 
(ArCH), 131.6 (ArCH), 135.6 and 140.7 (ArCCH3), 138.9 and 140.2 (C=N), 140.5 
and 140.9 (ArCN), 162.0 and 162.1 (C=O) ester, 174.1 and 174.3 (C=O) amide; 
HRMS (ESI+): exact mass calculated for C16H20N2O3 [M + H]+ 289.2379. Found 
289.2383. 
 
Ethyl 5-ethyl-1-butyryl-1H-indazole-3-carboxylate 195  
δH (CDCl3, 400MHz): 1.08 [3H, t, J 7.4, 
C(O)CH2CH2CH3],  1.50 (3H, dt, J 2.5, 7.1, 
OCH2CH3), 1.88 [2H, dd, J 7.4, 4.8, 
C(O)CH2CH2CH3], 2.54 (3H, s, ArCH3), 3.29 [2H, 
t J ,7.3, C(O)CH2CH2CH3],  4.55 (2H, dq, J 3.8, 7.1, 
OCH2CH3), 7.42 (1H, d, J 8.2, ArCH), 8.06 (1H, d, 
J 8.2, ArCH), 8.30 (1H, s, ArCH).  
 
 
Ethyl 6-methyl-1-butyryl-1H-indazole-3-carboxylate 196 
δH (CDCl3, 400MHz): 1.08 [3H, t, J 7.4, 
C(O)CH2CH2CH3],  1.50 (3H, dt, J 2.5, 7.1, 
OCH2CH3), 1.88 [2H, dd, J 7.4, 4.8, 
C(O)CH2CH2CH3], 2.52 (3H, s, ArCH3),  3.29 [2H, 
t J ,7.3, C(O)CH2CH2CH3],  4.55 (2H, dq, J 3.8, 7.1, 
OCH2CH3), 7.27 (1H, d, J 8.1, ArCH), 7.98 (1H, s, 
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3.6 Attempted Syntheses of Azaindazole derivatives 




 5,8-Dihydro-5,8-epoxyquinoline57 201 
Using the procedure described for pentyl 1-acetyl-1H-indazole-
3-carboxylate 108, 3-(trimethylsilyl)pyridin-2-ol 58 (0.05 g, 0.3 
mmol, caesium carbonate (0.147 g, 0.45 mmol) in acetonitrile (3 
ml), caesium fluoride (23 mg, 0.15 mmol), furan 97 (0.065 ml, 0.9 mmol) and 
nonafluorobutanesulfonyl fluoride (81 μL, 0.45 mmol) were stirred at 60 °C under 
a nitrogen atmosphere. TLC analysis after 24 h indicated the presence of starting 
material only in the reaction mixture. After a further 24 h, water (10 mL) was 
added to the reaction flask and the layers separated. The aqueous layer was 
extracted with diethyl ether (3 × 10 mL), the organic layers combined, dried with 
MgSO4 and concentrated under reduced pressure. The 1H NMR spectrum of the 
crude material showed no evidence of product formation with only unreacted 
starting material recovered. 
 
3.6.2 Attempted Syntheses of Azaindazole derivatives 








carboxylate 108, 3-(trimethylsilyl)pyridin-2-ol 58 (100 mg, 0.6 mmol), caesium 
carbonate (174 mg, 0.9 mmol) in acetonitrile (6 ml), caesium fluoride (46 mg, 0.3 
N
O
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mmol),  pentyl 2-diazo-3-oxobutanoate 23 (238 mg, 1.2 mmol) and 
nonafluorobutanesulfonyl fluoride (272 mg, 0.9 mmol) were stirred at 60 °C under 
a nitrogen atmosphere. TLC analysis after 24 h indicated the presence of starting 
material only in the reaction mixture. After a further 24 h, water (10 mL) was 
added to the reaction flask and the layers separated. The aqueous layer was 
extracted with diethyl ether (3 × 10 mL), the organic layers combined, dried with 
MgSO4 and concentrated under reduced pressure. The 1H NMR spectrum of the 
crude material showed no evidence of product formation with only unreacted 
starting material recovered. 
 
Isopropyl 1-acetyl-4-chloro-1H-pyrazolo[4,3-c]pyridine-3-carboxylate 205 
and/or isopropyl 1-acetyl-7-chloro-1H-pyrazolo[3,4-c]pyridine-3-carboxylate 
204  




(100 mg, 0.5 mmol), caesium 
carbonate (245 mg, 0.75 mmol) 
in acetonitrile (6 ml), caesium fluoride (38 mg, 0.25 mmol), isopropyl 2-diazo-3-
oxobutanoate 20 (93.5 mg, 0.6 mmol) and nonafluorobutanesulfonyl fluoride (227 
mg, 0.75 mmol) were stirred at 60 °C under a nitrogen atmosphere. TLC analysis 
after 24 h indicated the presence of starting material only in the reaction mixture. 
After a further 24 h, water (10 mL) was added to the reaction flask and the layers 
separated. The aqueous layer was extracted with diethyl ether (3 × 10 mL), the 
organic layers combined, dried with MgSO4 and concentrated under reduced 
pressure. The 1H NMR spectrum of the crude material showed no evidence of 
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3.7 N-Deacylation of 1-acyl indazoles 





Methyl 1H-indazole-3-carboxylate 208  
Thionyl chloride (0.04 mL, 0.36 mmol) was added to t-butyl 
1-acetyl-1H-indazole-3-carboxylate 106 (78 mg, 0.36 
mmol) in methanol (5 mL) at 0 ºC and the mixture was then 
stirred at reflux for 1.5 h. The reaction mixture was 
concentrated under reduced pressure and a solution of saturated sodium 
bicarbonate (10 mL) was added to the residue. The crude mixture was extracted 
with diethyl ether (2 × 10 mL), dried with MgSO4 and concentrated under reduced 
pressure. The residue was purified using column chromatography on silica gel 
using hexane:ethyl acetate (3:1-1:3) to yield methyl 1H-indazole-3-carboxylate 
208 as a white solid (31 mg, 49%),  m.p. 159-162 ºC, (Lit.52 162-163 ºC). 1H NMR 
analysis showed N-deacylation but also transesterification of the ester side chain, 
from t-butyl to methyl. δH (CDCl3, 400MHz): 4.08 (1H, s, COCH3), 7.35 (1H, t, J 
7.6, ArCH), 7.48 (1H, t, J 7.6, ArCH), 7.70 (1H, d, J 8.5, ArCH),  8.24 (1H, d, J 
8.2, ArCH), 11.82 (1H, br s, NH); δC(CDCl3, 100 MHz): 52.1 (OCH3), 110.8 
(ArCH), 121.8 (ArCH), 122.5 (ArCq), 123.4 (ArCH), 127.5 (ArCH), 136.4 (C=N), 
141.2 (ArCN), 163.3 (C=O); max (KBr)/cm-1 3430, 2954, 1727, 1474, 1148; m/z 
(ESI+) 177 [M + H]+ (40%); HRMS (ESI+): exact mass calculated for C9H9N2O2 
[M + H]+ 177.0664. Found 177.0658. Spectral details are in agreement with those 
reported in the literature.52 
 
Note: This reaction was repeated using DCM as solvent but was unsuccessful and 
only recovered unreacted starting material. 
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Ethyl 1H-indazole-3-carboxylate 211 
A solution of ethyl 1-acetyl 1H-indazole-3-carboxylate 
99 (54 mg, 0.23 mmol), ethyl 1-phenyl-1H-indazole-3-
carboxylate 117 (11 mg, 0.04 mmol) (inseparable) in 
THF (10 mL)  and TBAF (1M in THF, 0.92 mL, 0.92 
mmol, 4 equiv.) was stirred at room temperature for 1 h. 
The solution obtained was diluted with water (10 mL) and extracted with diethyl 
ether (2 × 10 mL). This solution was washed with water (5 × 20 mL) to remove 
excess TBAF. Column chromatography on silica gel using hexane:ethyl acetate 
(3:1) isolated ethyl 1-phenyl-1H-indazole-3-carboxylate 117 as a white solid (8 
mg, 73%), m.p.  109-112 ºC, (Lit.52 112-114 ºC) and hexane:ethyl acetate (1:3) 
isolated ethyl 1H-indazole-3-carboxylate 211 as a white solid (11 mg, 26%), m.p. 
127-129 ºC, (Lit.59 130 ºC). δH (CDCl3, 400MHz): 1.50 (3H, t, J 7.1, CH2CH3),  
4.54 (2H, q, J 7.2, OCH2), 7.35 (1H, t, J 7.6, ArCH), 7.47 (1H, t, J 7.7, ArCH), 
7.60 (1H, d, J 8.3, ArCH),  8.25 (1H, d, J 8.0, ArCH), 10.85 (1H, br s, NH); 
δC(CDCl3, 100 MHz): 14.4 (CH2CH3), 61.1 (OCH2), 110.3 (ArCH), 122.1 
(ArCH), 122.6 (ArCq), 123.3 (ArCH), 127.5 (ArCH), 135.2 (C=N), 141.5 (ArCN), 
162.7 (C=O); max (KBr)/cm-1 2984, 1730, 1500, 1194; m/z (ESI+) 213 [M + Na]+ 
(100%), 191 [M + H]+ (10); HRMS (ESI+): exact mass calculated for C10H11N2O2 
[M + H]+ 191.0821. Found 191.0820. Spectral details are in agreement with those 
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Ethyl 1-phenyl-1H-indazole-3-carboxylate 225 
 δH (CDCl3, 400MHz): 1.51 (3H, t, J 7.1, CH2CH3),  
4.56 (2H, q, J 7.1, OCH2), 7.36-7.61 (5H, m, 5 × 
ArCH), 7.70-7.79 (3H, m, 3 × ArCH),  8.32 (1H, d, J 
8.1, ArCH); δC(CDCl3, 100 MHz): 14.5 (CH2CH3), 
61.2 (OCH2), 110.9 (ArCH), 122.5 (ArCH), 123.7 
(ArCq indazole), 124.0 (2 × ArCH), 124.5 (ArCH), 
127.6 (ArCH), 128.0 (ArCH), 129.5 (2 × ArCH), signals for (ArCq phenyl), 
(ArCN), (C=N) and (C=O) too close to the baseline to detect; max (KBr)/cm-1 
2967, 1708, 1598, 1476, 1189; m/z (ESI+) 267 [M + H]+ (14%); HRMS (ESI+): 
exact mass calculated for C16H15N2O2 [M + H]+ 267.1134. Found 267.1121. 
Spectral details are in agreement with those reported in the literature.52 
 
Propyl 1H-indazole-3-carboxylate 223  
A solution of propyl 1-pentanoyl 1H-indazole-3-
carboxylate 120 (20 mg, 76.5 μmol) and TBAF (1M in 
THF, 0.31 mL, 0.31 mmol, 4 equiv.) was stirred in THF 
(6 mL) at room temperature for 1 h. The solution 
obtained was diluted with water (10 mL) and extracted 
with diethyl ether (2 × 10 mL). This solution was washed with water (5 × 20 mL) 
to remove excess TBAF. The reaction mixture was concentrated under reduced 
pressure for an extended period of time to remove the pentanoyl fluoride 
deacylation by-product and propyl 1H-indazole-3-carboxylate 223 was isolated as 
a white solid with no further purification required (14.0 mg, 84%), m.p. 133-135 
ºC, (Lit. value not reported). δH(CDCl3, 400 MHz): 1.08 (3H, t, J 7.4, CH3), 1.84-
1.94 (2H, m, CH2), 4.46 (2H, t, J 6.7,  OCH2, 7.34 (1H, ddd, J 7.9, 6.9,  0.8, ArCH), 
7.47 (1H, ddd, J 8.4, 6.9, 1.1, ArCH), 7.71 (1H, d, J 8.5, ArCH), 8.22 (1H, d, J 
8.2, ArCH), 12.50 (1H, br s, NH);  δC(CDCl3, 100 MHz):  10.6 (CH3), 22.2 (CH2), 
66.7 (OCH2), 111.4 (ArCH), 121.7 (ArCH), 122.4 (ArCq), 123.2 (ArCH), 127.2 
(ArCH), 136.6 (C=N), 141.5 (ArCN), 163.3 (C=O); max (KBr)/cm-1: 3278, 2969, 
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1719, 1421, 1139; m/z (ESI+) 205 [M + H]+ (4%); HRMS (ESI)+: Exact mass 
calculated for C11H13N2O2 [M + H]+ 205.0977.  Found 205.0971.  
Compound reported in literature without spectral details.60 
 
Isopropyl 1H-indazole-3-carboxylate 212  
The title compound was prepared in the same manner as 
propyl 1H-indazole-3-carboxylate 223 using isopropyl 1-
acetyl 1H-indazole-3-carboxylate 105 (20 mg, 81.2 
μmol) and TBAF (1M in THF, 0.32 mL, 0.32 mmol) in 
THF (6 mL). Following the work-up, isopropyl 1H-
indazole-3-carboxylate 212 was isolated as a white solid with no further 
purification required (12.8 mg, 79%), m.p. 127-130 ºC, (Lit. value not reported). 
δH(CDCl3, 400 MHz): 1.47 [6H, d, J 6.3, CH(CH3)2], 5.45 [1H, sept, J 6.3, 
CH(CH3)2], 7.29-7.36 (1H, m, ArCH), 7.46 (1H, ddd, J 8.3, 6.9, 1.1, ArCH), 7.72 
(1H, d, J 9.1, ArCH), 8.22 (1H, d, J 8.2, ArCH), 11.87 (1H, br s, NH); δC(CDCl3, 
100 MHz): 22.1 (2 × CH3), 68.8 [C(CH3)2], 111.1 (ArCH), 121.9 (ArCH), 123.2 
(ArCH), 122.4 (ArCq), 127.2 (ArCH), 137.0 (C=N), 141.4 (ArCN), 162.6 (C=O); 
max (KBr)/cm-1 3260, 2980, 1715, 1472, 1104; m/z (ESI-) 203 [M - H]- (100%), 
204 [M+] (18); HRMS (ESI+): exact mass calculated for C11H13N2O2 [M + H]+ 
205.0977. Found 205.0970. Compound reported in literature without spectral 
details.60 
 
t-Butyl 1H-indazole-3-carboxylate 213  
The title compound was prepared in the same manner as 
propyl 1H-indazole-3-carboxylate 223 using t-butyl 1-
acetyl 1H-indazole-3-carboxylate 106 (20 mg, 76.5 μmol) 
and TBAF (1M in THF, 0.306 mmol, 0.31 mL) in THF (6 
mL). Following the work-up, t-butyl 1H-indazole-3-
carboxylate 213 was isolated as a white solid with no further purification required 
(14.0 mg, 84%), m.p. 137-139 ºC, (Lit. value not reported). δH(CDCl3, 400 MHz): 
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1.71 [9H, s, (CH3)3], 7.29-7.35 (1H, m, ArCH), 7.45 (1H, t, J 7.5, ArCH), 7.57 
(1H, d, J 8.4, ArCH), 8.21 (1H, d, J 8.1, ArCH), 10.61 (1H, br s, NH); δC(CDCl3, 
100 MHz): 28.4 (3 × CH3), 82.0 (ArCH), 122.2 (ArCH), 123.1 (ArCH), 127.3 
(ArCH), (ArCq), (ArCN), (C=N) and (C=O) not detected; max (KBr)/cm-1 3269, 
2954, 1722, 1467, 1141; m/z (ESI+) 241 [M + Na]+ (100%), 242 (15). Spectral 
details are in agreement with those reported in the literature.53 
 
sec-Butyl 1H-indazole-3-carboxylate 214  
The title compound was prepared in the same manner 
as propyl 1H-indazole-3-carboxylate 223 using sec-
butyl 1-acetyl 1H-indazole-3-carboxylate 107 (20 mg, 
76.8 μmol) and TBAF (1M in THF, 0.3 mmol, 0.3 mL) 
in THF (6 mL). Following the work-up, sec-butyl 1H-
indazole-3-carboxylate 214 was isolated as a yellow 
solid with no further purification required  (8 mg, 51%), m.p. 115-117 ºC.  δH 
(CDCl3, 400 MHz):  1.04 (3H, t, J 7.5, CH3),  1.45 (3H, d, J 6.3, CH3), 1.70-1.93 
(2H, m, CH2), 5.27-5.36 (1H, m, OCH), 7.29-7.35 (1H, m, ArCH), 7.46 (1H, ddd, 
J 8.3, 7.0, 1.0,  ArCH), 7.78 (1H, d, J 8.5, ArCH), 8.20 (1H, d, J 8.2, ArCH), 12.47 
(1H, br s, NH); δC(CDCl3, 100 MHz): 9.9 (CH3), 19.8 (CH3), 29.1 (CH2), 73.3 
(CH), 111.4 (ArCH), 121.8 (ArCH), 122.3 (ArCq), 123.1 (ArCH), 127.1 (ArCH),  
136.9 (C=N), 141.5 (ArCN), 162.9 (C=O); max (KBr)/cm-1: 3264, 2972, 2934, 
1717, 1622, 1471, 1151; m/z (ESI+) 219 [M + H]+ (3%), 186 (100); HRMS (ESI)+: 
Exact mass calculated for C12H15N2O2 [M + H]+ 219.1134.  Found 219.1136.  
 
Pentyl 1H-indazole-3-carboxylate 215  
The title compound was prepared in the same 
manner as propyl 1H-indazole-3-carboxylate 223 
using pentyl 1-acetyl 1H-indazole-3-carboxylate 
108 (73 μmol, 20 mg) and TBAF (1M in THF, 
0.03 mmol, 0.03 mL) in THF (6 mL). Following 
the work-up, the residue was purified using column chromatography on silica gel 
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using hexane:ethyl acetate (3:1-1:3) to yield pentyl 1H-indazole-3-carboxylate 
215 as a yellow solid (10.5 mg, 62%), m.p. 76-79 ºC. δH(CDCl3, 400 MHz): 0.92 
(3H, t, J 7.2, CH2CH3), 1.35-1.50 (4H, m, 2 × CH2), 1.81-1.90 (2H, m, CH2), 4.50 
(2H, t, J 6.8, OCH2), 7.33 (1H, ddd J 7.9, 6.9, 0.8, ArCH), 7.46 (1H, ddd, J 8.4, 
6.9, 1.1, ArCH), 7.77 (1H, d, J 8.5, ArCH), 8.21 (1H, td, J 8.5, 0.9, ArCH), 12.37 
(1H, br s, NH); δC(CDCl3, 100 MHz): 13.9 (CH3), 22.4 (CH2), 28.2 (CH2), 28.5 
(CH2), 65.3 (OCH2), 111.3 (ArCH), 121.8 (ArCH), 122.4 (ArCq), 123.2 (ArCH), 
127.2 (ArCH), 136.6 (ArCN), 141.4 (C=N), 163.2 (C=O); max (KBr)/cm-1 3283, 
2960, 1718, 1670, 1624, 1476, 1147; m/z (ESI-) 231 [M - H]- (10%), 149 (20); 
HRMS (ESI+): exact mass calculated for C13H17N2O2 [M + H]+ 233.1290. Found 
233.1280. 
 
Note: The 1H NMR spectrum showed the presence of 2% unreacted starting 
material after chromatography. 
 
Isopentyl 1H-indazole-3-carboxylate 216  
The title compound was prepared in the same 
manner as propyl 1H-indazole-3-carboxylate 223 
using isopentyl 1-acetyl 1H-indazole-3-
carboxylate 109 and and TBAF (1M in THF, 0.23 
mmol, 0.23 mL) in THF (6 mL). Following the 
work-up, isopentyl 1H-indazole-3-carboxylate 216 was isolated as a yellow solid 
with no further purification required (8.8 mg, 52%) m.p. 68-70 °C.  δH(CDCl3, 400 
MHz): 1.00 (6H, d, J 6.4, 2 × CH3), 1.70-1.90 [3H, m, containing OCH2CH2 and 
CH(CH3)2], 4.52 (2H, t, J 6.8, OCH2), 7.38 (1H, t, J 7.6, ArCH), 7.60 (1H, t, J 7.6, 
ArCH), 7.67 (1H, d, J 8.4, ArCH), 8.22 (1H, d, J 8.2, ArCH), 11.48 (1H, br d, 
NH); δC(CDCl3, 100 MHz): 22.5 (2 × CH3), 25.2 (CH), 37.5 (CH2), 63.8 (OCH2), 
110.7 (ArCH), 121.9 (ArCH), 122.5 (ArCq), 123.3 (ArCH), 127.4 (ArCH), 136.9 
(C=N), 141.2 (ArCN), 163.0 (C=O); max (KBr)/cm-1 2959, 1721, 1472, 1148; m/z 
(ESI-) 231 [M - H]- (50%), 232 [M+] (8); HRMS (ESI+): exact mass calculated for 
C13H17N2O2 [M + H]+ 233.1290. Found 233.1283. 
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Benzyl 1H-indazole-3-carboxylate 217 
The title compound was prepared in the same manner 
as propyl 1H-indazole-3-carboxylate 223 using 
benzyl 1-acetyl 1H-indazole-3-carboxylate (10 mg, 
0.034 mmol) 110 and TBAF (1M in THF, 0.12 mmol, 
0.12 mL) in THF (4 mL). Following the work-up, 
benzyl 1H-indazole-3-carboxylate 217 was isolated as a yellow solid with no 
further purification required (4 mg, 47%), m.p. 136-138 ºC, (Lit. value not 
reported).  δH(CDCl3, 400 MHz): 5.54 (2H, s, OCH2), 7.24-7.60 (7H, m, 5 × ArCH 
phenyl and 2 × ArCH indazole), 7.71 (1H, d, J 8.5, ArCH), 8.17 (1H, d, J 8.2, 
ArCH), 12.51 (1H, br s, NH); δC(CDCl3, 100 MHz): 66.8 (OCH2C6H5), 111.2 
(ArCH indazole), 121.7 (ArCH indazole), 123.4 (ArCq indazole), 123.3 (ArCH 
indazole), 127.3 (ArCH indazole), 128.4 (ArCH benzyl), 128.4 (2 × ArCH 
benzyl), 128.7 (2 × ArCH benzyl), 135.8 (Cq) benzyl, 136.3 (C=N), 141.4 (ArCN), 
162.9 (C=O); max (KBr)/cm-1 3256, 2924, 1723, 1470, 1146; m/z (ESI+) 253 [M 
+ H]+ (8%), 242 (100). Spectral details are in agreement with those reported in the 
literature.61 
 
2-Ethylbutyl 1H-indazole-3-carboxylate 218  
The title compound was prepared in the same manner 
as propyl 1H-indazole-3-carboxylate 223 using 2-
ethylbutyl 1-acetyl 1H-indazole-3-carboxylate 111 
(20 mg, 69.2 μmol) and TBAF (1M in THF, 0.277 
mmol, 0.28 mL) in THF (6 mL). Following the work-
up, 2-ethylbutyl 1H-indazole-3-carboxylate 218 was isolated as a low melting 
white solid with no further purification required (87%, 13 mg). δH(CDCl3, 400 
MHz): 0.98 (6H, t, J 7.5, 2 × CH3), 1.52 (4H, m, 2 × CH2), 1.78 (1H, td, J 12.4, 
6.2, CH), 4.42 (2H, d, J 5.9, OCH2), 7.34 (1H, ddd, J 7.9, 6.9, 0.9, ArCH), 7.46 
(1H, ddd, J 8.4, 6.9, 1.1, ArCH), 7.68 (1H, dd, J 8.4, 0.8, ArCH), 8.2 (1H, td, J 
8.2, 1.0, ArCH), 11.43 (1H, bs, NH); δC(CDCl3, 100 MHz): 11.1 (2 × CH3), 23.5 
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123.3 (ArCH), 127.3 (ArCH), 137.0 (C=N), 141.3 (ArCN), 163.1 (C=O); υmax 
(film)/cm-1 2956, 1728, 1711, 1255; m/z (ESI-) 245 [M - H]- (50%), 246 (8); 
HRMS (ESI)+: Exact mass calculated for C14H19N2O2 [M + H]+ 247.1447.  Found 
247.1436. 
 
Note: The 1H NMR spectrum showed the presence of 4% N-aryl by-product from 
the 2-ethylbutyl 1-acetyl 1H-indazole-3-carboxylate 111 starting material. 
 
2-Ethylhexyl 1H-indazole-3-carboxylate 219  
The title compound was prepared in the same 
manner as propyl 1H-indazole-3-carboxylate 223 
using 2-ethylhexyl 1-acetyl-1H-indazole-3-
carboxylate 112 (63.2 μmol, 20 mg) and TBAF 
(1M in THF, 0.25 mmol, 0.25 mL) was stirred in 
THF (6 mL). Following the work-up, 2-ethylhexyl 
1H-indazole-3-carboxylate 219 was isolated as a yellow oil with no further 
purification required (51%, 10 mg).  δH (CDCl3, 400 MHz):  0.88-1.0 [6H, m, 
containing 0.90 (3H, t, J 7.1, CH3) and 0.97 (3H, t, J 7.5, CH3)], 1.29-1.60 (8H, 
m, 4 × CH2), 1.82 (1H, td, J 12.3, 6.1, CH), 4.43 (2H, dd, J 5.8, 2.5, OCH2), 7.34 
(1H, ddd, J 8.0, 6.9, 0.8, ArCH), 7.44-7.49 (1H, m, ArCH), 7.75 (d, J 8.5, ArCH), 
8.2 (dd, J 8.2, 0.8, ArCH), 11.99 (1H, s, NH); δC(CDCl3, 100 MHz): 11.0 (CH3), 
14.0 (CH3), 23.0 (CH2), 24.0 (CH2), 29.0 (CH2), 30.5 (CH2), 39.0 (CH), 67.5 
(OCH2), 111.1 (ArCH), 121.8 (ArCH), 122.4 (ArCq), 123.2 (ArCH), 127.3 
(ArCH), 136.8 (C=N), 141.4 (ArCN), 163.3 (C=O); max (KBr)/cm-1 2957, 2928, 
1722, 1471, 1148; m/z (ESI+) 275 [M + H]+ (10%), 298 (20), 297 (100); HRMS 
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Decyl 1H-indazole-3-carboxylate 220 
The title compound was prepared in 
the same manner as propyl 1H-
indazole-3-carboxylate 223 using 
decyl 1-acetyl-1H-indazole-3-
carboxylate 113 (20 mg, 58.06 μmol) 
and TBAF (1M in THF, 0.23 mmol, 0.23 mL) in THF (6 mL). Following the work-
up, decyl 1H-indazole-3-carboxylate 220 was isolated as a low melting solid with 
no further purification required (12 mg, 72%). δH(CDCl3, 400 MHz): 0.87 (3H, t, 
J 6.9, CH3), 1.24-1.53 (14H, m, 7 × CH2), 1.81-1.90 (2H, m, CH2), 4.48 (2H, t, J 
6.8, OCH2), 7.33 (1H, ddd, J 7.9, 6.9, 0.8, ArCH), 7.45 (1H, ddd, J 8.3, 6.9, 1.1  
ArCH), 7.65 (1H, d, J 8.5, ArCH), 8.21 (1H, td, J 8.2, 0.9, ArCH), 11.99 (1H, br 
s, NH); δC(CDCl3, 75.5 MHz): 14.1 (CH3), 22.7 (CH2), 26.0 (CH2), 28.8 (CH2), 
29.3 (CH2), 29.3 (CH2), 29.5 (CH2), 29.5 (CH2), 31.9 (CH2), 65.3 (OCH2), 111.23 
(ArCH), 121.8 (ArCH), 122.4 (ArCq), 123.2 (ArCH), 127.2 (ArCH), 136.6 (C=N), 
141.4 (ArCN), 163.2 (C=O); max (KBr)/cm-1 1718, 1474, 1232, 1147; m/z (ESI-) 
301 [M - H]- (20%), 302 (5), 277 (100); HRMS (ESI+): exact mass calculated for 
C18H27N2O2 [M + H]+ 303.2073. Found 303.2063.  
 
Note: The 1H NMR spectrum showed the presence of 4% N-aryl by-product from 
the decyl 1-acetyl-1H-indazole-3-carboxylate 113 starting material. 
 
Undec-10-en-1-yl 1H-indazole-3-carboxylate 221  
The title compound was 
prepared in the same manner as 
propyl 1H-indazole-3-
carboxylate 223 using undec-10-
en-1-yl 1-acetyl 1H-indazole-3-
carboxylate (15 mg, 0.04 mmol) 126 and TBAF (1M in THF, 0.16 mmol, 0.16 
mL) in THF (6 mL). Following the work-up, the residue was purified by column 
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chromatography on silica gel using hexane:ethyl acetate (3:1-1:3) to isolate undec-
10-en-1-yl 1H-indazole-3-carboxylate 221 as a yellow oil (8 mg, 62%). δH(CDCl3, 
400 MHz): 1.25-1.53 (12H, m, 6 × CH2), 1.82-1.90 (2H, m, CH2), 2.03 (2H, dd, J 
13.8, 7.2, CH2), 4.48 (2H, t, J 6.8, OCH2), 4.90-5.03 (2H, m, CH=CH2), 5.81 (1H, 
m, CH=CH2), 7.31-7.37 (1H, m, ArCH), 7.47 (1H, dd, J 8.2, 7.2,  ArCH), 7.67 
(1H, d, J 8.4, ArCH), 8.23 (1H, d, J 8.2, ArCH), 11.50 (1H, br s, NH); δC(CDCl3, 
100 MHz): 26.0 (CH2), 28.8, (CH2), 28.9 (CH2), 29.1 (CH2), 29.3 (CH2), 29.4 
(CH2), 29.5 (CH2), 33.8 (CH2), 65.3 (OCH2), 110.7 (ArCH), 114.1 (CH2) alkene, 
121.9 (ArCH), 122.5 (ArCq), 123.3 (ArCH), 127.4 (ArCH), 136.6 (C=N), 139.2 
(CH) alkene, 141.4 (ArCN), 163.0 (C=O); max (film)/cm-1 3193, 2926, 2855, 
1724, 1471, 1299, 1143; m/z (ESI-) 313 [M - H]- (100%), 314 (22); HRMS (ESI)+: 
Exact mass calculated for C19H27N2O2 [M + H]+ 315.2073.  Found 315.2058. 
 
Note:  The undec-10-en-1-yl 1-acetyl 1H-indazole-3-carboxylate 223 starting 
material contained trace amounts of the N-arylated by-product which was isolated 
here as a yellow oil (1 mg).  
 
Undec-10-en-1-yl 1-phenyl 1H-indazole-3-carboxylate 226 
δH(CDCl3, 400 MHz): 1.25-1.40 
(12H, m, 6 × CH2), 1.84-1.92 (2H, m, 
CH2), 2.00-2.07 (2H, m, CH2), 4.49 
(2H, t, J 6.9, OCH2), 4.90-5.03 (2H, 
m, CH=CH2), 5.75-5.85 (1H, m, 
CH=CH2), 7.31-7.59 (5H, m, 5 × 
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2-(Methacryloyloxy)ethyl 1H-indazole-3-carboxylate 222  
The title compound was prepared in the same 
manner as propyl 1H-indazole-3-carboxylate 
223 using  2-(methacryloyloxy)ethyl 1-acetyl 
1H-indazole-3-carboxylate 125 (20 mg, 58 
μmol)  and TBAF (1M in THF, 0.23 mmol, 0.23 
mL) in THF (6 mL). Following the work-up, the 
residue was purified by column chromatography 
on silica gel using hexane:ethyl acetate (3:1-1:3) to isolate 2-
(methacryloyloxy)ethyl 1H-indazole-3-carboxylate 222 as a yellow solid (12 mg, 
72%), m.p. 69-75 ºC. δH(CDCl3, 400 MHz): 1.95 (3H, s, CH3), 4.59 (2H, dd, J 5.7, 
3.8, OCH2), 4.74-4.77 (2H, m, OCH2), 5.58 (1H, s, one of alkene CH2), 6.16 (1H, 
s, one of alkene CH2), 7.33 (1H, t, J 7.6, ArCH), 7.48 (1H, t, J 7.6, ArCH), 7.72 
(1H, d, J 8.4, ArCH), 8.20 (1H, d, J 8.2, ArCH), 11.98 (1H, br s, NH); δC(CDCl3, 
100 MHz): 18.3 (CH3), 62.5 (OCH2), 62.7 (OCH2), 111.0 (ArCH), 121.8 (ArCH), 
122.5 (ArCq), 123.4 (ArCH), 126.3 (CH2 alkene), 127.5 (ArCH), 135.9 (Cq) 
alkene, 136.2 (C=N), 141.3 (ArCN), 162.7 (C=O) ester, 167.2 (C=O) methacrylate 
ester; max (KBr)/cm-1 3270, 2957, 1723, 1147; m/z (ESI+) 275 [M + H]+ (72%), 
196 (40), 113 (100); HRMS (ESI+): exact mass calculated for C14H15O4N2 [M + 
H]+ 275.1032. Found 275.1035. 
 
Note 1: The 1H NMR spectrum still showed the presence of 6% 1-acyl starting 
material after chromatography  
Note 2:  The 2-(methacryloyloxy)ethyl 1-acetyl 1H-indazole-3-carboxylate 
starting material contained 10% of the N-arylated by-product 227 which was 
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2-(Methacryloyloxy)ethyl 1-phenyl-1H-indazole-3-carboxylate 227 
δH(CDCl3, 400 MHz): 1.97 (3H, s, CH3), 4.57-
4.61 (2H, m, OCH2), 4.74-4.78 (2H, m, OCH2), 
5.60 (1H, s, one of alkene CH2), 6.18 (1H, s, one 
of alkene CH2), 7.34-7.67 (5H, m, 5 × ArCH), 
7.70-7.81 (3H, m, 3 × ArCH),  8.28 (1H, d, J 8.1, 
ArCH); δC(CDCl3, 100 MHz): 18.3 (CH3), 62.5 
(OCH2), 62.6 (OCH2), 123.9 (2 × ArCH) and 
129.6 (2 × ArCH) were the only characteristic 
signals visible. 
 
Amide side chain 
N,N-Dimethyl-1H-indazole-3-carboxamide 228  
The title compound was prepared in the same manner as 
propyl 1H-indazole-3-carboxylate 223 using N,N-
dimethyl 1H-indazole-3-carboxamide 140 (20 mg, 0.09 
mmol) and TBAF (1M in THF, 0.35 mmol, 0.35 mL) in 
THF (6 mL). Following the work-up, N,N-dimethyl-1H-
indazole-3-carboxamide 228 was isolated as a white solid with no further 
purification required (8 mg, 49%), m.p. 186-189 ºC, (Lit.62 187-189 ºC). 
δH(CDCl3, 400 MHz): 3.21 (3H, s, NCH3), 3.41 (3H, s, NCH3), 7.26 (1H, t, J 7.7, 
ArCH), 7.42 (1H, t, J 7.5, ArCH), 7.49 (1H, dd, J 8.4, 0.9, ArCH), 8.16 (1H, td, J 
8.2, 0.9, ArCH), 10.23 (NH); δC(CDCl3, 100 MHz): 39.0 (2 × NCH3), 109.5 
(ArCH),  122.4 (ArCH), 122.48 (ArCq), 122.50 (ArCH), 127.3 (ArCH), 140.4 
(C=N), 142.2 (ArCN), 164.1 (C=O); m/z (ESI+) 212 [M + Na]+ (100%), 190 (10); 
HRMS (ESI+): exact mass calculated for C10H12O2N3 [M + H]+ 190.0980. Found 
190.0979; max (KBr)/cm-1 3430, 2978, 2934, 1629, 1381. Spectral details are in 
agreement with those reported in the literature.62 
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N,N-Diethyl-1H-indazole-3-carboxamide 229  
The title compound was prepared in the same manner as 
propyl 1H-indazole-3-carboxylate 223 using N,N-
diethyl 1-acetyl 1H-indazole-3-carboxamide 141 (20 
mg, 0.08 mmol) and TBAF (1M in THF, 0.31 mmol, 
0.31 mL) in THF (6 mL). Following the work-up, N,N-
diethyl-1H-indazole-3-carboxamide 229 isolated as a white solid with no further 
purification required (10 mg, 55%), m.p. 170-172 ºC, (Lit.63 172.5-174 ˚C). 
δH(CDCl3, 400 MHz): 1.27 (6H, t, J 7.0, 2 × CH3), 3.64 (2H, q, J 6.6, CH2), 3.79 
(2H, q, J 6.7, CH2) 7.26 (1H, dd, J 6.8, 1.0, ArCH),  7.39-7.44 (1H, m, ArCH), 
7.49 (1H, d, J 8.4,  ArCH), 8.17 (1H, d, J 8.2, ArCH), 10.16 (1H, br s, NH); 
δC(CDCl3, 100 MHz): 13.0 (CH3), 14.7 (CH3), 40.8 (NCH2), 43.1 (NCH2), 109.4 
(ArCH), 122.2 (ArCH). 122.5 (ArCq), 122.6 (ArCH), 127.2 (ArCH), 139.2 (C=N), 
140.4 (ArCN), 163.4 (C=O); max (KBr)/cm-1 3148, 2850, 1684, 1597, 1579, 1495, 
1242; m/z (ESI+) 256 [M + Na]+ (12%).Spectral details are in agreement with those 
reported in the literature.63 
 
Methylene dioxy substituted aryl ring 
sec-Butyl 1H-[1,3]dioxolo[4,5-f] indazole-3-carboxylate 230 
The title compound was prepared in the same manner 
as propyl 1H-indazole-3-carboxylate 223 using sec-
butyl 1-acetyl-1H-[1,3]dioxolo[4,5-f]indazole-3-
carboxylate 156 (20 mg, 0.07 mmol) and TBAF (1M 
in THF, 0.26 mmol, 0.26 mL) in THF (6 mL). 
Following the work-up, sec-butyl 1H-[1,3]dioxolo[4,5-f] indazole-3-carboxylate 
230 was isolated with no further purification required (12 mg, 67%), m.p. 92-93 
ºC. δH(CDCl3, 400 MHz): 1.02 (3H, t, J 7.5, CH3),  1.42 (3H, d, J 6.4, CH3), 1.70-
1.89 (2H, m, CH2), 5.20-5.30 (1H, m, J 6.9, OCH), 6.05 (2H, s, OCH2O), 7.07 
(1H, s, ArCH), 7.45 (1H, s, ArCH), 11.76 (1H, br s, NH); δC(CDCl3, 100 MHz): 
9.9 (CH2CH3),  19.7 (CHCH3), 29.0 (CH2), 73.2 (OCH), 90.6 (ArCH), 98.5 
(ArCH), 101.7 (OCH2O), 117.8 (ArCq), 135.9 (C=N), 138.8 (ArCN), 146.4 
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(ArCOCH2), 149.4 (ArCOCH2), 162.6 (C=O); max (film)/cm-1 3455, 2959, 1736, 
1485; m/z (ESI+) 285 [M + Na]+ (10%); HRMS (ESI+): exact mass calculated for 
C13H15N2O4 [M + H]+ 262.1032. Found 263.1024. 
 
Isopentyl 1H-[1,3]dioxolo[4,5-f]indazole-3-carboxylate 231  
The title compound was prepared in the same 
manner as propyl 1H-indazole-3-carboxylate 223 
using isopentyl 1-acetyl-1H-[1,3]dioxolo[4,5-
f]indazole-3-carboxylate 24 (20 mg, 0.06 mmol) 
and TBAF (1M in THF, 0.25 mmol, 0.25 mL) in 
THF (6 mL). Following the work-up, isopentyl 1H-[1,3]dioxolo[4,5-f]indazole-3-
carboxylate 231 was isolated as a white solid with no further purification required 
(13 mg, 78%), m.p. 90-91 ºC. δH(CDCl3, 400 MHz): 0.99 (6H, d, J 8.5, 2 × CH3), 
1.65-1.90 [3H, m, containing 1.74 (2H, dd, OCH2CH2) and CH(CH3)2], 4.49 (2H, 
t, J 6.8, OCH2), 6.05 (2H, s, OCH2O), 7.07 (1H, s, ArCH), 7.44 (1H, s, ArCH) 
11.41 (1H, br s, NH); δC(CDCl3, 100 MHz): 22.5 (2 × CH3), 25.2 (CH), 37.5 
(CH2), 63.7 (OCH2), 90.5 (ArCH), 98.4 (ArCH), 101.7 (OCH2O), 117.8 (ArCq), 
138.7 (C=N), 138.8 (ArCN), 146.4 (ArCOCH2), 149.5 (ArCOCH2), 163.0 (C=O); 
max (film)/cm-1 3407, 2956, 1732, 1484, 1262; m/z (ESI+) 277 [M + H]+ (74%), 
243 (4);  HRMS (ESI)+: Exact mass calculated for C14H17N2O4 [M + H]+ 277.1188. 
Found 277.1184. 
 
2-Ethylbutyl 1H-[1,3]dioxolo[4,5-f]indazole-3-carboxylate 232  
The title compound was prepared in the same 
manner as propyl 1H-indazole-3-carboxylate 223 
using 2-ethylbutyl 1-acetyl-1H-[1,3]dioxolo[4,5-
f]indazole-3-carboxylate 157 (20 mg, 0.06 mmol) 
and TBAF (1M in THF, 0.24 mmol, 0.24 mL) in 
THF (6 mL). Following the work-up, 2-ethylbutyl 1H-[1,3]dioxolo[4,5-
f]indazole-3-carboxylate 232 was isolated as a white solid with no further 
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(6H, t, J 7.5, 2 × CH3), 1.46-1.54 (4H, m, 2 × CH2), 1.75 [1H, td, J 12.4, 6.2, 
CH(CH2)2], 4.40 (2H, d, J 5.8, OCH2), 6.05 (2H, s, OCH2O), 7.12 (1H, s, ArCH), 
7.42 (1H, s, ArCH), NH signal not visible; δC(CDCl3, 100 MHz): 11.1 (2 × CH3), 
23.5 (2 × CH2), 40.5 (CH), 67.0 (OCH2), 90.8 (ArCH), 98.3 (ArCH), 101.7 
(OCH2O), 117.7 (ArCq), 135.6 (C=N), 138.8 (ArCN), 146.4 (ArCOCH2), 149.4 
(ArCOCH2), 163.1 (C=O); max (KBr)/cm-1 3429, 2955, 2934, 2861, 1729, 1137; 
m/z (ESI+) 291 [M + H]+ (5%), 242 (100); HRMS (ESI)+: Exact mass calculated 
for C15H19N2O4 [M + H]+ 291.1345.  Found 291.1341.  
 
2-Ethylhexyl 1H-[1,3]dioxolo[4,5-f]indazole-3-carboxylate 233  
The title compound was prepared in the 
same manner as propyl 1H-indazole-3-
carboxylate 223 using 2-ethylhexyl 1-acetyl-
1H-[1,3]dioxolo[4,5-f]indazole-3-
carboxylate 156 (20 mg, 0.06 mmol) and 
TBAF (1M in THF, 0.25 mmol, 0.25 mL) in 
THF (6 mL). Following the work-up, 2-ethylhexyl 1H-[1,3]dioxolo[4,5-
f]indazole-3-carboxylate 233 was isolated as a white solid with no further 
purification required (74%, 14 mg), m.p. 83-86 ºC. δH(CDCl3, 400 MHz) : 0.80-
1.00 [6H, m, containing 0.90 (3H, t, J 7.1, CH3) and 0.96 (3H, t, J 7.5, CH3)], 1.22-
1.90 [9H, m, containing 4 × CH2 and 1.80 (1H, td, J 12.3, 6.2, CH)], 4.38 (2H, dd, 
J 5.8, 2.7, OCH2), 6.06 (2H, s, OCH2O), 7.09 (1H, s, ArCH), 7.43 (1H, s, ArCH), 
11.74 (1H, br s, NH); δC(CDCl3, 100 MHz): 11.0 (CH3), 14.0 (CH3), 22.9 (CH2), 
23.9 (CH2), 28.9 (CH2), 30.5 (CH2), 38.9 (CH), 67.4 (OCH2), 90.7 (OCH2O), 98.3 
(ArCH),  101.7 (ArCH), 117.8 (ArCq), 136.4 (C=N), 138.8 (ArCN), 146.5 
(ArCOCH2), 149.5 (ArCOCH2), 163.0 (C=O) ester; max (KBr)/cm-1 3423, 2928, 
1727, 1463, 1138; m/z (ESI+) 319 [M + H]+ (100%), 277 (25);  HRMS (ESI)+: 
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Decyl 1H-[1,3]dioxolo[4,5-f]indazole-3-carboxylate 234  
The title compound was prepared in 
the same manner as propyl 1H-
indazole-3-carboxylate 223 using 
decyl 1-acetyl-1H-
[1,3]dioxolo[4,5-f]indazole-3-carboxylate 158 (20 mg, 0.05 mmol) and TBAF 
(1M in THF, 0.21 mmol, 0.21 mL) in THF (6 mL). Following the work-up, decyl 
1H-[1,3]dioxolo[4,5-f]indazole-3-carboxylate 234 was isolated as a white solid 
with no further purification required (15 mg, 88%), m.p. 104-105 ºC.  δH(CDCl3, 
400 MHz): 0.87 (3H, t, J 6.9, CH3), 1.20-1.32 (12H, m, 6 × CH2), 1.40-1.51 (2H, 
m, CH2), 1.79-1.87 (2H, m, CH2 ), 4.45 (2H, t, J 6.8, OCH2), 6.05 (2H, s, OCH2O), 
7.12 (1H, s, ArCH), 7.44 (1H, s, ArCH), 12.11 (1H, br s, NH); δC(CDCl3, 100 
MHz): 14.1 (CH2CH3), 22.7 (CH2), 26.0 (CH2), 28.8 (CH2), 29.3 (CH2), 29.5 
(CH2), 29.52 (2 × CH2), 31.9 (OCH2CH2), 65.2 (OCH2), 90.7 (ArCH),  98.4 
(ArCH), 101.7 (OCH2O), 117.8 (ArCq), 135.7 (C=N), 138.7 (ArCN), 146.4 
(ArCOCH2), 149.5 (ArCOCH2), 163.0 (C=O); max (film)/cm-1 3382, 2956, 1732, 
1484, 1262; m/z (ESI+) 347 [M + H]+ (100%); HRMS (ESI)+: Exact mass 
calculated for C19H27N2O4[M + H]+ 347.1971.  Found 347.1971. 
 
Undec-10-en-1-yl 1H-[1,3]dioxolo[4,5-f]indazole-3-carboxylate 235  
The title compound was prepared 
in the same manner as propyl 1H-
indazole-3-carboxylate 223 using 
undec-10-en-1-yl 1-acetyl-1H-
[1,3]dioxolo[4,5-f]indazole-3-carboxylate 159 (20 mg, 0.08 mmol) and TBAF in 
THF 1M 0.31 mmol, 0.31 mL) in THF (6 mL). Following the work-up, undec-10-
en-1-yl 1H-[1,3]dioxolo[4,5-f]indazole-3-carboxylate 235 was isolated as a cream 
solid with no further purification required (15 mg, 83%), m.p. 128-129 ºC.   
δH(CDCl3, 400 MHz): 1.26-1.50 (12H, m, 6 × CH2), 1.79-1.88 (2H, m, CH2 ), 2.03 
(2H, dd, J 13.9, 7.3, CH2), 4.43 (2H, t, J 6.8, OCH2), 4.95 (2H, m, CH=CH2), 5.81 
(1H, tdd, J  17.0, 10.2, 6.7, CH=CH2), 6.05 (2H, s, OCH2O), 6.99 (1H, s, ArCH), 
7.46 (1H, s, ArCH), NH signal not visible;  δC(CDCl3, 100 MHz): 26.0 (CH2), 28.8 
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(CH2), 28.9 (CH2), 29.1 (CH2), 29.3 (CH2), 29.4 (CH2), 29.4 (CH2), 33.8 (CH2), 
65.2 (OCH2), 90.2 (ArCH), 98.5 (ArCH), 101.8  (OCH2O), 114.1 (CH2) alkene, 
139.2 (CH) alkene, 146.5 (ArCOCH2), 149.6 (ArCOCH2), 162.7 (C=O), ArCq, 
ArCN and C=N not detected; max (KBr)/cm-1 3193, 2926, 2855, 1724, 1471, 1299, 
1143; m/z (ESI+) 359 [M + H]+ (50%); HRMS (ESI)+: Exact mass calculated for 
C20H27N2O4[M + H]+ 359.1971.  Found 359.1962. 
 
Dimethyl substituted aryl ring 
Isopropyl 5,6-dimethyl-1H-indazole-3-carboxylate 236 
The title compound was prepared in the same manner 
as propyl 1H-indazole-3-carboxylate 223 using 
isopropyl 1-acetyl-1H-5,6-dimethylindazole-3-
carboxylate 168 (20 mg, 0.07 mmol) and TBAF (1M 
in THF, 0.29 mL, 0.29 mmol) in THF (6 mL). 
Following the work-up, isopropyl 5,6-dimethyl-1H-indazole-3-carboxylate 236 
was isolated as a yellow solid with no further purification required (69%, 11 mg), 
m.p. 148-150 ºC. δH(CDCl3, 400 MHz): 1.46 (6H, t, J 6.1, 2 × CH3), 2.40 (6H, s, 
2 × ArCH3), 5.38-5.46 (1H, m, OCH), 7.40 (1H, s, ArCH), 7.94 (1H, s, ArCH), 
11.38 (1H, br s, NH); δC(CDCl3, 100 MHz): 20.4 (ArCH3), 20.9 (ArCH3), 22.1 (2 
× CH3), 68.6 (CH), 110.4 (ArCH), 121.1 (ArCH), 121.3 (ArCq), 132.8 (ArCCH3), 
136.2 (C=N), 137.4 (ArCCH3), 140.7 (ArCN), 162.8 (C=O); max (KBr)/cm-1 
3267, 2978, 1718, 1105; m/z (ESI+) 255 [M + Na]+ (80%), 256 (20); HRMS (ESI)+: 
Exact mass calculated for C13H17N2O2[M + H]+ 233.1290.  Found 233.1282. 
 
Decyl 5,6-dimethyl-1H-indazole-3-carboxylate 237  
The title compound was prepared 
in the same manner as propyl 1H-
indazole-3-carboxylate 223 using 
decyl 1-acetyl-1H-5,6-dimethyl 
indazole-3-carboxylate 169 (20 
mg, 0.07 mmol) and TBAF (1M in THF, 0.29 mL, 0.29 mmol) in THF (6 mL). 
Following the work-up, decyl 5,6-dimethyl-1H-indazole-3-carboxylate 237 was 
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isolated as a white solid with no further purification required (57%, 13 mg), m.p. 
79-80 ºC. δH(CDCl3, 400 MHz): 0.87 (3H, t, J 6.6, CH3), 1.22-1.30 (12H, m, 6 × 
CH2), 1.41-1.51 (2H, m, CH2), 1.78-1.88 (2H, m, CH2), 2.40 (2 × ArCH3), 4.47 
(2H, t, J 6.8, OCH2), 7.47 (1H, s, ArCH), 7.93 (1H, s, ArCH), 12.18 (1H, br s, 
NH); δC(CDCl3, 75.5 MHz): 14.1 (CH2CH3), 20.4 (ArCH3), 20.9 (ArCH3), 22.7 
(CH2), 26.1 (CH2), 28.8 (CH2), 29.3 (2 × CH2), 29.5 (2 × CH2), 31.9 (OCH2CH2), 
65.1 (OCH2), 110.8 (ArCH), 120.9 (ArCH), 121.3 (ArCq), 132.8 (ArCCH3), 135.7 
(C=N), 137.3 (ArCCH3), 140.8  (ArCN), 163.4 (C=O); max (KBr)/cm-1 3382, 
2956, 1732, 1484, 1213; m/z (ESI+) 353 [M + Na]+ (100%), 304 (30); HRMS 
(ESI)+: Exact mass calculated for C20H31N2O2 [M + H]+ 331.2386.  Found 
331.2374. 
 
Difluoro substituted aryl ring 
Isopropyl 5,6-difluoro-1H-indazole-3-carboxylate 238  
The title compound was prepared in the same manner 
as propyl 1H-indazole-3-carboxylate 223 using 
isopropyl 1-acetyl-1H-5,6-difluoroindazole-3-
carboxylate 179 (20 mg, 0.07 mmol) and TBAF (1M 
in THF, 0.29 mL, 0.29 mmol) in THF (6 mL). 
Following the work-up, isopropyl 5,6-difluoro-1H-indazole-3-carboxylate 238 
was isolated as a white solid with no further purification required (12 mg, 73%), 
m.p. 239-241 ºC. δH(CDCl3, 400 MHz): 1.51 (6H, t, J 6.2, 2 × CH3), 5.42-5.51 
(1H, m, CH), 7.66 (1H, dd, 1JHF 9.5, 1JHF 6.6, ArCH), 7.92 (1H, dd, 1JHF 9.0, 1JHF 
8.1, ArCH), 12.37 (1H, br s, NH); δC(CDCl3, 75.5 MHz): 22.1 (2 × CH3), 69.4 
(OCH), 99.2 (d, 1JHF 22.0, ArCH), 108.0 (d, 1JHF 18.8, ArCH), 117.7 (d, 1JHF 9.6, 
ArCq), [137.2 (d, 1JHF 6.9) and 137.3 (d, 1JHF 6.1), ArCN and C=N], 148.8 (d, 1JHF 
261.8, ArCF), 151.5 (d, 1JHF 251.1, ArCF), 162.2 (C=O); max (KBr)/cm-1 3212, 
1726, 1489, 1441, 1146; m/z (ESI-) 239 [M – H]- (100%), 240 (12); HRMS (ESI)+: 
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2-Ethylbutyl 5,6-difluoro-1H-indazole-3-carboxylate 239 
The title compound was prepared in the same 
manner as propyl 1H-indazole-3-carboxylate 223 
using 2-ethylbutyl 1-acetyl-1H-5,6-
difluoroindazole-3-carboxylate 183 (20 mg, 0.07 
mmol) and TBAF (1M in THF, 0.29 mL, 0.29 
mmol) in THF (6 mL). Following the work-up, 2-
ethylbutyl 5,6-difluoro-1H-indazole-3-carboxylate 239 was isolated with no 
further purification required as a white solid (14 mg, 71%), m.p. 195-197 ºC. 
δH(CDCl3, 400 MHz): 1.01 (6H, t, J 7.3, 2 × CH3), 1.49-1.59 (4H, m, 2 × CH2), 
1.78 (1H, dt, J 6.4, 12.1, CH), 4.50 (2H, d, J 5.6, OCH2), 7.84 (2H, m,  2 × ArCH), 
13.35 (1H, br s, NH); δC(CDCl3, 100 MHz): 11.1 (2 × CH3), 23.6 (2 × CH2), 40.7 
(CH), 67.5 (OCH2), 99.95 (d, 2JCF 22.6, ArCH), 107.5 (d, 2JCF 20.6, ArCH), 117.5 
(d, 3JCF 9.0, ArCq), 136.8 (d, 4JCF 5.9, C=N), 137.5 (d, 3JCF 11.0 ArCN), 149.0 (dd, 
1JCF 261.1, 2JCF 17.2, ArCF), 150.3 (dd, 1JCF 250.4, 2JCF 16.5, ArCF), 163.1 (C=O); 
max (KBr)/cm-1 3647, 2962, 1733, 1507, 1319, 1157; m/z (ESI-) 281 [M - H]- 
(100%), 113 (6); HRMS (ESI)+: Exact mass calculated for C14H17N2F2O2 [M + 
H]+ 283.1258.  Found 283.1251.  
 
5/6-Substituted aryl ring 
Methyl-5-methyl-1H-indazole-3-carboxylate 240 and methyl-6-methyl 1H-
indazole-3-carboxylate 241 1:1  
The title compounds were prepared in the same manner as propyl 1H-indazole-3-
carboxylate 223 using methyl-5/6-methyl-1-pentanoyl 1H-indazole-3-carboxylate 
193/194 (20 mg, 0.07 mmol) and TBAF (1M in THF, 0.29 mL, 0.29 mmol) in 
THF (6 mL). Following the work-up, the residue was purified using column 
chromatography on silica gel using hexane:ethyl acetate (3:1-1:3) as eluent and 
the 50:50 mixture of regioisomers were isolated as a white solid (8 mg, 62%), m.p. 
91-92 ºC. δC(CDCl3, 100 MHz): 21.5 and 22.0 (ArCH3), 52.0 (OCH3), 110.1 and 
110.6 (ArCH), 120.7 and 121.3 (ArCH), 120.8 and 122.9 (ArCq), 125.7 and 129.6 
(ArCH),  133.1 and 137.8 (ArCCH3), 135.7 and 140.0 (C=N), 136.3 and 141.9 
(ArCN), 163.4 and 163.5 (C=O); max (KBr)/cm-1 3269, 2954, 1722, 1467, 1141; 
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m/z (ESI+) 191 [M + H]+ (65%); HRMS (ESI+): exact mass calculated for 
C10H11N2O2 [M + H]+ 191.0821. Found 191.0814. 
 
Methyl-5-methyl-1H-indazole-3-carboxylate 240 
δH (CDCl3, 400MHz): 2.52 (3H, s, ArCH3),  4.05 or 
4.06 (3H, s, OCH3), 7.30 (1H, d, J 8.5, ArCH), 7.58 
(1H, d, J 8.6, ArCH),  8.09 (1H, d, J 8.4, ArCH), 11.7 
(1H, br s, NH). 
 
Methyl-6-methyl 1H-indazole-3-carboxylate 241 
δH (CDCl3, 400MHz): 2.52 (3H, s, ArCH3),  4.05 or 
4.06 (3H, s, OCH3) 7.17 (1H, d, J 8.4, ArCH), 7.44 
(1H, s, ArCH), 8.00 (1H, s, ArCH), 11.7 (1H, br s, 
NH). 
 
Ethyl 5-methyl-1H-indazole-3-carboxylate 242 and ethyl 6-methyl-1H-
indazole-3-carboxylate 243 
The title compounds were prepared in the same manner as propyl 1H-indazole-3-
carboxylate 223 using ethyl-5/6-methyl-1-butyryl 1H-indazole-3-carboxylate 
195/196 (20 mg, 0.07 mmol) and TBAF (1M in THF, 0.29 mL, 0.29 mmol) in 
THF (6 mL). Following the work-up, the 50:50 mixture of regioisomers were 
isolated as a yellow oil with no further purification required (11 mg, 80%). 
δC(CDCl3, 100 MHz): 14.4 (CH3CH2O), 21.6 and 21.9 (ArCH3), 61.0 (CH3CH2O), 
110.1 and 110.5 (ArCH), 120.8 and 121.4 (ArCH), 121.4 and 123.0 (ArCq), 125.6 
and 129.5 (ArCH), 133.0 and 137.8 (ArCCH3), 136.0 and 141.9 (C=N), 136.6 and 
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Ethyl 5-methyl-1H-indazole-3-carboxylate 242 
δH (CDCl3, 400MHz): 1.47 (3H, dt, J 7.0, 1.3, 
OCH2CH3), 2.51 (3H, s, ArCH3), 4.54 (2H, dq, J 3.7, 
7.1, OCH2CH3), 7.29 (1H, d, J 8.9, ArCH), 7.43 (1H, 
s, ArCH), 8.00 (1H, s, ArCH), 11.63 (1H, br s, NH). 
 
Ethyl 6-methyl-1H-indazole-3-carboxylate 243 
δH (CDCl3, 400MHz): 1.47 (3H, dt, J 7.0, 1.3, 
OCH2CH3), 2.51 (3H, s, ArCH3), 4.54 (2H, dq, J 
3.7, 7.1, OCH2CH3), 7.16 (1H, d, J 8.4, ArCH), 
7.57 (1H, d, J 8.6, ArCH), 8.08 (1H, d, J 8.3, 
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3.8 Alkylations of 1-H-indazole derivatives to yield N-1 and N-2 isomers64,65 
Pentyl 2-benzyl-2H-indazole-3-carboxylate 253  
A solution containing pentyl 1H-indazole-3-
carboxylate 215 (50 mg, 0.2 mmol), 
benzylbromide 339 (25 µL, 0.2 mmol) and 
potassium carbonate (55 mg, 0.4 mmol) in DMF 
(5 mL) was stirred under nitrogen at 80 ºC. After 8 
h, the reaction solution was diluted with brine (10 mL), extracted with methyl t-
butyl ether (3 × 10 mL), washed with water (3 × 10 mL), dried with MgSO4 and 
concentrated under reduced pressure to yield a residue which was further purified 
by column chromatography on silica gel using hexane:ethyl acetate (95:5) initially 
to yield pure N-2 benzylated isomer 253 (10 mg, 16%), m.p. 69-70 ºC and then 
hexane:ethyl acetate (70:30) to isolate pure N-1 benzylated isomer 252 (18 mg, 
28%) as a yellow oil. δH(CDCl3, 400 MHz): 0.93 (3H, t, J 7.1, CH3), 1.35-1.49 
(4H, m, 2 × CH2), 1.78-1.87 (2H, m, CH2), 4.40 (2H, t, J 6.7, OCH2), 6.12 (2H, s, 
benzyl CH2), 7.23-7.39 (7H, m, containing 5 × ArCH benzyl and 2 × ArCH of 
indazole), 7.82 (1H, dd, J 8.1, 0.9, ArCH), 8.02 (1H, td, J 8.4, 1.0, ArCH); 
δC(CDCl3, 100 MHz): 13.9 (CH3), 22.3 (CH2), 28.2 (CH2), 28.4 (CH2), 56.6 
(benzyl CH2), 65.2 (OCH2), 118.4 (ArCH), 121.5 (ArCH), 123.7 (ArCq indazole), 
123.8 (ArCq phenyl), 125.1 (ArCH), 126.4 (ArCH), 127.8 (2 × ArCH), 127.9 (p-
ArCH), 128.6 (2 × ArCH), 136.5 (ArCN), 147.7 (C=N), 160.3 (C=O); max 
(film)/cm-1 2957, 1709, 1465, 1206; HRMS (ESI+): exact mass calculated for 
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Pentyl 1-benzyl-1H-indazole-3-carboxylate 252  
δH(CDCl3, 400 MHz): 0.94 (3H, t. J 7.1, CH3), 
1.36-1.52 (4H, m, 2 × CH2), 1.84-1.92 (2H, m, 
CH2), 4.47 (2H, t, J 6.9, OCH2), 5.71 (2H, s, benzyl 
CH2), 7.20-7.38 (8H, m, containing 5 × ArCH 
benzyl and 3 × ArCH indazole), 8.21 (1H, d, J 8.1, 
ArCH); δC(CDCl3, 100 MHz): 14.0 (CH3), 22.4 
(CH2), 28.2 (CH2), 28.6 (CH2), 54.1 (benzyl CH2), 65.2 (OCH2), 110.1 (ArCH), 
122.4 (ArCH), 123.1 (ArCH), 124.0 (ArCq indazole), 126.9 (ArCH), 127.3 (2 × 
ArCH), 128.1 (p-ArCH), 128.8 (2 × ArCH), 135.4 (ArCq phenyl), 135.7 (ArCN), 
140.6 (C=N), 162.8 (C=O); max (film)/cm-1 2935, 2865, 1710, 1497, 1277, 1085; 
m/z (ESI+) 322 [M + H]+ (100%) 324 (22) 325 (4); HRMS (ESI+): exact mass 
calculated for C20H22N2O2 [M + H]+ 323.1760. Found 323.1758. 
 
Isopropyl 2-benzyl-2H-indazole-3-carboxylate 249  
Using the procedure described for pentyl 1-benzyl-1H-
indazole-3-carboxylate 252 and pentyl 2-benzyl-1H-
indazole-3-carboxylate 253, a solution containing 
isopropyl 1H-indazole-3-carboxylate 212 (52 mg, 0.25 
mmol), benzylbromide 339 (30 µL, 0.25 mmol) and 
potassium carbonate (69 mg, 0.5 mmol) in DMF (5 mL) 
was stirred for 8 h under nitrogen at 80 ºC. Following the work-up, the residue was 
further purified by column chromatography on silica gel using hexane:ethyl 
acetate (95:5) to yield pure N-2 benzylated isomer 249 as a yellow oil (17 mg, 
23%) followed by hexane:ethyl acetate (70:30) to isolate pure N-1 benzylated 
isomer 248 as a yellow solid (19 mg, 26%), m.p. 63-64 ºC. δH(CDCl3, 400 MHz): 
1.42 (6H, d, J 6.3, 2 × CH3), 5.27-5.38 (1H, m, OCH), 6.12 (2H, s, benzyl CH2), 
7.27-7.38 (7H, m, containing 5 × ArCH benzyl and 2 × ArCH indazole), 7.81 (1H, 
td, J 8.6, 0.9, ArCH, indazole), 8.03 (1H, td, J 8.4, 1.0, ArCH, indazole); 
δC(CDCl3, 100 MHz): 22.1 (2 × CH3), 56.5 (CH2 benzyl), 68.9 (OCH), 118.4 
(ArCH), 121.6 (ArCH), 125.0 (ArCH), 126.4 (ArCq indazole and ArCH), 127.7 (2 
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× ArCH), 127.9 (p-ArCH), 128.0 (2 × ArCH), 128.6 (Cq benzyl), 136.6 (C-N), 
147.7 (ArC=N), 159.7 (C=O);max (KBr)/cm-1 2981, 1707, 1465, 1081; m/z (ESI+) 
295 [M + H]+ (100%) 296 (20); HRMS (ESI+): exact mass calculated for 
C18H19N2O2 [M + H]+ 295.1447. Found 295.1447.  
 
Isopropyl 1-benzyl-1H-indazole-3-carboxylate 248   
δH(CDCl3, 400 MHz): 1.48 (6H, d, J 6.3, 2 × CH3), 5.38-
5.48 (1H, m, CH), 5.72 (2H, s, benzyl CH2), 7.20-7.38 
(8H, m, containing 5 × ArCH phenyl and 3 × ArCH 
indazole), 8.21 (1H, d, J 8.1, ArCH, indazole); δC(CDCl3, 
100 MHz):  22.1 (2 × CH3), 54.1 (CH2 benzyl), 68.6 
(OCH), 110.1 (ArCH), 122.5 (ArCH), 123.0 (ArCH), 
124.0 (ArCH), 126.9 (ArCq indazole), 127.3 (2 × ArCH), 
128.0 (p-ArCH), 128.8 (2 × ArCH), 135.7 (ArCq benzyl), 135.8 (ArCN), 140.6 
(C=N), 162.4 (C=O); max (KBr)/cm-1 2980, 1709, 1477, 1166; m/z (ESI+) 294 [M 
+ H]+ (100%) 296 (22); HRMS (ESI+): exact mass calculated for C18H19N2O2 [M 
+ H]+ 295.1447. Found 295.1440. 
 
sec-Butyl 2-benzyl-2H-indazole-3-carboxylate 251  
Using the procedure described for pentyl 1-benzyl-
1H-indazole-3-carboxylate 252 and pentyl 2-benzyl-
1H-indazole-3-carboxylate 253, a solution 
containing sec-butyl 1H-indazole-3-carboxylate 214 
(15 mg, 0.069 mmol), benzylbromide 339 (8 µL, 
0.069 mmol) and potassium carbonate (19 mg, 0.138 mmol) in DMF (5 mL) was 
stirred for 8 h under nitrogen at 80 ºC. Following the work-up, the residue was 
further purified by column chromatography on silica gel using hexane:ethyl 
acetate (95:5) initially to yield pure N-2 benzylated isomer 251 as a white solid (6 
mg, 28%), m.p. 166-169 ºC followed by hexane:ethyl acetate (70:30) to isolate 
pure N-1 benzylated isomer 250 as a yellow oil (5 mg, 23%). δH(CDCl3, 400 
MHz): 0.98 (3H, t, J 7.5, CH3), 1.38 (3H, d, J 6.3, CH3), 1.66-1.90 (2H, m, CH2), 
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5.18 (1H, dd, J 12.6, 6.5, OCH), 6.13 (2H, s, benzyl CH2), 7.26-7.38 (7H, m, 
containing 5H × ArCH phenyl and 2 × ArCH indazole), 7.81 (1H, d, J 8.1, ArCH), 
8.03 (1H, d, J 8.4, ArCH); δC(CDCl3, 100 MHz): 9.8, (CH2CH3)  19.7 (CHCH3), 
29.0 (CH2), 56.5 (CH2 benzyl), 73.4 (OCH), 118.4 (ArCH), 121.6 (ArCH), 125.0 
(ArCH), 126.4 (ArCH), 126.4 (ArCq indazole), 127.7 (2 × ArCH), 127.9 (p-
ArCH), 128.6 (2 × ArCH) and ArCq benzyl), 136.6 (C-N), 147.6 (ArC=N), 162.2 
(C=O); max (KBr)/cm-1 2981, 1707, 1465, 1081; m/z (ESI+) 309 [M + H]+ (34%); 
HRMS (ESI+): exact mass calculated for C19H21N2O2 [M + H]+ 309.1603. Found 
309.1599.  
 
sec-Butyl 1-benzyl-1H-indazole-3-carboxylate 250  
δH(CDCl3, 400 MHz): 1.04 (3H, t, CH3, J 7.4), 1.45 (3H, 
d, J 6.2, CH3), 1.67-1.93 (2H, m, CH2), 5.25-5.31 (1H, 
m, OCH), 5.72 (2H, s, benzyl CH2), 7.20-7.37  (8H, m, 
containing 5 × ArCH phenyl and 3 × ArCH indazole), 
8.20 (1H, d, J 8.1, ArCH indazole); δC(CDCl3, 100 
MHz): 10.0 (CH2CH3), 19.8 (CHCH3), 29.0 (CH2), 54.1 
(CH2 benzyl), 73.2 (OCH), 110.1 (ArCH), 122.4 (ArCH), 123.1 (ArCH), 124.0 
(ArCq indazole), 126.9 (ArCH), 127.3 (2 × ArCH), 128.1 (p-ArCH), 128.8 (2 × 
ArCH), 135.7 (ArCq benzyl), 135.8 (ArCN), 140.6 (C=N), 162.6 (C=O); max 
(KBr)/cm-1 2980, 1709, 1477, 1166; m/z (ESI+) 331 [M + Na]+ (60%), 332 (12); 
HRMS (ESI+): exact mass calculated for C19H21N2O2 [M + H]+ 309.1603. Found 
309.1591.  
 
2-Ethylhexyl 2-benzyl-2H-indazole-3-carboxylate 255  
Using the procedure described for pentyl 1-
benzyl-1H-indazole-3-carboxylate 252 and 
pentyl 2-benzyl-1H-indazole-3-carboxylate 
253, a solution containing 2-ethyl-butyl 1H-
indazole-3-carboxylate 219 (15 mg, 0.069 
mmol), benzylbromide 339 (8 µL, 0.069 mmol) and potassium carbonate (19 mg, 
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0.138 mmol) in DMF (5 mL) was stirred for 8 h under nitrogen at 80 ºC. Following 
the work-up, the residue was further purified by column chromatography on silica 
gel using hexane:ethyl acetate (95:5) to yield pure N-2 isomer 255 (6 mg, 24%) 
followed hexane:ethyl acetate (70:30) to isolate pure N-1 benzylated isomer 254 
(9 mg, 35%) as colourless oils. δH(CDCl3, 400 MHz): 0.89-0.96 {6H, m, 
containing [0.90 (3H, t, J 7.0, CH3) and 0.95 (3H, t, J 7.4, CH3)]}, 1.22-1.65 (8H, 
m, 4 × CH2), 1.77 (1H, td, J 12.2, 6.1, CH),  4.34 (2H, d, J 5.6, OCH2), 6.13 (2H, 
s, benzyl CH2), 7.24-7.45 (7H, m, containing 5 × ArCH benzyl and 2 × ArCH 
indazole), 7.82 (1H, d, J 8.6, ArCH), 8.02 (1H, d, J 6.4, ArCH); δC(CDCl3, 100 
MHz): 11.0 (CH3), 14.0 (CH3), 22.9 (CH2), 24.0 (CH2), 28.9 (CH2), 30.6 (CH2), 
39.0 (CH), 56.6 (CH2 benzyl), 67.3 (OCH2), 118.4 (ArCH), 121.4 (ArCH), 125.1 
(ArCH), 126.4 (ArCH and ArCq indazole), 127.7 (2 × ArCH), 128.0 (p-ArCH), 
128.6 (2 × ArCH), 128.9 (ArCq benzyl), 136.5 (C-N), 147.7 (ArC=N), 160.5 
(C=O);max (KBr)/cm-1 2958, 2928, 1709, 1465, 1204; m/z (ESI+) 365 [M + H]+ 
(100%), 328 (5); HRMS (ESI+): exact mass calculated for C23H29N2O2 [M + H]+ 
365.2229. Found 365.2245. 
 
2-Ethylhexyl 1-benzyl-1H-indazole-3-carboxylate 254  
δH(CDCl3, 400 MHz): 0.90 (3H, t, J 7.0, CH3), 
0.98 (3H, t, J 7.5, CH3), 1.30-1.65 (8H, m, 4 × 
CH2), 1.81-1.89 (1H, m, CH),  4.40 (2H, d, J 
5.9, OCH2), 5.71 (2H, s, benzyl CH2), 7.21-7.37 
(8H, m, containing 5 × ArCH phenyl and 3 × 
ArCH indazole), 8.18 (1H, d, J 8.1, ArCH, 
indazole); δC(CDCl3, 100 MHz): 11.0 (CH3), 
14.0 (CH3), 23.0 (CH2), 24.0 (CH2), 29.0 (CH2), 30.6 (CH2), 39.0 (CH), 54.1 (CH2 
benzyl) 67.5 (OCH2), 110.1 (ArCH), 122.3 (ArCH), 123.1 (ArCH), 123.9 (ArCH), 
126.8 (ArCq indazole), 127.3 (2 × ArCH), 128.1 (p-ArCH), 128.8 (2 × ArCH), 
135.5 (ArCq benzyl), 135.7 (ArCN), 140.6 (C=N), 163.0 (C=O); max (KBr)/cm-1 
2959, 2930, 1708, 1639, 1163; m/z (ESI+) 365 [M + H]+ (100%), 328 (20), 275 
(11); HRMS (ESI+): exact mass calculated for C23H29N2O2 [M + H]+ 365.2229. 
Found 365.2227. 
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Isopropyl 2-benzyl-2H-indazole-3-carboxylate 266  
Using the procedure described for pentyl 1-benzyl-
1H-indazole-3-carboxylate 252 and pentyl 2-benzyl-
1H-indazole-3-carboxylate 253, a solution isopropyl 
1-H-5,6-difluoro-1H-indazole-3-carboxylate 238 
(26 mg, 0.11 mmol), benzylbromide 339 (13 µL, 
0.11 mmol) and potassium carbonate (30 mg, 0.22 
mmol) in DMF (5 mL) was stirred for 8 h under nitrogen at 80 ºC. Following the 
work-up, the residue was further purified by column chromatography on silica gel 
using hexane:ethyl acetate (90:10) to yield isopropyl 2-benzyl-2H-indazole-3-
carboxylate 266 (4 mg, 11%), m.p. 80-81 ºC followed by hexane:ethyl acetate 
(50:50) to isolate isopropyl 1-benzyl-5,6-difluoro-1H-indazole-3-carboxylate 267 
(6 mg, 17%), m.p. 67-68 ºC. δH(CDCl3, 400 MHz): 1.42 (6H, d, J 6.3, 2 × CH3), 
5.27-5.35 (1H, m, OCH), 6.06 (2H, s, benzyl CH2), 7.27-7.34 (5H, m, 5 × ArCH 
phenyl), 7.50 (1H, dd, 2JHF 10.1, 3JHF 7.1, ArCH indazole), 7.71 (1H, dd, 2JHF 10.2, 
3JHF 7.9, ArCH, indazole); δC(CDCl3, 100 MHz):  22.0 (2 × CH3), 56.7 (CH2 
benzyl), 69.4 (OCH), 104.2 (d, 2JCF 19.9, ArCH), 107.0 (d, 2JCF 21.4, ArCH), 
119.5 (d, 3JCF 10.4, ArCq indazole), 124.9 (d, 4JCF 6.0, C-N indazole), 127.8 (2 × 
ArCH phenyl), 128.1 (p-ArCH phenyl), 128.7 (2 × ArCH phenyl), 136.2 (ArCq 
phenyl), 143.4 (d, 3JCF 11.1, ArC=N), 150.1 (dd, 1JCF , 248.6, 2JCF 89.0, ArCF), 
151.5 (d, 1JCF 268.0, ArCF), 159.1 (C=O); max (KBr)/cm-1 2981, 1711, 1485, 
1178; m/z (ESI+) 331 [M + H]+ (74%); HRMS (ESI+): exact mass calculated for 
C18H17N2O2F2 [M + H]+ 331.1258. Found 331.1252.  
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Isopropyl 1-benzyl-5,6-difluoro-1H-indazole-3-carboxylate 266  
δH(CDCl3, 400 MHz): 1.48 (6H, d, J 6.3, 2 × CH3), 
5.37-5.47 (1H, m, OCH), 5.66 (2H, s, benzyl CH2), 
7.05 (1H, dd, 2JHF 9.5, 3JHF 6.3, ArCH indazole), 7.19-
7.23 (2H, m, 2 × ArCH phenyl), 7.31-7.34 (3H, m, 3 × 
phenyl ArCH), 7.94 (1H, dd, 2JHF 9.7, 3JHF 7.7, ArCH, 
indazole); δC(CDCl3, 100 MHz):  22.0 (2 × CH3), 54.6 
(CH2 benzyl), 69.0 (OCH), 97.8 (d, 2JCF 22.2, ArCH), 
108.7 (dd, 2JCF 20.4, 3JCF 1.4, ArCH), 119.5 (d, 3JCF 8.9, ArCq indazole), 127.2 (2 
× ArCH phenyl), 128.4 (p-ArCH phenyl), 129.0 (2 × ArCH phenyl), 135.0 (ArCq 
phenyl), 135.9 (dd, 4JCF 5.3, 5JCF 1.4, C=N), 136.2 (d, 3JCF 10.0, ArCN indazole), 
148.6 (dd, 1JCF 239.1, 2JCF 8.6, ArCF), 151.1 (dd, 1JCF 244.9, 2JCF 10.1, ArCF), 
161.8 (C=O); ; max (KBr)/cm-1 2982, 1720, 1492, 1146; m/z (ESI+) 353 [M + Na]+ 
(100%), 331 (4); HRMS (ESI+): exact mass calculated for C18H17N2O2F2 [M + H]+ 
331.1258. Found 331.1250. 
 
Isopropyl 2-benzyl-5,6-dimethyl-2H-indazole-3-carboxylate 265  
Using the procedure described for pentyl 1-benzyl-
1H-indazole-3-carboxylate 252 and pentyl 2-benzyl-
1H-indazole-3-carboxylate 253, a solution containing 
isopropyl 5,6-dimethyl-1H-indazole-3-carboxylate 
236 (70 mg, 0.3 mmol), benzylbromide 339 (36 µL, 
0.3 mmol) and potassium carbonate (83 mg, 0.6 
mmol) in DMF (8 mL) was stirred for 8 h under nitrogen at 80 ºC. Following the 
work-up, the residue was further purified by column chromatography on silica gel 
using hexane:ethyl acetate (95:5) to yield pure N-2 benzylated isomer isopropyl 2-
benzyl-5,6-dimethyl-2H-indazole-3-carboxylate 265 as a colourless oil (12 mg, 
12%) and then hexane:ethyl acetate (70:30) to isolate pure N-1 benzylated isomer 
isopropyl 1-benzyl-5,6-dimethyl-1H-indazole-3-carboxylate 264 (15 mg, 15%), 
m.p. 103-104 ºC. δH(CDCl3, 400 MHz): 1.41 (6H, d, J 6.2, 2 × CH3), 2.38 (6H, s, 
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m, 5 × ArCH phenyl), 7.55 (1H, s, ArCH indazole), 7.75 (1H, s, ArCH, indazole); 
δC(CDCl3, 100 MHz): 20.8 (ArCH3), 20.9 (ArCH3), 22.0 (2 × CH3), 56.4 (CH2 
benzyl), 68.7 (OCH), 117.2 (ArCH), 120.2 (ArCH), 122.9 (ArCq indazole), 123.1 
(Cq phenyl),  127.5 (2 × ArCH), 127.7 (p-ArCH), 128.5 (2 × ArCH), 135.3 
(ArCH3), 136.6 (ArCH3), 136.9 (C-N), 147.4 (ArC=N), 159.8 (C=O); max 
(KBr)/cm-1 2994, 1726, 1489, 1146; m/z (ESI+) 323 [M + H]+ (100%), 345 [M + 
Na]+ (15); HRMS (ESI+): exact mass calculated for C20H23N2O2 [M + H]+ 
323.1760. Found 323.1744. 
 
Isopropyl 1-benzyl-5,6-dimethyl-1H-indazole-3-carboxylate 264 
δH(CDCl3, 400 MHz): 1.48 (6H, d, J 6.3, 2 × CH3), 2.33 
(3H, s, ArCH3), 2.37 (3H, s, ArCH3), 5.36-5.48 (1H, m, 
CH), 5.66 (2H, s, benzyl CH2), 7.08 (1H, s, ArCH, 
indazole), 7.15-7.20 (2H, m, 2 × phenyl ArCH), 7.24-
7.32 (3H, m, 3 × phenyl ArCH), 7.94 (1H, s, ArCH, 
indazole); δC(CDCl3, 100 MHz): 20.4 (ArCH3), 21.0 
(ArCH3), 22.2 (2 × CH3), 53.9 (CH2 benzyl), 68.6 
(OCH), 109.8 (ArCH), 121.7 (ArCH), 123.0 (ArCq indazole), 127.2 (2 × ArCH), 
128.0 (p-ArCH), 128.9 (2 × ArCH), 132.8 (ArCH3), 135.0 (Cq phenyl),  136.2 
(ArCH3), 137.1 (ArCN), 140.1 (C=N), 162.7 (C=O);max (film)/cm-1 2980, 1709, 
1477, 1166; m/z (ESI+) 345 [M + Na]+ (8); 323 [M + H]+ (8%); HRMS (ESI+): 
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3.9 Side-chain transformations 
3.9.1 Epoxidations of alkene-containing derivatives 66 
5-(3,3-Dimethyloxiran-2-yl)-3-methylpentyl 3-oxobutanoate 270  
3,7-Dimethyloct-6-enyl 3-oxobutanoate 3 (103 mg, 0.42 mmol) was 
dissolved in DCM (4.0 mL) and the mixture was cooled to 0 °C in an ice-bath. m-
Chloroperoxybenzoic acid (111 mg, 0.64 mmol, 70%, 1.5 equiv.) was dissolved 
in DCM (4.0 mL) and the first half added to the ester 3 dropwise at 0 °C. The 
second half was added as the reaction mixture was allowed to warm to room 
temperature. The reaction was stirred under a nitrogen atmosphere at room 
temperature. TLC analysis after 3 h showed complete consumption of the ester 
starting material. The crude reaction mixture was washed with saturated sodium 
bicarbonate solution (2 × 30 mL), water (30 mL) and brine (30 mL). The organic 
layer was dried with MgSO4 and concentrated under reduced pressure to yield 5-
(3,3-dimethyloxiran-2-yl)-3-methylpentyl 3-oxobutanoate 270 as an orange oil 
(95 mg, 91%) which was used with no further purification required. δH(CDCl3, 
400 MHz): 0.93 (3H, d, J 6.6, CHCH3), 1.10-1.76 [13H, m, containing 1.27 (3H, 
s, CH3), 1.31 (3H, s, CH3), 3 × CH2 and CH], 2.27 [3H, s, C(O)CH3], 2.69 (1H, t, 
J 6.0, CH of epoxide), 3.45 [2H, s, C(O)CH2C(O)], 4.12-4.26 (2H, m, OCH2); max 
(film)/cm-1 2961, 2927, 1739, 1736, 1248; m/z (ESI+) 257 [M + H]+ (22%), 155 
(35), 141 (70); HRMS (ESI+): exact mass calculated for C14H25O4 [M + H]+ 
257.1753. Found 257.1744. 
 
Note 1: Trace amount of both enol forms visible in 13C NMR spectrum with 
characteristic peaks at δC(ppm) 21.1 (CH3COH), 39.5 and 39.8 (CH2-COH), 53.4 
(Cq), 89.7 (CH) alkene, 168.3 (C=O) ester, 175.4 (COH). 
Note 2: The 13C NMR spectrum also contained a duplication of signals for 
diastereoisomers of 270 which could not be distinguished from each other: 
δC(CDCl3, 100 MHz): 18.6 and 18.7 (CH3CH), 19.2 and 19.3 [(CH3)2Cq], 24.8 
[C(O)CH3], 26.2 and 26.3 (CH2), 29.6 and 30.1 (d, CH), 33.4 and 33.5 (CH2), 35.1 
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and 35.3 (CH2), 50.1 [C(O)CH2C(O)], 58.2 and 58.3 (Cq), 63.7 (d, OCH2), 64.4 
(d, CH) epoxide, 167.1 (C=O) ester, 200.5 (C=O) ketone. 
 
5-(3,3-Dimethyloxiran-2-yl)-3-methylpent-2-en-1-yl 3-oxobutanoate 274  
The title compound was prepared following the procedure described for 5-
(3,3-dimethyloxiran-2-yl)-3-methylpentyl 3-oxobutanoate 270 using 3,7-
dimethylocta-2,6-dienyl 3-oxobutanoate 2 (103 mg, 0.42 mmol) in DCM (4.0 
mL), m-chloroperoxybenzoic acid (111 mg, 0.64 mmol) in DCM (4.0 mL) at 0 °C. 
The reaction was stirred under a nitrogen atmosphere and allowed to warm to room 
temperature. TLC analysis after 3 h showed complete consumption of the ester 
starting material. Following the work-up, the organic layer was dried with MgSO4 
and concentrated under reduced pressure to yield 5-(3,3-dimethyloxiran-2-yl)-3-
methylpent-2-en-1-yl 3-oxobutanoate 274 as a yellow oil (80 mg, 75%) which was 
used without further purification. δH(CDCl3, 400 MHz): 1.26 (3H, s, CH3), 1.30 
(3H, s, CH3), 1.66 (2H, td, J 14.0, 7.0, CH2CH), 1.74 (3H, s, CH3),  2.10-2.26 {3H, 
m, containing CH2 and 2.26 [3H, s, C(O)CH3]}, 2.70 (1H, t, J 6.0, CH of epoxide), 
3.45 [2H, s, C(O)CH2C(O)], 4.67 (2H, d, J 7.0 OCH2), 5.36-5.42 (1H, m, CH 
alkene); δC(CDCl3, 100 MHz): 16.4 (CH3), 18.7 (CH3), 24.8 (CH3), 27.0 (CH2), 
30.1 [C(O)CH3], 36.1 (CH2), 50.1 [C(O)CH2C(O)], 58.3 (OCH2), 62.0 [C(CH3)2], 
63.7 (CH) epoxide, 118.3 (C=CH), 142.0 (C=CCH3) 167.1 (C=O) ester, 200.5 
(C=O) ketone; max (film)/cm-1 2965, 2930, 1725, 1743, 1314, 960; m/z (ESI+) 254 
[M + H]+ (4%), 253 (14), 153 (72); HRMS (ESI+): exact mass calculated for 
C14H23O4 [M + H]+ 255.1596. Found 255.1584. 
Note: Trace amount of enol form visible in 13C NMR spectrum with characteristic 
peaks at δC(ppm) 21.1 (CH3COH), 89.7 (CH) enol alkene), 118.9 (OCH2CH) 





    Chapter 3: Experimental 
354 
 
5-(3,3-Dimethyloxiran-2-yl)-3-methylpentyl 2-diazo-3-oxobutanoate 273  
Triethylamine (0.034 mL, 0.24 mmol) was 
added to a stirred solution of 5-(3,3-
dimethyloxiran-2-yl)-3-methylpentyl 3-
oxobutanoate 270 (60 mg, 0.24 mmol) in acetonitrile (5.0 mL). After 2 min a 
solution of p-toluenesulfonyl azide 13 (46 mg, 0.24 mmol) in acetonitrile (5 mL) 
was carefully added dropwise, at room temperature, to yield a bright yellow 
solution. The reaction was stirred at room temperature under a nitrogen 
atmosphere. TLC analysis after 2.5 h showed complete consumption of the starting 
material and the acetonitrile was removed under reduced pressure, keeping the 
temperature of the water bath below 30 °C. The resulting yellow oil was dissolved 
in diethyl ether (15 mL) and washed with 9% KOH (2 × 25 mL), water (25 mL), 
dried with MgSO4 and concentrated under reduced pressure. The residue obtained 
was purified by column chromatography on silica gel using hexane:ethyl acetate 
(90:10) to yield 5-(3,3-dimethyloxiran-2-yl)-3-methylpentyl 2-diazo-3-
oxobutanoate 273 as a yellow oil (254 mg, 77%). δH(CDCl3, 400 MHz): 0.96 (3H, 
d, J 6.3, CHCH3), 1.27 (3H, s, CH3), 1.30 (3H, s, CH3), 1.37-1.65 (5H, m, 
containing CH and 2 × CH2), 1.67-1.81 (2H, m, CH2), 2.47 [3H, s, C(O)CH3], 2.68 
(1H, t, J 6.3, CH of epoxide), 4.22-4.36 (2H, m, OCH2); max (film)/cm-1 2149, 
1772, 1642; m/z (ESI-) 281 [M - H]- (10%), 255 (20); HRMS (ESI+): exact mass 
calculated for C14H23N2O4 [M + H]+ 283.1658. Found 283.1654. 
Note 1: The 13C NMR spectrum contained a duplication of signals for 
diastereoisomers of 273:  
δC(CDCl3, 100 MHz): 18.7 (d, CH3), 19.3 and 19.4 (CH3), 24.8 (CH3), 26.2 and 
26.4 (CH2), 28.2 (CH), 29.7 and 29.8 [C(O)CH3], 33.5 and 33.6 (CH2), 35.3 and 
35.6 (CH2), 58.1 and 58.2 [C(CH3)2], 63.7 (OCH2), 64.3 and 64.4 (CH) epoxide, 











The title compound was prepared following 
the procedure described for 5-(3,3-
dimethyloxiran-2-yl)-3-methylpentyl 2-
diazo-3-oxobutanoate 273 using triethylamine (0.034 mL, 0.24 mmol, 5-(3,3-
dimethyloxiran-2-yl)-3-methylpent-2-en-1-yl 3-oxobutanoate 274 (60 mg, 0.24 
mmol in acetonitrile (5.0 mL) and p-toluenesulfonyl azide 13 (46 mg, 0.24 mmol 
in acetonitrile (5 mL). The reaction was stirred at room temperature under a 
nitrogen atmosphere. TLC analysis after 2.5 h showed complete consumption of 
the starting material and the acetonitrile was removed under reduced pressure, 
keeping the temperature of the water bath below 30 °C. The resulting yellow oil 
was dissolved in diethyl ether (15 mL) and washed with 9% KOH (2 × 25 mL), 
water (25 mL), dried with MgSO4 and concentrated under reduced pressure. The 
residue obtained was purified by column chromatography on silica gel using 
hexane:ethyl acetate (90:10)  to yield 5-(3,3-dimethyloxiran-2-yl)-3-methylpent-
2-en-1-yl 2-diazo-3-oxobutanoate 275 as a yellow oil (254 mg, 77%). δH(CDCl3, 
400 MHz): 1.27 (3H, s, CH3), 1.31 (3H, s, CH3), 1.63-1.71 (2H, m, CH2CH), 1.77 
(3H, s, CH3C=C), 2.13-2.30 (2H, m, CH2C=C), 2.48 [3H, s, C(O)CH3], 2.70 (1H, 
t, CH of epoxide, J 6.2), 4.76 (2H, d, J 7.1, OCH2), 5.42 (1H, dt, J 7.1, 1.2, CH 
alkene); δC(CDCl3, 100 MHz): 16.5 (CH3C=C), 18.7 (CH3CO), 24.8 (CH3), 27.0 
(CH2), 28.2 [C(O)CH3], 36.2 (CH2), 58.3 [Cq(CH3)2], 62.0 (OCH2), 63.7 (CH) 
epoxide, 118.3 (CH) alkene, 142.2 (Cq) alkene, 161.4 (C=O) ester, 190.1 (C=O) 
ketone; max (film)/cm-1 2141, 1715, 1659, 1309; HRMS (ESI+): exact mass 












carboxylate 298  
The title compound was prepared following 
the procedure described for methyl 1-acetyl-
1H-indazole-3-carboxylate 104 using 2-
(trimethylsilyl)phenyl-
trifluoromethanesulfonate 49 (100 mg, 0.33 
mmol), 5-(3,3-dimethyloxiran-2-yl)-3-
methylpentyl 2-diazo-3-oxobutanoate  273 
(51 mg, 0.3 mmol) in acetonitrile (4 mL) and 
caesium fluoride (103 mg, 0.6 mmol). The reaction was stirred at room 
temperature under a nitrogen atmosphere for 24 h. Following the work-up, the 
residue was purified by column chromatography on silica gel using hexane:ethyl 
acetate (90:10) as eluent to yield 5-(3,3-dimethyloxiran-2-yl)-3-methylpent-2-en-
1-yl 1-acetyl-1H-indazole-3-carboxylate 298 as an orange oil (80 mg, 74%). 
δH(CDCl3, 400 MHz): 1.03 (3H, d, J 6.3, CHCH3), 1.27 (3H, d, J 1.4, CH3), 1.30 
(3H, d, J 1.3, CH3), 1.42-1.68 (4H, m, 2 × CH2), 1.70-1.80 (2H, m, CH2), 1.90-
1.99 (1H, m, CH), 2.71(1H, t, J 5.9, CH of epoxide), 2.87 [3H, s, C(O)CH3], 4.51-
4.58 (2H, m, OCH2), 7.46 (1H, dd, J 8.4, 0.8, ArCH), 7.61 (1H, ddd, J 8.4, 7.1, 
1.1, ArCH), 8.20 (1H, dd, J 8.0, 0.8, ArCH), 8.48 (1H, dd, J 8.4, 0.8, ArCH); 
δC(CDCl3, 100 MHz): 18.7 (CH3CH), 19.5 [C(O)CH3], 23.1 (CH3CO), 24.9 
(CH3CO), 26.3 (CH2CH), 29.9 (CHCH3), 33.6 (CH2), 35.3 (CH2), 35.6 (CH2), 58.2 
(Cq epoxide), 64.2 (OCH2), 64.4 (CH epoxide), 115.6 (ArCH), 122.2 (ArCH), 
125.7 (ArCH), 125.9 (ArCq), 129.9 (ArCH), 140.3 (C=N), 140.8 (ArCN), 161.9 
(C=O) ester, 172.2 (C=O) amide; max (film)/cm-1 2959, 1731, 1375, 1193; HRMS 











carboxylate 299  
The title compound was prepared following the 
procedure described for methyl 1-acetyl-1H-
indazole-3-carboxylate 104 using 2-
(trimethylsilyl)phenyl-
trifluoromethanesulfonate 49 (100 mg, 0.33 
mmol), 5-(3,3-dimethyloxiran-2-yl)-3-
methylpent-2-en-1-yl 2-diazo-3-oxobutanoate 
275 (51 mg, 0.3 mmol) in acetonitrile (4 mL) 
and caesium fluoride (103 mg, 0.6 mmol).  The reaction was stirred at room 
temperature under a nitrogen atmosphere for 24 h. Following the work-up, the 
residue was purified by column chromatography on silica gel using hexane:ethyl 
acetate eluent (90:10) and then DCM:ethyl acetate eluent (95:5) and 5-(3,3-
dimethyloxiran-2-yl)-3-methylpentyl 1-acetyl-1H-indazole-3-carboxylate 299 
was obtained as an orange oil (74 mg, 69%).  δH(CDCl3, 400 MHz): 1.29 (6H, d, 
J 10.9, 2 × CH3), 1.71 (2H, td, J 14.0, 7.1, CH2CH), 1.85 (3H, s, CH3), 2.19-2.32 
(2H, m, CH2C=C), 2.73 (1H, t, J 6.2, CH of epoxide), 2.87 [3H, s, C(O)CH3], 5.02 
(2H, d, J 7.1, OCH2), 5.61 (1H, t, J 7.1, CH alkene), 7.43-7.48 (1H, m, ArCH), 
7.60 (1H, ddd, J 8.3, 7.2, 1.1, ArCH), 8.21 (1H, d, J 8.1, ArCH), 8.47 (1H, d, J 
8.5, ArCH); δC(CDCl3, 100 MHz): 16.7 (CH3C=C), 18.8 [C(O)CH3], 23.1 
(CH3CO), 24.8 (CH3CO), 27.1 (CH2CH), 36.3 (CH2C=C), 58.4 [Cq(CH3)2], 62.5 
(OCH2), 63.9 (CH epoxide), 115.5 (ArCH), 118.4 (CH) alkene, 122.2 (ArCH), 
123.9 (ArCq), 125.7 (ArCH), 129.9 (ArCH), 140.3 (C=N), 140.81 (ArCN), 142.4 
(C=Cq), 161.8 (C=O) ester, 171.5 (C=O) amide;max (film)/cm-1 2959, 1731, 1616, 
1193; HRMS (ESI+): exact mass calculated for C20H25N2O4 [M + H]+ 357.1814. 
Found 357.1810 
Note: 6% of the N-acyl by-product was formed in this reaction which could not 









The title compound was prepared following the 
procedure described for pentyl 1-acetyl-1H-
indazole-3-carboxylate 108 using caesium 
fluoride (76 mg, 0.5 mmol), 
nonafluorobutanesulfonyl fluoride (453 mg, 
1.5 mmol), 2-(trimethylsilyl)phenol 58 (166 
mg,  1 mmol), 5-(3,3-dimethyloxiran-2-yl)-3-
methylpent-2-en-1-yl 2-diazo-3-oxobutanoate 
275 (338 mg, 1.2 mmol) and caesium carbonate (500 mg, 1.5 mmol) in acetonitrile 
(10 mL). The reaction was stirred at 60 °C under a nitrogen atmosphere for 24 h. 
After work-up, the residue obtained was purified by column chromatography on 
silica gel using hexane:ethyl acetate (95:5) to yield 5-(3,3-dimethyloxiran-2-yl)-
3-methylpentyl 1-acetyl-1H-indazole-3-carboxylate 299. 
as a colourless oil. Spectral details as described previously. 
 
Note: Due to insufficient diazo starting material, only 1.2 equiv. was present in 
comparison to the preferred 3 equiv. in the reaction, therefore, 10% of the N-acyl 
by-product was formed which could not be removed by column chromatography 
on silica gel. Characteristic signals at δH(ppm) 7.73 (3H, dd, J 10.4, 8.3, 3 × ArCH) 
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3.9.2 Oxidative cleavage of epoxide derivatives and subsequent diazo 
transfer reactions67 
Note: All aldehyde derivatives were found to be unstable for short periods even 
when stored in the freezer.  
 
3-Methyl-6-oxohexyl 3-oxobutanoate 276   
Periodic acid(107 mg, 0.56 mmol, 1.4 equiv.) 
was stirred in diethyl ether (10.0 mL) in a two-
neck round-bottomed flask. The reaction 
temperature was maintained at 25 °C using an oil bath and reflux condenser under 
a nitrogen atmosphere. The epoxide 5-(3,3-dimethyloxiran-2-yl)-3-methylpentyl 
3-oxobutanoate 270 (100 mg, 0.39 mmol) dissolved in diethyl ether (5.0 mL) was 
added dropwise and the reaction was stirred vigorously at 25 °C for ten min. The 
reaction was quenched using water (20 mL). The organic layer was separated and 
washed with water (2 × 50 mL), dried with MgSO4 and concentrated under 
reduced pressure to yield 3-methyl-6-oxohexyl 3-oxobutanoate 276 as an orange 
oil (58 mg, 71%). δH(CDCl3, 400 MHz): 0.93 (3H, d, J 6.0, CHCH3), 1.42-1.77 
(5H, m, containing CH and 2 × CH2), 2.27 [3H, s, C(O)CH3], 2.42-2.45 [2H, m, 
CH2C(O)H], 3.45 [2H, s, C(O)CH2C(O)], 4.12-4.26 (2H, m, OCH2), 9.78 [1H, t, 
J 6.0, CH2C(O)H]; δC(CDCl3, 100 MHz): 19.1 (CH3), 28.6 (CH), 29.4 (CH2), 30.2 
[C(O)CH3], 35.1 (CH2), 41.4 (CH2), 50.1 [C(O)CH2C(O)], 63.5 (OCH2), 167.1 
(C=O) ester, 202.3 (C=O) ketone and (C=O) aldehyde; max (film)/cm-1 2958, 
1755, 1640, 1304; HRMS (ESI+): exact mass calculated for C11H19O4 [M + H]+ 
215.1283. Found 215.1277. 
 
3-Methyl-6-oxohexyl 2-diazo-3-oxobutanoate 283  
The title compound was prepared following the 
procedure described for 5-(3,3-dimethyloxiran-
2-yl)-3-methylpentyl 2-diazo-3-oxobutanoate 
273 using triethylamine (0.034 mL, 0.24 mmol), 3-methyl-6-oxohexyl 3-
oxobutanoate 276 (60 mg, 0.24 mmol) in acetonitrile (5.0 mL) and p-
toluenesulfonyl azide 13 (46 mg, 0.24 mmol) in acetonitrile (5.0 mL). TLC 
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analysis after 2.5 h showed complete consumption of the starting material and 
Following the work-up,the residue was concentrated under reduced pressure and 
purified using column chromoatography on silica gel using hexane:ethyl acetate 
(90:10-80:20) to yield 3-methyl-6-oxohexyl 2-diazo-3-oxobutanoate 283 as a 
yellow oil (124 mg, 75%). δH(CDCl3, 400 MHz): 0.95 (3H, d, J 6.4, CH3), 1.46-
1.61 (3H, m, containing CH and CH2), 1.69-1.77 (2H, m, CH2), 2.41-2.53 {5H, m, 
containing CH2C(O)H and 2.47 [3H, s, C(O)CH3]}, 4.25-4.33 (2H, m, OCH2), 
9.79 [1H, t, J 6.0, CH2C(O)H]; δC(CDCl3, 100 MHz): 19.1 (CH3), 28.2 (CH), 28.5 
(CH2), 29.4 [C(O)CH3], 35.3 (CH2), 41.3 (CH2), 63.5 (OCH2), 161.4 (C=O) ester, 
190.0 (C=O) ketone, 202.1 (C=O) aldehyde, no signal observed for C=N2; m/z 
(ESI+) 263 [M + Na]+(40%), 240 (4), (239) (10); max (film)/cm-1 2961, 2932, 2143, 
1711, 1656, 1156; HRMS (ESI+): exact mass calculated for C11H17N2O4 [M + H]+ 
241.1188. Found 241.1180. 
 
3-Methyl-6-oxohex-2-en-1-yl 3-oxobutanoate 277  
The title compound was prepared following the 
procedure described for 3-methyl-6-oxohexyl 
3-oxobutanoate 276 using periodic acid(107 
mg, 0.56 mmol) in diethyl ether (10.0 mL) and the epoxide 5-(3,3-dimethyloxiran-
2-yl)-3-methylpentyl 3-oxobutanoate 274 (100 mg, 0.39 mmol) in diethyl ether 
(5.0 mL). Following the work-up, the organic layers were concentrated under 
reduced pressure to yield 3-methyl-6-oxohex-2-en-1-yl 3-oxobutanoate 277 as an 
orange oil (62 mg, 74%). δH(CDCl3, 400 MHz): 1.73 (3H, s, CHCH3), 2.27 [3H, 
s, C(O)CH3], 2.38 [2H, t, J 7.4, CH2C(O)H], 2.58 (2H, dt, J 7.5, 1.5, CH2), 3.45 
[2H, s, C(O)CH2C(O)], 4.65 (2H, d, J 7.0, OCH2), 5.34-5.41 (1H, m, CH alkene), 
9.77 [1H, t, J 1.5, CH2C(O)H]; max (film)/cm-1 2950, 1747, 1664; HRMS (ESI+): 
exact mass calculated for C11H17O4 [M + H]+ 213.1127. Found 213.1124. 
 
Note 1: Some peaks belonging to the epoxide starting material could be seen in 
the 13C NMR spectrum. δC(CDCl3, 100 MHz): 16.6 (CH3), 30.1 [C(O)CH3], 31.4 
(CH2), 41.7 (CH2CHO), 50.0 [C(O)CH2C(O)], 61.9 (OCH2), 118.7 (CH) alkene, 
140.8 (Cq) alkene, 167.1 (C=O) ester, 200.5 (C=O) ketone, 201.6 (C=O) aldehyde; 
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Note 2: Trace amount of enol form visible in 13C NMR spectrum with 
characteristic peaks at δC(ppm) 89.7 (CH) alkene, 175.6 (COH).  
 
Attempted synthesis of 3-methyl-6-oxohex-2-en-1-yl 2-diazo-3-oxobutanoate 
342  
The title compound was prepared following 
the procedure described for 5-(3,3-
dimethyloxiran-2-yl)-3-methylpentyl 2-diazo-
3-oxobutanoate 273 using triethylamine (0.034 mL, 0.24 mmol), 3-methyl-6-
oxohexyl 3-oxobutanoate 277 (51 mg, 0.24 mmol) in acetonitrile (5.0 mL) and p-
toluenesulfonyl azide 13 (46 mg, 0.24 mmol) in acetonitrile (5.0 mL). TLC 
analysis after 2.5 h showed complete consumption of the starting material and 1H 
NMR analysis of the crude reaction mixture showed the presence of the desired 
compound. The residue obtained after concentration under reduced pressure was 
purified by column chromatography on silica gel using hexane:ethyl acetate 
(90:10) to yield 3-methyl-6-oxohex-2-en-1-yl 2-diazoacetate 284 as  a yellow oil 
(40 mg, 85%) as the major product with 10% of the desired compound as an 
inseparable mixture. δH(CDCl3, 400 MHz): 1.73 (3H, s, CHCH3), 2.38 [2H, t, J 
7.5, CH2C(O)H], 2.48 [3H, s, C(O)CH3], 2.55-2.61 (2H, m, CH2), 4.67 (2H, d, J 
7.0, OCH2), 5.34-5.39 (1H, m, CH alkene), 9.78 [1H, t, J 1.6, CH2C(O)H]. 
 
3-Methyl-6-oxohex-2-en-1-yl 2-diazoacetate 284 
δH(CDCl3, 400 MHz): 1.73 (3H, s, CHCH3), 
2.38 [2H, t, J 7.5,  CH2C(O)H], 2.55-2.61 (2H, 
m, CH2), 4.67 (2H, d, J 7.0, OCH2), 4.74 (1H, 
s, CH), 5.34-5.39 (1H, m, CH alkene), 9.78 [1H, t, J 1.6, CH2C(O)H]; δC(CDCl3, 
100 MHz): 16.6 (CH3), 31.5 (CH2), 41.7 (CH2CHO), 61.4 (OCH2), 119.3 (CH) 
alkene, 140.3 (Cq) alkene, 171.1 (C=O) ester, (C=O) aldehyde;max (film)/cm-1: 
2966, 2140, 1717, 1662, 1312; HRMS (ESI-): exact mass calculated for 
C9H11N2O3 [M + H]+ 197.0803. Found 197.0809. 
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**Initial attempts were made to form the indazole cycloadduct using the diazo 
1,3-dipoles of the aldehyde and tertiary amine derivatives, however, little success 
was achieved with these routes and therefore the epoxide derivative of the 
indazole was carried through the synthesis instead** 
 
3-Methyl-6-oxohexyl 1-acetyl-1H-indazole-3-carboxylate 300  
The title compound was prepared following 
the procedure described for 3-methyl-6-
oxohexyl 3-oxobutanoate 276 using periodic 
acid(53 mg, 0.28 mmol) in diethyl ether (5 
mL) and the epoxide 5-(3,3-dimethyloxiran-
2-yl)-3-methylpentyl 1H-indazole-3-
carboxylate 298 (67 mg, 0.19 mmol) 
dissolved in diethyl ether (5.0 mL). 
Following the work-up, the organic layers were concentrated under reduced 
pressure to yield 3-methyl-6-oxohexyl 1-acetyl-1H-indazole-3-carboxylate 300 as 
an orange oil (33 mg, 56%). δH(CDCl3, 400 MHz): 1.09 (3H, d, J 6.9, CHCH3), 
1.48-2.00 (5H, m, CH and 2 × CH2), 2.49-2.54 (2H, m, CH2CHO), 2.87 [3H, s, 
C(O)CH3], 4.55 (2H, dd, J 11.9, 5.0, OCH2), 7.47 (1H, dt, J 7.6, 0.7, ArCH), 7.61 
(1H, ddd, J 8.4, 7.2, 1.1, ArCH), 8.19 (1H, dd, J 1.0, 8.1, ArCH), 8.47 (1H, d, J  
8.5, ArCH), 9.80 [1H, t, J 1.6, CH2C(O)H]; δC(CDCl3, 100 MHz): 19.0 (CH3), 
28.6 (CH), 29.3 (CH2), 30.1 [C(O)CH3], 35.1 (CH2), 41.4 (CH2), 50.0 
[C(O)CH2C(O)], 63.5 (OCH2), 115.6 (ArCH), 122.2 (ArCH), 124.7 (ArCq), 125.7 
(ArCH), 129.9 (ArCH), 167.1 (C=O) ester, 200.5 (C=O) ketone, 202.3 (C=O) 
aldehyde; max (film)/cm-1 2977, 1741, 1716, 1646, 1456; m/z (ESI+) 315 [M - H]- 
(100%), M+ (20); HRMS (ESI+): exact mass calculated for C17H21N2O4 [M + H]+ 
317.1841. Found 317.1853. 
 
Note 1: Significant impurity peaks visible in 13C NMR spectrum, possibly for 
decomposition products. 
Note 2: This reaction did not reach completion, despite many attempts at 
increasing periodic acid equiv. and length of reaction time.  
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3-Methyl-6-oxohex-2-en-1-yl 1-acetyl-1H-indazole-3-carboxylate 301 
The title compound was prepared 
following the procedure described for 3-
methyl-6-oxohexyl 3-oxobutanoate 276 
using periodic acid(45 mg, 0.2 mmol) in 
diethyl ether (5 mL) and the epoxide 5-
(3,3-dimethyloxiran-2-yl)-3-methylpentyl 
1-acetyl-1H-indazole-3-carboxylate 299 
(47 mg, 0.13 mmol) dissolved in diethyl 
ether (5.0 mL). Following the work-up, the 
organic layers were concentrated under reduced pressure to yield 3-methyl-6-
oxohex-2-en-1-yl 1-acetyl-1H-indazole-3-carboxylate 301 as a colourless oil (57 
mg, 93%). δH(CDCl3, 400 MHz): 1.84 (3H, s, C=CCH3), 2.43 (2H, t, J 7.5, CH2), 
2.62 (2H, ddd, J 8.9, 7.8, 0.6, CH2), 2.87 [3H, s, C(O)CH3], 5.00 (2H, d, J 7.1, 
OCH2), 5.57 (dt, J 7.1, 1.3, CH alkene), 7.45 (1H, t, J 7.6, ArCH), 7.56-7.62 (1H, 
m, ArCH), 8.19 (1H, d, J 8.1, ArCH), 8.46 (1H, dd, J  8.5, 0.7, ArCH), 9.79 [1H, 
t, J 1.5, CH2C(O)H]. 
 
Note 1: The epoxide starting material used for this reaction contained 10% of the 
N-aryl-by-product which was converted to the aldehyde.  
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3.9.3 Reductive amination of aldehyde derivatives68 
3-Methyl-6-thiomorpholinohexyl 3-oxobutanoate 293  
 Sodium triacetoxyborohydride (0.48 g, 
2.28 mmol) was added to a stirred 
solution of the aldehyde, 3-methyl-6-
oxohexyl 3-oxobutanoate 276, (0.35 g, 1.63 mmol) and thiomorpholine 292 (0.14 
mL, 1.63 mmol) in 1,2-dichloroethane (15.0 mL) under a nitrogen atmosphere at 
room temperature. TLC analysis after 1.5 h showed complete consumption of the 
aldehyde starting material and the reaction was quenched using saturated sodium 
bicarbonate solution (15.0 mL). The organic layer was extracted with ethyl acetate 
(2 × 15 mL) and washed with water (2 × 15 mL) followed by brine (15 mL). The 
organic layer was dried with MgSO4 and concentrated under reduced pressure to 
yield the crude product which was purified using column chromatography on silica 
gel using hexane:ethyl acetate (90:10) to yield 3-methyl-6-thiomorpholinohexyl 
3-oxobutanoate 293 as an orange oil (0.35 g, 76%). δH(CDCl3, 400 MHz): 0.91 
(3H, d, CHCH3, J 6.5), 1.09-1.36 (2H, m, CH2), 1.40-1.60 (4H, m, containing 2 × 
CH2), 1.62-1.74 (1H, m, CHCH3), 2.27-2.35 {5H, m, containing 2.27 [3H, s, 
C(O)CH3] and NCH2}, 2.66-2.72 (8H, m, containing 2 × NCH2 and 2 × SCH2), 
3.44 [2H, s, C(O)CH2C(O)], 4.13-4.21 (2H, m, OCH2); δC(CDCl3, 100 MHz): 19.4 
(CH3), 23.2 (CH2), 27.4 (2 × SCH2), 29.7 (CH), 30.2 [C(O)CH3], 34.5 (CH2), 35.3 
(CH2),  50.1 (CH2), 54.7 (2 × NCH2), 59.2 [C(O)CH2C(O)], 63.8 (OCH2), 167.2 
(C=O) ester, 200.5 (C=O) ketone; max (film)/cm-1 2951, 1743, 1715, 1305; m/z 
(ESI+) 302 [M + H]+ (100%), 303 (20), 304 (10); HRMS (ESI+): exact mass 
calculated for C15H27NO3S [M + H]+ 302.1790 Found 302.1791. 
 
Note: Trace amount of enol form visible in 13C NMR spectrum with characteristic 
peaks at δC(ppm) 89.7 (CH) alkene, 172.7 (C=O) ester, 175.4 (COH). 
 
3-Methyl-6-thiomorpholinohexyl 2-diazo-3-oxobutanoate 294  
The title compound was prepared 
following the procedure described for 5-
(3,3-dimethyloxiran-2-yl)-3-
methylpentyl 2-diazo-3-oxobutanoate 
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273 using triethylamine (0.16 mL, 1.12 mmol), 3-methyl-6-thiomorpholinohexyl 
3-oxobutanoate 293 (0.32 g, 1.12 mmol) in acetonitrile (8.0 mL) and p-
toluenesulfonyl azide 13 (0.22 g, 1.12 mmol) in acetonitrile (4.0 mL). The reaction 
was stirred for 18 h under a nitrogen atmosphere, after which time TLC analysis 
showed complete consumption of the ester starting material. Following the work-
up, the residue obtained was purified using column chromatography on silica gel 
using hexane:ethyl acetate (90:10-50:50) to isolate 3-methyl-6-
thiomorpholinohexyl 2-diazo-3-oxobutanoate 294 as a red oil (260 mg, 71%). 
δH(CDCl3, 400 MHz): 0.93 (3H, d, J 6.6, CHCH3), 1.08-1.80 (7H, m, containing 
3 × CH2 and CH), 2.30-2.38 (2H, m, NCH2), 2.48 [3H, s, C(O)CH3], 2.66-2.75 
(8H, m, containing 2 × NCH2 and 2 × SCH2), 4.24-4.31 (2H, m, OCH2); δC(CDCl3, 
75.5 MHz): 19.4 (CH3), 23.8 (CH2), 27.9 (2 × SCH2), 28.2 (CH), 29.8 [C(O)CH3], 
34.5 (CH2), 35.5 (CH2), 55.0 (2 × NCH2), 59.5 (NCH2), 63.9 (OCH2), 161.5 (C=O) 
ester, 190.1 (C=O) ketone; max (film)/cm-1 2952, 2141, 1718, 1651, 1309; m/z 
(ESI+) 328 [M + H]+ (100%), 300 (5); HRMS (ESI+): exact mass calculated for 




The title compound was 
prepared following the 
procedure described for 3-
methyl-6-thiomorpholinohexyl 3-oxobutanoate 293 using sodium 
triacetoxyborohydride (0.48 g, 2.28 mmol), 3-methyl-6-oxohex-2-en-1-yl 3-
oxobutanoate 277, (0.35 g, 1.63 mmol) and 2-(piperazin-1-yl)ethan-1-ol 295 (0.14 
mL, 1.63 mmol) in 1,2-dichloroethane (15.0 mL). TLC analysis after 1.5 h showed 
complete consumption of the aldehyde starting material and the reaction was 
quenched using saturated sodium bicarbonate solution (15.0 mL). Following the 
work-up, the organic layers were dried with MgSO4 and concentrated under 
reduced pressure. The residue obtained was purified using column 
chromatography on silica gel chloroform:methanol (95:5) to yield 6-(4-(2-
hydroxyethyl)piperazin-1-yl)-3-methylhex-2-en-1-yl 3-oxobutanoate 296 as a 
yellow oil (0.35 g, 76%). δH(CDCl3, 400 MHz): 1.58-1.71 [5H, m, containing CH2 
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and 1.71 (3H, s, CH3)], 2.02-2.08 (2H, m, CH2), 2.30-2.35 {5H, m, containing 2.27 
[3H, s, C(O)CH3], and NCH2}, 2.48-2.62 (11H, m, containing 5 × NCH2 and OH), 
3.45 [2H, s, C(O)CH2C(O)], 3.61-3.66 (2H, m, CH2OH),  4.66 (2H, d, J 7.1, 
OCH2), 5.35 (1H, ddd, J 7.1, 2.4, 1.2, CH alkene); δC(CDCl3, 100 MHz): 16.4 
(CH3), 24.7 (CH2), 30.1 [C(O)CH3], 37.2 (CH2), 50.1 [C(O)CH2C(O)], 52.8 (2 × 
NCH2), 53.2 (2 × NCH2), 57.7 (CH2OH), 58.0 (NCH2CH2OH), 59.3 (NCH2), 62.2 
(OCH2), 118.5 (CH) alkene, 142.2 (Cq) alkene, 161.4 (C=O) ester; max (film)/cm-
1 2955, 2834, 1740, 1722, 1651, 1309; m/z (ESI+) 327 [M + H]+ (100%), 328 (20), 
329 (4). HRMS (ESI+): exact mass calculated for C17H31N2O4 [M + H]+ 327.2284. 
Found 327.2282. 
 
Attempted synthesis of 3-methyl-6-(piperazin-1-yl)hex-2-en-1-yl 2-diazo-3-
oxobutanoate 343  
The title compound was 
prepared following the 
procedure described for 5-
(3,3-dimethyloxiran-2-yl)-
3-methylpentyl 2-diazo-3-oxobutanoate 273 using triethylamine (0.068 mL, 0.48 
mmol), 3-methyl-6-piperazine-hexyl 3-oxobutanoate 296 (60 mg, 0.24 mmol) in 
acetonitrile (5.0 mL) and p-toluenesulfonyl azide 13 (46 mg, 0.24 mmol) in 
acetonitrile (5.0 mL). 1H NMR analysis of the crude mixture showed the presence 
of 297 as the major product with trace amounts of the desired product. Attempted 
purification of the residue by column chromatography on silica gel using 
hexane:ethyl acetate (90:10-50:50) isolated 297 as the major product still 
contaminated by a large amount of impurities and starting material.  The only 
characteristic signal differing from major product below: δH(CDCl3, 400 MHz): 











δH(CDCl3, 400 MHz): 1.50-1.70 
[5H, m, containing CH2 and 1.71 
(3H, s, CH3)], 1.94-2.00 (2H, m, 
CH2), 2.20-2.26 (2H, m, CH2), 
2.37-2.51 (11H, m, 5 × NH2 and OH], 3.54 (2H, t, J 10.7, CH2OH),  4.06 (2H, d, 
J 7.1, OCH2), 4.67 (1H, br s, CH), 5.29 (1H, t, J 7.1, CH alkene); δC(CDCl3, 100 
MHz): 16.4 (CH3), 24.8 (CH2), 37.3 (CH2), 52.9 (2 × NCH2), 53.3 (2 × NCH2), 
57.7 (CH2OH), 58.1 (NCH2CH2OH), 59.2 (NCH2), 61.7 (OCH2), 118.0 (CH) 
alkene, 142.7 (Cq) alkene, 167.1 (C=O) ester.   
 
Attempted synthesis of  3-methyl-6-thiomorpholinohexyl 1-acetyl-1H-
indazole-3-carboxylate 344  
Following the procedure described for 3-
methyl-6-thiomorpholinohexyl 3-
oxobutanoate 293, sodium 
triacetoxyborohydride (82 mg, 0.39 mmol), 
the aldehyde, 3-methyl-6-oxohexyl 1-
acetyl-1H-indazole-3-carboxylate 300, (89 
mg, 0.28 mmol) and thiomorpholine 292 (45 
µL, 0.45 mmol) were stirred in 1,2-
dichloroethane (5.0 mL) at room temperature. TLC analysis after 1.5 h showed 
complete consumption of the aldehyde starting material. Following the work-up, 
the crude product was further purified using column chromatography on silica gel 
using hexane:ethyl acetate (90:10) eluent to yield 3-methyl-6-
thiomorpholinohexyl 1H-indazole-3-carboxylate 306 as an orange oil (0.06 g, 
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3-Methyl-6-thiomorpholinohexyl 1H-indazole-3-carboxylate 306 
δH(CDCl3, 400 MHz): 0.99 (3H, d J 
6.4, CHCH3), 1.09-2.00 (7H, m, 
containing 3 × CH2 and CHCH3), 2.38 
(2H, t, J 7.6, NCH2), 2.64-2.75 (8H, m, 
containing 2 × NCH2 and 2 × SCH2), 
4.45-4.68 (2H, m, OCH2), 7.30-7.35 
(1H, m, ArCH), 7.46 (1H, dd, J 8.1, 7.2, ArCH), 7.67 (1H, d, J 8.4, ArCH), 8.21 
(1H, d, J 8.2, ArCH), no signal for NH observed; δC(CDCl3, 100 MHz): 19.6 
(CH3), 23.5 (CH2), 27.8 (2 × SCH2), 29.9 (CH), 34.6 (CH2), 35.5 (CH2), 54.9 (2 × 
NCH2), 59.4 (NCH2), 63.5 (OCH2 ), 110.7 (ArCH), 121.9 (ArCH), 122.5 (ArCq), 
123.3 (ArCH), 127.3 (ArCH), 136.7 (C=N), 141.3 (ArCN), 163.0 (C=O) ester; 
max (film)/cm-1 3200, 2926, 1713; m/z (ESI+) 362 [M + H]+ (100%) 363 (20) 364 
(10). HRMS (ESI+): exact mass calculated for C19H28N3O2S [M + H]+ 362.1902. 
Found 362.1905. 
 
Attempted synthesis of 6-(4-(2-hydroxyethyl)piperazin-1-yl)-3-methylhexyl 
1-acetyl-1H-indazole-3-carboxylate 307 
The title compound was 
prepared following the 
procedure described for 3-
methyl-6-thiomorpholinohexyl 
3-oxobutanoate 293 using 
sodium triacetoxyborohydride 
(62 mg, 0.29 mmol), the 
aldehyde, 3-methyl-6-oxohex-2-
en-1-yl 1-acetyl-1H-indazole-3-
carboxylate 301, (66 mg, 0.21 mmol) and 2-(piperazin-1-yl)ethan-1-ol 295 (44 
mg, 0.34 mmol) in 1,2-dichloroethane (5.0 mL) under a nitrogen atmosphere. The 
reaction was stirred at room temperature for 18 h and following the work-up, the 
1H NMR of the crude residue showed no evidence of the desired product 
formation. The residue was further purified using column chromatography on 
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silica gel using hexane:ethyl acetate (90:10 to 100% ethyl acetate) to see if any 
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